<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vrml-20171231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.15.0.1-->
<!--Created on: 3/13/2018 3:29:55 PM-->
<html>
	<head>
		<title>
			20171231 10K
		</title>
	</head>
	<body><div style="margin-left:36pt;margin-right:36pt;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;line-height:80%;text-align:center;border-bottom:1pt none #D9D9D9 ;font-family:Courier New;font-size: 12pt">
			&nbsp;<a name="_GoBack"></a>
		</p>
		<p style="margin:0pt;line-height:80%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Courier New;font-size: 12pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:80%;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Courier New;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:8pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:80%;text-align:center;font-family:Univers;font-weight:bold;font-size: 12pt">
			<font style="display: inline;font-family:Times New Roman;font-size:12pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-weight:bold;font-size:12pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:550.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:550.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.70pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:550.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:13.05pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">UNITED STATES</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:550.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;font-size:12pt;">SECURITIES AND EXCHANGE COMMISSION</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:550.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						<font style="font-size:12pt;border-bottom-style:solid;border-bottom-width:2pt;height:100%;text-indent:0pt;">Washington, D. C. 20549</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:550.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;font-weight:bold;font-size:12pt;">FORM 10-K</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.74%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:96.26%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.74%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-weight:bold;text-transform:uppercase;font-size:11pt;">&#x2612;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:96.26%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;text-transform:uppercase;">Annual Report Pursuant to Section 13 or 15(</font><font style="display: inline;font-weight:bold;">d</font><font style="display: inline;font-weight:bold;text-transform:uppercase;">) of the Securities Exchange Act of 1934</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.74%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-weight:bold;text-transform:uppercase;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:96.26%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">For the fiscal year ended December 31, 201</font><font style="display: inline;">7</font><font style="display: inline;"> or</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:03.74%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-weight:bold;text-transform:uppercase;font-size:11pt;">&#x2610;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:96.26%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.74%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-weight:bold;text-transform:uppercase;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:96.26%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">For the transition period from __________ to __________</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:559.80pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.00%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.00%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:100.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="border-bottom-style:solid;border-bottom-width:2pt;height:100%;text-indent:0pt;">Commission file number:&nbsp;&nbsp;001-34810</font></p>
					<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;overflow: hidden;">
						&nbsp;</p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 14pt">
						<font style="display: inline;font-weight:bold;font-size:14pt;">Vermillion, Inc.</font></p>
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">(Exact name of registrant as specified in its charter)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Univers;font-weight:bold;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Delaware</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">33-0595156</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Univers;font-weight:bold;font-size: 8pt">
						<font style="display: inline;font-weight:normal;font-size:8pt;">(State or Other Jurisdiction of Incorporation or Organization)</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">(I.R.S. Employer Identification No.)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Univers;font-weight:bold;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-size:8pt;">&#xFEFF;</font></p>
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Univers;font-weight:bold;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">12117 Bee Caves Road, Building Three, Suite 100 </font></p>
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Univers;font-weight:bold;overflow: hidden;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Univers;font-weight:bold;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Austin, Texas</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">78738</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Univers;font-weight:bold;font-size: 8pt">
						<font style="display: inline;font-weight:normal;font-size:8pt;">(Address of Principal Executive Offices)</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">(Zip Code)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Univers;font-weight:bold;font-size: 8pt">
						<font style="display: inline;font-family:Times New Roman;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:550.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:550.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:550.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Registrant's telephone number, including area code: </font><font style="display: inline;font-weight:bold;"> (512) 519-0400</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:550.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:559.80pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:284.40pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:275.40pt;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:284.40pt;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;text-decoration:underline;">Title of each class </font></p>
				</td>
				<td valign="top" style="width:275.40pt;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;text-decoration:underline;">Name of each exchange on which registered </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:284.40pt;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Common Stock, par value $0.001 per share</font></p>
				</td>
				<td valign="top" style="width:275.40pt;height:9.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 30.6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">The NASDAQ Stock Market</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Securities registered pursuant to Section 12(g) of the Act:&nbsp; </font><font style="display: inline;font-weight:bold;">None</font>
		</p>
		<p style="margin:0pt;line-height:80%;text-align:center;font-family:Times New Roman;font-size: 10pt">
			&nbsp;
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:80%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </font><font style="display: inline;">&#x2610;</font><font style="display: inline;"> No </font><font style="display: inline;text-transform:uppercase;">&#x2612;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:80%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </font><font style="display: inline;">&#x2610;</font><font style="display: inline;"> No </font><font style="display: inline;text-transform:uppercase;">&#x2612;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </font><font style="display: inline;text-transform:uppercase;">&#x2612;</font><font style="display: inline;"> No </font><font style="display: inline;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T </font><font style="display: inline;color:#000000;font-size:10pt;">(&#xA7; 232.405 of this chapter) </font><font style="display: inline;color:#000000;font-size:10pt;">during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes </font><font style="display: inline;text-transform:uppercase;">&#x2612;</font><font style="display: inline;color:#000000;font-size:10pt;"> No </font><font style="display: inline;color:#000000;font-size:10pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K </font><font style="display: inline;">(&#xA7; 229.405) </font><font style="display: inline;">is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. </font><font style="display: inline;text-transform:uppercase;">&#x2612;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&nbsp;&nbsp;See the definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer</font><font style="display: inline;">,</font><font style="display: inline;">&#x201D; &#x201C;smaller reporting company&#x201D; </font><font style="display: inline;">and &#x201C;emerging growth company&#x201D; </font><font style="display: inline;">in Rule 12b-2 of the Exchange Act. </font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.00%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.00%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;font-family:Times New Roman;font-size: 10pt">

			<font style="text-indent:0pt;margin-left:0pt; padding-right:260.8pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:center"><font style="display: inline;font-family:Garamond;"></font></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Large accelerated filer </font><font style="display: inline;font-weight:bold;">&#x2610;</font></p>
				</td>
				<td valign="middle" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Accelerated filer </font><font style="display: inline;font-weight:bold;">&#x2610;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Non - accelerated filer </font><font style="display: inline;font-weight:bold;">&#x2610;</font></p>
				</td>
				<td valign="middle" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Smaller reporting company </font><font style="display: inline;font-weight:bold;">&#x2612;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Emerging </font><font style="display: inline;">growth company </font><font style="display: inline;font-weight:bold;">&#x2610;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_1_16"></a><font style="display: inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Act.</font><font style="color:#0000FF;border-bottom-style:solid;border-bottom-width:1pt;height:100%;text-indent:0pt;">&nbsp;</font><font style="display: inline;font-weight:bold;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </font><font style="display: inline;">&#x2610;</font><font style="display: inline;"> No </font><font style="display: inline;text-transform:uppercase;">&#x2612;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_19"></a><font style="display: inline;font-size:10pt;">The aggregate market value of voting common stock held by non-affiliates of the registrant is $56,898,624</font><a name="_cp_text_4_20"></a><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">and is based upon the last sales price as quoted on The NASDAQ Capital Market as of June&nbsp;30, 2017.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:10pt;">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. </font><font style="display: inline;color:#000000;font-size:10pt;">Yes </font><font style="display: inline;text-transform:uppercase;">&#x2612;</font><font style="display: inline;color:#000000;font-size:10pt;"> No </font><font style="display: inline;color:#000000;font-size:10pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of </font><font style="display: inline;">March 9</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">, the registrant had </font><font style="display: inline;">60,</font><font style="display: inline;">03</font><font style="display: inline;">9</font><font style="display: inline;">,</font><font style="display: inline;">338</font><font style="display: inline;"> shares of common stock, par value $0.001 per share, outstanding.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Univers;font-weight:bold;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">DOCUMENTS INCORPORATED BY REFERENCE</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Certain information from the registrant&#x2019;s definitive Proxy Statement for its Annual Meeting of Stockholders</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">is incorporated by reference into Part III of this report. The registrant intends to file the Proxy Statement with the Securities and Exchange Commission within 120 days of December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			&nbsp;
		</p></div><div style="margin-left:36pt;margin-right:36pt;">
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;font-family:Times New Roman;font-size: 10pt">

			<font style="text-indent:0pt;margin-left:0pt; padding-right:260.8pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:center"><font style="display: inline;font-family:Garamond;"></font></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;;font-size: 11pt"><font style="display: inline;font-weight:bold;color:#000000;font-size:11pt;">VERMILLION, INC.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">FORM 10-K</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">For the Fiscal Year Ended December 31, </font><font style="display: inline;font-weight:bold;">201</font><font style="display: inline;font-weight:bold;">7</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Table of Contents</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:bold;color:#000000;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:183.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:252.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:72.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:183.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:252.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:72.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;text-decoration:underline;">Page No.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:10.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:26.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">PART I</font></p>
				</td>
				<td colspan="4" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:81.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 1.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Business</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 1A.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Risk Factors</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 1B.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Unresolved Staff Comments</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">31&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 2.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Properties</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 3.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Legal Proceedings</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 4.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Mine Safety Disclosures</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">PART II</font></p>
				</td>
				<td colspan="4" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:81.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">33&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 5.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Market For Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">33&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 6.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Selected Financial Data</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">34&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 7.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">35&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 7A.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Quantitative and Qualitative Disclosures About Market Risk</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">43&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 8.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Financial Statements and Supplementary Data</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">43&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 9.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">43&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 9A.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Controls and Procedures</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">43&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 9B.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Other Information</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">44&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">PART III</font></p>
				</td>
				<td colspan="4" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:81.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 10.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Directors, Executive Officers and Corporate Governance</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 11.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Executive Compensation</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 12.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 13.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Certain Relationships and Related Transactions, and Director Independence</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 14.</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:59.10%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Principal Accountant Fees and Services</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:10.90%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">PART IV</font></p>
				</td>
				<td colspan="4" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:81.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 15.</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:43.54%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Exhibits and Financial Statement Schedules</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:26.46%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:10.18%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.82%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ITEM 16.</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:43.54%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Form 10-K Summary</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:26.46%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:08.00%;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">49&nbsp;
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:22.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">SIGNATURES</font></p>
				</td>
				<td colspan="3" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:70.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:08.00%;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Vermillion, OVA1</font><font style="display: inline;font-style:italic;">, Overa</font><font style="display: inline;font-style:italic;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;font-style:italic;"> OvaCalc</font><font style="display: inline;"> are registered trademarks of Vermillion, Inc.</font><font style="display: inline;font-style:italic;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:center;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			&nbsp;
		</p></div><div style="margin-left:36pt;margin-right:36pt;">
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;font-family:Times New Roman;font-size: 10pt">

			<font style="text-indent:0pt;margin-left:0pt; padding-right:260.8pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:center"><font style="display: inline;font-family:Garamond;"></font></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;">PART I</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">This Annual Report on Form 10-K contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties. Words such as &#x201C;may,&#x201D; &#x201C;expects,&#x201D; &#x201C;intends,&#x201D; &#x201C;anticipates,&#x201D; &#x201C;believes,&#x201D; &#x201C;estimates,&#x201D; &#x201C;plans,&#x201D; &#x201C;seeks,&#x201D; &#x201C;could,&#x201D; &#x201C;should,&#x201D; &#x201C;continue,&#x201D; &#x201C;will,&#x201D; &#x201C;potential,&#x201D; &#x201C;projects&#x201D; and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements speak only as of the date on which this report is filed with the Securities and Exchange Commission (the &#x201C;SEC&#x201D;), and</font><font style="display: inline;">, except as required by law, </font><font style="display: inline;">Vermillion, Inc. (&#x201C;Vermillion&#x201D; and</font><font style="display: inline;">, together with</font><font style="display: inline;"> its subsidiaries </font><font style="display: inline;">the &#x201C;Company&#x201D;, &#x201C;we&#x201D;, &#x201C;our&#x201D; or &#x201C;us&#x201D;) does not assume any obligation to update, amend or clarify them to reflect events, new information or circumstances occurring after such date. </font><font style="display: inline;">Examples of forward-looking statements </font><font style="display: inline;">regarding our business </font><font style="display: inline;">include the following:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">projections </font><font style="display: inline;color:#000000;">or expectations regarding</font><font style="display: inline;color:#000000;"> our future </font><font style="display: inline;color:#000000;">test volumes, </font><font style="display: inline;color:#000000;">revenue</font><font style="display: inline;color:#000000;">, cost of revenue, operating expenses, </font><font style="display: inline;color:#000000;">cash flow, </font><font style="display: inline;color:#000000;">results of operations and financial condition;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_32"></a><a name="_cp_text_1_28"></a><font style="display: inline;color:#000000;">o</font><font style="display: inline;color:#000000;">ur plan to broaden our commercial focus from </font><a name="_cp_text_4_29"></a><font style="display: inline;color:#000000;">ovarian cancer </font><a name="_cp_text_1_30"></a><font style="display: inline;color:#000000;">to differential diagnosis of </font><a name="_cp_text_4_31"></a><font style="display: inline;color:#000000;">women with a </font><a name="_cp_text_1_33"></a><font style="display: inline;color:#000000;">range of gynecological disorders;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">our planned business strategy and the anticipated timing of the implementation thereof</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">plans with respect to our market expansion and growth, including plans to market </font><font style="display: inline;color:#000000;">OVA1 </font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Overa</font><font style="display: inline;color:#000000;"> outside the United States;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">plans to develop new algorithms and molecular diagnostic tests;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;text-decoration:none;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_29"></a><font style="display: inline;color:#000000;">p</font><font style="display: inline;color:#000000;">lans to develop a product or tool combining an OVA1 with results of a symptom index;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">plans to establish our own payer coverage </font><font style="display: inline;color:#000000;">for</font><font style="display: inline;color:#000000;"> Overa</font><font style="display: inline;color:#000000;"> and expand coverage for OVA1</font><font style="display: inline;color:#000000;">;</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">intentions to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and other issues in the fields of oncology and women&#x2019;s health;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">plans to leverage infrastructure and enhance our pipeline of future technologies by fostering relationships with in vitro diagnostic (&#x201C;IVD&#x201D;) companies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">plans with respect to ASPiRA IVD, Inc. (&#x201C;ASPiRA IVD&#x201D;);</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expected service revenue growth based on ASPiRA IVD</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and the size of ongoing customer projects</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;text-decoration:none;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">our planned focus on the execution of five core strategic business drivers in ovarian cancer diagnostics and specialized laboratory services to address unmet medical needs for women faced with gynecologic disease and other conditions and the continued development of our business;</font><a name="_cp_blt_1_34"></a><a name="_cp_text_1_35"></a><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;text-decoration:none;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">e</font><font style="display: inline;color:#000000;">xpectation to maintain consistent research and development expenses;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">anticipated efficacy of our products, product development activities and product innovations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expected competition in the markets in which we compete;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">plans with respect to ASPiRA LABS, Inc. (&#x201C;ASPiRA LABS&#x201D;);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expectations regarding future services provided by Quest Diagnostics</font><font style="display: inline;color:#000000;"> Incorporated (&#x201C;Quest Diagnostics&#x201D;)</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;color:#00C000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;color:#00C000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_39"></a><a name="_cp_text_1_40"></a><font style="display: inline;color:#000000;">p</font><font style="display: inline;color:#000000;">lans </font><font style="display: inline;color:#000000;">to expand our ovarian cancer franchise beyond OVA1, including </font><font style="display: inline;color:#000000;">with respect to </font><font style="display: inline;color:#000000;">Overa</font><font style="display: inline;color:#000000;"> and OvaX;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">plans regarding the commercialization of Overa;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_43"></a><a name="_cp_text_1_41"></a><font style="display: inline;color:#000000;">p</font><font style="display: inline;color:#000000;">lans to develop </font><font style="display: inline;color:#000000;">informatics products and develop </font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">perform </font><a name="_cp_text_4_42"></a><font style="display: inline;color:#000000;">laboratory develop</font><font style="display: inline;color:#000000;">ed</font><font style="display: inline;color:#000000;">&nbsp;</font><a name="_cp_text_1_44"></a><font style="display: inline;color:#000000;">tests (&#x201C;LDTs&#x201D;);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">plans with respect to the Company&#x2019;s pelvic mass registry, including anticipated sources of funding;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;color:#00C000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;color:#00C000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">anticipated effects on reimbursement for OVA1</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">from changes to Novitas Solutions&#x2019; administrative requirements;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;color:#00C000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;color:#00C000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expectations regarding</font><font style="display: inline;color:#000000;"> the Company&#x2019;s approach of monitoring and combining multiple protein biomarkers to create diagnostic tests to aid physicians considering treatment options for patients with complex diseases, and the Company&#x2019;s future development of new In Vitro Diagnostic Multivariate Index Assays</font><font style="display: inline;color:#000000;"> &nbsp;(</font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;color:#000000;">IVDMIA</font><font style="display: inline;color:#000000;">&#x201D;</font><font style="display: inline;color:#000000;">)</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;text-decoration:none;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_42"></a><a name="_cp_text_1_43"></a><font style="display: inline;color:#000000;">o</font><font style="display: inline;color:#000000;">ur ability to improve sensitivity and specificity over traditional diagnostic biomarkers;</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">1</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expectations regarding </font><font style="display: inline;color:#000000;">existing and future collaborations and partnerships</font><font style="display: inline;color:#000000;">, including OVA1 and Overa distribution agreements</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">plans regarding future publications;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">our continued ability to comply with applicable governmental regulations</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">, &nbsp;</font><font style="display: inline;color:#000000;">expectations regarding </font><font style="display: inline;color:#000000;">pending regulatory submissions and plans to seek regulatory approvals for our tests outside the United States</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">our ability to obtain and maintain the regulatory approvals required to market </font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">OVA1 and </font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">Overa in other countries;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">our continued ability to expand and protect our intellectual property portfolio;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">anticipated </font><font style="display: inline;color:#000000;">liquidity and capital requirements</font><font style="display: inline;color:#000000;">;</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">anticipated future losses and our ability to continue as a going concern;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expectations regarding the second disbursement from our financing arrangement</font><font style="display: inline;color:#000000;">, as amended,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">with</font><font style="display: inline;color:#000000;"> the State of Connecticut Department of Economic and Community Development (</font><font style="display: inline;color:#000000;">the </font><font style="display: inline;color:#000000;">&#x201C;DECD&#x201D;)</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expected expenditures</font><font style="display: inline;color:#000000;">, including the expected </font><font style="display: inline;color:#000000;">in</font><font style="display: inline;color:#000000;">crease in expenses related to </font><font style="display: inline;color:#000000;">sales and marketing</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of OVA1 and Overa </font><font style="display: inline;color:#000000;">in 201</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">our ability to use our net operating loss carryforwards;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;text-decoration:none;color:#000000;font-size:10pt;text-decoration:none;punctuation-wrap:hanging;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_6"></a><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">nticipated future tax liability under U.S. federal and state income tax legislation; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expected market adoption of our diagnostic tests, including OVA1</font><font style="display: inline;color:#000000;"> and Overa</font><font style="display: inline;color:#000000;">;</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expectations regarding our </font><font style="display: inline;color:#000000;">ability</font><font style="display: inline;color:#000000;"> to launch new products </font><font style="display: inline;color:#000000;">we </font><font style="display: inline;color:#000000;">develop, license, co-market or acquire;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expectations regarding raising capital and </font><font style="display: inline;color:#000000;">the amount of financing anticipated to be required to fund our planned operations;</font><font style="display: inline;color:#000000;"> and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:10pt;punctuation-wrap:hanging;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">expectations regarding </font><font style="display: inline;color:#000000;">reimbursement for our products, and our ability to obtain such reimbursement, from third-party payers such as private insurance companies and government insurance plans</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Forward-looking </font><font style="display: inline;color:#000000;">statements are subject to significant risks and uncertainties, including those </font><font style="display: inline;color:#000000;">discussed</font><font style="display: inline;color:#000000;"> in Part I Item&nbsp;1A, &#x201C;Risk Factors</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&#x201D; that could cause actual results to differ materially from those projected in such forward-looking statements due to various factors, including our ability to </font><a name="_cp_text_1_2"></a><font style="display: inline;color:#000000;">increase the volume of OVA1 </font><font style="display: inline;color:#000000;">or Overa </font><font style="display: inline;color:#000000;">sales</font><font style="display: inline;color:#000000;">; our ability to </font><a name="_cp_text_1_4"></a><font style="display: inline;color:#000000;">market our test through sales channels other than </font><font style="display: inline;color:#000000;">Quest Diagnostics</font><font style="display: inline;color:#000000;">, including ASPiRA LABS</font><font style="display: inline;color:#000000;">; failures by </font><font style="display: inline;color:#000000;">third-party</font><font style="display: inline;color:#000000;"> payers to reimburse OVA1 </font><font style="display: inline;color:#000000;">or Overa </font><font style="display: inline;color:#000000;">or changes or variances in reimbursement rates; our ability to secure </font><a name="_cp_text_1_6"></a><font style="display: inline;color:#000000;">additional capital </font><font style="display: inline;color:#000000;">on acceptable terms to execute our business plan; our ability to </font><a name="_cp_text_1_7"></a><font style="display: inline;color:#000000;">commercialize </font><font style="display: inline;color:#000000;">OVA1 </font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">Overa both within and outside the United States; in the event that we succeed in commercializing OVA1 and Overa outside the United States, the political, economic and other conditions affecting other countries (including foreign exchange rates); our ability to continue developing existing technologies; our ability to develop and commercialize additional diagnostic products and achieve market acceptance with respect to these products; our ability to compete successfully; our ability to obtain any regulatory approval required for our future diagnostic products; our or our suppliers&#x2019; ability to comply with Food and Drug Administration (&#x201C;FDA&#x201D;) requirements for production, marketing and post-market monitoring of our products; additional costs that may be required to make further improvements to our manufacturing operations; our ability to maintain sufficient or acceptable supplies of immunoassay kits from our suppliers; our ability to continue to develop, protect and promote our proprietary technologies; our ability to use intellectual property directed to diagnose biomarkers; our ability to successfully defend our proprietary technology against third parties; future litigation against us, including infringement of intellectual property and product liability exposure; our ability to retain key employees; business</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">interruptions; legislative actions resulting in higher compliance costs; changes in healthcare policy; our ability to comply with </font><font style="display: inline;color:#000000;">environmental laws</font><font style="display: inline;color:#000000;">;</font><font style="display: inline;color:#000000;"> our ability to generate sufficient demand for ASPiRA LABS&#x2019; services to cover </font><font style="display: inline;color:#000000;">it</font><font style="display: inline;color:#000000;">s operating costs; our ability to comply with the additional laws and regulations that apply to us in connection with the operation of ASPiRA LABS;</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">our ability to comply with FDA regulations that relate to our products and to </font><font style="display: inline;color:#000000;">obtain any FDA clearance or approval required to develop and perform LDTs</font><font style="display: inline;color:#000000;">; ASPiRA IVD&#x2019;s lack of operating history; ASPiRA IVD&#x2019;s ability to generate and maintain business; fluctuations over time with respect to ASPiRA IVD&#x2019;s operating results; ASPiRA IVD&#x2019;s ability to enter into profitable contracts; ASPiRA IVD&#x2019;s ability to maintain effective information systems without significant interruption; ASPiRA IVD&#x2019;s ability to perform its services in compliance with contractual requirements, regulatory standards and ethical considerations; </font><font style="display: inline;color:#000000;">our ability to integrate and achieve anticipated results from any acquisitions or strategic alliances; </font><font style="display: inline;color:#000000;">and our ability to continue as a going concern</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">2</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">I</font><font style="display: inline;font-weight:bold;">TEM 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><a name="Business"></a><font style="display: inline;font-weight:bold;">BUSINESS</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Company </font><font style="display: inline;font-weight:bold;">Overview</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Corporate Vision:</font><font style="display: inline;font-weight:bold;font-style:italic;"> &nbsp; &nbsp;</font><font style="display: inline;">To </font><font style="display: inline;">drive</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the advancement of women&#x2019;s health by providing innovative methods to detect, monitor and manage the treatment of </font><font style="display: inline;color:#000000;">both benign and malignant </font><font style="display: inline;">gynecologic disease</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;color:#000000;">with our primary focus being </font><font style="display: inline;color:#000000;">diseases of the female pelvic cavity</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have expanded our corporate strategy with the goal of transforming </font><font style="display: inline;">t</font><font style="display: inline;">he Company </font><font style="display: inline;">from a </font><font style="display: inline;">technology license company to a </font><font style="display: inline;">global </font><font style="display: inline;">diagnostic</font><font style="display: inline;"> and </font><font style="display: inline;">bio-analytic solutions provider. </font><font style="display: inline;">Our plan </font><font style="display: inline;">is </font><font style="display: inline;">to broaden our commercial focus from ovarian cancer to differential diagnosis of women with a range of gynecological disorders</font><font style="display: inline;">. Our strategy</font><font style="display: inline;"> is</font><font style="display: inline;"> be</font><font style="display: inline;">ing</font><font style="display: inline;"> deployed in </font><font style="display: inline;">three</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">phases.&nbsp;&nbsp;</font><font style="display: inline;">The </font><font style="display: inline;">three </font><font style="display: inline;">phases are </font><font style="display: inline;">a rebuild phase, which </font><font style="display: inline;color:#000000;">was completed in 2015, </font><font style="display: inline;">a</font><font style="display: inline;"> transformation phase</font><font style="display: inline;">, which </font><font style="display: inline;">wa</font><font style="display: inline;">s virtually complete</font><font style="display: inline;">d in 2017</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">with the exception of our </font><font style="display: inline;">continuing expansion of payer coverage</font><font style="display: inline;">, and a</font><font style="display: inline;"> market expansion and growth phase, which </font><font style="display: inline;">we plan to continue</font><font style="display: inline;"> in 2018</font><font style="display: inline;"> and 2019</font><font style="display: inline;">.&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During the first phase, we expanded our leadership team by hiring several new senior leaders including a chief executive officer.&nbsp;&nbsp;In addition, we expanded our commercial strategy, reestablished medical and advisory support, rebuilt our patient advocacy strategy and established a billing system and a payer strategy outside of our relationship with Quest Diagnostics.&nbsp; </font><font style="display: inline;">During the </font><font style="display: inline;">second</font><font style="display: inline;"> phase, </font><font style="display: inline;color:#000000;">we completed the process of obtaining licensure of ASPiRA LABS in all of the states that require licenses</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">are in the process of</font><font style="display: inline;color:#000000;"> establish</font><font style="display: inline;color:#000000;">ing</font><font style="display: inline;color:#000000;"> our own payer coverage for OVA1</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="font-weight:bold;display: inline;font-weight:normal;color:#44474B;">Multivariate Index Assay</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(MIA)</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">launch</font><font style="display: inline;color:#000000;">ed</font><font style="display: inline;color:#000000;"> a second-generation OVA1 test, trademarked Overa</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="font-weight:bold;display: inline;font-weight:normal;color:#44474B;">Multivariate Index Assay, 2</font><font style="font-weight:bold;display: inline;font-weight:normal;color:#44474B;font-size:5pt;vertical-align:super;line-height:100%">nd</font><font style="font-weight:bold;display: inline;font-weight:normal;color:#44474B;"> Generation</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">(MIA2G)</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">on a targeted basis</font><font style="display: inline;color:#000000;">.&nbsp; </font><font style="display: inline;">In the </font><font style="display: inline;">third</font><font style="display: inline;"> phase</font><font style="display: inline;">,</font><font style="display: inline;"> we </font><a name="_cp_text_1_10"></a><font style="display: inline;">plan to </font><font style="display: inline;">globally</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">commercialize </font><font style="display: inline;">OVA1 and </font><font style="display: inline;">Overa</font><font style="display: inline;"> by utilizing </font><font style="display: inline;">the full national licensure of ASPiRA LABS, </font><font style="display: inline;">select laboratories</font><font style="display: inline;"> for distribution</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">managed care coverage in select markets, </font><a name="_cp_text_1_12"></a><font style="display: inline;">our </font><font style="display: inline;">sales force and </font><a name="_cp_text_4_15"></a><font style="display: inline;">existing customer base</font><font style="display: inline;">.&nbsp;&nbsp;Unlike OVA1, </font><font style="display: inline;">Overa</font><font style="display: inline;"> uses a global testing platform, which allow</font><font style="display: inline;">s</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Overa</font><font style="display: inline;"> to </font><a name="_cp_text_4_17"></a><font style="display: inline;">be deployed </font><a name="_cp_text_1_18"></a><font style="display: inline;">internationally.&nbsp; </font><font style="display: inline;">We initiated the targeted launch of Overa in October 2016 with two key accounts converting from OVA1 to Overa. </font><font style="display: inline;color:#000000;">I</font><font style="display: inline;color:#000000;">n October 2015, we </font><font style="display: inline;">announced registration of the CE mark for and clearance to market Overa in the European Union.&nbsp; </font><font style="display: inline;">We also plan to </font><font style="display: inline;">continue our development of informatics products such as the OVA1 plus test report </font><font style="display: inline;">as well as </font><font style="display: inline;">Laboratory Developed Tests (LDT&#x2019;s)</font><font style="display: inline;">, which we refer to internally as OvaX.&nbsp;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">We anticipate that OvaX will include not only biomarkers, but also clinical risk factors</font><font style="display: inline;">, other diagnostics</font><font style="display: inline;"> and patient history data in order to boost predictive value.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Mission Statement:</font><font style="display: inline;font-weight:bold;font-style:italic;"> &nbsp; &nbsp;</font><font style="display: inline;">We are dedicated to the discovery, development and commercialization of novel high-value </font><a name="_cp_text_1_106"></a><font style="display: inline;">diagnostic and bio-analytical solutions </font><font style="display: inline;">that help physicians diagnose, treat and improve outcomes for </font><font style="display: inline;">women</font><font style="display: inline;">. Our tests are intended to </font><font style="display: inline;">detect, </font><font style="display: inline;">characterize</font><font style="display: inline;"> and stage disease, and to </font><font style="display: inline;">help guide decisions regarding </font><font style="display: inline;">patient </font><font style="display: inline;">treatment</font><font style="display: inline;">, which</font><font style="display: inline;"> may include decisions to refer patients to specialists, to perform additional testing, or to assist in </font><font style="display: inline;">monitoring </font><font style="display: inline;">response to </font><font style="display: inline;">therapy. A distinctive feature of our approach </font><font style="display: inline;">is the combination of multi-modal diagnostics and data. Our goal </font><font style="display: inline;">is to combine multiple </font><font style="display: inline;">bio</font><font style="display: inline;">markers</font><font style="display: inline;">, other modalit</font><font style="display: inline;">ies and diagnostics</font><font style="display: inline;">,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">clinical risk factors and patient data </font><font style="display: inline;">into a single, reportable</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">index score that has higher diagnostic </font><font style="display: inline;">accuracy </font><font style="display: inline;">than </font><font style="display: inline;">its </font><font style="display: inline;">constituents. We concentrate our development of novel diagnostic tests</font><font style="display: inline;"> for</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">gyne</font><font style="display: inline;">cologic </font><font style="display: inline;">disease</font><font style="display: inline;">, with </font><font style="display: inline;">an </font><font style="display: inline;">initial focus on ovarian cancer. We also intend to address clinical </font><font style="display: inline;">questions </font><font style="display: inline;">related to early disease detection, treatment response, monitoring of disease progression</font><font style="display: inline;">,</font><font style="display: inline;"> prognosis </font><font style="display: inline;">and others </font><font style="display: inline;">through collaborations with leading academic and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">research institutions.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Business:</font><font style="display: inline;font-weight:bold;font-style:italic;"> &nbsp; &nbsp;</font><font style="display: inline;">Our </font><font style="display: inline;">initial</font><font style="display: inline;"> product, OVA1, is a blood test designed to</font><font style="display: inline;">, in addition to a physician&#x2019;s clinical assessment of a woman with a pelvic mass,</font><font style="display: inline;"> identify women who are at high risk of having a malignant ovarian tumor prior to </font><font style="display: inline;">planned </font><font style="display: inline;">surgery. The FDA cleared OVA1 in September 2009</font><font style="display: inline;">,</font><font style="display: inline;"> and we commercially launched OVA1 in March 2010. We have </font><font style="display: inline;">launched on a targeted basis</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">a second-generation </font><font style="display: inline;">biomarker</font><font style="display: inline;"> panel</font><font style="display: inline;"> known as Overa, which is</font><font style="display: inline;"> intended to maintain our product&#x2019;s high sensitivity while improving specificity. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">We received </font><font style="display: inline;">FDA clearance for Overa on March </font><font style="display: inline;">18</font><font style="display: inline;">, 2016. </font><font style="display: inline;">Overa </font><font style="display: inline;">use</font><font style="display: inline;">s</font><font style="display: inline;"> the Roche </font><font style="display: inline;">cobas</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">platform</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In June 2014, </font><font style="display: inline;font-size:10pt;">we</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">launched ASPiRA LABS, </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">a &nbsp;</font><font style="display: inline;font-size:10pt;">Clinical Laboratory Improvement Amendments of 1988 (&#x201C;CLIA&#x201D;)</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> certified national laboratory </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">which specializes in applying biomarker-based technologies, to address critical needs in the management of gynecologic cancers</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;font-size:10pt;">and disease</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">. ASPiRA LABS provides expert diagnostic </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">services </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">using a state-of-the-art biomarker-based diagnostic algorithm to </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">aid in </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">clinical decision making and advance personalized treatment plans. The lab currently processes our OVA1</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> and Overa</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> test</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">s</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">,</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> and w</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">e plan to expand the testing to other gynecologic conditions with high unmet need. &nbsp;We also plan to develop and perform LDTs at ASPiRA LAB</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">S</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">.&nbsp;&nbsp;ASPiRA </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">LABS </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">holds a </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">CLIA </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">Certificate of </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">Registration </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">and a state laboratory license in California</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">,</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;font-size:10pt;">Florida, Maryland, New York, Pennsylvania </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">and Rhode Island. </font><font style="display: inline;font-size:10pt;">This allows the lab to process OVA1 on a national basis. </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">The </font><font style="display: inline;font-size:10pt;">Centers for Medicare and Medicaid Services (&#x201C;CMS&#x201D;) issued a provider number to</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">A</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">SPiRA </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">LABS </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">i</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">n March 2015.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In 2016, we </font><font style="display: inline;font-size:10pt;">created</font><font style="display: inline;font-size:10pt;"> a service within the ASPiRA channel strategy, &#x201C;an ASPiRA </font><font style="display: inline;font-size:10pt;">IVD Services </font><font style="display: inline;font-size:10pt;">Program&#x201D;. </font><font style="display: inline;font-size:10pt;">In April 2016, we formed ASPiRA IVD to offer IVD trial services to third-party customers. ASPiRA IVD is a specialized laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize&nbsp;high-complexity&nbsp;assays.&nbsp;ASPiRA IVD was built around a core of laboratory&nbsp;expertise and an FDA-compliant quality system, and strives to deliver accurate and reliable&nbsp;results to its third-party customers suitable for&nbsp;FDA submission. ASPiRA IVD received a CLIA laboratory license in June 2016 and commenced operations in the second quarter of 2016.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">3</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-size:10pt;">In th</font><font style="display: inline;font-size:10pt;">e ASPiRA IVD</font><font style="display: inline;font-size:10pt;"> program, we </font><font style="display: inline;font-size:10pt;">are</font><font style="display: inline;font-size:10pt;"> leverag</font><font style="display: inline;font-size:10pt;">ing</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">our </font><font style="display: inline;font-size:10pt;">existing infrastructure </font><font style="display: inline;font-size:10pt;">and </font><font style="display: inline;font-size:10pt;">enhanc</font><font style="display: inline;font-size:10pt;">ing</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">our pipeline of future technologies by fostering relationships with IVD companies </font><font style="display: inline;font-size:10pt;">that </font><font style="display: inline;font-size:10pt;">are developing new diagnostics including companion diagnostics platforms. We believe this </font><font style="display: inline;font-size:10pt;">approach</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">will allow us to continue to be innovative in evaluating potential diagnostics. Our goal with the addition of this line of business is to invest in our </font><font style="display: inline;font-size:10pt;">short-</font><font style="display: inline;font-size:10pt;">term and </font><font style="display: inline;font-size:10pt;">long-</font><font style="display: inline;font-size:10pt;">term enterprise value while leveraging specimen bank, database, FDA experience, laboratory informatics and operating efficiency.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In the first half of 2017, ASPiRA IVD services landed two top pharmaceutical trial service agreements including one enrollment study.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Strategy:</font><font style="display: inline;font-weight:bold;font-style:italic;"> &nbsp; &nbsp;</font><font style="display: inline;">We are focused on the execution of </font><font style="display: inline;">five </font><font style="display: inline;">core strategic business drivers in ovarian cancer diagnostics </font><font style="display: inline;">and specialized laboratory servi</font><font style="display: inline;">c</font><font style="display: inline;">es </font><font style="display: inline;">to build long-term value for our investors: </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;punctuation-wrap:hanging;vertical-align:baseline;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Maximizing the existing OVA1 opportunity in the United States by lead</font><font style="display: inline;color:#000000;">ing</font><font style="display: inline;color:#000000;"> in payer coverage and commercialization of OVA1.&nbsp; </font><font style="display: inline;color:#000000;">This strategy included the launch of a </font><font style="display: inline;background-color: #FFFFFF;color:#000000;">CLIA</font><font style="display: inline;color:#000000;"> certified clinical laboratory, ASPiRA LABS, in June 2014</font><font style="display: inline;color:#000000;">, multiple publications, inclusion in the ACOG adnexal mass guidelines, payer traction and finally the addition of OVA1 to CMS National Fee schedule as of January 2018</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">E</font><font style="display: inline;color:#000000;">xpanding the </font><font style="display: inline;color:#000000;">distribution platform </font><font style="display: inline;color:#000000;">beyond the U.S. </font><font style="display: inline;color:#000000;">by</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">launching</font><font style="display: inline;color:#000000;"> Overa, a </font><font style="display: inline;color:#000000;">next generation</font><font style="display: inline;color:#000000;"> biomarker panel, </font><font style="display: inline;color:#000000;">on a targeted basis </font><font style="display: inline;color:#000000;">while </font><font style="display: inline;color:#000000;">building the clinical utility and health economics foundation of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">both </font><font style="display: inline;color:#000000;">OVA1</font><font style="display: inline;color:#000000;"> and Overa</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">which we believe may allow </font><font style="display: inline;color:#000000;">for better domestic market penetration and international expansion</font><font style="display: inline;color:#000000;"> (FDA clearance</font><font style="display: inline;color:#000000;"> for Overa</font><font style="display: inline;color:#000000;"> was received </font><font style="display: inline;color:#000000;">i</font><font style="display: inline;color:#000000;">n March 2016)</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Leveraging our existing database and specimen bank while building the largest specimen and data repository of gynecologic pelvic mass patients worldwide</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 4)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">Expanding our product offerings </font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">to additional pelvic disease conditions such as endometriosis and poly</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">c</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">y</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">s</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">tic ovarian </font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">syndrome (</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">&#x201C;</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">PCOS</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">&#x201D;</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">) &nbsp;</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">by adding additional gynecologic bio-analytic solutions involving biomarkers, other modalities (e.g., imaging), clinical risk factors and patient data to aid diagnosis and risk stratification of women presenting with a pelvic mass disease</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;punctuation-wrap:hanging;vertical-align:baseline;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 5)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">Expanding our </font><font style="display: inline;color:#000000;">revenue channels and </font><font style="display: inline;color:#000000;">customer offerings with the launch of our ASPiRA IVD laboratory services.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 54pt;punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">We</font><font style="display: inline;color:#000000;"> believe that these business drivers will contribute significantly to addressing unmet medical needs for women faced with gynecologic disease and other conditions and the continued development of our business.</font>
		</p>
		<p style="margin:12pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Our Product</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">OVA1</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;">addresses a clear clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. Numerous studies have documented the benefit of referral of these women to gynecologic oncologists for their initial surgery. Prior to the clearance of OVA1, no blood test had been cleared by the FDA for physicians to use in the pre-surgical management of ovarian adnexal masses. OVA1 </font><font style="display: inline;color:#000000;">and Overa are </font><font style="display: inline;color:#000000;">qualitative serum test</font><font style="display: inline;color:#000000;">s</font><font style="display: inline;color:#000000;"> that utilize five well-established biomarkers and proprietary software cleared as part of the OVA1 510(k) to determine the likelihood of malignancy in women over age 18, with a pelvic mass for whom surgery is planned. OVA1 </font><font style="display: inline;color:#000000;">or Overa </font><font style="display: inline;color:#000000;">should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery.&nbsp;Incorrect use of OVA1 </font><font style="display: inline;color:#000000;">or Overa </font><font style="display: inline;color:#000000;">carries the risk of unnecessary testing, surgery and/or delayed diagnosis. OVA1 was developed through large pre-clinical studies in collaboration with numerous academic medical centers encompassing over 2,500 clinical samples. OVA1 was fully validated in a prospective multi-center clinical trial encompassing 27 sites reflective of the diverse nature of the clinical centers at which ovarian adnexal masses are evaluated.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In March 2015, we entered into a new commercial agreement with Quest Diagnostics.&nbsp;&nbsp;Pursuant to this agreement, </font><font style="display: inline;color:#000000;">all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to </font><font style="display: inline;color:#000000;">Vermillion&#x2019;s wholly-owned subsidiary, ASPiRA LABS, </font><font style="display: inline;color:#000000;">as of August 2015.&nbsp;&nbsp;Pursuant to this agreement, as amended as of March 1, 2018, Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens to ASPiRA LABS for testing </font><font style="display: inline;color:#000000;">through at least March 11, 2019 in exchange for a market value fee</font><font style="display: inline;color:#000000;">.&nbsp; </font><font style="display: inline;color:#000000;"> Per the terms of the </font><font style="display: inline;color:#000000;">new commercial </font><font style="display: inline;color:#000000;">agreement, we will not offer to existing or future Quest Diagnostics customers CA 125-II or other tests that Quest Diagnostics offers.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">We have</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">active </font><font style="display: inline;font-size:10pt;color:#000000;">international distribution agreement</font><font style="display: inline;font-size:10pt;color:#000000;">s</font><font style="display: inline;font-size:10pt;color:#000000;"> for Overa </font><font style="display: inline;font-size:10pt;color:#000000;">with</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">Pro-Genetics LTD in Israel and MacroHealth, Inc. in the Philippines. </font><font style="display: inline;font-size:10pt;color:#000000;">The </font><font style="display: inline;font-size:10pt;color:#000000;">MacroHealth </font><font style="display: inline;font-size:10pt;color:#000000;">agreement </font><font style="display: inline;font-size:10pt;color:#000000;">was</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">our </font><font style="display: inline;font-size:10pt;color:#000000;">first decentralized international agreement with Overa specimen testing to be performed in the Philippines.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_16"></a>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-size:10pt;">Novitas Solutions, the Medicare contractor, covers and reimburses for OVA1. This local coverage determination from Novitas Solutions essentially provides national coverage for patients enrolled in Medicare as well as Medicare Advantage health plans. However, ASPiRA LABS initially experienced difficulty in obtaining payment from Novitas Solutions for most claims submitted due to Novitas Solutions&#x2019; administrative requirements. In October 2016, Novitas Solutions updated its administrative requirements for OVA1 reimbursement which has improved our ability to obtain reimbursement for OVA1 from Novitas Solutions.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In October 2016, we launched our pelvic mass specimen and data repository and began the collection of patient consents under </font><font style="display: inline;font-size:10pt;">Institut</font><font style="display: inline;font-size:10pt;">ional Review Board (&#x201C;IRB&#x201D;) for collection and cataloguing of serum samples for future research purposes.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:107.92%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In November 2016, The American College of Obstetricians and Gynecologists ("ACOG&#x201D;) issued Practice Bulletin Number 174</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;"> which included OVA1 as a &#x201C;</font><font style="display: inline;font-size:10pt;">Multivariate </font><font style="display: inline;font-size:10pt;">Index Assay&#x201D;. This bulletin outlines ACOG's &#x201C;new&#x201D; clinical management guidelines for adnexal mass management.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:107.92%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">These new clinical management guidelines replace the July 2007 version, Practice Bulletin </font><font style="display: inline;font-size:10pt;">Number </font><font style="display: inline;font-size:10pt;">83. Practice Bulletins summarize current information on techniques and clinical management issues for the practice of obstetrics and gynecology. Practice Bulletins are evidence-based documents, and recommendations are based on the evidence.&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Under Practice Bulletin Number 174, t</font><font style="display: inline;font-size:10pt;">he only Level A recommendation for the work up of the adnexal mass is </font><font style="display: inline;font-size:10pt;">a &nbsp;</font><font style="display: inline;font-size:10pt;">pelvic ultrasound. If </font><font style="display: inline;font-size:10pt;">a pelvic </font><font style="display: inline;font-size:10pt;">ultrasound is unable to definitively diagnose either a benign condition or a malignancy, clinicians have the ability to do </font><font style="display: inline;font-size:10pt;">a &nbsp;</font><font style="display: inline;font-size:10pt;">further work up with biomarker panels such as OVA1 (MIA), which has a Level B evidence designation.</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Based on this, OVA1 has now achieved parity with CA125 as a Level B recommendation for the management of adnexal masses</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">In December 2016, we received an FDA Clarification Letter regarding OVA1 and Overa. This letter was in reference to the September 7, 2016 FDA Safety Communication advising women and their physicians against the use of ovarian cancer screening tests for asymptomatic women.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">In order to avoid any confusion</font><font style="display: inline;color:#000000;font-size:10pt;">,</font><font style="display: inline;color:#000000;font-size:10pt;"> as well as to document the FDA position on OVA1 and Overa, Jeffrey Shuren, M.D, J.D, Director</font><font style="display: inline;color:#000000;font-size:10pt;"> for the</font><font style="display: inline;color:#000000;font-size:10pt;"> Center for Devices and Radiological Health at the FDA, sent a letter to Vermillion, dated December 21, 2016. In the letter, Dr. Shuren stated: </font><font style="display: inline;color:#000000;font-size:10pt;">&#x201C;</font><font style="display: inline;color:#000000;font-size:10pt;">We agree that this safety communication does not apply to Vermillion</font><font style="display: inline;color:#000000;font-size:10pt;">&#x2019;</font><font style="display: inline;color:#000000;font-size:10pt;">s FDA-cleared tests, OVA1 (MIA) and Overa (MIA2G), which are not screening tests for ovarian cancer.</font><font style="display: inline;color:#000000;font-size:10pt;">&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#x201C;</font><font style="display: inline;color:#000000;font-size:10pt;">FDA cleared OVA1 (MIA) and Overa (MIA2G) as aids to further assess the likelihood that malignancy is present when the physician</font><font style="display: inline;color:#000000;font-size:10pt;">&#x2019;</font><font style="display: inline;color:#000000;font-size:10pt;">s independent clinical and radiological evaluation does not indicate malignancy. The intended uses of the two assays are the same</font><font style="display: inline;color:#000000;font-size:10pt;">&#x2014;</font><font style="display: inline;color:#000000;font-size:10pt;">to help physicians more reliably identify which patients would benefit from consultation with or referral to a gynecologic oncologist. OVA1 (MIA) and Overa (MIA2G) are indicated for women who present with an adnexal mass.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Studies</font><font style="display: inline;font-weight:bold;"> and </font><font style="display: inline;font-weight:bold;">Publications</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The benefit of </font><font style="display: inline;">OVA1 was </font><font style="display: inline;">established in </font><font style="display: inline;">large clinical studies in collaboration with numerous academic medical centers encompassing over 2,500 clinical samples. OVA1 was fully validated in a prospective multi-center clinical trial encompassing 27 sites reflecti</font><font style="display: inline;">ng</font><font style="display: inline;"> the diverse nature of the clinical centers at which ovarian adnexal masses are evaluated.[1] The results of the clinical trial demonstrated that in a clinical cohort of 516 patients, OVA1, in conjunction with clinical evaluation, was able to identify 95.7% (154/161) of the malignant ovarian tumors overall, and to rule out malignancy with a negative predictive value (&#x201C;NPV&#x201D;) of 94.6%&nbsp;&nbsp;(123/130). At the 2010 International Gynecologic Cancer Society Meeting, data was presented demonstrating the high sensitivity of OVA1 for epithelial ovarian cancers; OVA1 detected 95</font><font style="display: inline;"> out of </font><font style="display: inline;">96 epithelial ovarian cancer cases for a sensitivity of 99.0%, including 40/41 stage I and stage II epithelial ovarian cancers</font><font style="display: inline;">. These findings resulted in</font><font style="display: inline;"> an overall sensitivity of 97.6% for early stage epithelial ovarian cancers, as compared to 65.9% for </font><font style="display: inline;">the previous single-marker </font><font style="display: inline;">CA125 </font><font style="display: inline;">test </font><font style="display: inline;">using the ACOG cutoffs. The improvement in sensitivity was even greater among premenopausal women; for OVA1, sensitivity for early stage epithelial ovarian cancer </font><font style="display: inline;">in premenopausal women </font><font style="display: inline;">was 92.9% </font><font style="display: inline;">compared </font><font style="display: inline;">to </font><font style="display: inline;">CA125</font><font style="display: inline;"> with a 35.7%</font><font style="display: inline;"> sensitivity. Overall, OVA1 detected 76% of malignancies missed by </font><font style="display: inline;">the </font><font style="display: inline;">CA125</font><font style="display: inline;"> assay</font><font style="display: inline;">, including all advanced stage malignancies. OVA1 is not indicated for use as a screening or stand-alone diagnostic assay.</font><font style="display: inline;"> &nbsp;The study results were published in </font><font style="display: inline;font-style:italic;">Obstetrics and Gynecology</font><font style="display: inline;"> in 2011.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In February 2013</font><font style="display: inline;">,</font><font style="display: inline;"> results from </font><font style="display: inline;">a second pivotal clinical study of OVA1, called the &#x201C;OVA500 study&#x201D; led by Dr. Robert E. Bristow, Director of Gynecologic Oncology Services </font><font style="display: inline;">at</font><font style="display: inline;"> &nbsp;U</font><font style="display: inline;">niversity of California</font><font style="display: inline;"> Irvine Healthcare</font><font style="display: inline;">, were published in </font><font style="display: inline;font-style:italic;">Gynecologic Oncology</font><font style="display: inline;">. The study evaluated OVA1 diagnostic performance in a population of 494 evaluable patients who underwent surgery for an </font><font style="display: inline;">ovarian </font><font style="display: inline;">adnexal mass by a non-gynecologic oncologist. Like the earlier OVA1 validation study, this was a prospective, multi-center study of consecutively enrolled, eligible subjects coordinated through 27 sites across the </font><font style="display: inline;">United States</font><font style="display: inline;">. In the OVA500 study, adnexal surgery patients were only enrolled from non-gynecologic oncology caregivers. As a result, the patient population in this study more </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">5</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">closely resembled the intended use population for routine OVA1 testing</font><font style="display: inline;">:</font><font style="display: inline;"> women aged 18 years or older, with an adnexal mass requiring surgery</font><font style="display: inline;">,</font><font style="display: inline;"> but not yet referred to</font><font style="display: inline;"> &nbsp;a</font><font style="display: inline;"> gynecologic oncologist, and </font><font style="display: inline;">for</font><font style="display: inline;"> which the mass was determined to be benign or malignant </font><font style="display: inline;">following</font><font style="display: inline;"> enrollment</font><font style="display: inline;"> in the study</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">O</font><font style="display: inline;">f the 27 sites in each study, only 10 were common to both</font><font style="display: inline;"> studies</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">Therefore</font><font style="display: inline;">, the two studies </font><font style="display: inline;">collectively </font><font style="display: inline;">evaluated 1,024 eligible subjects at a total of 44 sites. Despite difference</font><font style="display: inline;">s</font><font style="display: inline;"> in population and the number of sites</font><font style="display: inline;"> in the two studies</font><font style="display: inline;">, the sensitivity of OVA1 added to clinical impression (also called OVA1 dual assessment) was identical, at 95.7% (88/92). </font><font style="display: inline;">O</font><font style="display: inline;">verall prevalence of malignancy in the OVA500 study </font><font style="display: inline;">was 18.6% overall (92/494) and 11.2% (31/277) in premenopausal surgery patients. Th</font><font style="display: inline;">ese</font><font style="display: inline;"> malignancy rate</font><font style="display: inline;">s</font><font style="display: inline;"> &nbsp;w</font><font style="display: inline;">ere</font><font style="display: inline;"> lower </font><font style="display: inline;">than the 31.2% (161/516) </font><font style="display: inline;">found </font><font style="display: inline;">previously in the earlier OVA1 validation study. This difference </font><font style="display: inline;">is likely</font><font style="display: inline;"> explained by the exclusion of subjects enrolled by gynecologic oncologist</font><font style="display: inline;">s</font><font style="display: inline;">, a potentially malignancy-enriched subset of all adnexal mass surgeries. Even so, OVA1 sensitivity was 93.5% (29/31) in premenopausal subjects, with or without clinical assessment. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">NPV is another critical element of OVA1 performance in the context of a </font><font style="display: inline;">presurgical </font><font style="display: inline;">triage test</font><font style="display: inline;"> or referral to a gynecologic oncologist</font><font style="display: inline;">. In </font><font style="display: inline;">the </font><font style="display: inline;">OVA500</font><font style="display: inline;"> study</font><font style="display: inline;">, overall NPV of OVA1 dual assessment was 98.1% (204/208), higher than the 94.6% NPV found in the earlier validation study. In premenopausal subjects, where functional ovarian cysts are more common and gynecologists may elect to operate more frequently, the NPV of OVA1 with or without clinical assessment was 98.6%. In contrast, clinical assessment predicted just 73.9% of malignancies overall, and only 64.5% of premenopausal malignancies. Together, the differential sensitivity and high NPV of OVA1 strongly confirmed previous findings</font><font style="display: inline;"> that</font><font style="display: inline;"> support the clinical utility </font><font style="display: inline;">of OVA1 </font><font style="display: inline;">in the presurgical triage of patients </font><font style="display: inline;">scheduled for</font><font style="display: inline;"> adnexal mass surgery. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">An important</font><font style="display: inline;"> additional finding related to medical necessity was the detection of early stage malignancies, since stage I cancers </font><font style="display: inline;">have a</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">90-95% </font><font style="display: inline;">5-year survival rate</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">if appropriately operated and treated. Of the 92 malignancies in OVA500, 35 were early stage and 28 were stage I</font><font style="display: inline;">;</font><font style="display: inline;"> 38.0% and 30.4% of all malignancies, respectively. OVA1 standalone sensitivity in stratifying patients as high-risk was 91.4% (32/35) for all early stage and 89.3% (25/28) for stage I malignancies, respectively. Comparatively, CA</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">125-II sensitivity was 65.7% (23/35) for all early stage and 64.3% (18/28) for stage I malignancies</font><font style="display: inline;">, respectively</font><font style="display: inline;">. The success rate of OVA1 classifying a benign mass as low risk, although of secondary importance (considering surgery will be performed regardless), was also measured in the OVA500 study. This statistic (specificity) was 53.5% (215/402) overall, and in premenopausal patients was 61.4% (151/246). Overall, the results strongly and independently confirmed the value of OVA1 in </font><font style="display: inline;">the presurgical risk assessment for ovarian cancer and </font><font style="display: inline;">the </font><font style="display: inline;">appropriate triage of women with adnexal masses, even in premenopausal women and </font><font style="display: inline;">in </font><font style="display: inline;">masses that had early stage cancers</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In May 2013, the SGO issued a position statement on OVA1.&nbsp;This second SGO statement on OVA1 since its FDA clearance in 2009 represent</font><font style="display: inline;font-size:10pt;">ed</font><font style="display: inline;font-size:10pt;"> another significant step toward acceptance of OVA1 as the standard of care for presurgically evaluating the risk of ovarian cancer in women with adnexal masses.&nbsp;The statement, titled &#x201C;Multiplex Serum Testing for Women with Pelvic Mass&#x201D;, reads: </font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#x201C;Blood levels of five proteins in women with a known ovarian mass have been reported to change when ovarian cancer is present. Tests measuring these proteins may be useful in identifying women who should be referred to a gynecologic oncologist. Recent data have suggested that such tests, along with physician clinical assessment, may improve detection rates of malignancies among women with pelvic masses planning surgery.[1],[2] Results from such tests should not be interpreted independently, nor be used in place of a physician&#x2019;s clinical assessment. Physicians are strongly encouraged to reference the ACOG&#x2019;s 2011 Committee Opinion &#x201C;The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer&#x201D; to determine an appropriate care plan for their patients. It is important to note that no such test has been evaluated for use as, nor cleared by, the FDA as a screening tool for ovarian cancer. SGO does not formally endorse or promote any specific products or brands.&#x201D;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We believe the position statement does two things: </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp; &nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:13pt;"><p style="width:13pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Lists as references the publications of OVA1's two pivotal clinical studies, comprised of the original FDA validation study published in June 2011 and the OVA500 "intended use" study published in 2013. Together, this offers an extensive, peer-reviewed proof source for physicians and payers to assess OVA1's clinical performance and comparative medical benefits versus today's standard of care.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 31.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:13pt;"><p style="width:13pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Places OVA1 use in the context of current ACOG practice guidelines, where CA125 has been used off-label for many years to predict malignancy before surgery, although with inferior performance as compared to OVA1.</font></p></td></tr></table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">6</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-size:10pt;">In June 2013</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;"> a study was published in </font><font style="display: inline;font-style:italic;font-size:10pt;">Gynecologic Oncology</font><font style="display: inline;font-size:10pt;"> analyzing </font><font style="display: inline;font-size:10pt;">the medical records of 13,321 women with epithelial </font><font style="display: inline;font-size:10pt;">ovarian </font><font style="display: inline;font-size:10pt;">cancer, the most common type of ovarian cancer, diagnosed from 1999 to 2006 in California</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;"> [3]</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Led by Dr. Robert Bristow, this study demonstrated that o</font><font style="display: inline;font-size:10pt;">nly 37</font><font style="display: inline;font-size:10pt;">%</font><font style="display: inline;font-size:10pt;"> of these patients received treatment that adhered to </font><font style="display: inline;font-size:10pt;">care </font><font style="display: inline;font-size:10pt;">guidelines </font><font style="display: inline;font-size:10pt;">established </font><font style="display: inline;font-size:10pt;">by the </font><font style="display: inline;font-size:10pt;">National Comprehensive Cancer Network (&#x201C;</font><font style="display: inline;font-size:10pt;">NCCN</font><font style="display: inline;font-size:10pt;">&#x201D;)</font><font style="display: inline;font-size:10pt;">, an alliance of 23 major cancer centers with expert panels that analyze, research and recommend cancer treatments. </font><font style="display: inline;font-size:10pt;">The work, although initiated separately from any Vermillion-related work, points to a continuing need for better presurgical management of patients at risk for ovarian cancer.</font><font style="display: inline;font-size:10pt;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The study </font><font style="display: inline;font-size:10pt;">also </font><font style="display: inline;font-size:10pt;">found that surgeons who operated on 10 or more women </font><font style="display: inline;font-size:10pt;">per</font><font style="display: inline;font-size:10pt;"> year for ovarian cancer, and hospitals that treated 20 or more </font><font style="display: inline;font-size:10pt;">women </font><font style="display: inline;font-size:10pt;">a year</font><font style="display: inline;font-size:10pt;"> for ovarian cancer</font><font style="display: inline;font-size:10pt;">, were more likely to adhere to NCCN guidelines and their patients lived longer. Among women with advanced disease &#x2014; the stage at which ovarian cancer is usually first found &#x2014; 35</font><font style="display: inline;font-size:10pt;">%</font><font style="display: inline;font-size:10pt;"> survived at least five years if their care met the guidelines, compared with 25</font><font style="display: inline;font-size:10pt;">%</font><font style="display: inline;font-size:10pt;"> of those whose care fell short.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Results of this</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">study w</font><font style="display: inline;font-size:10pt;">ere</font><font style="display: inline;font-size:10pt;"> featured on the front page of </font><font style="display: inline;font-style:italic;font-size:10pt;">The </font><font style="display: inline;font-style:italic;font-size:10pt;">New York Times</font><font style="display: inline;font-size:10pt;"> under the headline, "Widespread Flaws Found in Ovarian Cancer Treatment." According to Dr. Bristow, principal investigator of the study, &#x201C;If we could just make sure that women get to the people who are trained to take care of them, the impact would be much greater than that of any new chemotherapy drug or biological agent.&#x201D; (NY Times, March 11, 2013, Denise Grady)</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In November</font><font style="display: inline;font-size:10pt;"> 2013, we announced that a new study of OVA1 clinical performance in the presurgical detection of ovarian cancer, entitled &#x201C;Clinical Performance of a Multivariate Index Assay For Detecting Early-Stage Ovarian Cancer&#x201D; was published in </font><font style="display: inline;font-style:italic;font-size:10pt;">The American Journal of Obstetrics &amp;&nbsp;Gynecology</font><font style="display: inline;font-size:10pt;">.[4] Co-authored by Dr. Robert E. Bristow (</font><font style="display: inline;color:#000000;font-size:10pt;">University of California</font><font style="display: inline;font-size:10pt;"> Irvine Healthcare) and Dr. Frederick R. Ueland (University of Kentucky), the new analysis focused on presurgical detection of early-stage ovarian cancer among 1,016 ovarian mass surgery patients in two previous pivotal trials conducted in 2007 and 2012. The study compared OVA1 performance in early-stage ovarian cancer to commonly used cancer risk assessment protocols: overall clinical assessment, the CA125 biomarker or modified-American College of Obstetricians and Gynecologists guidelines for evaluation of suspicious pelvic masses. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In a statement regarding this new study, Dr. Bristow stated, &#x201C;Early-stage ovarian cancer constitutes an important opportunity to improve survival and care for this most deadly gynecologic cancer. However, as evidenced by recent studies, most ovarian cancer patients fail to be referred to the doctors and hospitals best equipped to treat them, resulting in unfortunate consequences. Our new study demonstrates OVA1&#x2019;s ability to detect the majority of all early-stage ovarian cancers prior to surgery and thereby aid in appropriately involving a gynecologic oncologist in their care. Even among premenopausal patients where primary ovarian cancer prevalence was just 15%, clinical assessment with OVA1 detected stage I ovarian cancer with almost 90% sensitivity. This is a very encouraging development for the diagnosis and treatment of ovarian cancer.&#x201D; </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Also in November</font><font style="display: inline;font-size:10pt;"> 2013, we announced that a</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;">clinical study published in </font><font style="display: inline;font-style:italic;font-size:10pt;">The American Journal of Obstetrics &amp; Gynecology </font><font style="display: inline;font-size:10pt;">reported superior sensitivity of OVA1 for presurgical triage of ovarian cancer, compared with commonly used risk assessment methods.</font><font style="display: inline;font-size:10pt;">[5]</font><font style="display: inline;font-weight:bold;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">The study compared OVA1 performance to benchmark triage methods, within a combined cohort of 770 ovarian mass surgery patients (including 164 malignancies) from two independent but related OVA1 pivotal trials conducted in 2007 and 2012. The study also compared the actual rate of patient referral from non-specialist physicians to gynecologic oncologists with rates predicted from clinical assessment, OVA1, CA125 or from the modified-American College of Obstetricians and Gynecologists guidelines. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Dr. Robert Bristow, lead author of the study, commented: &#x201C;Despite widely endorsed treatment standards published by the National Comprehensive Cancer Network, several studies published earlier this year show that only a minority of ovarian cancer patients actually receive treatment by the doctors and hospitals best equipped to care for them. Our new publication shows that the FDA-cleared OVA1 test achieves significantly higher sensitivity than two commonly used methods. And despite lower specificity, the referral rates predicted by OVA1 were roughly comparable to actual clinical practice.&#x201D; </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">I</font><font style="display: inline;font-size:10pt;">n March 2014, we announced that a </font><font style="display: inline;font-size:10pt;">study of OVA1 clinical performance, titled "The Effect of Ovarian Imaging on the Clinical Interpretation of a Multivariate Index Assay," </font><font style="display: inline;font-size:10pt;">was</font><font style="display: inline;font-size:10pt;"> released as an online advance publication of </font><font style="display: inline;font-style:italic;font-size:10pt;">The American Journal of Obstetrics &amp; Gynecology</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;"> The study examines the relationship between two commonly used imaging methods &#x2013; ultrasound (US) and computed tomography (CT) &#x2013; and the OVA1 test result, in assessing the risk of ovarian cancer among patients planning surgery for an ovarian mass. </font><font style="display: inline;font-size:10pt;">We view this study as an initial proof of concept for </font><font style="display: inline;font-size:10pt;">our </font><font style="display: inline;font-size:10pt;">planned </font><font style="display: inline;font-size:10pt;">OvaX</font><font style="display: inline;font-size:10pt;"> products.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">"This new study advances our understanding of how OVA1 and imaging work together in the presurgical assessment of ovarian cancer risk," said study co-author </font><font style="display: inline;font-size:10pt;">Fred Ueland</font><font style="display: inline;font-size:10pt;">, M.D., associate professor of gynecologic oncology at the </font><font style="display: inline;font-size:10pt;">University of Kentucky's</font><font style="display: inline;font-size:10pt;"> Markey Cancer Center. "This is important for two reasons. First, adding OVA1 reduced the number of ovarian cancers missed with imaging alone, by 85</font><font style="display: inline;font-size:10pt;">-</font><font style="display: inline;font-size:10pt;">90</font><font style="display: inline;font-size:10pt;">%</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-weight:bold;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Recent publications have reinforced that the first surgery is an important opportunity to improve ovarian cancer survival by ensuring that cancers are detected earlier and that they are operated on by the most experienced specialists. Second, this study provides new evidence of how menopausal status, imaging and OVA1 score may interrelate."</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">7</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-size:10pt;">Dr. </font><font style="display: inline;font-size:10pt;">Scott Goodrich</font><font style="display: inline;font-size:10pt;"> of the </font><font style="display: inline;font-size:10pt;">University of Kentucky</font><font style="display: inline;font-size:10pt;"> led the study in collaboration with colleagues Drs. </font><font style="display: inline;font-size:10pt;">Fred Ueland</font><font style="display: inline;font-size:10pt;"> and </font><font style="display: inline;font-size:10pt;">Rachel Ware Miller</font><font style="display: inline;font-size:10pt;">. The authors compared the performance of each imaging method alone, to the performance of OVA1 alone (for risk stratification), as well as in combination with OVA1. In addition, the authors presented logistic regression models showing how menopausal status, high- or low-risk imaging and OVA1 score interact in the assessment of ovarian cancer risk. The researchers concluded that "serum biomarkers and imaging are a complementary set of clinica</font><font style="display: inline;font-size:10pt;">l tools and that when the OVA1</font><font style="display: inline;font-size:10pt;"> score is further stratified by imaging risk and menopausal status, there is a better understanding of the clinical risk of ovarian malignancy."</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:28.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:255.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:255.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In December</font><font style="display: inline;font-size:10pt;"> 2015, </font><font style="display: inline;font-size:10pt;">results from a cost-effectiveness analysis study </font><font style="display: inline;font-size:10pt;">were</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">published in the peer reviewed journal, </font><font style="font-style:italic;display: inline;font-size:10pt;">Current Medical Research &amp; Opinion</font><font style="display: inline;font-size:10pt;">. The study was co-authored by Dr. Robert E. Bristow and Dr. Gareth K. Forde, clinicians at the University of California at Irvine, and Dr. John Hornberger, a leading health economist at Stanford University School of Medicine. The study, entitled &#x201C;Cost Effectiveness Analysis of a Multivariate Index Assay compared to Modified ACOG Criteria and CA-125 in the Triage of Women with Adnexal Masses&#x201D;, compared the cost-effectiveness of triaging ovarian masses using OVA1 versus two important clinical benchmarks: the CA-125 biomarker and the modified ACOG (American College of Obstetricians and Gynecologists) guideline for ovarian cancer risk assessment (&#x201C;mod-ACOG&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Study endpoints included treatment costs, quality-adjusted life-years (&#x201C;QALYs&#x201D;) and incremental cost-effectiveness ratio (&#x201C;ICER&#x201D;). The health economic model utilized OVA1 performance data from the OVA500 prospective trial, published survival, cost and QALY parameters, and a best-practice patient management decision tree. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Several important health economic and quality outcome conclusions were reported in the study:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Use of OVA1 resulted in fewer projected re-operations and pre-treatment CT scans versus CA 125-II or mod-ACOG</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">,</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">OVA1 was QALY-increasing and cost-effective relative to CA 125-II or mod-ACOG</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">,</font></p></td></tr></table></div>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">ICERs of $12,189/QALY and $35,094/QALY were calculated </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">for OVA1 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">versus CA 125-II and mod-ACOG, respectively</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> resulting in a &#x201C;cost-effective&#x201D; outcome based on the $50,000 threshold</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">, and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Relative to the best-practice mod-ACOG benchmark, OVA1 projected an annual increase in patient survival and QALY in excess of 1,000 years, when the surgical cohort was projected to national annual adnexal mass surgeries including about 22,000 new cases of ovarian cancer</font><font style="display: inline;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:CLNCM M+ Times;color:#000000;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">In April 2016, we announced the publication of the first clinical utility data demonstrating that identification of high-risk patients using OVA1 prior to surgery resulted in referral of nearly all patients who had primary ovarian malignancies to gynecologic oncologists.&nbsp;The study, en</font><font style="display: inline;font-size:10pt;color:#000000;">titled &#x201C;The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients,&#x201D; was published in the June 2016 issue of the peer-reviewed journal, </font><font style="font-style:italic;display: inline;font-size:10pt;color:#000000;">Current Medical Research &amp; Opinion</font><font style="display: inline;font-size:10pt;color:#000000;">.</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">The study surveyed physicians who frequently used OVA1, and identified 122 patients who underwent surgery for a pelvic mass after a high-risk OVA1 score was reported. Of these, 65 had a primary ovarian malignancy, while the remainder were benign or had a metastatic cancer of non-ovarian origin. Pre-surgical involvement of a gynecologic oncologist was documented, including referral, consultation or availability on stand-by; and the specialty of the surgeon who performed the adnexal surgery was also recorded. </font><font style="display: inline;font-size:10pt;color:#000000;">In this cohort, 80% of the patients were referred to a gynecologic oncologist, and an additional 9% had one available if needed in surgery.&nbsp;&nbsp;94% of the initial surgeries were performed by gynecologic oncologists.&nbsp;&nbsp;&nbsp;Prior studies in the literature show a 33-60% referral rate in ovarian cancer patients.&nbsp;&nbsp;This is significant because the NCCN guidelines recommend that all patients with ovarian cancer undergo surgery by a gynecologic oncologist and studies have documented that treatment by a gynecologic oncologist leads to improved outcome</font><font style="display: inline;color:#000000;font-size:10pt;">s.&nbsp;&nbsp;The surveys also documented 48% of the primary ovarian malignancies associated with elevated risk OVA1 scores were stage I or II, supporting the clinical validation of OVA1 in detection of early stage ovarian cancer.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">In July 2016, t</font><font style="display: inline;font-size:10pt;color:#000000;">he study on the clinical validation of Overa (MIA2G in peer review literature) was published in the American Journal of Obstetrics &amp; Gynecology</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">[6]. </font><font style="display: inline;font-size:10pt;color:#000000;">The data show significant improvement in Overa specificity compared to OVA1, while maintaining strong sensitivity (92% for OVA1 in a 2013 study). </font><font style="display: inline;font-size:10pt;color:#000000;">We received FDA clearance for Overa </font><font style="display: inline;font-size:10pt;color:#000000;">i</font><font style="display: inline;font-size:10pt;color:#000000;">n March 2016 and </font><font style="display: inline;font-size:10pt;color:#000000;">launch</font><font style="display: inline;font-size:10pt;color:#000000;">ed</font><font style="display: inline;font-size:10pt;color:#000000;"> Overa </font><font style="display: inline;font-size:10pt;color:#000000;">on a</font><font style="display: inline;font-size:10pt;color:#000000;"> targeted</font><font style="display: inline;font-size:10pt;color:#000000;"> basis </font><font style="display: inline;font-size:10pt;color:#000000;">in </font><font style="display: inline;font-size:10pt;color:#000000;">October </font><font style="display: inline;font-size:10pt;color:#000000;">2016</font><font style="display: inline;font-size:10pt;color:#000000;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">8</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font><font style="display: inline;">Highlights of the </font><font style="display: inline;">publication</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">are as follows:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:34.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #D9D9D9;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">+</font></p>
				</td>
				<td valign="middle" style="width:15.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #D9D9D9;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #D9D9D9;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #D9D9D9;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #D9D9D9;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:34.62%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Validation Study</font><font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">&#x2020;</font><font style="display: inline;color:#000000;"> (N=493)</font></p>
				</td>
				<td valign="middle" style="width:15.38%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">OVA1</font></p>
				</td>
				<td valign="middle" style="width:16.34%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Overa</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(MIA2G)</font></p>
				</td>
				<td valign="middle" style="width:16.34%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Variance</font></p>
				</td>
				<td valign="middle" style="width:17.30%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">% Variance</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.62%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 8.1pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Sensitivity</font></p>
				</td>
				<td colspan="4" valign="middle" style="width:65.38%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">n.s. (not significantly different)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.62%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 8.1pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Specificity</font></p>
				</td>
				<td valign="middle" style="width:15.38%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">53.6%</font></p>
				</td>
				<td valign="middle" style="width:16.34%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">69.1%</font></p>
				</td>
				<td valign="middle" style="width:16.34%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">+1</font><font style="display: inline;color:#000000;">5</font><font style="display: inline;">.5%*</font></p>
				</td>
				<td valign="middle" style="width:17.30%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">+28.9%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.62%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 8.1pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Positive predictive value</font></p>
				</td>
				<td valign="middle" style="width:15.38%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">31.4%</font></p>
				</td>
				<td valign="middle" style="width:16.34%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">40.4%</font></p>
				</td>
				<td valign="middle" style="width:16.34%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">+9.0%*</font></p>
				</td>
				<td valign="middle" style="width:17.30%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">+28.7%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.62%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 8.1pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Negative predictive value</font></p>
				</td>
				<td colspan="4" valign="middle" style="width:65.38%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">n.s. (not significantly different)</font><font style="display: inline;color:#000000;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.62%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 8.1pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Overall clinical accuracy</font><font style="display: inline;font-weight:bold;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">&#x2020;</font></p>
				</td>
				<td valign="middle" style="width:15.38%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">60.9%</font></p>
				</td>
				<td valign="middle" style="width:16.34%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">73.2%</font></p>
				</td>
				<td valign="middle" style="width:16.34%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">+12.3%</font></p>
				</td>
				<td valign="middle" style="width:17.30%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">+20.2%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-family:Calibri;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">&#x2020;</font><font style="display: inline;color:#000000;">Risk stratification performance, for analytical purposes only; OVA1/Overa are not standalone diagnostic tests</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">*</font><font style="display: inline;color:#000000;">Statistically significant difference (p&lt;0.001); </font><font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">n.s.</font><font style="display: inline;color:#000000;"> Difference not statistically significant (p&#x2265;0.05)</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">I</font><font style="display: inline;color:#000000;font-size:10pt;">n March 2017, we announced the acceptance for publication of the original research titled, </font><font style="display: inline;color:#000000;font-size:10pt;">&#x201C;</font><font style="display: inline;color:#000000;font-size:10pt;">Evaluation of a Validated Biomarker Test in Combination </font><font style="display: inline;color:#000000;font-size:10pt;">w</font><font style="display: inline;color:#000000;font-size:10pt;">ith </font><font style="display: inline;color:#000000;font-size:10pt;">a Symptom Index (&#x201C;SI&#x201D;) to Predict Ovarian Malignancy. In a 2016 study performed with 218 patients who presented with pelvic masses, the combination of SI and OVA1 showed a sensitivity to detect primary ovarian malignancy of 100%, detecting both early and late stage cancers better than either SI or OVA1 alone. Additionally, the negative predictive value of SI and OVA1 combined was also 100%, indicating that all women that tested negative for both tests were certain not to have a primary ovarian malignancy</font><font style="display: inline;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On November 16, 2017, we announced the acceptance and publication of a novel paper, &#x201C;</font><font style="display: inline;color:#000000;font-size:10pt;text-decoration:underline;">Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers</font><font style="display: inline;color:#000000;font-size:10pt;">&#x201D; in the journal </font><font style="font-style:italic;display: inline;font-weight:bold;color:#000000;font-size:10pt;">American Health and Drug Benefits</font><font style="font-weight:bold;display: inline;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:5pt 0pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The paper details the base case of a budget impact model that dynamically tracks the effect of OVA1 adoption in lieu of CA125 in the appropriate patient population on overall cost, both at a plan and per member per month (</font><font style="display: inline;color:#000000;font-size:10pt;">&#x201C;</font><font style="display: inline;color:#000000;font-size:10pt;">PMPM</font><font style="display: inline;color:#000000;font-size:10pt;">&#x201D;</font><font style="display: inline;color:#000000;font-size:10pt;">) level. Claims data from a total of over 92,000 health plan members, comprising over 48,000 commercially insured members and 44,000 Medicare beneficiaries, were used in the development of the model. Sensitivity analysis revealed potential savings of up to $0.17 PMPM for commercially insured patients and up to $0.05 </font><font style="display: inline;color:#000000;font-size:10pt;">PMPM </font><font style="display: inline;color:#000000;font-size:10pt;">for Medicare beneficiaries. These results of the budget impact model base case support the use of OVA1 instead of CA125, by indicating that cost-savings can be achieved, while reaping the clinical benefits of improved diagnostic accuracy, early disease detection, and reductions in multiple, and possibly non-medically necessary, referrals to gynecologic oncologists.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Current and former academic and research institutions that we have or have had collaborations with include the Johns Hopkins University S</font><font style="display: inline;">chool of Medicine</font><font style="display: inline;"> (&#x201C;JHU&#x201D;)</font><font style="display: inline;">; the University of Texas M.D. Anderson Cancer Center</font><font style="display: inline;"> (&#x201C;M.D. Anderson&#x201D;)</font><font style="display: inline;">; University College London</font><font style="display: inline;"> (&#x201C;UCL&#x201D;)</font><font style="display: inline;">; the University of Texas Medical Branch</font><font style="display: inline;"> (&#x201C;UTMB&#x201D;)</font><font style="display: inline;">; the Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet, Copenhagen University Hospital</font><font style="display: inline;"> (&#x201C;Rigshospitalet&#x201D;)</font><font style="display: inline;">; the Ohio State University </font><font style="display: inline;">Office of Sponsored Programs</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(&#x201C;OSU&#x201D;)</font><font style="display: inline;">; Stanford; </font><font style="display: inline;">the University of Kentucky (&#x201C;UK&#x201D;)</font><font style="display: inline;">,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">UC </font><font style="display: inline;">Irvine</font><font style="display: inline;"> and Southern California Permanente Medical Group (&#x201C;SCPMG&#x201D;)</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:5pt 0pt 9pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">[1] Bristow RE, et al. 2013. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol 128: 252&#x2013;259. </font>
		</p>
		<p style="margin:5pt 0pt 9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">[2] Ueland FR, et al. 2011. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 117:1289-1297.</font>
		</p>
		<p style="margin:5pt 0pt 9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">[3] Bristow, RE et al. 2013. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol 121:1226-1234.</font>
		</p>
		<p style="margin:5pt 0pt 9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">[4] Longoria TC, et al. 2013. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. Am J Obstet Gynecol Jan;210(1):78.e1-9.</font>
		</p>
		<p style="margin:5pt 0pt 9pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">[5] Bristow, RE, et al. 2013. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. Am J Obstet Gynecol Dec;209(6):581.e1-8.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">[6] Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, Zhang Z, Wolf J. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. Am J Obstet Gynecol. 2016 Jul;215(1):82.e1-82.e11</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">9</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">The </font><font style="display: inline;font-weight:bold;">Diagnostic </font><font style="display: inline;font-weight:bold;">M</font><font style="display: inline;font-weight:bold;">arket</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The economics of healthcare demand </font><font style="display: inline;">effective and efficient</font><font style="display: inline;"> allocation of resources </font><font style="display: inline;">which </font><font style="display: inline;">can be </font><font style="display: inline;">accomplished </font><font style="display: inline;">through disease prevention, early detection of disease leading to early intervention, and diagnostic tools that can triage patients to more appropriate therapy and intervention. </font><font style="display: inline;">In September 2017, </font><font style="display: inline;">Allied Market Research, a market research</font><font style="display: inline;"> and business consulting partnership</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">published a study </font><font style="display: inline;">that </font><font style="display: inline;">forecasts </font><font style="display: inline;">IVD market revenue will reach $</font><font style="display: inline;">84 </font><font style="display: inline;">billion by 202</font><font style="display: inline;">3.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">We have</font><font style="display: inline;"> chosen to concentrate </font><font style="display: inline;">our business focus </font><font style="display: inline;">in the areas of oncology and women&#x2019;s health</font><font style="display: inline;"> where we have established strong key opinion leader</font><font style="display: inline;">s, and</font><font style="display: inline;"> provider and patient relationships</font><font style="display: inline;">. Demographic trends suggest that, as the population ages, the burden from </font><font style="display: inline;">gynecologic </font><font style="display: inline;">diseases, including </font><font style="display: inline;">cancers</font><font style="display: inline;">,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">will increase and the demand for quality diagnostic, prognostic and predictive tests will </font><font style="display: inline;">escalate</font><font style="display: inline;">. In addition, the areas</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of oncology and women&#x2019;s health</font><font style="display: inline;"> generally lack quality diagnostic tests and, therefore, we believe patient outcomes can be significantly improved by the development of novel diagnostic tests</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our</font><font style="display: inline;"> focus on translational </font><font style="display: inline;">biomarkers</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and informatics </font><font style="display: inline;">enables </font><font style="display: inline;">us</font><font style="display: inline;"> to address the market for novel diagnostic tests that simultaneously measure multiple biomarkers. A biomarker is a </font><font style="display: inline;">biomolecule or variant biomolecule</font><font style="display: inline;"> that is present at </font><font style="display: inline;">measurably </font><font style="display: inline;">greater or lesser concentrations in a disease state versus a normal condition. Conventional protein tests measure a single protein biomarker whereas most diseases are complex. We believe that efforts to diagnose cancer and other complex diseases have failed in large part because the disease is heterogeneous at the causative level (i.e.</font><font style="display: inline;">,</font><font style="display: inline;"> most diseases can be traced to multiple potential etiologies) and at the human response level (i.e.</font><font style="display: inline;">,</font><font style="display: inline;"> each individual afflicted with a given disease can respond to that ailment in a specific manner). </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Consequently, measuring a single biomarker when multiple biomarkers may be altered in a complex disease is unlikely to provide meaningful information about the disease state. We believe that our approach of monitoring and combining multiple</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">biomarkers using a variety of analytical techniques </font><font style="display: inline;">has allowed and </font><font style="display: inline;">will </font><font style="display: inline;">continue to </font><font style="display: inline;">allow </font><font style="display: inline;">us</font><font style="display: inline;"> to create diagnostic tests with sufficient sensitivity and specificity about the disease state to aid the physician considering treatment options for patients with complex diseases.</font><font style="display: inline;"> Such assays are commonly referred to as IVD</font><font style="display: inline;">MIA (</font><font style="display: inline;">also known as </font><font style="display: inline;">In Vitro Diagnostic Multiv</font><font style="display: inline;">ariate Index Assays),</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and often utilize advanced algorithms based on logistic regression, pattern recognition and the like. Often, IVDMIA algorithms are non-intuitive, and therefore require rigorous clinical validation and error modeling. Vermillion and its collaborators are </font><font style="display: inline;">considered </font><font style="display: inline;">expert</font><font style="display: inline;">s</font><font style="display: inline;"> in these areas and</font><font style="display: inline;">,</font><font style="display: inline;"> in the case of OVA1, presented both the clinical validation and error modeling </font><font style="display: inline;">needed </font><font style="display: inline;">in order to gain 510(k) clearance of OVA1 as an IVD software device.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Ovarian Cancer</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Background</font><font style="display: inline;font-weight:bold;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Commonly known as the &#x201C;silent killer</font><font style="display: inline;">,</font><font style="display: inline;">&#x201D; ovarian cancer leads to </font><font style="display: inline;">approximately</font><font style="display: inline;"> 14</font><font style="display: inline;">,000 deaths each year in the United States. </font><font style="display: inline;">As of early</font><font style="display: inline;"> 201</font><font style="display: inline;">8</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">The American Cancer Society (</font><font style="display: inline;">&#x201C;</font><font style="display: inline;">ACS</font><font style="display: inline;">&#x201D;</font><font style="display: inline;">) estimate</font><font style="display: inline;">d</font><font style="display: inline;"> that </font><font style="display: inline;">over</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">2</font><font style="display: inline;">2</font><font style="display: inline;">,000 new ovarian cancer cases </font><font style="display: inline;">will be </font><font style="display: inline;">diagnosed, with </font><font style="display: inline;">the majority of</font><font style="display: inline;"> patients </font><font style="display: inline;">diagnosed </font><font style="display: inline;">in the late stages of the disease in which the cancer has spread beyond the ovary. Unfortunately, ovarian cancer patients in the late stages of the disease have a poor prognosis, which leads to high mortality rates. </font><font style="display: inline;">According to the A</font><font style="display: inline;">CS</font><font style="display: inline;">, when ovarian cancer is diagnosed at its earliest stage, </font><font style="display: inline;">Stage 1A,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the patient has a 5-year survival rate of </font><font style="display: inline;">9</font><font style="display: inline;">4</font><font style="display: inline;">%. Ovarian cancer patients have up to a 90% </font><font style="display: inline;">5-year survival</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">rate following surgery and/or chemotherapy if detected in stage 1. However, only </font><font style="display: inline;">15</font><font style="display: inline;">% of ovarian cancer patients are diagnosed before the tumor has spread outside the ovary. For ovarian cancer patients diagnosed in the late-stages of the disease, the 5-year survival rate falls to </font><font style="display: inline;">as low as </font><font style="display: inline;">1</font><font style="display: inline;">7</font><font style="display: inline;">%.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">While the diagnosis of ovarian cancer in its earliest stages greatly increases the likelihood of </font><font style="display: inline;">long-term </font><font style="display: inline;">survival from the disease, another factor that predicts </font><font style="display: inline;">clinical outcome</font><font style="display: inline;">s</font><font style="display: inline;"> from ovarian cancer is the specialized training of the surgeon who operates on the ovarian cancer patient. Numerous studies have demonstrated that treatment of malignant ovarian tumors by specialists such as gynecologic oncologists or at specialist medical centers improves outcomes for women with these </font><font style="display: inline;">tumors</font><font style="display: inline;">. Published guidelines from the SGO and the ACOG</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">recommend referral of women with malignant ovarian tumors to specialists. Unfortunately, </font><font style="display: inline;">we believe</font><font style="display: inline;"> only about one</font><font style="display: inline;">-</font><font style="display: inline;">third of women with these types of tumors are operated on by specialists, in part because of inadequate </font><font style="display: inline;">diagnostics</font><font style="display: inline;"> that can identify such malignancies with high sensitivity. Accordingly, </font><font style="display: inline;">there is a </font><font style="display: inline;">clinical need </font><font style="display: inline;">for</font><font style="display: inline;"> a diagnostic test that can provide adequate predictive value to stratify patients with a pelvic mass into those with a high risk of invasive ovarian cancer versus those with a low risk of ovarian cancer, which is essential for improving overall survival in patients with ovarian cancer. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Although adnexal </font><font style="display: inline;">masses </font><font style="display: inline;">are relatively common, malignant tumors </font><font style="display: inline;">are less so</font><font style="display: inline;">. Screening studies have indicated that the prevalence of </font><font style="display: inline;">simple ovarian cysts</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in women </font><font style="display: inline;">55 years </font><font style="display: inline;">of age and </font><font style="display: inline;">old</font><font style="display: inline;">er</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">can be as high as </font><font style="display: inline;">14</font><font style="display: inline;">%</font><font style="display: inline;">.</font><font style="display: inline;">[1]</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">A</font><font style="display: inline;">dnexal </font><font style="display: inline;">masses </font><font style="display: inline;">are thought to be even more common in premenopausal women, but there are more non-persistent, physiologic ovarian </font><font style="display: inline;">masses</font><font style="display: inline;"> in this demographic</font><font style="display: inline;"> group</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">For instance, in the University of Kentucky ovarian cancer screening project, the rate of postmenopausal women with persistently abnormal ultrasound findings requiring sur</font><font style="display: inline;">g</font><font style="display: inline;">ery was 1.4%.[2]&nbsp; </font><font style="display: inline;">According to </font><font style="display: inline;">2010</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">U</font><font style="display: inline;">.</font><font style="display: inline;">S</font><font style="display: inline;">.</font><font style="display: inline;"> census </font><font style="display: inline;">data, there are </font><font style="display: inline;">36.8</font><font style="display: inline;"> million women </font><font style="display: inline;">between </font><font style="display: inline;">the age</font><font style="display: inline;">s</font><font style="display: inline;"> of 50</font><font style="display: inline;"> and 70</font><font style="display: inline;"> in the U.S.</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">suggesting that </font><font style="display: inline;">there are </font><font style="display: inline;">more than </font><font style="display: inline;">500,000</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">suspicious </font><font style="display: inline;">adnexal masses in this segment alone.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">T</font><font style="display: inline;">hose that do require evaluation </font><font style="display: inline;">for</font><font style="display: inline;"> the likelihood </font><font style="display: inline;">for </font><font style="display: inline;">malignancy</font><font style="display: inline;"> could potentially benefit from the use of </font><font style="display: inline;">OVA1</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or</font><font style="display: inline;"> Overa</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The ACOG </font><font style="display: inline;">Ovarian Cancer Guidelines </font><font style="display: inline;">and the SGO guidelines help physicians evaluate adnexal </font><font style="display: inline;">masses </font><font style="display: inline;">for malignancy. These guidelines take into account menopausal status, CA125 levels, and physical and imaging findings. However, these guidelines </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">10</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">have notable shortcomings because of their reliance on </font><font style="display: inline;">diagnostics </font><font style="display: inline;">with certain weaknesses. Most notably, the CA125 blood test, which is cleared by the FDA only for monitoring for recurrence of ovarian cancer, is </font><font style="display: inline;">negative</font><font style="display: inline;"> in up to 50% of early stage ovarian cancer cases. Moreover, CA125 can be elevated in </font><font style="display: inline;">numerous conditions and </font><font style="display: inline;">diseases other than ovarian cancer, including benign ovarian </font><font style="display: inline;">masses</font><font style="display: inline;"> and endometriosis. These shortcomings limit the CA125 blood test&#x2019;s utility in distinguishing benign from malignant ovarian tumors or for use in detection of early stage ovarian cancer. Transvaginal ultrasound is another diagnostic modality used with patients with ovarian </font><font style="display: inline;">masses</font><font style="display: inline;">. Attempts at defining specific morphological criteria that can aid in a benign versus malignant diagnosis have led to the morphology index and the risk of malignancy index, with reports of 40-70% predictive value. However</font><font style="display: inline;">, ultrasound interpretation can be variable and dependent on the experience of the operator. Accordingly, the ACOG and SGO guidelines perform only modestly in identifying early stage ovarian cancer and malignancy in pre-menopausal women. Efforts to improve detection of cancer by lowering the cutoff for CA125 (the &#x201C;Modified ACOG/SGO Guidelines&#x201D;) provide only a modest benefit, since CA125 is absent in </font><font style="display: inline;">about 20%</font><font style="display: inline;"> of epithelial ovarian cancer </font><font style="display: inline;">cases </font><font style="display: inline;">and is poorly detected in early stage ovarian cancer</font><font style="display: inline;"> overall</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">[1] Greenlee RT, Kessel B, Williams CR, Riley TL, Ragard LR, Hartge P, Buys SS, Partridge EE, Reding DJ. Prevalence, incidence, and natural history of simple ovarian cysts among women &gt;55 years old in a large cancer screening trial. Am J Obstet Gynecol. 2010 Apr;202(4):373.e1-9.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">[2] van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007 May 1;109(9):1887-96.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Commercialization</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Commercialization </font><font style="display: inline;">through Quest Diagnostics </font><font style="display: inline;">started in 2010 </font><font style="display: inline;">and </font><font style="display: inline;">ended 2015. </font><font style="display: inline;">Starting in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">2014, w</font><font style="display: inline;">e offer</font><font style="display: inline;">ed</font><font style="display: inline;"> OVA1 </font><font style="display: inline;">via</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">ASPiRA LABS</font><font style="display: inline;"> as well</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">I</font><font style="display: inline;">n March 2015, </font><font style="display: inline;">we</font><font style="display: inline;"> entered into a new commercial agreement with Quest Diagnostics. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion&#x2019;s wholly-owned subsidiary, ASPiRA LABS. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Pursuant to this agreement as amended, </font><font style="display: inline;">Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens to ASPiRA LABS for testing through at least March 11, 201</font><font style="display: inline;">9</font><font style="display: inline;"> in exchange for a market value fee. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Per the terms of the agreement, </font><font style="display: inline;">we</font><font style="display: inline;"> will not offer to existing or future Quest Diagnostics customers CA 125-II or other tests that Quest Diagnostics offers.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Customers</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">In the United States, the IVD market can be segmented into three major groups: clinical reference laboratories, the largest of which are </font><font style="display: inline;">Quest Diagnostics</font><font style="display: inline;"> and Laboratory Corporation of America</font><font style="display: inline;">,</font><font style="display: inline;"> hospital laboratories</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">and physician offices. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">In 2015, </font><font style="display: inline;">our </font><font style="display: inline;">revenue </font><font style="display: inline;">was</font><font style="display: inline;"> generated through Quest Diagnostics and ASPiRA LABS</font><font style="display: inline;"> and</font><font style="display: inline;">,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">since </font><font style="display: inline;">2016</font><font style="display: inline;">,</font><font style="display: inline;"> solely through ASPiRA LABS</font><font style="display: inline;"> and ASPiRA IVD</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Both within and o</font><font style="display: inline;">utside the United States, laboratories may become customers, either directly with </font><font style="display: inline;">us</font><font style="display: inline;"> or via distribution rel</font><font style="display: inline;">ationships established between us</font><font style="display: inline;"> and authorized distributors. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Our</font><font style="display: inline;"> research and development efforts center on the discovery and validation of biomarkers and combinations of biomarkers that can be developed into diagnostic assays. </font><font style="display: inline;">We </font><font style="display: inline;">have done</font><font style="display: inline;"> this predominantly through collaborations </font><font style="display: inline;">we have</font><font style="display: inline;"> established with academic institutions such as JHU</font><font style="display: inline;"> and M.D. Anderson</font><font style="display: inline;"> as well as through contract research organizations such as PrecisionMed</font><font style="display: inline;">, Inc.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">In addition, we actively seek collaborations and initiate dialog with clinical academics, in order to generate publications, intellectual property or test development in broader areas of gynecologic oncology</font><font style="display: inline;"> and other gynecologic diseases</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Our research and development expenses were $</font><font style="display: inline;">837</font><font style="display: inline;">,000 and $</font><font style="display: inline;">2,172</font><font style="display: inline;">,000 for the years ended December 31, 201</font><font style="display: inline;">7</font><font style="display: inline;"> and 201</font><font style="display: inline;">6</font><font style="display: inline;">, respectively. </font><font style="display: inline;">This decrease was primarily due to the expiration of our collaboration agreement with JHU in March 2016 as well as lower personnel and </font><font style="display: inline;">personnel</font><font style="display: inline;">-</font><font style="display: inline;">related expenses due to the clearance of Overa in March 2016.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Also, in</font><font style="display: inline;"> October 2016, we began the collection of patient consents under IRB for collection and cataloguing of serum samples for future research purposes at a much lower cost.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Scientific Background</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Genes are the hereditary coding system of living organisms. Genes encode proteins that are responsible for cellular functions. The study of genes and their functions has led to the discovery of new targets for drug development. Industry sources estimate that, within the human genome, there are approximately 30,000 genes. Although the primary structure of a protein is determined by a gene, the active structure of a protein is frequently altered by interactions with additional genes or proteins. These subsequent modifications result in hundreds of thousands of different proteins. In addition, proteins may interact with one another to form complex structures that are ultimately responsible for cellular functions. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Genomics allows researchers to establish the relationship between gene activity and disease. However, many diseases are manifested not at the genetic level, but at the protein level. The complete structure of modified proteins cannot be determined by reference to the encoding gene alone. Thus, while genomics provides some information about diseases, it does not provide a full understanding of disease processes. </font><font style="display: inline;">We are</font><font style="display: inline;"> focused on converting advances in proteomics into clinically useful diagnostic tests.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">11</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;">Relationship Between Proteins and Diseases </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">The entire genetic content of any organism, known as its genome, is encoded in strands of deoxyribonucleic acid (&#x201C;DNA&#x201D;). Cells perform their normal biological functions through the genetic instructions encoded in their DNA, which results in the production of proteins. The process of producing proteins from DNA is known as gene expression or protein expression. Differences in living organisms result from variability in their genomes, which can affect the types of genes expressed and the levels of gene expression. Each cell of an organism expresses only approximately 10% to 20% of the genome. The type of cell determines which genes are expressed and the amount of a particular protein produced. For example, liver cells produce different proteins from those produced by cells found in the heart, lungs, skin, etc. Proteins play a crucial role in virtually all biological processes, including transportation and storage of energy, immune protection, generation and transmission of nerve impulses and control of growth. Diseases may be caused by a mutation of a gene that alters a protein directly or indirectly, or alters the level of protein expression. These alterations interrupt the normal balance of proteins and create disease symptoms. A protein biomarker is a protein or protein variant that is present in a greater or lesser amount in a disease state versus a normal condition. By studying changes in protein biomarkers, researchers may identify diseases prior to the appearance of physical symptoms. Historically, researchers discovered protein biomarkers as a byproduct of basic biological disease research, which resulted in the validation by researchers of approximately 200 protein biomarkers that are being used in commercially available clinical diagnostic products. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Limitations of Existing Diagnostic Approaches </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">The IVD industry manufactures and distributes products that are used to detect thousands of individual components present in human derived specimens. However, the vast majority of these assays are used specifically to identify single protein biomarkers. The development of new diagnostic products has been limited by the complexity of disease states, which may be caused or characterized by several or many proteins or post-translationally modified protein variants. Diagnostic assays that are limited to the detection of a single protein often have limitations in clinical specificity (true negatives) and sensitivity (true positives) due to the complex nature of many diseases and the inherent biological diversity among populations. Diagnostic products that are limited to the detection of a single protein may lack the ability to detect more complex diseases, and thus produce results that are unacceptable for practical use. The heterogeneity of disease and of the human response to disease often underlies the shortcoming of single biomarkers to diagnose and predict many diseases accurately. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Our</font><font style="display: inline;font-weight:bold;font-style:italic;"> Solution </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Our</font><font style="display: inline;"> studies</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in ovarian cancer have given </font><font style="display: inline;">us</font><font style="display: inline;"> a better understanding of both the disease pathophysiology and the host response. By using multiple biomarkers</font><font style="display: inline;"> rather than a single biomarker</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">we are</font><font style="display: inline;"> able to better characterize the disease and host response heterogeneity. In addition, by examining specific biomarkers </font><font style="display: inline;">and their variants</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(e.g.</font><font style="display: inline;">,</font><font style="display: inline;"> post-translational modifications</font><font style="display: inline;">)</font><font style="display: inline;">, we believe </font><font style="display: inline;">we</font><font style="display: inline;"> can improve </font><font style="display: inline;">sensitivity and specificity over traditional</font><font style="display: inline;"> diagnostic biomarkers because these </font><font style="display: inline;">biomarker combinations</font><font style="display: inline;"> reflect both the pathophysiology and host response. This is accomplished using novel </font><font style="display: inline;">biomarker panels</font><font style="display: inline;"> coupled with multivariate </font><font style="display: inline;">pattern recognition</font><font style="display: inline;"> software to identify </font><font style="display: inline;">IVDMIA algorithms</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">which can be commercialized as</font><font style="display: inline;"> disease-specific assays. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">We are</font><font style="display: inline;"> applying translational </font><font style="display: inline;">biomarker</font><font style="display: inline;"> research, </font><font style="display: inline;">algorithm </font><font style="display: inline;">development tools, and </font><font style="display: inline;">statistical error modeling </font><font style="display: inline;">methods to discover </font><font style="display: inline;">robust </font><font style="display: inline;">associations between </font><font style="display: inline;">biomarker panels</font><font style="display: inline;"> and </font><font style="display: inline;">clinically relevant </font><font style="display: inline;">disease</font><font style="display: inline;"> endpoint</font><font style="display: inline;">s. </font><font style="display: inline;">We</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">plan</font><font style="display: inline;"> to develop new </font><font style="display: inline;">IVDMIA algorithms and diagnostic</font><font style="display: inline;"> tests based on known and newly identified protein markers to help physicians </font><font style="display: inline;">better </font><font style="display: inline;">predict </font><font style="display: inline;">and manage disease and treatment, and thereby improve patient outcomes and overall health economic resource utilization.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Examples of diagnostic applications include, but are not limited to: asymptomatic population screening, early detection, triage to specialists, aid in diagnosis, prognosis or disease sub-classification, prediction or selection of therapy, monitoring of therapeutic response or residual disease, monitoring for recurrence or identification of appropriate fallback therapy or clinical trial eligibility.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">We </font><font style="display: inline;">anticipate </font><font style="display: inline;">partner</font><font style="display: inline;">ships</font><font style="display: inline;"> with leading scientific and clinical institutions who have active proteomic or genomic programs in the area of gynecologic cancers</font><font style="display: inline;">, or with relevant clinical trial interests,</font><font style="display: inline;"> with the goal of expanding our product portfolio with relevant solu</font><font style="display: inline;">tions to unmet medical needs in</font><font style="display: inline;"> women&#x2019;s health.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Addressing the Heterogeneity of Disease </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Our </font><font style="display: inline;">approach</font><font style="display: inline;"> is to create a diagnostics paradigm that is based on risk </font><font style="display: inline;">estimation</font><font style="display: inline;">, multiple-biomarker testing and information integration. This is based on the belief that </font><font style="display: inline;">cancer and other gynecologic</font><font style="display: inline;"> disease</font><font style="display: inline;">s</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">are</font><font style="display: inline;"> heterogeneous and, therefore, </font><font style="display: inline;">that </font><font style="display: inline;">relying on a single disease biomarker to provide a simple &#x201C;yes-no&#x201D; answer is likely to fail. We believe that efforts to diagnose cancer and other complex diseases have failed in large part because the disease is heterogeneous at the causative level, meaning that most diseases can be traced to multiple potential etiologies, and at the </font><font style="display: inline;">individual</font><font style="display: inline;"> response level, meaning that each individual afflicted with a given disease can respond to that ailment in a specific manner. Consequently, diagnosis, disease monitoring and treatment decisions can be challenging. This heterogeneity of disease and difference in human response to disease and/or treatment underlies the shortcomings of single biomarkers to predict and identify many diseases. A better understanding of heterogeneity of disease and human response is necessary for improved diagnosis and treatment of many diseases. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_1_371"></a><font style="display: inline;font-weight:bold;font-style:italic;">New Ovarian Cancer Indications</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">12</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">While our focus on supporting the commercialization of OVA1 is our primary priority, we also may e</font><font style="display: inline;">xten</font><font style="display: inline;">d</font><font style="display: inline;"> our ovarian cancer franchise beyond OVA1</font><font style="display: inline;">,</font><font style="display: inline;"> enabled by </font><font style="display: inline;">several factors:&nbsp; </font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">We </font><font style="display: inline;color:#000000;">received</font><font style="display: inline;color:#000000;"> FDA clearance </font><font style="display: inline;color:#000000;">of a product improvement to OVA1, known as Overa, i</font><font style="display: inline;color:#000000;">n March 2016</font><font style="display: inline;color:#000000;">;&nbsp; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">The collection of clinical samples from prospectively enrolled adnexal surgery patients enables further biomarker and bio-analytical research, both in detection of ovarian cancer and also markers and risk factors for other gynecologic diseases which present with similar signs and symptoms;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">We </font><font style="display: inline;color:#000000;">possess </font><font style="display: inline;color:#000000;">a large and growing portfolio of intellectual property, generated through collaborative research and licensing; </font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">We have</font><font style="display: inline;color:#000000;"> highly curated clinical samples, intellectual property and promising biomarker leads. These have the potential to further amplify our </font><font style="display: inline;color:#000000;">ovarian cancer diagnostic</font><font style="display: inline;color:#000000;"> efforts </font><font style="display: inline;color:#000000;">in the future</font><font style="display: inline;color:#000000;">; &nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">Clinical collaborations such as the independent clinical research program mentioned above typically include licensing options when valuable intellectual property or product opportunities result; </font><font style="display: inline;color:#000000;">and</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">Our</font><font style="display: inline;color:#000000;"> success in translating biomarkers into FDA-cleared, widely available commercial products creates increasing interest in licensing, co-marketing and/or acquisition of intellectual property and products from academics and technology providers.</font><font style="display: inline;color:#000000;"> We </font><font style="display: inline;color:#000000;">believe we </font><font style="display: inline;color:#000000;">are well-positioned in gynecologic health markets to launch new products developed, licensed, co-marketed or acquired by any of these routes.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Commercial Operations</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">We have</font><font style="display: inline;font-size:10pt;color:#000000;"> a commercial infrastructure, including sales and marketing </font><font style="display: inline;font-size:10pt;color:#000000;">and reimbursement </font><font style="display: inline;font-size:10pt;color:#000000;">expertise. </font><font style="display: inline;font-size:10pt;color:#000000;">We also operate a national CLIA </font><font style="display: inline;font-size:10pt;color:#000000;">certified clinical </font><font style="display: inline;font-size:10pt;color:#000000;">laboratory, ASPiRA </font><font style="display: inline;font-size:10pt;color:#000000;">LABS</font><font style="display: inline;font-size:10pt;color:#000000;">. &nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">Our </font><font style="display: inline;font-size:10pt;color:#000000;">sales representatives work to identify opportunities for </font><font style="display: inline;font-size:10pt;color:#000000;">educating general gynecologists and gynecologic oncologists on the </font><font style="display: inline;font-size:10pt;color:#000000;">benefits of </font><font style="display: inline;font-size:10pt;color:#000000;">OVA1</font><font style="display: inline;font-size:10pt;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">In February 2015, Vermillion received ISO 13485:2003 certification for our quality management system from the British Standards Institution (BSI), one of the world's leading certification bodies.</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">In March 2015, we announced that OVA1 was CE marked, a requirement for marketing the test in the European Union</font><font style="display: inline;color:#000000;font-size:10pt;">.</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">In October 2015, we announced registration of the CE mark for and clearance to market Overa in the European Union. </font><font style="display: inline;color:#000000;font-size:10pt;">We </font><font style="display: inline;color:#000000;font-size:10pt;">are</font><font style="display: inline;color:#000000;font-size:10pt;"> target</font><font style="display: inline;color:#000000;font-size:10pt;">ing</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">markets outside of the United States </font><font style="display: inline;color:#000000;font-size:10pt;">now that </font><font style="display: inline;color:#000000;font-size:10pt;">we have </font><font style="display: inline;font-size:10pt;color:#000000;">Overa cleared</font><font style="display: inline;font-size:10pt;color:#000000;"> on </font><font style="display: inline;font-size:10pt;color:#000000;">the Roche </font><font style="display: inline;font-size:10pt;color:#000000;">cobas</font><font style="display: inline;font-size:10pt;color:#000000;"> platform</font><font style="display: inline;font-size:10pt;color:#000000;">, which is</font><font style="display: inline;font-size:10pt;color:#000000;"> available globally. In 201</font><font style="display: inline;font-size:10pt;color:#000000;">6</font><font style="display: inline;font-size:10pt;color:#000000;">, we </font><font style="display: inline;font-size:10pt;color:#000000;">signed our first contracts with</font><font style="display: inline;font-size:10pt;color:#000000;"> distributors outside the</font><font style="display: inline;font-size:10pt;color:#000000;"> United States so that we </font><font style="display: inline;font-size:10pt;color:#000000;">could</font><font style="display: inline;font-size:10pt;color:#000000;"> begin marketing </font><font style="display: inline;font-size:10pt;color:#000000;">Overa and </font><font style="display: inline;font-size:10pt;color:#000000;">OVA1 outside the United States in 201</font><font style="display: inline;font-size:10pt;color:#000000;">7</font><font style="display: inline;font-size:10pt;color:#000000;">.</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Approximately </font><font style="display: inline;font-size:10pt;color:#000000;">8,575</font><font style="display: inline;font-size:10pt;color:#000000;"> OVA1 tests were performed in 201</font><font style="display: inline;font-size:10pt;color:#000000;">7</font><font style="display: inline;font-size:10pt;color:#000000;"> compared to </font><font style="display: inline;font-size:10pt;color:#000000;">9,125</font><font style="display: inline;font-size:10pt;color:#000000;"> in 201</font><font style="display: inline;font-size:10pt;color:#000000;">6</font><font style="display: inline;font-size:10pt;color:#000000;">,</font><font style="display: inline;font-size:10pt;color:#000000;"> with the decrease being attributed to </font><font style="display: inline;font-size:10pt;color:#000000;">the </font><font style="display: inline;font-size:10pt;color:#000000;">loss </font><font style="display: inline;font-size:10pt;color:#000000;">of a large reference laboratory account in July 2017</font><font style="display: inline;font-size:10pt;color:#000000;">. &nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">In </font><font style="display: inline;font-size:10pt;color:#000000;">201</font><font style="display: inline;font-size:10pt;color:#000000;">7</font><font style="display: inline;font-size:10pt;color:#000000;">, w</font><font style="display: inline;font-size:10pt;color:#000000;">e continue</font><font style="display: inline;font-size:10pt;color:#000000;">d</font><font style="display: inline;font-size:10pt;color:#000000;"> to develop the market through exp</font><font style="display: inline;font-size:10pt;color:#000000;">erienced </font><a name="_cp_text_1_410"></a><font style="display: inline;font-size:10pt;color:#000000;">market development specialists</font><font style="display: inline;font-size:10pt;color:#000000;">, &nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">and </font><font style="display: inline;font-size:10pt;color:#000000;">customer </font><font style="display: inline;font-size:10pt;color:#000000;">account managers</font><font style="display: inline;font-size:10pt;color:#000000;">.&nbsp;&nbsp;As market awareness continues to build, these managers are focused on efforts that will have a positive impact on regional payers and create positive coverage decisions.&nbsp;&nbsp;They are working with local key opinion leaders and meeting with medical directors to discuss the clinical need, our technology assessment package and increasing experience and cases studies showing the positive outcomes utilizing OVA1.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;color:#000000;">There are still obstacles to overcome and significant milestones </font><font style="display: inline;color:#000000;">ahead</font><font style="display: inline;color:#000000;">.&nbsp;&nbsp;First, the average </font><font style="display: inline;color:#000000;">g</font><font style="display: inline;color:#000000;">ynecologist will only see about 2 to 4 patients per month</font><font style="display: inline;color:#000000;"> who may need our test</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and additional effort will be required to establish a consistent ordering pattern.&nbsp;&nbsp;Second, </font><font style="display: inline;color:#000000;">despite gains in positive medical policy coverage</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and contract agreements</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">insurance coverage and patient bills </font><font style="display: inline;color:#000000;">remain </font><font style="display: inline;color:#000000;">a concern to the physician and can disrupt the ordering pattern of a generalist who is supportive of OVA1. </font><font style="display: inline;color:#000000;">We have instituted a &#x201C;Patient Advocacy Program&#x201D; to assist with this process to proactively assess insurance and educate patients on testing costs prior to testing being performed.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Reimbursement</font>
		</p>
		<p style="margin:5pt 0pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">In the United States, revenue for diagnostic tests comes from several sources, including third-party payers such as insurance companies</font><font style="display: inline;font-size:10pt;color:#000000;">,</font><font style="display: inline;font-size:10pt;color:#000000;"> government healthcare programs, such as Medicare and Medicaid</font><font style="display: inline;font-size:10pt;color:#000000;">,</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">client bill accounts </font><font style="display: inline;font-size:10pt;color:#000000;">and patients</font><font style="display: inline;font-size:10pt;color:#000000;">. &nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">Novitas Solutions</font><font style="display: inline;font-size:10pt;color:#000000;">, the Medicare contractor </font><font style="display: inline;font-size:10pt;color:#000000;">for areas including Texas</font><font style="display: inline;font-size:10pt;color:#000000;">,</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">now </font><font style="display: inline;font-size:10pt;color:#000000;">cover</font><font style="display: inline;font-size:10pt;color:#000000;">s</font><font style="display: inline;font-size:10pt;color:#000000;"> and reimburses </font><font style="display: inline;font-size:10pt;color:#000000;">ASPiRA LABS </font><font style="display: inline;font-size:10pt;color:#000000;">for</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">OVA1</font><font style="display: inline;font-size:10pt;color:#000000;">. &nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">The </font><font style="display: inline;font-size:10pt;color:#000000;">local coverage determination from </font><font style="display: inline;font-size:10pt;color:#000000;">Novitas Solutions</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">essentially </font><font style="display: inline;font-size:10pt;color:#000000;">provide</font><font style="display: inline;font-size:10pt;color:#000000;">s</font><font style="display: inline;font-size:10pt;color:#000000;"> national coverage for patients enrolled in Medicare as well as Medicare Advantage health plans. </font><font style="display: inline;font-size:10pt;color:#000000;">ASPiRA LABS also bills third-party commercial and other government payers as well as client bill accounts and patients for OVA1.</font>
		</p>
		<p style="margin:5pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">In December 2013, the CMS made its final determination and authorized Medicare contractors</font><font style="display: inline;color:#000000;font-size:10pt;"> to set prices for Multianalyte Assays with Algorithmic Analyses (&#x201C;MAAA&#x201D;) test CPT codes when they determine it is payable.&nbsp;&nbsp;In late 2016, OVA1 was included on the list of clinical diagnostic laboratory test procedure codes as one for which the CMS would require reporting of private payer rates as part of the implementation of Protecting Access to Medicare Act of 2014 (</font><font style="display: inline;color:#000000;font-size:10pt;">&#x201C;</font><font style="display: inline;color:#000000;font-size:10pt;">PAMA</font><font style="display: inline;color:#000000;font-size:10pt;">&#x201D;</font><font style="display: inline;color:#000000;font-size:10pt;">). </font><font style="display: inline;color:#000000;font-size:10pt;">In </font><font style="display: inline;color:#000000;font-size:10pt;">November 2017, we announced that the CMS released the Final 2018 Clinical Lab Fee Schedule</font><font style="display: inline;color:#000000;font-size:10pt;"> (&#x201C;CLFS&#x201D;)</font><font style="display: inline;color:#000000;font-size:10pt;">, effective January 1, 2018. Under the new fee schedule, the price for </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">13</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:5pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;color:#000000;font-size:10pt;">OVA1(MIA) (code 81503) is $897. This is a four-fold increase over the previous</font><font style="display: inline;color:#000000;font-size:10pt;"> CMS rate, and this new rate was</font><font style="display: inline;color:#000000;font-size:10pt;"> based on the median of private payer payments submitted to CMS by companies, including ASPiRA Labs, as part of the market-based payment reform mandated through</font><font style="display: inline;color:#000000;font-size:10pt;"> PAMA</font><font style="display: inline;color:#000000;font-size:10pt;">. &nbsp;</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;font-size:10pt;">The rate is scheduled to be in effect for a three-year term from January 2018 thr</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;font-size:10pt;">ough</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;font-size:10pt;"> December 2020.</font>
		</p>
		<p style="margin:5pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">CMS also published a final price for Overa of $</font><font style="display: inline;color:#000000;font-size:10pt;">950</font><font style="display: inline;color:#000000;font-size:10pt;">, which was benchmarked to the only proteomic test currently on the CLFS that uses biomarkers and an algorithm to produce a prognostic score.</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;font-size:10pt;">The rate is</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;font-size:10pt;">&nbsp;</font><font style="font-style:italic;display: inline;font-style:normal;color:#000000;font-size:10pt;">scheduled to be in effect for a three-year term from January 2018 through December 2020.</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Starting in</font><font style="display: inline;font-size:10pt;"> 2016, </font><font style="display: inline;font-size:10pt;">we were able</font><font style="display: inline;font-size:10pt;"> to </font><font style="display: inline;font-size:10pt;">make progress in </font><font style="display: inline;font-size:10pt;">achiev</font><font style="display: inline;font-size:10pt;">ing</font><font style="display: inline;font-size:10pt;"> positive medical policy and/or </font><font style="display: inline;font-size:10pt;">payer </font><font style="display: inline;font-size:10pt;">contract</font><font style="display: inline;font-size:10pt;">s.</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">We have continued to make progress with increased payer positive medical polices for a</font><font style="display: inline;font-size:10pt;">n &nbsp;</font><font style="display: inline;font-size:10pt;">estimated total of over 12</font><font style="display: inline;font-size:10pt;">5</font><font style="display: inline;font-size:10pt;"> million covered lives</font><font style="display: inline;font-size:10pt;"> as of March </font><font style="display: inline;font-size:10pt;">1</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;"> 2018</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;This represents an increase from an estimated 80 million covered lives </font><font style="display: inline;font-size:10pt;">as</font><font style="display: inline;font-size:10pt;"> of </font><font style="display: inline;font-size:10pt;">December 31, </font><font style="display: inline;font-size:10pt;">2016.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">N</font><font style="display: inline;">ew and innovative diagnostic tests often face reimbursement challenges that can affect adoption, including:&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 6pt 43.5pt;text-indent: -7.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt 43.5pt;text-indent: -7.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Coding</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">We </font><font style="display: inline;color:#000000;">received</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">an American Medical Association (&#x201C;AMA&#x201D;) Current Procedural Terminology (&#x201C;CPT&#x201D;) Category I </font><font style="display: inline;color:#000000;">code specific for OVA1</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">which was effective beginning January 1, 2013</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Achieving </font><font style="display: inline;color:#000000;">the</font><font style="display: inline;color:#000000;"> unique Category I C</font><font style="display: inline;color:#000000;">PT c</font><font style="display: inline;color:#000000;">ode </font><font style="display: inline;color:#000000;"># 81503 </font><font style="display: inline;color:#000000;">was</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">a critical step </font><font style="display: inline;color:#000000;">in </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> commercialization process.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">We received a Proprietary Laboratory Analyses (PLA) code #0003U for Overa from the AMA</font><font style="display: inline;color:#000000;">&#x2019;</font><font style="display: inline;color:#000000;">s CPT</font><font style="display: inline;color:#000000;">&#xAE;</font><font style="display: inline;color:#000000;"> Editorial Panel effective January 1, 2017. This new code is included in the first set of PLA codes to be released by the AMA to support the implementation of Section 216 of PAMA, which replaces the current Medicare Clinical Laboratory Fee Schedule with a new fee schedule based upon laboratory-reported private payer rates. PLA codes are proprietary clinical laboratory analyses that can be either provided by a single (</font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;color:#000000;">sole-source</font><font style="display: inline;color:#000000;">&#x201D;</font><font style="display: inline;color:#000000;">) laboratory or licensed or marketed to multiple providing laboratories (e.g.</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> cleared or approved by </font><font style="display: inline;color:#000000;">the </font><font style="display: inline;color:#000000;">FDA).</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 43.5pt;text-indent: -7.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;color:#000000;">Claims Process</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">In the launch of a product, claims can be rejected due to lack of medical necessity, lack of payer understanding</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> or even billing process errors.&nbsp;&nbsp;To </font><font style="display: inline;color:#000000;">address</font><font style="display: inline;color:#000000;"> these</font><font style="display: inline;color:#000000;"> items</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">ASPiRA LABS expanded its patient advocacy program nationally in July 2017 to assist patients with proactive benefit checks, with over 90% resulting in OVA1 utilization.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;"> &nbsp; &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 43.5pt;text-indent: -7.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;color:#000000;">Payer Coverage</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">We </font><font style="display: inline;color:#000000;">have </font><font style="display: inline;color:#000000;">continue</font><font style="display: inline;color:#000000;">d</font><font style="display: inline;color:#000000;"> to focus ongoing efforts toward obtaining national coverage decisions.&nbsp;&nbsp;However, these </font><font style="display: inline;color:#000000;">decisions </font><font style="display: inline;color:#000000;">typically have a much longer lead time due to industry established processes and time frames.&nbsp;&nbsp;In most cases, these entail clinical and technical reviews that are performed on an annual basis.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">We have launched a program to aid local key opinion leaders to work with health plans to support coverage for OVA1.&nbsp;&nbsp;These strategic actions are necessary steps to convert those plans representing numerous regional payers and late adopters.&nbsp; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Competition</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;color:#000000;">The diagnostics industry in which </font><font style="display: inline;color:#000000;">we</font><font style="display: inline;color:#000000;"> operate is competitive and evolving. There is intense competition among healthcare, biotechnology and diagnostics companies attempting to discover candidates for potential new diagnostic products. These companies may: </font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">develop new diagnostic products in advance of </font><font style="display: inline;color:#000000;">us</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> collaborators; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">develop diagnostic products that are more effective or cost-effective than those developed by </font><font style="display: inline;color:#000000;">us</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> collaborators; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">obtain regulatory clearance or approval of their diagnostic products more rapidly than </font><font style="display: inline;color:#000000;">us</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> collaborators; or </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">obtain patent protection or other intellectual property rights that would limit </font><font style="display: inline;color:#000000;">our or our collaborators&#x2019;</font><font style="display: inline;color:#000000;"> ability to develop and commercialize, or a customers&#x2019; ability to use </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> collaborators&#x2019; diagnostic products. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;color:#000000;">We</font><font style="display: inline;color:#000000;"> compete with companies in the United States and abroad that are engaged in the development and commercialization of novel biomarkers that may form the basis of novel diagnostic tests. These companies may develop products that are competitive with and/or perform the same or similar </font><font style="display: inline;color:#000000;">functions as </font><font style="display: inline;color:#000000;">the products offered by </font><font style="display: inline;color:#000000;">us or our</font><font style="display: inline;color:#000000;"> collaborators, such as biomarker specific reagents or diagnostic test kits. Also, clinical laboratories may offer testing services that are competitive with the products sold by </font><font style="display: inline;color:#000000;">us</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> collaborators. For example, a clinical laboratory can either use reagents purchased from manufacturers other than </font><font style="display: inline;color:#000000;">us</font><font style="display: inline;color:#000000;"> or use its own internally developed reagents to make diagnostic tests. If clinical laboratories make tests in this manner for a particular disease, they </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">14</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt"><font style="display: inline;">could offer testing services for that disease as an alternative to products sold by </font><font style="display: inline;">us</font><font style="display: inline;"> used to test for the same disease. The testing services offered by clinical laboratories may be easier to develop and market than test kits developed by </font><font style="display: inline;">us</font><font style="display: inline;"> or </font><font style="display: inline;">our</font><font style="display: inline;"> collaborators because the testing services are not subject to the same clinical validation requirements that are applicable to FDA-cleared or approved diagnostic test kits.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Fujirebio Diagnostics </font><font style="display: inline;">sells</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;">Risk of Ovarian Malignancy Algorithm</font><font style="display: inline;"> (&#x201C;ROMA&#x201D;). ROMA</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">combines</font><font style="display: inline;"> two tumor markers </font><font style="display: inline;">and menopausal status into a numerical score using</font><font style="display: inline;"> a publicly available algorithm.&nbsp;&nbsp;Th</font><font style="display: inline;">is test has the sam</font><font style="display: inline;">e intended use </font><font style="display: inline;">and precautions</font><font style="display: inline;"> as OVA1.</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">ROMA </font><font style="display: inline;">is currently marketed as having utility limited to epithelial ovarian cancers, which accounts for 80% of ovarian malignancies. </font><font style="display: inline;">Based upon the results of a 2013 study, we believe that OVA1 has superior performance when compared to the Fujirebio Diagnostics test</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<a name="_cp_text_1_438"></a><font style="display: inline;">In addition, competitors such as Becton Dickinson and Abbott Laboratories have publicly disclosed that they have been or are currently working on ovarian cancer diagnostic assays. Academic institutions periodically report new findings </font><a name="_cp_text_4_439"></a><font style="display: inline;">in ovarian cancer </font><font style="display: inline;">diagnostics that may have commercial value. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Intellectual Property Protection</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Our</font><font style="display: inline;"> intellectual property includes </font><font style="display: inline;">the registered trademarks for</font><font style="display: inline;font-style:italic;"> Vermillion, OVA1</font><font style="display: inline;font-style:italic;">, Overa</font><font style="display: inline;font-style:italic;">&nbsp;</font><font style="display: inline;">and</font><font style="display: inline;font-style:italic;"> OvaCalc</font><font style="display: inline;"> and </font><font style="display: inline;">a portfolio of owned, co-owned or licensed patents and patent applications. As of </font><font style="display: inline;">December 31</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">our</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">clinical diagnostics </font><font style="display: inline;">patent portfolio included </font><font style="display: inline;">20 </font><font style="display: inline;">issued United States patents, </font><font style="display: inline;">9</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">pending United States patent applications, and numerous pending patent applications and issued patents outside the United States. These patents and patent applications </font><font style="display: inline;">fall into </font><font style="display: inline;">2</font><font style="display: inline;">4</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">patent families and </font><font style="display: inline;">are directed to </font><font style="display: inline;">diagnostic technologies</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<a name="_cp_text_1_447"></a><font style="display: inline;">O</font><font style="display: inline;">ur research collaboration agreement with JHU </font><a name="_cp_text_1_449"></a><font style="display: inline;">expire</font><font style="display: inline;">d</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">i</font><font style="display: inline;">n &nbsp;</font><font style="display: inline;">March</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">2016</font><font style="display: inline;">.&nbsp; </font><font style="display: inline;">There were no JHU collaboration costs in 2017. </font><font style="display: inline;">Collaboration costs </font><font style="display: inline;">with</font><font style="display: inline;"> JHU were </font><font style="display: inline;">$</font><font style="display: inline;">264</font><font style="display: inline;">,000</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">for the </font><font style="display: inline;">year</font><font style="display: inline;"> ended </font><font style="display: inline;">December </font><font style="display: inline;">3</font><font style="display: inline;">1</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">. In addition, under the terms of </font><font style="display: inline;">our</font><font style="display: inline;"> amended research collaboration agreement</font><font style="display: inline;"> with JHU</font><font style="display: inline;">, we are required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $5</font><font style="display: inline;">7</font><font style="display: inline;">,</font><font style="display: inline;">5</font><font style="display: inline;">00.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Manufacturing</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">We are</font><font style="display: inline;"> the manufacturer of </font><font style="display: inline;">OVA1</font><font style="display: inline;"> and Overa</font><font style="display: inline;">. Components of </font><font style="display: inline;">OVA1 </font><font style="display: inline;">and Overa </font><font style="display: inline;">include </font><font style="display: inline;">purchased </font><font style="display: inline;">reagents for each of the component assays as well as the OvaCalc</font><font style="display: inline;">&#xAE;</font><font style="display: inline;"> software. Because </font><font style="display: inline;">we do</font><font style="display: inline;"> not directly manufacture the component assays, </font><font style="display: inline;">we are</font><font style="display: inline;"> required to maintain supply agreements with manufacturers of each of the assays. As part of </font><font style="display: inline;">our</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">quality systems</font><font style="display: inline;">, reagent lots for these assays are tested to ensure they meet specifications required for inclusion in </font><font style="display: inline;">OVA1</font><font style="display: inline;"> and Overa</font><font style="display: inline;">. Only reagent lots determined by </font><font style="display: inline;">us</font><font style="display: inline;"> as having met these specifications are permitted for use in </font><font style="display: inline;">OVA1</font><font style="display: inline;"> and Overa</font><font style="display: inline;">.</font><font style="display: inline;"> Our principal suppliers are Roche Diagnostics Corporation and Siemens Healthcare Diagnostics, Inc.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Environmental Matters</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Medical Waste</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">We </font><font style="display: inline;">are </font><font style="display: inline;">subject to licensing and regulation under federal, state and local laws relating to the handling and disposal of medical specimens and hazardous waste as well as to the safety and health of laboratory employees. </font><font style="display: inline;">ASPiRA LABS </font><font style="display: inline;">and ASPiRA IVD are</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">operated in material compliance with applicable federal and state laws and regulations relating to disposal of all laboratory specimens. We </font><font style="display: inline;">utilize</font><font style="display: inline;"> outside vendors for disposal of specimens. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these materials. We could be subject to </font><font style="display: inline;">fines, penalties and </font><font style="display: inline;">damages </font><font style="display: inline;">claims </font><font style="display: inline;">in the event of an improper or unauthorized release of, or exposure of individuals to, hazardous materials. In addition, claimants may sue us for injury or contamination that results from our use, or the use by third parties, of these materials, and our liability may exceed our total assets. Compliance with environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development or production efforts.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Occupational Safety</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">In addition to its comprehensive regulation of safety in the workplace, the Federal Occupational Safety and Health Administration has established extensive requirements relating to workplace safety for healthcare employers whose workers may be exposed to blood-borne pathogens such as HIV and the hepatitis virus. These regulations, among other things, require work practice controls, protective clothing and equipment, training, medical follow-up, vaccinations and other measures designed to minimize exposure to chemicals and transmission of the blood-borne and airborne pathogens. Although we believe that we </font><font style="display: inline;">have complied</font><font style="display: inline;"> in all material respects with such federal, state and local laws, failure to comply could subject us to denial of the right to conduct business, fines, criminal penalties and other enforcement actions.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">15</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;">Specimen Transportation</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Regulations of the Department of Transportation, the International Air Transportation Agency, the Public Health Service and the Postal Service apply to the surface and air transportation of clinical laboratory specimens.</font><font style="display: inline;"> &nbsp;Although we believe that we </font><font style="display: inline;">have complied </font><font style="display: inline;">in all material respects with such federal, state and local laws, failure to comply could subject us to denial of the right to conduct business, fines, criminal penalties and other enforcement actions.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Government </font><font style="display: inline;font-weight:bold;">Regulation</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">General.</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">Our activities related to diagnostic products are, or have the potential to be, subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of our products. The </font><font style="display: inline;">Federal </font><font style="display: inline;">Food, Drug and Cosmetic Act requires that medical devices introduced to the United States market, unless exempted by regulation, be the subject of either a pre-market notification clearance, known as a 510(k) clearance or 510(k) </font><font style="display: inline;font-style:italic;">de novo</font><font style="display: inline;"> clearance, or a </font><font style="display: inline;">pre-market approval (&#x201C;</font><font style="display: inline;">PMA</font><font style="display: inline;">&#x201D;)</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">OVA1 was cleared by the FDA in September</font><font style="display: inline;"> 2009 under the 510(k) </font><font style="display: inline;font-style:italic;">de novo</font><font style="display: inline;"> guidelines.&nbsp;&nbsp;OVA1 was the first FDA-cleared blood test for the pre-operative assessment of ovarian </font><font style="display: inline;">masses</font><font style="display: inline;">. We</font><a name="_cp_text_1_467"></a><font style="display: inline;">&nbsp;</font><font style="display: inline;">received</font><font style="display: inline;"> 510(k) clearance for </font><font style="display: inline;">Overa, </font><font style="display: inline;">our second-generation biomarker panel </font><font style="display: inline;">i</font><font style="display: inline;">n March 2016.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Even in the case of devices like analyte specific reagents (&#x201C;ASRs&#x201D;), which may be exempt from 510(k) clearance or PMA approval requirements, the FDA may impose restrictions on marketing. Our potential future ASR products may be sold only to clinical laboratories certified under CLIA to perform high complexity testing. In addition to requiring approval or clearance for new products, the FDA may require approval or clearance prior to marketing products that are modifications of existing products or the intended uses of these products. Additionally, the FDA will generally conduct a pre-approval inspection for PMA devices. </font><font style="display: inline;color:#231F20;">Our suppliers&#x2019;</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">manufacturing</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">facilities</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">are subject</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">to periodic</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">and unannounced</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">inspections</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">by the</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">FDA</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">and state</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">agencies</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">for</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">compliance</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">with Quality</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">System</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">Regulations</font><font style="display: inline;color:#231F20;">&nbsp;</font><font style="display: inline;color:#231F20;">(&#x201C;QSRs&#x201D;). </font><font style="display: inline;">Although we believe that we and our suppliers will be able to operate in compliance with the FDA&#x2019;s QSRs for ASRs, we cannot </font><font style="display: inline;">ensure</font><font style="display: inline;"> that we or our suppliers will be in or be able to maintain compliance in the future. </font><font style="display: inline;">We passed</font><font style="display: inline;"> an FDA inspection </font><font style="display: inline;">in 2016.&nbsp;&nbsp;However, we</font><font style="display: inline;"> cannot </font><font style="display: inline;">ensure</font><font style="display: inline;"> that we will pass an</font><font style="display: inline;">y future</font><font style="display: inline;"> inspection, if and when it occurs. If the FDA believes that we or our suppliers are not in compliance with applicable laws or regulations, the FDA can issue a Form 483 List of Observations </font><font style="display: inline;">or </font><font style="display: inline;">warning letter, detain or seize our products, issue a recall notice, enjoin future violations and assess civil and criminal penalties against us. In addition, approvals or clearances could be withdrawn under certain circumstances.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">ASPiRA LABS and any</font><font style="display: inline;"> customers using our products for clinical use in the United States may be regulated under CLIA, which is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration, participation in proficiency testing, patient test management, quality control, quality assurance and inspections. The regulations promulgated under CLIA establish three levels of diagnostic tests - namely, waived, moderately complex and highly complex - and the standards applicable to a clinical laboratory depend on the level of the tests it performs. </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">FDA</font><font style="display: inline;font-weight:bold;"> Regulation of Cleared Tests</font><font style="display: inline;font-weight:bold;font-style:italic;">.&nbsp; </font><font style="display: inline;">Once granted, a 510(k) clearance or PMA approval may place substantial restrictions on how our device is marketed or to whom it may be sold. All devices cleared by the FDA are subject to continuing regulation by the FDA and certain sta</font><font style="display: inline;">te</font><font style="display: inline;"> agencies. </font><font style="display: inline;">As a medical device manufacturer, we are also required to register and list our products with the FDA. </font><font style="display: inline;">We are required to set forth and adhere to a </font><font style="display: inline;">quality policy</font><font style="display: inline;"> and other regulations. </font><font style="display: inline;">In addition, we are required to comply with the FDA&#x2019;s QSRs, which require that our devices be manufactured and records be maintained in a prescribed manner with respect to manufacturing, testing and control activities. </font><font style="display: inline;">Additionally, we may be subject to inspection by federal and state regulatory agencies. Non-compliance with these standards can result in, among other things, fines, injunctions, civil penalties, recalls, </font><font style="display: inline;">and </font><font style="display: inline;">total or partial suspension of production. </font><font style="display: inline;">Further, we are required to comply with FDA requirements for labeling and promotion. For example, the FDA prohibits cleared or approved devices from being promoted for uncleared or unapproved uses. </font><font style="display: inline;">Labeling and promotional activities are subject to scrutiny by the FDA, which prohibits the marketing of medical devices for unapproved uses. </font><font style="display: inline;">Additionally, the FDA require</font><font style="display: inline;">s</font><font style="display: inline;"> us to perform certain post-marketing studies to verify or validate the clinical performance of FDA-</font><font style="display: inline;">cleared tests</font><font style="display: inline;">, as is permitted by their statutory authority</font><font style="display: inline;">.</font><font style="display: inline;"> Failure to comply with </font><a name="_cp_text_1_485"></a><font style="display: inline;">our post-marketing study requirements may </font><a name="_cp_text_4_486"></a><font style="display: inline;">lead to </font><a name="_cp_text_1_487"></a><font style="display: inline;">enforcement actions by the FDA, including seizure of our product, injunction, prosecution and/or </font><a name="_cp_text_4_488"></a><font style="display: inline;">civil money penalties</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition, the medical device reporting regulation requires that we provide information to the FDA whenever evidence reasonably suggests that one of our devices may have caused or contributed to a death or serious injury, or where a malfunction has occurred that would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Foreign Government Regulation of </font><font style="display: inline;font-weight:bold;">Our</font><font style="display: inline;font-weight:bold;"> Products</font><font style="display: inline;font-weight:bold;font-style:italic;">.</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">We intend to obtain regulatory approval in other countries to market our tests. </font><a name="_cp_text_4_489"></a><font style="display: inline;">Medical device laws and regulations are </font><a name="_cp_text_4_490"></a><font style="display: inline;">in effect in many of the countries in which we may do business outside the United States. These range from comprehensive device approval requirements for some or all of our potential future medical device products, to requests for product data or certifications. The number and scope of these requirements are increasing. In addition, products which have not yet been cleared or approved for domestic commercial distribution may be subject to the FDA Export Reform and </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">16</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">Enhancement Act of 1996</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">Each country </font><font style="display: inline;">also </font><font style="display: inline;">maintains its own regulatory review process, tariff regulations, duties and tax requirements, product standards, and labeling requirements. </font><font style="display: inline;">In February </font><a name="_cp_text_1_494"></a><font style="display: inline;">2015</font><a name="_cp_text_1_495"></a><font style="display: inline;">, Vermillion also received ISO 13485:2003 certification for our quality management system from the British Standards Institution (BSI), one of the world's leading certification bodies.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">In March 2015, OVA1 was CE marked, a requirement for marketing the test in the European Union. </font><font style="display: inline;color:#000000;">I</font><font style="display: inline;color:#000000;">n October 2015, we </font><font style="display: inline;">announced registration of the CE mark for and clearance to market Overa in the European Union.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Employees</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, we had </font><font style="display: inline;">39</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">employees</font><font style="display: inline;"> who are</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">full-time</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and 1 employee</font><font style="display: inline;"> who is part-time</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">We </font><font style="display: inline;">also</font><font style="display: inline;"> engage independent contractors</font><font style="display: inline;"> from time to </font><font style="display: inline;">time</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Code of Ethics for Executive Officers</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have adopted a Code of Ethics for Executive Officers. We publicize the Code of Ethics for Executive Officers by posting the policy on our website, </font><font style="display: inline;text-decoration:underline;">www.vermillion.com</font><font style="display: inline;">. We will disclose on our website any waivers of, or amendments to, our Code of Ethics.</font><a name="_cp_text_1_496"></a>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Corporate Information</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_1_497"></a><font style="display: inline;">We were originally incorporated in 1993, and we had our initial public offering in 2000.&nbsp;&nbsp;Our executive offices are located at 12117 Bee Caves Road, Building Three, Suite 100, Austin, Texas 787</font><font style="display: inline;">38</font><font style="display: inline;">, and our telephone number is (512) 519-0400.&nbsp;&nbsp;We maintain a website at </font><font style="display: inline;color:#000000;">www.vermillion.com</font><font style="display: inline;"> and </font><font style="display: inline;color:#000000;">www.aspiralab.com</font><font style="display: inline;"> where general information about us is available.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Information About </font><font style="display: inline;font-weight:bold;">Us</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We</font><font style="display: inline;"> file annual reports, quarterly reports, </font><font style="display: inline;">current</font><font style="display: inline;"> reports, proxy statements, and other information with the SEC. You may read and copy any material </font><font style="display: inline;">we</font><font style="display: inline;"> file with the SEC at the SEC&#x2019;s Public Reference Room located at the following address:</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:0pt;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">100 F Street, NE</font><br /><font style="display: inline;">Washington, DC&nbsp;&nbsp;20549 </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">You may obtain information on the operation of the SEC&#x2019;s Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website, </font><font style="display: inline;text-decoration:underline;">www.sec.gov</font><font style="display: inline;">, that contains reports, proxy statements, and other information regarding issuers that file electronically with the SEC.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition, </font><font style="display: inline;">we</font><font style="display: inline;"> make available free of charge under the Investor </font><font style="display: inline;">Overview </font><font style="display: inline;">section of </font><font style="display: inline;">our</font><font style="display: inline;"> website, www.vermillion.com, the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934</font><font style="display: inline;">, as amended (&#x201C;Exchange Act&#x201D;) </font><font style="display: inline;">as soon as reasonably practicable after </font><font style="display: inline;">we have</font><font style="display: inline;"> electronically filed such material with or furnished </font><font style="display: inline;">such material to the SEC. </font><font style="display: inline;">You may also obtain these documents free of charge by submitting a written request for a paper copy to the following address:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Investor Relations</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;">Vermillion, Inc.</font><br /><font style="display: inline;">12117 Bee Caves Road, Building T</font><font style="display: inline;">hree</font><font style="display: inline;">, Suite 100</font><br /><font style="display: inline;">Austin, TX 78738</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The information contained on our website</font><font style="display: inline;">s</font><font style="display: inline;"> is not incorporated by reference in this Annual Report on Form 10-K and should not be considered a part of this Annual Report on Form 10-K.</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">17</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 1A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">RISK </font><font style="display: inline;font-weight:bold;">FACTORS</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-decoration:none;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_1_506"></a><font style="display: inline;font-style:italic;">Investing in our securities involves a high degree of risk. </font><font style="display: inline;font-style:italic;">You should carefully consider the following risk factors and uncertainties together with all of the other information contained in this Annual Report on Form 10-K, including our audited consolidated financial statements and the accompanying notes in Part II Item&nbsp;8, &#x201C;Financial Statements and Supplementary Data</font><font style="display: inline;font-style:italic;">.</font><font style="display: inline;font-style:italic;">&#x201D; &nbsp;</font><a name="_cp_text_1_507"></a><font style="display: inline;font-style:italic;">If any of the following risks materializes, </font><a name="_cp_text_4_508"></a><font style="display: inline;font-style:italic;">our business, financial condition</font><a name="_cp_text_1_509"></a><font style="display: inline;font-style:italic;">, &nbsp;</font><a name="_cp_text_4_510"></a><font style="display: inline;font-style:italic;">results of operations </font><a name="_cp_text_1_511"></a><font style="display: inline;font-style:italic;">and growth prospects could be materially adversely affected, </font><a name="_cp_text_4_512"></a><font style="display: inline;font-style:italic;">and the value of </font><font style="display: inline;font-style:italic;">an investment in our common stock may decli</font><font style="display: inline;font-style:italic;">ne significantly. </font><font style="display: inline;font-style:italic;">The risks and uncertainties describe</font><font style="display: inline;font-style:italic;">d</font><font style="display: inline;font-style:italic;"> below are </font><font style="display: inline;font-style:italic;">not </font><font style="display: inline;font-style:italic;">the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also </font><font style="display: inline;font-style:italic;">materially </font><font style="display: inline;font-style:italic;">adversely affect our </font><font style="display: inline;font-style:italic;">business</font><font style="display: inline;font-style:italic;">,</font><font style="display: inline;font-style:italic;"> financial condition</font><font style="display: inline;font-style:italic;">,</font><font style="display: inline;font-style:italic;"> results of operations</font><font style="display: inline;font-style:italic;"> and growth prospects</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Risks Related to Our Business</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.08%;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_157"></a><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">There is substantial doubt about our ability to continue as a going concern, and this may adversely affect our stock price and our ability to raise capital.</font><font style="display: inline;font-family:Calibri;color:#000000;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.08%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_158"></a><font style="display: inline;color:#000000;font-size:10pt;">We have incurred significant losses and negative cash flows from operations since inception and have an accumulated deficit of over $396 million as of the end of the period covered by this report. The Company also expects to incur a net loss and negative cash flows from operations in 2018.&nbsp;&nbsp;Given these conditions, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern and</font><font style="display: inline;font-family:Calibri;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">our independent registered public accounting firm&#x2019;s report on our financial statements for the year ended December 31, 2017 includes an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern given our recurring net losses and negative cash flows from operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.08%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_159"></a><font style="display: inline;color:#000000;font-size:10pt;">The Company&#x2019;s management believes that successful achievement of the business objectives will require additional financing.&nbsp;The Company expects to raise capital through a variety of sources, which may include the exercise of common stock warrants, equity offerings, debt financing, collaborations, licensing arrangements, grants and government funding and strategic alliances. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, </font><a name="_cp_text_1_160"></a><font style="display: inline;color:#000000;font-size:10pt;">distribution</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><a name="_cp_text_4_161"></a><font style="display: inline;color:#000000;font-size:10pt;">or other operations on the scope or scale of current activity and that could have a material adverse effect on the Company&#x2019;s business, results of operations and financial condition.</font><font style="display: inline;font-family:Calibri;color:#000000;font-size:10pt;">&nbsp;</font><a name="_cp_text_4_162"></a>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.08%;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="font-family:Calibri;color:#008000;font-size:10pt;border-bottom-style:double;border-bottom-width:2pt;height:100%;text-indent:0pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">If we are unable to increase the volume of OVA1 sales, our </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">business</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">, results of operations and financial condition w</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">ill</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> be adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We have experienced significant operating losses each year since our inception and we expect to incur a net loss for fiscal year </font><font style="display: inline;font-size:10pt;">201</font><font style="display: inline;font-size:10pt;">8</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;Our losses have resulted principally from costs incurred in </font><font style="display: inline;font-size:10pt;">cost of revenue, </font><font style="display: inline;font-size:10pt;">sales and marketing, general and administrative costs</font><font style="display: inline;font-size:10pt;"> and research and development</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Prior to August 2015</font><font style="display: inline;font-size:10pt;">, all of our revenues were generated from sales of OVA1 tests performed by Quest Diagnostics. Pursuant to our March 2015 agreement with Quest Diagnostics, OVA1 testing in the United States for Quest Diagnostics customers was transitioned from Quest Diagnostics to ASPiRA LABS as of August 2015</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;"> If we are unable to increase the volume of OVA1 sales, our </font><font style="display: inline;font-size:10pt;">business, </font><font style="display: inline;font-size:10pt;">results of operations and financial condition </font><font style="display: inline;font-size:10pt;">will </font><font style="display: inline;font-size:10pt;">be adversely affected.</font>
		</p>
		<p style="margin:13.5pt 0pt 6pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">In the past, a significant amount</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">of our revenue was</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> derived from Quest Diagnostics</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">,</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">and</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">as testing services have been transitioned to ASPiRA LABS,</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">there is no guarantee that we will be able to successfully market our test through additional channels</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">, including ASPiRA </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">LABS</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">,</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> in the future</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;">The majority of</font><font style="display: inline;"> our revenue </font><font style="display: inline;">through </font><font style="display: inline;">201</font><font style="display: inline;">5</font><font style="display: inline;"> was derived through our strategic partnership with Quest Diagnostics </font><font style="display: inline;">prior to</font><font style="display: inline;"> transition</font><font style="display: inline;">ing</font><font style="display: inline;"> OVA1 testing services for its customers to ASPiRA LABS.&nbsp;&nbsp;Prior to the transition, revenue generated from Quest Diagnostics </font><font style="display: inline;">was based on the number of OVA1 tests performed by Quest Diagnostics and the reimbursement rate received by Quest Diagnostics for those tests. </font><a name="_cp_text_66_176"></a><font style="display: inline;">W</font><font style="display: inline;">e &nbsp;</font><font style="display: inline;">continue to </font><font style="display: inline;">depend on Quest Diagnostics for blood draw and logistics for a significant portion of our specimens</font><font style="display: inline;"> under a contract through at least </font><font style="display: inline;">March 11, 201</font><font style="display: inline;">9</font><font style="display: inline;">.</font><a name="_cp_text_2_178"></a><font style="display: inline;">&nbsp;</font><a name="_cp_text_66_182"></a><font style="display: inline;">There is no guarantee that Quest Diagnostics will perform as expected, or provide a sufficient volume of OVA1 test samples to support our business</font><font style="display: inline;">, or extend the contract past the current expiration date</font><font style="display: inline;">. Due in part to this uncertainty, we </font><font style="display: inline;">plan to offer OVA1 through additional channels in the future</font><font style="display: inline;">, although there can be no assurance that we will be able to do so.&nbsp;&nbsp;I</font><font style="display: inline;">f we are not successful in adding additional sales channels or if we do not experience growing OVA1 test volumes or receive less reimbursement per test than expected, </font><font style="display: inline;">there could be </font><font style="display: inline;">a material adverse effect on our </font><font style="display: inline;">business, </font><font style="display: inline;">results of operations and financial condition</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Failures </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">by third</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">-</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">party payers </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">to reimburse OVA1 or changes </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">or variances </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">in reimbursement rates could materially and adversely affect our </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">business, financial condition and results of operations</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">18</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-size:10pt;">W</font><font style="display: inline;font-size:10pt;">e &nbsp;</font><font style="display: inline;font-size:10pt;">are</font><font style="display: inline;font-size:10pt;"> responsibl</font><font style="display: inline;font-size:10pt;">e</font><font style="display: inline;font-size:10pt;"> for obtaining payment from third-party payers</font><font style="display: inline;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-size:10pt;">Accordingly, </font><font style="display: inline;font-size:10pt;">our future revenues will be dependent upon </font><font style="display: inline;font-size:10pt;">third</font><font style="display: inline;font-size:10pt;">-</font><font style="display: inline;font-size:10pt;">party </font><font style="display: inline;font-size:10pt;">reimbursement</font><font style="display: inline;font-size:10pt;"> payments</font><font style="display: inline;font-size:10pt;"> to ASPiRA LABS</font><font style="display: inline;font-size:10pt;">. Insurance coverage and reimbursement rates for diagnostic tests are uncertain, subject to change and particularly volatile during the early stages of commercialization. There remain questions as to what extent </font><font style="display: inline;font-size:10pt;">third-party payers</font><font style="display: inline;font-size:10pt;">, like Medicare, Medicaid and private insurance companies will provide coverage for OVA1</font><font style="display: inline;font-size:10pt;"> and Overa</font><font style="display: inline;font-size:10pt;"> and for which indications.&nbsp;</font><font style="display: inline;font-size:10pt;">While CMS has issued PAMA reimbursement rate</font><font style="display: inline;font-size:10pt;">s</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">for</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">OVA1 and Overa effective January 1, 2018, t</font><font style="display: inline;font-size:10pt;">here is no guarantee that CMS </font><font style="display: inline;font-size:10pt;">will </font><font style="display: inline;font-size:10pt;">continue to </font><font style="display: inline;font-size:10pt;">cover the OVA1 test or that the payment rate will be comparable to </font><font style="display: inline;font-size:10pt;">the </font><font style="display: inline;font-size:10pt;">PAMA rate</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;Such uncertainty could create payment uncertainty from other payers as well.&nbsp;&nbsp;The reimbursement rates for OVA1 </font><font style="display: inline;font-size:10pt;">and Overa </font><font style="display: inline;font-size:10pt;">are largely out of our control.&nbsp;&nbsp;We </font><font style="display: inline;font-size:10pt;">have </font><font style="display: inline;font-size:10pt;">experienced volatility in the coverage and reimbursement of OVA1 due to contract negotiation with </font><font style="display: inline;font-size:10pt;">third-party</font><font style="display: inline;font-size:10pt;"> payers and implementation requirements and the reimbursement amounts </font><font style="display: inline;font-size:10pt;">we have </font><font style="display: inline;font-size:10pt;">received from </font><font style="display: inline;font-size:10pt;">third-party </font><font style="display: inline;font-size:10pt;">payers varies from payer to payer, and, in some cases, the variation is material.&nbsp;</font><a name="_cp_text_1_572"></a><font style="display: inline;font-size:10pt;"> &nbsp; &nbsp;</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Third-party</font><font style="display: inline;font-size:10pt;"> payers, including private insurance companies as well as government payers such as Medicare and Medicaid, have increased their efforts to control the cost, utilization and delivery of healthcare services. These measures have resulted in reduced payment rates and decreased utilization of diagnostic tests such as OVA1. From time to time, Congress has considered and implemented changes to the Medicare fee schedules in conjunction with budgetary legislation, and pricing for tests covered by Medicare is subject to change at any time. Reductions in </font><font style="display: inline;font-size:10pt;">third-party</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">payer reimbursement rates may occur in the future. Reductions in the price at which OVA1</font><font style="display: inline;font-size:10pt;"> and Overa</font><font style="display: inline;font-size:10pt;"> is reimbursed could have a material adverse effect on our </font><font style="display: inline;font-size:10pt;">business, results of operations and financial condition</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;If we are unable to establish and maintain broad coverage and reimbursement for OVA1</font><font style="display: inline;font-size:10pt;"> and Overa</font><font style="display: inline;font-size:10pt;"> or if </font><font style="display: inline;font-size:10pt;">third-party</font><font style="display: inline;font-size:10pt;"> payers change their coverage or reimbursement policies with respect to OVA1, our business, financial condition and results of operations could be materially adversely affected. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">We </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">will </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">need to raise additional capital in the future</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">,</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> and if we are unable to secure adequate funds on terms acceptable to us, we may be unable to execute our business plan. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We </font><font style="display: inline;font-size:10pt;">will </font><font style="display: inline;font-size:10pt;">seek to raise additional capital through the issuance of equity or debt securities in the public or private markets, or through a collaborative arrangement or sale of assets. Additional financing opportunities may not be available to us, or if available, may not be on favorable terms. The availability of financing opportunities will depend, in part, on market conditions, and the outlook for our business. Any future issuance of equity securities or securities convertible into equity could result in substantial dilution to our stockholders, and the securities issued in such a financing may have rights, preferences or privileges senior to those of our common stock. </font><font style="display: inline;font-size:10pt;">If we are unable to obtain additional capital, we may not be able to continue our sales and marketing</font><font style="display: inline;font-size:10pt;">, research and development</font><font style="display: inline;font-size:10pt;">, distribution</font><font style="display: inline;font-size:10pt;"> or other operations on the scope or scale of our current activity.</font>
		</p>
		<p style="margin:13.5pt 0pt 5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Our success depends, in part, on our ability to commercialize </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">OVA1 and</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">/or</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Overa </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">both within and </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">outside the United States, and there is no assurance that we will be able to do so successfully. </font>
		</p>
		<p style="margin:13.5pt 0pt 5pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We received FDA clearance for Overa </font><font style="display: inline;font-size:10pt;">i</font><font style="display: inline;font-size:10pt;">n March 2016</font><font style="display: inline;font-size:10pt;"> and</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">launched</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Overa with customers on a targeted basis </font><font style="display: inline;font-size:10pt;">in </font><font style="display: inline;font-size:10pt;">October </font><font style="display: inline;font-size:10pt;">2016</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;Overa is intended to maintain our product&#x2019;s high sensitivity while improving specificity.&nbsp;&nbsp;Though we plan to leverage off our existing infrastructure for OVA1, including ASPiRA </font><font style="display: inline;font-size:10pt;">LABS</font><font style="display: inline;font-size:10pt;">, there can be no assurance that we will be successfully able to commercialize Overa in the United States, or that we will be able to obtain reimbursement for Overa from third-party payers at the same rate as OVA1.&nbsp;&nbsp;If we are unable to successfully commercialize Overa, the results of our operations could be adversely affected.</font>
		</p>
		<p style="margin:5pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Additionally, i</font><font style="display: inline;font-size:10pt;">n 201</font><font style="display: inline;font-size:10pt;">6</font><font style="display: inline;font-size:10pt;"> and 201</font><font style="display: inline;font-size:10pt;">7</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">virtually </font><font style="display: inline;font-size:10pt;">all of our product revenue was generated in the United States.&nbsp;&nbsp;In 201</font><font style="display: inline;font-size:10pt;">6</font><font style="display: inline;font-size:10pt;">, we </font><font style="display: inline;font-size:10pt;">entered into our initial contracts with</font><font style="display: inline;font-size:10pt;"> customers and other distributors and partners outside the United States</font><a name="_cp_text_1_29"></a><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">and</font><font style="display: inline;font-size:10pt;"> beg</font><font style="display: inline;font-size:10pt;">a</font><font style="display: inline;font-size:10pt;">n directly or indirectly marketing and selling </font><font style="display: inline;font-size:10pt;">Overa</font><font style="display: inline;font-size:10pt;"> outside the United States in 201</font><font style="display: inline;font-size:10pt;">7</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;We may not be able to find suitable customers or other distributors or partners outside the United States that are willing to enter into business relationships with us on terms that are advantageous to us or at all.&nbsp;&nbsp;Moreover, </font><font style="display: inline;font-size:10pt;">while we registered the CE mark and in October 2015 obtained clearance to market Overa in the European Union, </font><font style="display: inline;font-size:10pt;">we may be prohibited </font><font style="display: inline;font-size:10pt;">in the future </font><font style="display: inline;font-size:10pt;">from directly or indirectly marketing or selling </font><font style="display: inline;font-size:10pt;">Overa</font><font style="display: inline;font-size:10pt;"> in </font><font style="display: inline;font-size:10pt;">the European Union or </font><font style="display: inline;font-size:10pt;">various </font><font style="display: inline;font-size:10pt;">other </font><font style="display: inline;font-size:10pt;">jurisdictions outside the United States if we are unable to obtain applicable regulatory approvals.&nbsp;&nbsp;In addition, we will need to ensure that third-party payers, including insurance companies and government payers, in jurisdictions outside the United States will pay or reimburse for </font><font style="display: inline;font-size:10pt;">OVA1 or </font><font style="display: inline;font-size:10pt;">Overa</font><font style="display: inline;font-size:10pt;"> tests performed in those jurisdictions.&nbsp; </font>
		</p>
		<p style="margin:5pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">If we are able to </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">establish operations in countries </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">outside </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">of </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">the United States, we</font><font style="display: inline;font-size:10pt;">&nbsp;</font><a name="_cp_text_4_584"></a><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">may be subject to political, economic and other conditions affecting these countries that could result in increased operating expenses and regulation. </font>
		</p>
		<p style="margin:5pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_1_586"></a><font style="display: inline;font-size:10pt;">In 2016 and 2017, virtually all of our product revenue was generated in the United States. </font><font style="display: inline;font-size:10pt;">If we are able to </font><a name="_cp_text_4_587"></a><font style="display: inline;font-size:10pt;">successfully commercialize</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">OVA1 and </font><font style="display: inline;font-size:10pt;">Overa</font><font style="display: inline;font-size:10pt;">&nbsp;</font><a name="_cp_text_1_588"></a><font style="display: inline;font-size:10pt;">outside the United States, there are risks inherent in conducting business internationally, including the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;text-decoration:none;color:#000000;text-decoration:none;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_589"></a><a name="_cp_text_1_590"></a><font style="display: inline;color:#000000;">d</font><font style="display: inline;color:#000000;">ata privacy laws that may apply to the transmission of any clients&#x2019; and employees&#x2019; data to the United States;</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">19</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;text-decoration:none;color:#000000;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_591"></a><a name="_cp_text_1_592"></a><font style="display: inline;color:#000000;">i</font><font style="display: inline;color:#000000;">mport/export sanctions and restrictions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;text-decoration:none;color:#000000;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_593"></a><a name="_cp_text_1_594"></a><font style="display: inline;color:#000000;">c</font><font style="display: inline;color:#000000;">ompliance with applicable anti-corruption laws;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;text-decoration:none;color:#000000;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_595"></a><a name="_cp_text_1_596"></a><font style="display: inline;color:#000000;">d</font><font style="display: inline;color:#000000;">ifficulties in managing international distributors;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;text-decoration:none;color:#000000;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_597"></a><a name="_cp_text_1_598"></a><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">ccounting, tax and legal complexities arising from international operations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;text-decoration:none;color:#000000;text-decoration:none;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_599"></a><a name="_cp_text_1_600"></a><font style="display: inline;color:#000000;">p</font><font style="display: inline;color:#000000;">otential difficulties in transferring funds generated overseas to the United States in a tax efficient manner; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;text-decoration:none;color:#000000;text-decoration:none;border-top:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_603"></a><a name="_cp_text_1_601"></a><font style="display: inline;color:#000000;">p</font><font style="display: inline;color:#000000;">olitical and </font><a name="_cp_text_4_602"></a><font style="display: inline;color:#000000;">economic instability</font><a name="_cp_text_1_604"></a><font style="display: inline;color:#000000;">, including recent recessionary trends.</font></p></td></tr></table></div>
		<p style="margin:13.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_1_605"></a><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">If we are able to establish operations in countries outside of the United States, changes in foreign exchange rates may adversely affect our revenue and net income.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_1_609"></a><font style="display: inline;font-size:10pt;color:#000000;">If we are able to successfully commercialize </font><font style="display: inline;font-size:10pt;color:#000000;">OVA1 and</font><font style="display: inline;font-size:10pt;color:#000000;">/or</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">Overa</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><a name="_cp_text_4_610"></a><font style="display: inline;font-size:10pt;color:#000000;">outside the United States, </font><a name="_cp_text_1_611"></a><font style="display: inline;font-size:10pt;color:#000000;">we expect that revenue and expense from our foreign operations will typically be denominated in local currencies, thereby creating exposure to changes in exchange rates.&nbsp;&nbsp;Revenue and profit generated by any international operations will increase or decrease as a result of changes in foreign currency exchange rates.&nbsp;&nbsp;Adverse changes to foreign exchange rates could decrease the value of revenue we receive from our contemplated international operations and </font><a name="_cp_text_4_612"></a><font style="display: inline;font-size:10pt;color:#000000;">have a material adverse impact on our </font><a name="_cp_text_1_613"></a><font style="display: inline;font-size:10pt;color:#000000;">business, </font><a name="_cp_text_4_614"></a><font style="display: inline;font-size:10pt;color:#000000;">results of operations </font><a name="_cp_text_1_615"></a><font style="display: inline;font-size:10pt;color:#000000;">and financial condition. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">If we fail to continue to develop our existing technologies, we may not be able to successfully foster adoption of our products and services</font><a name="_cp_text_1_202"></a><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">. &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_203"></a><font style="display: inline;font-size:10pt;color:#000000;">Our technologies are new and complex, and are subject to change as new discoveries are made. New discoveries and advancements in the diagnostic field are essential if we are to foster the adoption of our product offerings. Development of</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><a name="_cp_text_1_204"></a><font style="display: inline;font-size:10pt;color:#000000;">our existing </font><a name="_cp_text_4_205"></a><font style="display: inline;font-size:10pt;color:#000000;">technologies remains a substantial risk to us due to various factors, includ</font><font style="display: inline;font-size:10pt;color:#000000;">ing the scientific challenges involved, our ability to find and collaborate successfully with others working in the diagnostic field, and competing technologies, which may prove more successful than our technologies. </font><a name="_cp_text_4_206"></a>
		</p>
		<p style="margin:13.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">We may not succeed in developing additional diagnostic products, and, even if we do succeed in developing additional diagnostic products, the diagnostic products may never achieve significant commercial market acceptance. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Our success depends on our ability to continue to develop and commercialize diagnostic products. There is considerable risk in developing diagnostic products based on our biomarker discovery efforts, as candidate biomarkers may fail to validate results in larger clinical studies or may not achieve acceptable levels of clinical accuracy. For example, markers being evaluated for one or more next-generation diagnostic tests may not be validated in downstream pre-clinical or clinical studies, once we undertake and perform such studies. </font><font style="display: inline;font-size:10pt;color:#000000;">In addition, development of products combining biomarkers with imaging, patient risk factors or other risk indicators carry higher than average risks due to technical, clinical and regulatory uncertainties. While we have published proof of concept on combining OVA1 </font><font style="display: inline;font-size:10pt;color:#000000;">and </font><font style="display: inline;font-size:10pt;color:#000000;">imaging, for example, our ability to develop, verify and validate an algorithm that generalizes to routine testing populations cannot be guaranteed. </font><font style="display: inline;font-size:10pt;color:#000000;">In addition, our efforts to develop diagnostic tests for </font><font style="color:#00C000;display: inline;color:#000000;font-size:10pt;text-decoration:none;">endometriosis and PCOS are in the discovery phase</font><font style="color:#00C000;display: inline;color:#000000;font-size:10pt;text-decoration:none;">,</font><font style="color:#00C000;display: inline;color:#000000;font-size:10pt;text-decoration:none;"> and future pre-clinical or clinical studies may not support our early data. </font><font style="display: inline;font-size:10pt;color:#000000;">If successful, the regulatory pathway and clearance/approval process may require extensive discussion with applicable authorities and possibly medical panels or other oversight mechanisms. These pose considerable risk in projecting launch dates, requirements for clinical evidence and eventual pricing and return on investment. </font><font style="display: inline;font-size:10pt;color:#000000;">Although we are </font><font style="display: inline;font-size:10pt;color:#000000;">engaging important stakeholders representing gynecologic oncology, benign gynecology, patient advocacy, women&#x2019;s health research, reimbursement and others</font><font style="display: inline;font-size:10pt;color:#000000;">, &nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">success, timelines and value will be uncertain and require active management at all stages of innovation and development.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Clinical testing is expensive, takes many years to complete and can have an uncertain outcome. Clinical failure can occur at any stage of the testing. Clinical trials for our next generation ovarian cancer tests, and other future diagnostic tests</font><font style="display: inline;font-size:10pt;color:#000000;">,</font><font style="display: inline;font-size:10pt;color:#000000;"> may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and/or non-clinical testing on these tests. In addition, the results of our clinical trials may identify unexpected risks relative to safety or efficacy, which could complicate, delay or halt clinical trials, or result in the denial of regulatory approval by the FDA and other regulatory authorities. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">If we do succeed in developing additional diagnostic tests with acceptable performance characteristics, we may not succeed in achieving commercial market acceptance for those tests. Our ability to successfully commercialize diagnostic products, including OVA1</font><font style="display: inline;font-size:10pt;color:#000000;"> and</font><font style="display: inline;font-size:10pt;color:#000000;">/or</font><font style="display: inline;font-size:10pt;color:#000000;"> Overa</font><font style="display: inline;font-size:10pt;color:#000000;">, will depend on many factors, including: </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:92.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">20</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:05.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2022;</font></p>
				</td>
				<td valign="top" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:92.00%;padding:0pt;">
					<p style="margin:5pt 0pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">our ability to convince the medical community of the safety and clinical efficacy of our products and their advantages over existing diagnostic products; </font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.45pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:4.45pt;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.45pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:4.45pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.45pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:4.45pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:92.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.45pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:4.45pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:05.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2022;</font></p>
				</td>
				<td valign="top" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:92.00%;padding:0pt;">
					<p style="margin:5pt 0pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">our success in establishing new clinical practices or changing previous ones, such that utilization of the tests fail to meet established standards of care, medical guidelines and the like; </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:496.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:05.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2022;</font></p>
				</td>
				<td valign="top" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:496.80pt;padding:0pt;">
					<p style="margin:5pt 0pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">our ability to </font><font style="display: inline;font-size:10pt;color:#000000;">develop</font><font style="display: inline;font-size:10pt;color:#000000;"> business relationships with diagnostic or laboratory companies that can assist in the commercialization of these products in the U</font><font style="display: inline;font-size:10pt;color:#000000;">.</font><font style="display: inline;font-size:10pt;color:#000000;">S</font><font style="display: inline;font-size:10pt;color:#000000;">.</font><font style="display: inline;font-size:10pt;color:#000000;"> and globally; and </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:496.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:05.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2022;</font></p>
				</td>
				<td valign="top" style="width:01.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:496.80pt;padding:0pt;">
					<p style="margin:5pt 0pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">the scope and extent of the agreement by Medicare and third-party payers to provide full or partial reimbursement coverage for our products, which will affect patients&#x2019; willingness to pay for our products and will likely heavily influence physicians&#x2019; decisions to recommend or use our products. </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">These factors present obstacles to commercial acceptance of our existing and potential diagnostic products, for which we will have to spend substantial time and financial resources to overcome, and there is no guarantee that we will be successful in doing so. Our inability to do so successfully would prevent us from generating revenue from </font><font style="display: inline;font-size:10pt;color:#000000;">OVA1</font><font style="display: inline;font-size:10pt;color:#000000;">, Overa</font><font style="display: inline;font-size:10pt;color:#000000;"> and </font><font style="display: inline;font-size:10pt;color:#000000;">future diagnostic products.</font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">The diagnostics market is competitive</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">,</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;"> and we may not be able to compete successfully, which would adversely impact our ability to generate revenue. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Our principal competition currently comes from the many clinical options available to medical personnel involved in clinical decision making. For example, rather than ordering an OVA1 </font><font style="display: inline;font-size:10pt;color:#000000;">or Overa </font><font style="display: inline;font-size:10pt;color:#000000;">test </font><font style="display: inline;font-size:10pt;color:#000000;">for a woman with an adnexal mass, obstetricians, gynecologists, and gynecologic oncologists may choose a different clinical option or none at all. If we are not able to convince clinicians that OVA1 </font><font style="display: inline;font-size:10pt;color:#000000;">and Overa </font><font style="display: inline;font-size:10pt;color:#000000;">provide significant improvement over current clinical practices, our ability to commercialize OVA1 </font><font style="display: inline;font-size:10pt;color:#000000;">and Overa </font><font style="display: inline;font-size:10pt;color:#000000;">w</font><font style="display: inline;font-size:10pt;color:#000000;">ill</font><font style="display: inline;font-size:10pt;color:#000000;"> be adversely affected. Additionally, in September 2011</font><font style="display: inline;font-size:10pt;color:#000000;">, &nbsp;</font><a name="_cp_text_4_624"></a><font style="display: inline;font-size:10pt;color:#000000;">Fujirebio Diagnostics received FDA clearance for its ROMA test. ROMA combines two tumor markers and menopausal status into a numerical score using a publicly available algorithm. This test has the same intended use and precautions as </font><font style="display: inline;font-size:10pt;color:#000000;">OVA1</font><font style="display: inline;font-size:10pt;color:#000000;">,</font><font style="display: inline;font-size:10pt;color:#000000;"> and our revenues could be materially and adversely affected if the ROMA test is successfully commercialized. In addition, competitors, such as Becton Dickinson, ArrayIt Corporation, and Abbott Lab</font><font style="display: inline;font-size:10pt;color:#000000;">oratories</font><font style="display: inline;font-size:10pt;color:#000000;"> have publicly disclosed that they have been or are currently working on ovarian cancer diagnostic assays. Academic institutions periodically report new findings in ovarian cancer diagnostics that may have commercial value. Our failure to compete with any competitive diagnostic assay if and when commercialized could adversely affect our business</font><font style="display: inline;font-size:10pt;color:#000000;">, financial condition and results of operations</font><font style="display: inline;font-size:10pt;color:#000000;">. &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">We have priced OVA1</font><font style="display: inline;font-size:10pt;color:#000000;"> and </font><font style="display: inline;font-size:10pt;color:#000000;">Overa</font><font style="display: inline;font-size:10pt;color:#000000;"> at a point that recognizes the value-added by its increased sensitivity for ovarian malignancy. If others develop a test that is viewed to be similar to OVA1</font><font style="display: inline;font-size:10pt;color:#000000;"> or </font><font style="display: inline;font-size:10pt;color:#000000;">Overa</font><font style="display: inline;font-size:10pt;color:#000000;"> in efficacy but is priced at a lower point, we and/or our strategic partners may have to lower the price of OVA1</font><font style="display: inline;font-size:10pt;color:#000000;"> or </font><font style="display: inline;font-size:10pt;color:#000000;">Overa</font><font style="display: inline;font-size:10pt;color:#000000;"> in order to effectively compete, which would impact our margins and potential for profitability.</font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_630"></a><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Our diagnostic tests are subject to ongoing regulation by the FDA</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">; the </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">commercialization of our diagnostic tests may be </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">adversely </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">affected by changing FDA regulations</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;"> and any delay by or failure of the FDA to approve our diagnostic tests submitted to the FDA may adversely affect our </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">business</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">, results of operations and financial condition. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_634"></a><font style="display: inline;font-size:10pt;color:#000000;">The FDA cleared </font><font style="display: inline;font-size:10pt;color:#000000;">Overa in March 2016</font><font style="display: inline;font-size:10pt;color:#000000;"> and OVA1 in September 2009</font><font style="display: inline;font-size:10pt;color:#000000;">.&nbsp;&nbsp;In connection with the clearance of OVA1 we agreed to conduct certain post-market surveillance </font><a name="_cp_text_1_635"></a><font style="display: inline;font-size:10pt;color:#000000;">studies </font><a name="_cp_text_4_636"></a><font style="display: inline;font-size:10pt;color:#000000;">to further analyze performance of </font><font style="display: inline;font-size:10pt;color:#000000;">OVA1</font><font style="display: inline;font-size:10pt;color:#000000;">.&nbsp; </font><font style="display: inline;font-size:10pt;color:#000000;">While the OVA1 post-market study has been completed and closed with the FDA, Overa also has a post-market surveillance requirement which is </font><font style="display: inline;font-size:10pt;color:#000000;">under</font><font style="display: inline;font-size:10pt;color:#000000;"> discus</font><font style="display: inline;font-size:10pt;color:#000000;">sion</font><font style="display: inline;font-size:10pt;color:#000000;"> with the FDA. </font><font style="display: inline;font-size:10pt;color:#000000;">Failure to comply with our post-marketing study requirements may lead to enforcement actions by </font><a name="_cp_text_1_637"></a><font style="display: inline;font-size:10pt;color:#000000;">the </font><a name="_cp_text_4_638"></a><font style="display: inline;font-size:10pt;color:#000000;">FDA, including seizure of our product, injunction, prosecution </font><a name="_cp_text_4_639"></a><font style="display: inline;font-size:10pt;color:#000000;">and/or civil money penalties, which may </font><a name="_cp_text_4_640"></a><font style="display: inline;font-size:10pt;color:#000000;">harm our business</font><a name="_cp_text_4_641"></a><font style="display: inline;font-size:10pt;color:#000000;">, results of operations and financial condition.</font><a name="_cp_text_4_642"></a>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;"> Our activities related to diagnostic products are, or have the potential to be, subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of our products. Failure to comply with applicable requirements can lead to sanctions, including withdrawal of products from the market, recalls, refusal to authorize government contracts, product seizures, civil money penalties, injunctions and criminal prosecution. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">The </font><font style="display: inline;font-size:10pt;color:#000000;">Federal </font><font style="display: inline;font-size:10pt;color:#000000;">Food, Drug and Cosmetic Act requires that medical devices introduced to the United States market, unless exempted by regulation, be the subject of either a pre-market notification clearance, known as a 510(k) clearance or 510(k) </font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">de novo</font><font style="display: inline;font-size:10pt;color:#000000;"> clearance, or a </font><font style="display: inline;font-size:10pt;color:#000000;">PMA</font><font style="display: inline;font-size:10pt;color:#000000;">. Some of our potential future clinical products may require a 510(k) or 510(k) </font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">de novo</font><font style="display: inline;font-size:10pt;color:#000000;"> clearance, while others may require a PMA. With respect to devices reviewed through the 510(k) process, we may not market a device until an order is issued by the FDA finding our product to be substantially equivalent to a legally marketed device known as a predicate device. A 510(k) submission may involve the presentation of a substantial volume of data, including clinical data. The FDA may agree that the product </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">21</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-size:10pt;">is substantially equivalent to a predicate device and allow the product to be marketed in the United States. On the other hand, the FDA may determine that the device is not substantially equivalent and require a PMA</font><font style="display: inline;font-size:10pt;"> or</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">a &nbsp;</font><font style="display: inline;font-style:italic;font-size:10pt;">de novo</font><font style="display: inline;font-size:10pt;"> 510(k), </font><font style="display: inline;font-size:10pt;">or require further information, such as additional test data, including data from clinical studies, before it is able to make a determination regarding substantial equivalence. By requesting additional information, the FDA can delay market introduction of our products. Delays in receipt of or failure to receive any necessary 510(k) clearance or PMA approval, or the imposition of stringent restrictions on the labeling and sales of our products, could have a material adverse effect on </font><font style="display: inline;font-size:10pt;">our business, results of operations and financial condition</font><font style="display: inline;font-size:10pt;">. If the FDA indicates that a PMA is required for any of our potential future clinical products, the application will require extensive clinical studies, manufacturing information and likely review by a panel of experts outside the FDA. Clinical studies to support either a 510(k) submission or a PMA application would need to be conducted in accordance with FDA requirements. Failure to comply with FDA requirements could result in the FDA&#x2019;s refusal to accept the data or the imposition of regulatory sanctions. We cannot assure that any necessary 510(k) clearance or PMA approval will be granted on a timely basis, or at all. To the extent we seek FDA 510(k) clearance or FDA pre-market approval for other diagnostic tests, any delay by or failure of the FDA to clear or approve those diagnostic tests may adversely affect our consolidated revenues, results of operations and financial condition.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">I</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">f we or our suppliers fail to comply with FDA requirements for production, marketing and post</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">-</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">market monitoring of our products, we may not be able to market our products and services and may be subject to stringent penalties, product restrictions or recall; further improvements to our manufacturing operations may be required that could entail additional costs. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The commercialization of our products could be delayed, halted or prevented by applicable FDA regulations. If the FDA were to view any of our actions as non-compliant, it could initiate enforcement actions, such as a warning letter and possible imposition of penalties. </font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">For instance, we are </font><font style="display: inline;font-size:10pt;">subject to a number of FDA requirements, including compliance with the FDA&#x2019;s </font><font style="display: inline;font-size:10pt;">Quality System Regulations &#x201C;</font><font style="display: inline;font-size:10pt;">QSR</font><font style="display: inline;font-size:10pt;">&#x201D;</font><font style="display: inline;font-size:10pt;"> requirements</font><font style="display: inline;font-size:10pt;">, which establish extensive requirements for quality assurance and control as well as manufacturing procedures. Failure to comply with these regulations could result in enforcement actions for us or our potential suppliers. Adverse FDA actions in any of these areas could significantly increase our expenses and </font><font style="display: inline;font-size:10pt;">reduce</font><font style="display: inline;font-size:10pt;"> our revenue. We will need to undertake steps to maintain our operations in line with the FDA&#x2019;s QSR requirements. Some components of OVA1</font><font style="display: inline;font-size:10pt;"> and Overa</font><font style="display: inline;font-size:10pt;"> are manufactured by other companies and we are required to </font><font style="display: inline;font-size:10pt;">ensure that, to the extent that we incorporate those components into our finished OVA1 </font><font style="display: inline;font-size:10pt;">or Overa </font><font style="display: inline;font-size:10pt;">test, we use those components in compliance with QSR. </font><font style="display: inline;font-size:10pt;"> Any failure to do so would have an adverse effect on our ability to commercialize OVA1</font><font style="display: inline;font-size:10pt;"> or Overa</font><font style="display: inline;font-size:10pt;">. Our suppliers&#x2019; manufacturing facilities</font><font style="display: inline;font-size:10pt;">, since they manufacture finished kits that we use in OVA1</font><font style="display: inline;font-size:10pt;"> and Overa</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">are</font><font style="display: inline;font-size:10pt;"> subject to periodic regulatory inspections by the FDA and other federal and state regulatory agencies. </font><font style="display: inline;font-size:10pt;">Our facility also is subject to FDA inspection. We or our suppliers may not satisfy such regulatory requirements, and any such failure to do so may adversely affect our business, financial condition and results of operations.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">If our suppliers fail to produce acceptable or sufficient stock, make changes to the design or labeling of their biomarker kits or discontinue production of existing biomarker kits</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> or instrument platforms</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">, we may be unable to meet market demand for OVA1</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> and Overa</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The commercialization of our OVA1 </font><font style="display: inline;font-size:10pt;">and Overa </font><font style="display: inline;font-size:10pt;">test</font><font style="display: inline;font-size:10pt;">s</font><font style="display: inline;font-size:10pt;"> depend on the supply of </font><font style="display: inline;font-size:10pt;">seven </font><font style="display: inline;font-size:10pt;">different immunoassay kits from third-party </font><font style="display: inline;color:#000000;font-size:10pt;">manufacturers</font><font style="display: inline;color:#000000;font-size:10pt;"> that</font><font style="display: inline;color:#000000;font-size:10pt;"> run on automated instruments</font><font style="display: inline;color:#000000;font-size:10pt;">. Failure </font><font style="display: inline;font-size:10pt;">by any of these manufacturers to produce kits that pass </font><font style="display: inline;font-size:10pt;">our </font><font style="display: inline;font-size:10pt;">quality control measures might lead to back-order and/or loss of revenue due to missed sales and customer dissatisfaction. In addition, if the design or labeling of any kit were to change, continued OVA1</font><font style="display: inline;font-size:10pt;"> or Overa</font><font style="display: inline;font-size:10pt;"> supply could be threatened since new validation and submission to the FDA for 510(k) clearance could be required as a condition of sale. Discontinuation of any of these kits </font><font style="display: inline;font-size:10pt;">c</font><font style="display: inline;font-size:10pt;">ould require identification, validation and 510(k) submission on a revised OVA1</font><font style="display: inline;font-size:10pt;"> or Overa</font><font style="display: inline;font-size:10pt;"> design. </font><font style="display: inline;color:#000000;font-size:10pt;">Likewise, discontinuation or failure to support or service the instruments may pose risk to ongoing operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">For example</font><font style="display: inline;font-size:10pt;">, o</font><font style="display: inline;font-size:10pt;">ne of the five immunoassay component kits that are used in </font><font style="display: inline;color:#000000;font-size:10pt;">OVA1 </font><font style="display: inline;color:#000000;font-size:10pt;">has </font><font style="display: inline;color:#000000;font-size:10pt;">ceased to</font><font style="display: inline;color:#000000;font-size:10pt;"> be supported on the instrument as the manufacturer </font><font style="display: inline;color:#000000;font-size:10pt;">transitioned</font><font style="display: inline;color:#000000;font-size:10pt;"> to a newer platform. While we </font><font style="display: inline;color:#000000;font-size:10pt;">have not experienced and </font><font style="display: inline;color:#000000;font-size:10pt;">do not anticipate disruption of ongoing operations, failure of </font><font style="display: inline;color:#000000;font-size:10pt;">a &nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">manufacturer to provide extended service or support might harm </font><font style="display: inline;color:#000000;font-size:10pt;">our</font><font style="display: inline;color:#000000;font-size:10pt;"> business. </font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Overa consolidates the five OVA1 immunoassays onto a single mainstream automated platform and substitutes a new immunoassay component kit for the discontinuing kit as a mitigating action. </font><font style="display: inline;font-size:10pt;">Although</font><font style="display: inline;font-size:10pt;"> we received a 510(k) clearance from the FDA for Overa</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">i</font><font style="display: inline;font-size:10pt;">n March 2016</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;"> there can be no assurances that there will not be future disruptions in our supply chain</font><font style="display: inline;font-size:10pt;">. Any resulting disruption to our supply of OVA1</font><font style="display: inline;font-size:10pt;"> or Overa</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">would </font><font style="display: inline;font-size:10pt;">adversely affect our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">If we fail to maintain our rights to utilize intellectual property directed to diagnostic biomarkers, we may not be able to offer diagnostic tests using those biomarkers. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">One aspect of our business plan is to develop diagnostic tests based on certain biomarkers, which we have the right to utilize through licenses with our academic collaborators, such as </font><font style="display: inline;font-size:10pt;">Johns Hopkins University School of Medicine and the University of Texas M.D. Anderson Cancer Center</font><font style="display: inline;font-size:10pt;">. In some cases, our collaborators own the entire right to the biomarkers. In other cases, we co-own the biomarkers with our collaborators. If, for some reason, we lose our license to biomarkers owned entirely by our collaborators, we may not be able to use those biomarkers in diagnostic tests. If we lose our exclusive license to biomarkers co-owned by us and our </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">22</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-size:10pt;">collaborators, our collaborators may license their share of the intellectual property to a </font><font style="display: inline;font-size:10pt;">third</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">party</font><font style="display: inline;font-size:10pt;"> that may compete with us in offering diagnostic tests, which would materially adversely affect our </font><font style="display: inline;font-size:10pt;">business</font><font style="display: inline;font-size:10pt;">, results of operations and financial condition.</font>
		</p>
		<p style="margin:6pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">If a </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">third</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">party</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> infringes on our proprietary rights, we may lose any competitive advantage we may have as a result of diversion of our time, enforcement costs and the loss of the exclusivity of our proprietary rights. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Our success depends in part on our ability to maintain and enforce our proprietary rights. We rely on a combination of patents, trademarks, copyrights and trade secrets to protect our technology and brand. We have submitted a number of patent applications covering biomarkers that may have diagnostic or therapeutic utility. Our patent applications may or may not result in additional patents being issued. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">If </font><font style="display: inline;font-size:10pt;">third parties</font><font style="display: inline;font-size:10pt;"> engage in activities that infringe on our proprietary rights, we may incur significant costs in asserting our rights</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;"> and the attention of our management may be diverted from our business</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">We may not be successful in asserting our proprietary rights</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">which could result in our patents being held invalid or a court holding that the competitor is not infringing, either of which </font><font style="display: inline;font-size:10pt;">may</font><font style="display: inline;font-size:10pt;"> harm our competitive position. We cannot be sure that competitors will not design around our patented technology. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We also rely upon the skills, knowledge and experience of our technical personnel. To help protect our rights, we require all employees and consultants to enter into confidentiality agreements that prohibit the disclosure of confidential information. These agreements may not provide adequate protection for our trade secrets, knowledge or other proprietary information in the event of any unauthorized use or disclosure. If any trade secret, knowledge or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, it could have a material adverse effect on our business, consolidated results of operations and financial condition. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">If others successfully assert their proprietary rights against us, we may be precluded from making and selling our products or we may be required to obtain licenses to use their technology. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Our success depends on avoiding infringing on the proprietary technologies of others. If a </font><font style="display: inline;font-size:10pt;">third</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">party</font><font style="display: inline;font-size:10pt;"> were to assert claims that we are violating </font><font style="display: inline;font-size:10pt;">its</font><font style="display: inline;font-size:10pt;"> patents, we might incur substantial costs defending ourselves in lawsuits against charges of patent infringement or other unlawful use of another&#x2019;s proprietary technology. Any such lawsuit may </font><font style="display: inline;font-size:10pt;">involve considerable management and financial resources and may </font><font style="display: inline;font-size:10pt;">not be decided in our favor</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">I</font><font style="display: inline;font-size:10pt;">f we are found liable, </font><font style="display: inline;font-size:10pt;">we</font><font style="display: inline;font-size:10pt;"> may be subject to monetary damages or </font><font style="display: inline;font-size:10pt;">an </font><font style="display: inline;font-size:10pt;">injunction </font><font style="display: inline;font-size:10pt;">prohibiting us from</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">using the technology. We may also be required to obtain licenses under patents owned by third parties and such licenses may not be available to us on commercially reasonable terms, if at all. </font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">F</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">uture litigation against us could be costly and time consuming to defend. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We are from time to time subject to legal proceedings and claims that arise in the ordinary course of business, such as claims brought by our clients in connection with commercial disputes, employment claims made by current or former employees, and claims brought by third parties alleging infringement o</font><font style="display: inline;font-size:10pt;">f</font><font style="display: inline;font-size:10pt;"> their intellectual property rights. In addition, we may bring claims against third parties for infringement o</font><font style="display: inline;font-size:10pt;">f</font><font style="display: inline;font-size:10pt;"> our intellectual property rights. Litigation may result in substantial costs and may divert our attention and resources, which may </font><font style="display: inline;font-size:10pt;">adversely affect</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">our business, results of operations and financial condition. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">An unfavorable judgment against us in any legal proceeding or claim could require us to pay monetary damages. In addition, an unfavorable judgment in which the counterparty is awarded equitable relief, such as an injunction, could harm our business, results of operations and financial condition. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Our diagnostic efforts may cause us to have significant product liability exposure. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:10pt;">The testing, manufacturing and marketing of medical diagnostic tests entail an inherent risk of product liability claims. Potential product liability claims may exceed the amount of our insurance coverage or may be excluded from coverage under the terms of the policy. We will need to increase our amount of insurance coverage in the future if we are successful at introducing new diagnostic products, and this will increase our costs. If we are held liable for a claim or for damages exceeding the limit of our insurance coverage, we may be required to make substantial payments. This may have an adverse effect on our business, financial condition and results of operations.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Because our business is highly dependent on key executives and employees, our inability to recruit and retain these people could hinder our business plans. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We are highly dependent on our executive officers and certain key employees. Our executive officers and key employees are employed at will by us. Any inability to engage new executive officers or key employees could impact operations or delay or curtail our research, development and commercialization objectives. To continue our research and product development efforts, we need people skilled in areas such as clinical operations, regulatory affairs and clinical diagnostics. Competition for qualified employees is intense. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">If we lose the services of any executive officers or key employees, our ability to achieve our business objectives could be harmed, which in turn could adversely affect our business</font><font style="display: inline;font-size:10pt;">, financial condition</font><font style="display: inline;font-size:10pt;"> and results</font><font style="display: inline;font-size:10pt;"> of operations</font><font style="display: inline;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">23</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Business interruptions could limit our ability to operate our business. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Our operations, as well as those of the collaborators on which we depend, are vulnerable to damage or interruption from fire; natural disasters, including earthquakes</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;"> computer viruses</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">human error</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">power shortages</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">telecommunication failures</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">international acts of terror</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">and similar events. Although we have certain business continuity plans in place, we have not established a formal comprehensive disaster recovery plan, and our back-up operations and business interruption insurance may not be adequate to compensate </font><font style="display: inline;font-size:10pt;">us</font><font style="display: inline;font-size:10pt;"> for losses we may suffer. A significant business interruption could result in losses or damages incurred by us and require us to cease or curtail our operations. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Legislative actions resulting in higher compliance costs </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">may</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> adversely affect our </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">business</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">, financial </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">condition and results of operations</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Compliance with laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002, and new regulations adopted by the SEC, are resulting in increased compliance costs. We, like all other public companies, are incurring expenses and diverting employees&#x2019; time in an effort to comply with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002. The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations. Compliance with these evolving standards will result in increased general and administrative expenses and may cause a diversion of our time and attention from revenue-generating activities to compliance activities. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Changes in healthcare policy</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> could increase our costs and impact sales of and reimbursement for our tests. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">T</font><font style="display: inline;font-size:10pt;">he Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the &#x201C;PPACA&#x201D;) </font><font style="display: inline;font-size:10pt;">requires </font><font style="display: inline;font-size:10pt;">each medical device manufacturer </font><font style="display: inline;font-size:10pt;">to pay</font><font style="display: inline;font-size:10pt;"> a sales tax in an amount equal to 2.3</font><font style="display: inline;font-size:10pt;">%</font><font style="display: inline;font-size:10pt;"> of the price for which such manufacturer sells its medical devices</font><font style="display: inline;font-size:10pt;"> (currently under a moratorium until December 31, 201</font><font style="display: inline;font-size:10pt;">9</font><font style="display: inline;font-size:10pt;">)</font><font style="display: inline;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-size:10pt;">PAMA</font><font style="display: inline;font-size:10pt;"> halted certain reductions in payment mandated by </font><font style="display: inline;font-size:10pt;">the </font><font style="display: inline;font-size:10pt;">PPACA as well as certain CMS policies</font><font style="display: inline;font-size:10pt;"> and has</font><font style="display: inline;font-size:10pt;"> instead establish</font><font style="display: inline;font-size:10pt;">ed</font><font style="display: inline;font-size:10pt;"> a market-based reimbursement system for clinical laboratories beginning in 201</font><font style="display: inline;font-size:10pt;">8</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">after </font><font style="display: inline;font-size:10pt;">requir</font><font style="display: inline;font-size:10pt;">ing</font><font style="display: inline;font-size:10pt;"> reporting of certain private payer reimbursement data by laboratories.&nbsp;&nbsp;CMS also issued various regulations and guidance generally effective</font><font style="display: inline;font-size:10pt;"> in</font><font style="display: inline;font-size:10pt;"> 2014 that limited reimbursement for clinical laboratory tests as a general matter, but permitted the continued ability for CMS to pay for </font><font style="display: inline;font-size:10pt;">Multianalyte Assays with Algorithmic Analyses </font><font style="display: inline;font-size:10pt;">in certain circumstances. In addition to these changes, a number of states are also contemplating significant reform of their healthcare policies. We cannot predict whether future healthcare initiatives will be implemented at the federal or state level, or the effect any future legislation or regulation will have on us. The taxes imposed by</font><font style="display: inline;font-size:10pt;"> the</font><font style="display: inline;font-size:10pt;"> PPACA have resulted in decreased profits to us and lower reimbursements by payers for our tests. Other changes to healthcare laws may adversely affect our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We expect that the </font><font style="display: inline;font-size:10pt;">current </font><font style="display: inline;font-size:10pt;">presidential administration </font><font style="display: inline;font-size:10pt;">and U.S. Congress will seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. </font><font style="display: inline;font-size:10pt;">In January 2017, the </font><font style="display: inline;font-size:10pt;">House and Senate passed a budget resolution that authorizes congressional committees to draft legislation to repeal all or portions of the Affordable Care Act and permits such legislation to pass with a majority vote in the Senate. President Trump</font><font style="display: inline;font-size:10pt;">, in response to Congress&#x2019; failure to act,</font><font style="display: inline;font-size:10pt;"> has also recently issued an executive order which </font><font style="display: inline;font-size:10pt;">encourages government agencies to make new rules that would allow more Americans to sign up for cheaper, less-regulated health plans</font><font style="display: inline;font-size:10pt;"> and </font><font style="display: inline;font-size:10pt;">allow </font><font style="display: inline;font-size:10pt;">federal agencies to waive, defer, grant exemptions from, or delay the implementation of burdensome provisions of the Affordable Care Act to the maximum extent permitted by law. There is still uncertainty with respect to the impact President Trump&#x2019;s administration and the U.S. Congress may have, if any, and any changes will likely take time to unfold</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">In December 2017, the House and Senate passed</font><font style="display: inline;font-size:10pt;"> a new tax bill </font><font style="display: inline;font-size:10pt;">that </font><font style="display: inline;font-size:10pt;">end</font><font style="display: inline;font-size:10pt;">ed</font><font style="display: inline;font-size:10pt;"> the individual mandate</font><font style="display: inline;font-size:10pt;">, which</font><font style="display: inline;font-size:10pt;"> could result in increased premiums and result in fewer covered individuals. This and other </font><font style="display: inline;font-size:10pt;">changes </font><font style="display: inline;font-size:10pt;">could have an impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by the Affordable Care Act. In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted that reduced payments to Medicare providers.</font><font style="display: inline;font-size:10pt;"> The ultimate implementation of any healthcare reform legislation and any new laws and regulations, and its impact on us, is impossible to predict. Any significant reforms made to the healthcare system in the United States, or in other jurisdictions, may have an adverse effect on our</font><font style="display: inline;font-size:10pt;"> business</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;"> financial condition and results of operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">W</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">e are subject to environmental laws and potential exposure to environmental liabilities. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We are subject to various international, federal, state and local environmental laws and regulations that govern our operations, including the handling and disposal of non-hazardous and hazardous wastes, the recycling and treatment of electrical and electronic equipment, and emissions and discharges into the environment. Failure to comply with such laws and regulations could result in costs for corrective action, penalties or the imposition of other liabilities. We are also subject to laws and regulations that impose liability and clean-up responsibility for releases of hazardous substances into the environment. Under certain of these laws and regulations, a current or previous owner or operator of property may be liable for the costs to remediate hazardous substances or petroleum products on or from its property, without regard to whether the owner or operator knew of, or caused, the contamination, as </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">24</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-size:10pt;">well as incur liability to third parties affected by such contamination. The presence of, or failure to remediate properly, such substances could adversely affect the value and the ability to transfer or encumber such property. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">The success of ASPiRA LABS depends, in part, on our ability to generate sufficient demand for its services to cover the laboratory&#x2019;s operating costs, and there is no assurance that we will be able to do so successfully. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The launch of our clinical laboratory, ASPiRA LABS, </font><font style="display: inline;font-size:10pt;">involved </font><font style="display: inline;font-size:10pt;">significant costs to us, including the costs of laboratory equipment and facilities, outside consulting fees for branding and other services and other general and administrative expenses.&nbsp;&nbsp;We expect to continue to incur significant costs to operate ASPiRA LABS in the future, such as salaries and related expenses for personnel, regulatory compliance costs and ongoing costs of outsourced billing services.&nbsp; There is no guarantee that we will be able to generate a sufficient volume of patients to access the laboratory and utilize its offerings to cover the fixed and ongoing costs of ASPiRA LABS. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">T</font><font style="display: inline;font-size:10pt;">here is no guarantee that we </font><font style="display: inline;font-size:10pt;">be able to generate sufficient revenue in the future to offset our costs</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;Our inability to successfully develop sufficient demand for the diagnostic tests processed by the laboratory could delay or prevent ASPiRA LABS from generating revenue</font><font style="display: inline;font-size:10pt;"> in excess of expenses</font><font style="display: inline;font-size:10pt;">, and we may not achieve profitability from ASPiRA LABS in the foreseeable future, if at all. If we are unable to generate </font><font style="display: inline;font-size:10pt;">sufficient </font><font style="display: inline;font-size:10pt;">revenues </font><font style="display: inline;font-size:10pt;">to </font><font style="display: inline;font-size:10pt;">achieve profitability, we may be unable to continue our ASPiRA LABS operations or we may be unable to expand our offerings at ASPiRA LABS beyond ovarian cancer to other gynecologic conditions with high unmet need as </font><font style="display: inline;font-size:10pt;">we intend</font><font style="display: inline;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">The </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">operation </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">of ASPiRA LABS requires us to comply with numerous laws and regulations, which is expensive and time-consuming and could adversely affect our business, financial condition and results of operations, and any failure to comply could result in exposure to substantial penalties and other harm to our business. </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In </font><font style="display: inline;font-size:10pt;">June </font><font style="display: inline;font-size:10pt;">2014, we launched a clinical laboratory, ASPiRA LABS. Clinical laboratories that perform tests on human subjects in the United States for the purpose of providing information for the diagnosis, prevention or treatment of disease must be certified under CLIA and licensed under applicable state laboratory laws. CLIA regulates the quality of clinical laboratory testing by requiring laboratories to comply with various technical, operational, personnel and quality requirements intended to ensure that the services provided are accurate, reliable and timely. State laws may require that additional quality standards be met and that detailed review of scientific validations and technical procedures for tests occur.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp; &nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">ASPiRA LABS holds a CLIA Certificate of Accreditation and a state laboratory license in California, </font><font style="display: inline;font-size:10pt;">Florida, Maryland, New York, Pennsylvania </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">and Rhode Island. </font><font style="display: inline;font-size:10pt;">Th</font><font style="display: inline;font-size:10pt;">is allows the lab to </font><font style="display: inline;font-size:10pt;">perform </font><font style="display: inline;font-size:10pt;">OVA1 </font><font style="display: inline;font-size:10pt;">testing </font><font style="display: inline;font-size:10pt;">on a national basis.&nbsp; </font><font style="display: inline;font-size:10pt;">We are subject to periodic surveys and inspections to maintain our CLIA certification, and such certification is also required to obtain payment from Medicare, Medicaid and certain other </font><font style="display: inline;font-size:10pt;">third-party</font><font style="display: inline;font-size:10pt;"> payers.&nbsp;&nbsp;Failure to comply with CLIA or state law requirements may result in the imposition of corrective action or </font><font style="display: inline;font-size:10pt;">the </font><font style="display: inline;font-size:10pt;">suspension or revocation of our CLIA certification or state licenses. If our CLIA certification or state licenses are suspended or revoked or our right to bill the Medicare and Medicaid programs or other </font><font style="display: inline;font-size:10pt;">third-party</font><font style="display: inline;font-size:10pt;"> payers is suspended, we would no longer be able to sell our tests, which would adversely affect our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition, no </font><font style="display: inline;">assurance can be given that ASPiRA LABS</font><a name="_cp_text_1_168"></a><font style="display: inline;">&#x2019; &nbsp;</font><font style="display: inline;">suppliers or commercial partners will remain in compliance with applicable CLIA and other federal or state regulatory requirements for laboratory operations and testing. ASPiRA </font><a name="_cp_text_1_172"></a><font style="display: inline;">LABS&#x2019; </font><font style="display: inline;">facilities and procedures and those of ASPiRA </font><a name="_cp_text_1_174"></a><font style="display: inline;">LABS&#x2019; </font><font style="display: inline;">suppliers and commercial partners are subject to ongoing regulation, including periodic inspection by regulatory and other government authorities. Possible regulatory actions for non-compliance could include warning letters, fines, damages, injunctions, civil penalties, recalls, seizures of ASPiRA </font><a name="_cp_text_1_176"></a><font style="display: inline;">LABS&#x2019; </font><font style="display: inline;">products, and criminal prosecution. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp; &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Our clinical laboratory business is also subject to regulation at both the federal and state level in the United States, as well as regulation in other jurisdictions outside of the United States, including: </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#x2022; Medicare and Medicaid coverage, coding and payment regulations applicable to clinical laboratories;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#x2022; the </font><font style="display: inline;font-size:10pt;">Federal</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Anti</font><font style="display: inline;font-size:10pt;">-</font><font style="display: inline;font-size:10pt;">Kickback</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Statute</font><font style="display: inline;font-size:10pt;"> and state anti-kickback prohibitions; </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#x2022; the federal physician self-referral prohibition, commonly known as the Stark Law, and state self-referral prohibitions;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#x2022; the Medicare civil monetary penalty and exclusion requirements;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#x2022; the Federal False Claims Act civil and criminal penalties and state equivalents; and</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">25</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#x2022; the Federal Health Insurance Portability and Accountability Act of 1996 (&#x201C;HIPAA&#x201D;) as amended by the </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;"> &nbsp; </font><font style="display: inline;font-size:10pt;">Health Information Technology for Economic and Clinical Health Act of 2009 (&#x201C;HITECH&#x201D;); </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Many of these laws and regulations prohibit a laboratory from making payments or furnishing other benefits to influence the referral of tests (by physicians or others) that are billed to Medicare, Medicaid or certain other federal or state healthcare programs. The penalties for violation of these laws and regulations may include monetary fines, criminal and civil penalties and/or suspension or exclusion from participation in Medicare, Medicaid and other federal healthcare programs. Several states have similar laws that may apply even in the absence of government payers.&nbsp;&nbsp;HIPAA and HITECH and similar state laws seek to protect the privacy and security of individually identifiable health information, and penalties for violations of these laws may include required reporting of breaches, monetary fines and criminal or civil penalties.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">While we seek to conduct our business in compliance with all applicable laws and develop compliance policies to address risk as appropriate, many of the laws and regulations applicable to us are vague or indefinite and have not been interpreted by governmental authorities or the courts. These laws or regulations also could in the future be interpreted or applied by governmental authorities or the courts in a manner that could require us to change our operations.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Any action brought against us for violation of these or other laws or regulations (including actions brought by private </font><font style="display: inline;font-style:italic;font-size:10pt;">qui tam</font><font style="display: inline;font-size:10pt;"> &#x201C;whistleblower&#x201D; plaintiffs), even if successfully defended, could divert management&#x2019;s attention from our business, damage our reputation, limit our ability to provide services, decrease demand for our services and cause </font><font style="display: inline;font-size:10pt;">us</font><font style="display: inline;font-size:10pt;"> to incur significant expenses for legal fees and damages.&nbsp; If we fail to comply with applicable laws and regulations, we could suffer civil and criminal penalties, fines, recoupment of funds received by </font><font style="display: inline;font-size:10pt;">us</font><font style="display: inline;font-size:10pt;">, exclusion from participation in federal or state healthcare programs, and the loss of various licenses, certificates and authorizations necessary to operate our business. We also could potentially incur additional liabilities from </font><font style="display: inline;font-size:10pt;">third-party</font><font style="display: inline;font-size:10pt;"> claims. If any of the foregoing were to occur, it could have a material adverse effect on our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">In the future, we plan to develop and perform LDTs at ASPiRA LABS. </font><font style="display: inline;font-weight:bold;font-style:italic;">T</font><font style="display: inline;font-weight:bold;font-style:italic;">he FDA </font><font style="display: inline;font-weight:bold;font-style:italic;">has not </font><font style="display: inline;font-weight:bold;font-style:italic;">finalize</font><font style="display: inline;font-weight:bold;font-style:italic;">d</font><font style="display: inline;font-weight:bold;font-style:italic;"> its October 2014 draft guidance documents that outline the FDA&#x2019;s proposal </font><font style="display: inline;font-weight:bold;font-style:italic;">to actively regulate </font><font style="display: inline;font-weight:bold;font-style:italic;">LDTs</font><font style="display: inline;font-weight:bold;font-style:italic;"> and instead on January 13, 2017 released a Discussion Paper on LDTs.&nbsp; </font><font style="display: inline;font-weight:bold;font-style:italic;">The </font><font style="display: inline;font-weight:bold;font-style:italic;">FDA&#x2019;s efforts to achieve broad regulation of LDTs appear to be on hold until a change in administration.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">We intend to develop and perform LDTs at ASPiRA LABS in the future.&nbsp; </font><font style="display: inline;font-size:10pt;">The FDA has historically exercised enforcement discretion and not required approvals or clearances for LDTs. </font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Instead</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;"> CMS oversees clinical laboratory operations through the Clinical Laboratory Improvement Amendments (</font><font style="display: inline;font-size:10pt;">&#x201C;</font><font style="display: inline;font-size:10pt;">CLIA</font><font style="display: inline;font-size:10pt;">&#x201D;</font><font style="display: inline;font-size:10pt;">) program.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"> Legislative proposals addressing the FDA&#x2019;s oversight of LDTs have been previously introduced, and we expect that new legislative proposals will be introduced from time to time. The likelihood that Congress will pass such legislation and the extent to which such legislation may affect the FDA&#x2019;s plans to regulate LDTs as medical devices is difficult to predict.</font><font style="display: inline;"> The 2017 Discussion Paper makes recommendations on what the agency would like to see </font><font style="display: inline;">better</font><font style="display: inline;">-</font><font style="display: inline;">controlled</font><font style="display: inline;">. However, it </font><font style="display: inline;">does not have the force of law</font><font style="display: inline;">,</font><font style="display: inline;"> and it </font><font style="display: inline;">is not </font><font style="display: inline;">a guidance document.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Even </font><font style="display: inline;">without any new</font><font style="display: inline;"> guidance documents, the FDA may assert that a test that we believe to be an LDT is not an LDT and could require us to seek clearance or approval to offer such tests for clinical use. If the FDA pre-market review or approval is required for any of the future LDTs we may develop, we may be forced to stop selling our tests or be required to modify claims or make such other changes while we work to obtain FDA clearance or approval. Our business, results of operations and financial condition would be negatively affected until such review is completed and clearance to market or approval is obtained.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">If pre-market review is required by the FDA or if we decide to voluntarily pursue FDA pre-market review of our future LDTs, there can be no assurance that any tests we develop in the future will be cleared or approved on a timely basis, if at all. Obtaining FDA clearance or approval for diagnostics can be expensive, time consuming and uncertain, and for higher-risk devices generally takes several years and requires detailed and comprehensive scientific and clinical data. In addition, medical devices are subject to ongoing FDA obligations and continued regulatory oversight and review. Ongoing compliance with FDA regulations for those tests would increase the cost of conducting our business and subject us to heightened regulation by the FDA and penalties for failure to comply with these requirements.</font>
		</p>
		<p style="margin:11pt 0pt 7.7pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">ASPiRA IVD is a </font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">recent </font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">business venture with </font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">little </font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">operating history and may subject us to additional risks.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">As of the date of the filing of this Annual Report on Form 10-K with the SEC</font><font style="display: inline;color:#000000;">, we have </font><font style="display: inline;color:#000000;">limited</font><font style="display: inline;color:#000000;"> operating results with respect to providing IVD trial services to third parties through ASPiRA IVD, and, therefore, we do not have an operating history upon which you can evaluate this new line of business or its prospects.&nbsp;&nbsp;Cash in-flows from our new IVD trial services business may not meet expectations, and ASPiRA IVD&#x2019;s prospects must be considered in light of the risks and uncertainties inherent in entering into a new line of business, including:</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">26</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">the potential diversion of management&#x2019;s attention and other resources away from our existing business;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">our relative inexperience with respect to offering IVD trial services;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">external factors, such as compliance with regulations, competitive alternatives and shifting market preferences;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">the need for additional capital and other resources to expand our IVD trial services business; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">its impact on our system of internal controls.</font></p></td></tr></table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Failure to successfully manage these risks in the development and implementation of ASPiRA IVD&#x2019;s trial services business could have an adverse effect on our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:11pt 0pt 7.7pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">The success of ASPiRA IVD depends on our ability to generate and maintain new business awards and contracts, and if we fail to do so, it could adversely affect our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The success of ASPiRA IVD depends on our ability to generate new business awards and new customers and contracts for clinical development services and other services. The time between when a study is awarded and when it goes to contract can be several months, and prior to a new business award going to contract, our potential customers will be able to cancel the award without notice. We expect that, once an award goes to contract, the majority of our customers will be able to terminate the contract with 30&nbsp;days' notice. Our IVD contracts may be delayed or terminated by our customers or reduced in scope for a variety of reasons beyond our control, including the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">decisions to forego or terminate a particular trial;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">budgetary limits or changing priorities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">actions by regulatory authorities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">production problems resulting in shortages of the drug or device being tested;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">failure of products being tested to satisfy safety requirements or efficacy criteria;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">unexpected or undesired clinical results for products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">insufficient patient enrollment in a trial;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">insufficient principal investigatory recruitment;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">shift of business to a competitor or internal resources; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">product withdrawal following market launch.</font></p></td></tr></table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:normal;color:#000000;font-size:10pt;">As a result, we expect that contract terminations, delays and modifications will be a regular part of ASPiRA IVD&#x2019;s business. In the event of termination, ASPiRA IVD&#x2019;s contracts will provide for fees for winding down the project, which include both fees incurred and actual and non-cancellable expenditures, and may also include a fee to cover a percentage of the remaining professional fees on the project. These fees may not be sufficient for us to maintain our margins, and termination may result in lower resource utilization rates and therefore lower operating margins. Cancellation of a clinical trial may also result in the unwillingness or inability of our customer</font><font style="display: inline;font-weight:normal;color:#000000;font-size:10pt;">s</font><font style="display: inline;font-weight:normal;color:#000000;font-size:10pt;"> to satisfy certain associated accounts receivable. Additionally, a change in the timing of a new business award could affect the period over which we recognize revenue and reduce our revenue in any one quarter. If ASPiRA IVD is unable to generate new business awards on a timely basis and subsequently enter into and maintain contracts for such awards, our business, financial condition and results of operations could be adversely affected.</font>
		</p>
		<p style="margin:11pt 0pt 7.7pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Operating results for ASPiRA IVD may fluctuate significantly between fiscal quarters, which may adversely affect the market price of our stock.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Operating results for ASPiRA IVD may fluctuate significantly from quarter to quarter and may be influenced by a variety of factors, such as:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">timing of contract amendments for changes in scope that could affect the value of a contract and potentially impact the amount of net new business awards and net service revenues from quarter to quarter;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">commencement, completion, execution, postponement or termination of large contracts;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">contract terms for the recognition of revenue milestones;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">progress of ongoing contracts and retention of customers;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">changes in the mix of services we are contracted to perform; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
				<font style="margin:11pt 0pt 9.9pt;font-family:Symbol;border-top:1pt none #D9D9D9;color:#000000;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:11pt 0pt 0pt;">
			<font style="display: inline;color:#000000;">potential customer disputes, penalties, or other issues that may impact the revenue we are able to recognize or the collectability of our related accounts receivable.</font></p></td></tr></table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">ASPiRA IVD&#x2019;s operating results for any particular quarter will not necessarily be a meaningful indicator of its future results. The resulting fluctuations in the Company&#x2019;s quarterly operating results could negatively affect the market price and liquidity of shares of our common stock.</font>
		</p>
		<p style="margin:11pt 0pt 7.7pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">27</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:11pt 0pt 7.7pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">If we underprice our IVD contracts, overrun our IVD cost estimates or fail to receive approval for or experience delays in documentation of IVD change orders, it could adversely affect our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We plan to price our IVD contracts based on assumptions regarding the scope of work required and cost to complete the work. We will bear the financial risk if we initially underprice our contracts or otherwise overrun our cost estimates, which could adversely affect ASPiRA IVD&#x2019;s cash flows and financial performance. In addition, we anticipate that contracts with ASPiRA IVD&#x2019;s customers will be subject to change orders, which may occur when the scope of work we perform needs to be modified from that originally contemplated in our customer contracts. This can occur, for example, when there is a change in a key study assumption or parameter or a significant change in timing. We may be unable to successfully negotiate changes in scope or change orders on a timely basis or at all, which may require us to incur cost outlays ahead of the receipt of any additional revenue. In addition, under generally accepted accounting principles in the United States we will not be able to recognize additional revenue anticipated from change orders until appropriate documentation is received by us from the customer authorizing the change. However, if we incur additional expense in anticipation of receipt of that documentation, we will need to recognize the expense as incurred. Any of the foregoing could adversely affect our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:11pt 0pt 7.7pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">The operation of ASPiRA IVD </font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">and ASPiRA LABS</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">depend on the effectiveness and availability of our information systems, including the information systems we use to provide services to our customers and to store employee data, and failures of these systems, including in connection with cyber-attacks, may materially limit our operations or have an adverse effect on our reputation.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The information systems we use for our IVD trial </font><font style="display: inline;color:#000000;">and ASPiRA LABS </font><font style="display: inline;color:#000000;">business are comprised of systems we have purchased or developed, </font><font style="display: inline;color:#000000;">our </font><font style="display: inline;color:#000000;">legacy information systems and, increasingly, web-enabled and other integrated information systems. In using these information systems, we may rely on third-party vendors to provide hosting services, where our infrastructure is dependent upon the reliability of their underlying platforms, facilities and communications systems. We also plan to utilize integrated information systems that we provide customers access to or install for our customers in conjunction with our delivery of services.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">As the breadth and complexity of ASPiRA IVD&#x2019;s </font><font style="display: inline;color:#000000;">and ASPiRA LABS </font><font style="display: inline;color:#000000;">information systems grows, we will increasingly be exposed to the risks inherent in maintaining the stability of our legacy systems due to prior customization, attrition of employees or vendors involved in their development, and obsolescence of the underlying technology as well as risks from the increasing number and scope of external data breaches on companies generally. Because certain customers and clinical trials may be dependent upon these legacy systems, we will also face an increased level of embedded risk in maintaining the legacy systems and limited options to mitigate such risk. We are also exposed to risks associated with the availability of all of our information systems, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:9pt 0pt 0pt;">
				<font style="margin:9pt 0pt 0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;color:#000000;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:9pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">disruption, impairment or failure of data centers, telecommunic</font><font style="display: inline;font-size:10pt;color:#000000;">ations facilities or other key infrastructure platforms, including those maintained by third-party vendors;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:9pt 0pt 0pt;">
				<font style="margin:9pt 0pt 0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:9pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">security breaches of, cyber-attacks on and other failures or malfunctions in our internal systems, including our employee data and communications, c</font><font style="display: inline;font-size:10pt;color:#000000;">ritical application systems and their associated hardware; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:9pt 0pt 0pt;">
				<font style="margin:9pt 0pt 0pt;font-family:Symbol;border-top:1pt none #D9D9D9;color:#000000;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:9pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">excessive costs, excessive delays and other deficiencies in systems development and deployment.</font></p></td></tr></table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The materialization of any of these risks may impede the processing of data, the delivery of databases and services, and the day-to-day management of our IVD trial </font><font style="display: inline;color:#000000;">and ASPiRA LABS </font><font style="display: inline;color:#000000;">business and could result in the corruption, loss or unauthorized disclosure of proprietary, confidential or other data. While we have disaster recovery plans in place in line with applicable regulations and industry standards, they might not adequately protect us in the event of a system failure. Despite any precautions we take, damage from fire, floods, hurricanes, the outbreak or escalation of war, acts of terrorism, power loss, telecommunications failures, computer viruses, break-ins and similar events at our various computer facilities or those of our third-party vendors could result in interruptions in the flow of data to us and from us to our customers. Corruption or loss of data may result in the need to repeat a trial at no cost to the customer, but at significant cost to us, the termination of a contract or damage to our reputation. As our business continues its efforts to expand globally, these types of risks may be further increased by instability in the geopolitical climate of certain regions, underdeveloped and less stable utilities and communications infrastructure, and other local and regional factors. Additionally, significant delays in system enhancements or inadequate performance of new or upgraded systems could damage our reputation and harm our business. Although we carry property and business interruption insurance which we believe is customary for our industry, our coverage might not be adequate to compensate us for all losses that may occur.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Unauthorized disclosure of sensitive or confidential data, whether through systems failure or employee negligence, cyber-attacks, fraud or misappropriation, could damage our reputation and cause us to lose customers and, to the extent any such unauthorized disclosure compromises the privacy and security of individually identifiable health information, could also cause us to face sanctions and fines under the Federal Health Insurance Portability and Accountability Act of 1996 as amended by the Health Information Technology for Economic and Clinical Health Act of 2009. Similarly, we have been and expect that we will continue to be subject to attempts to gain unauthorized access to or through our information systems or those we internally or externally develop for our customers, including a cyber-attack by computer programmers and hackers who may develop and deploy viruses, worms or </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">28</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;color:#000000;">other malicious software programs, process breakdowns, denial-of-service attacks, malicious social engineering or other malicious activities, or any combination of the foregoing. In addition, we may be susceptible to physical or computer-based attacks by terrorists or hackers due to ASPiRA IVD&#x2019;s role in the contract research organization industry. These concerns about security are increased when information is transmitted over the Internet. Threats include cyber-attacks such as computer viruses, worms or other destructive or disruptive software, and any of these could result in a degradation or disruption of our services or damage to our properties, equipment and data. They could also compromise data security. If such attacks are not detected immediately, their effect could be compounded. </font><font style="display: inline;color:#000000;">These same risks also apply to ASPiRA LABS. </font><font style="display: inline;color:#000000;">Successful attacks could result in negative publicity, significant remediation and recovery costs, legal liability and damage to our reputation and could have an adverse effect on our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:11pt 0pt 7.7pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">If ASPiRA IVD fails to perform its services in accordance with contractual requirements, regulatory standards and ethical considerations, we could be subject to significant costs or liability and our business or reputation could be harmed.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">We anticipate that ASPiRA IVD will contract with biopharmaceutical companies to perform a wide range of services to assist them in bringing new drugs to market. Our IVD trial services will include monitoring clinical trials, data and laboratory analysis, patient recruitment and other related services. Such services are complex and subject to contractual requirements, regulatory standards and ethical considerations. For example, ASPiRA IVD will be required to adhere to applicable regulatory requirements such as the FDA&#x2019;s Quality System Regulations, CLIA, and current Good Clinical Practices, which govern, among other things, the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. If ASPiRA IVD fails to perform its services in accordance with these requirements, regulatory authorities may take action against us or our customers. Such actions may include sanctions (e.g., injunctions or the failure of such regulatory authorities to grant marketing approval of products), imposition of clinical holds or delays, suspension or withdrawal of approvals, rejection of data collected in studies conducted by ASPiRA IVD, license revocation, product seizures or recalls, operational restrictions, civil or criminal penalties or prosecutions, damages or fines. Additionally, there is a risk that actions by regulatory authorities, if they result in significant inspectional observations or other measures, could harm our reputation and cause customers not to award ASPiRA IVD future contracts or to cancel existing contracts. Any such action could have an adverse effect on our business, financial condition and results of operations.</font><font style="display: inline;">&nbsp;</font><a name="s659B07563D6954FC985ABD225000E85"></a>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:120%;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">We selectively explore acquisition opportunities and strategic alliances relating to other businesses, products or technologies. We may not be successful in integrating other businesses, products or technologies with our business. Any such transaction also may not produce the results we anticipate, which could adversely affect our business, financial condition and </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">results of </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">operati</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">ons</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:120%;text-indent:18pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We selectively explore and may pursue acquisition and other opportunities to strengthen our business and grow our company. We may enter into business combination transactions, make acquisitions or enter into strategic partnerships, joint ventures or alliances, any of which may be material. The market for acquisition targets and strategic alliances is highly competitive, which could make it difficult to find appropriate merger or acquisition opportunities. If we are required to raise capital by incurring debt or issuing additional equity for any reason in connection with a strategic acquisition or investment, financing may not be available or the terms of such financing may not be favorable to us and our stockholders, whose interests may be diluted by the issuance of additional stock. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The process of integration may produce unforeseen regulatory issues and operating difficulties and expenditures and may divert the attention of management from the ongoing operation of our business and harm our reputation. We may not successfully achieve the integration objectives, and we may not realize the anticipated cost savings, revenue growth and synergies in full or at all, or it may take longer to realize them than expected, any of which could negatively impact our business, financial condition and </font><font style="display: inline;">results of </font><font style="display: inline;">operati</font><font style="display: inline;">ons</font><font style="display: inline;">.</font><font style="display: inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">29</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Risks Related to Owning </font><font style="display: inline;font-size:10pt;">O</font><font style="display: inline;font-size:10pt;">ur Stock</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">The liquidity and trading volume of our common stock may be low</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">,</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> and our ownership is concentrated. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The liquidity and trading volume of our common stock has at times been low in the past and may again be low in the future. If the liquidity and trading volume </font><font style="display: inline;font-size:10pt;">of our common stock is low,</font><font style="display: inline;font-size:10pt;"> this could</font><font style="display: inline;font-size:10pt;"> adversely</font><font style="display: inline;font-size:10pt;"> impact the trading price of our shares</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">our ability to issue stock and </font><font style="display: inline;font-size:10pt;">our stock</font><font style="display: inline;font-size:10pt;">holders</font><font style="display: inline;font-size:10pt;">&#x2019;</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">ability </font><font style="display: inline;font-size:10pt;">to obtain liquidity in their shares. </font><font style="display: inline;font-size:10pt;">Our stock issuances since May 2013 have primarily</font><font style="display: inline;font-size:10pt;"> involved a significant issuance of stock to a limited number of investors, significantly increasing the concentration of our share ownership in a few holders.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_776"></a><font style="display: inline;font-size:10pt;">According to </font><a name="_cp_text_1_777"></a><font style="display: inline;font-size:10pt;">information provided on Schedule</font><font style="display: inline;font-size:10pt;">s</font><font style="display: inline;font-size:10pt;"> 13D</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">and 13G</font><font style="display: inline;font-size:10pt;">, as amended, filed</font><font style="display: inline;font-size:10pt;"> as recent</font><font style="display: inline;font-size:10pt;">ly</font><font style="display: inline;font-size:10pt;"> as </font><font style="display: inline;font-size:10pt;">February </font><font style="display: inline;font-size:10pt;">13</font><font style="display: inline;font-size:10pt;">, 201</font><font style="display: inline;font-size:10pt;">8</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">five </font><font style="display: inline;font-size:10pt;">persons beneficially owned approximately </font><font style="display: inline;font-size:10pt;">6</font><font style="display: inline;font-size:10pt;">7</font><font style="display: inline;font-size:10pt;">% of our outstanding shares of common stock, and under a May 2013 stockholders agreement, two of these persons have certain rights to designate a director to be nominated by us to serve on the </font><a name="_cp_text_4_778"></a><font style="display: inline;font-size:10pt;">Board of Directors</font><a name="_cp_text_1_779"></a><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;As a result, these stockholders will be ab</font><font style="display: inline;font-size:10pt;">le to affect the outcome of, or exert significant influence over, all matters requiring stockholder approval, including the election and removal of directors and any change in control. In particular, this concentration of ownership of our common stock could have the effect of delaying or preventing a change in control of us or otherwise discouraging or preventing a potential acquirer from attempting to obtain control of us. This, in turn, could have a negative effect on the market price of our common stock. It could also prevent our stockholders from realizing a premium over the market prices for their shares of common stock. Moreover, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders. The concentration of ownership also contributes to the low trading volume and volatility of our common stock.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Our stock price has been, and may continue to be, highly volatile.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The trading price of our common stock has been highly volatile and could continue to be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">failure to significantly increase revenue</font><font style="display: inline;font-family:Times New Roman;color:#000000;"> and volumes of OVA1</font><font style="display: inline;font-family:Times New Roman;color:#000000;"> or Overa</font><font style="display: inline;font-family:Times New Roman;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">actual or anticipated period-to-period fluctuations in financial results;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">failure to achieve, or changes in, financial estimates by securities analysts;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">announcements or introductions of new products or services or technological innovations by us or our competitors;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">publicity regarding actual or potential discoveries of biomarkers by others;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">comments or opinions by securities analysts or stockholders;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">conditions or trends in the pharmaceutical, biotechnology </font><font style="display: inline;font-family:Times New Roman;color:#000000;">or</font><font style="display: inline;font-family:Times New Roman;color:#000000;"> life science industries;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">announcements by us of significant acquisitions and divestitures, strategic partnerships, joint ventures or capital commitments;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">developments regarding our patents or other intellectual property or that of our competitors;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">litigation or threat of litigation;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">additions or departures of key personnel;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">limited daily trading volume;</font><font style="display: inline;font-family:Times New Roman;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">our ability to continue as a going concern;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">economic and other external factors, disasters or crises</font><font style="display: inline;font-family:Times New Roman;color:#000000;">; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 16.00pt;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">our announcement of additional fundraisings. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 3pt 54pt;text-align:left;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">In addition, the stock market in general and the market for diagnostic technology companies, in particular, have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. These broad market and industry factors may </font><font style="display: inline;font-size:10pt;color:#000000;">adversely affect</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company&#x2019;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs, potential liabilities and the diversion of our attention and our resources.</font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Anti-takeover provisions in our charter, bylaws, other agreements and under Delaware law could make a third</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">-</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">party acquisition of the Company difficult. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_789"></a><font style="display: inline;font-size:10pt;color:#000000;">Certain provisions of our certificate of incorporation and bylaws may have the effect of making it more difficult for a third</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">party to acquire, or of discouraging a </font><font style="display: inline;font-size:10pt;color:#000000;">third</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">party</font><font style="display: inline;font-size:10pt;color:#000000;"> from attempting to acquire, control of us, even if a change of control might be </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">30</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-size:10pt;">deemed beneficial to our stockholders.&nbsp;&nbsp;Such provisions could limit the price that certain investors might be willing to pay in the future for our securities.&nbsp;&nbsp;Our certificate of incorporation eliminates the right of stockholders to call special meetings of stockholders or to act by written consent without a meeting, and our bylaws require advance notice for stockholder proposals and director nominations, which may preclude stockholders from bringing matters before an annual meeting of stockholders or from making nominations for directors at an annual meeting of stockholders.&nbsp;&nbsp;Our certificate of incorporation also authorizes undesignated preferred stock, which makes it possible for our board of directors, without stockholder approval, to issue preferred stock with voting or other rights or preferences that could adversely affect the voting power of holders of common stock.&nbsp;&nbsp;In addition, the likelihood that the holders of preferred stock will receive dividend payments and payments upon liquidation could have the effect of delaying, deferring or preventing a change in control. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In connection with our </font><font style="display: inline;font-size:10pt;">private placement </font><font style="display: inline;font-size:10pt;">offering of common stock and warrants </font><font style="display: inline;font-size:10pt;">i</font><font style="display: inline;font-size:10pt;">n May 2013, we entered into a </font><font style="display: inline;font-size:10pt;">stockholders</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">agreement which</font><font style="display: inline;font-size:10pt;">, among other things,</font><font style="display: inline;font-size:10pt;"> includes agreements limiting our ability </font><font style="display: inline;font-size:10pt;">to </font><a name="_cp_text_1_808"></a><font style="display: inline;font-size:10pt;">effect a change in control</font><font style="display: inline;font-size:10pt;"> without the consent of at least one of the two primary investors in that offering. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of us. The amendment of any of the provisions of either our certificate of incorporation or bylaws described in the preceding paragraph would require not only approval by our board of directors and the affirmative vote of at least 66 2/3% of our then outstanding voting securities, but also the consent of at least one of the two primary investors in the May 2013 offering</font><font style="display: inline;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-size:10pt;">We are also subject to certain provisions of Delaware law that could delay, deter or prevent a change in control of the Company.</font><font style="display: inline;font-size:10pt;"> These provisions could </font><a name="_cp_text_1_810"></a><font style="display: inline;font-size:10pt;">make a third-party acquisition of t</font><font style="display: inline;font-size:10pt;">he Company difficult and </font><a name="_cp_text_4_811"></a><font style="display: inline;font-size:10pt;">limit the price that investors might be willing to pay in the future for shares of our common stock</font><a name="_cp_text_1_812"></a><font style="display: inline;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Because we do not intend to pay dividends, our stockholders will benefit from an investment in our common stock only if it appreciates in value. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain our future earnings, if any, to finance the expansion of our business and do not expect to pay any cash dividends in the foreseeable future. As a result, the success of an investment in our common stock will depend entirely upon any future appreciation. There is no guarantee that our common stock will appreciate in value or even maintain the price at which our </font><font style="display: inline;font-size:10pt;">stockholders </font><font style="display: inline;font-size:10pt;">purchased their shares. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt;text-indent:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">We may need to sell additional shares of our common stock or other securities in the future to meet our capital requirements</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">,</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;"> which could cause significant dilution. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of </font><font style="display: inline;font-size:10pt;">the exercise of common stock warrants, public or private </font><font style="display: inline;font-size:10pt;">equity offerings, debt financings, collaborations, </font><font style="display: inline;font-size:10pt;">licensing arrangements, </font><font style="display: inline;font-size:10pt;">grants and government funding and strategic alliances.&nbsp;&nbsp;To the extent that we raise additional capital through the sale of equity or convertible debt, such financing may be dilutive to stockholders.&nbsp;&nbsp;Debt financing, if available, may involve restrictive covenants and potential dilution to stockholders.&nbsp;&nbsp;Furthermore, a perception that future sales of our common stock in the public market are likely to occur could affect prevailing trading prices of our common stock.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">As of December&nbsp;31, </font><font style="display: inline;font-size:10pt;">201</font><font style="display: inline;font-size:10pt;">7</font><font style="display: inline;font-size:10pt;">, we had </font><font style="display: inline;font-size:10pt;">60,036,017</font><font style="display: inline;font-size:10pt;"> shares of our common stock outstanding and </font><font style="display: inline;font-size:10pt;">2,054,633</font><font style="display: inline;font-size:10pt;"> shares of our common stock reserved for future issuance to employees, directors and consultants pursuant to our employee stock plans, which excludes </font><font style="display: inline;font-size:10pt;">4,219,568</font><font style="display: inline;font-size:10pt;"> shares of our common stock that were subject to outstanding options.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On February 17, 2017, Vermillion completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The exercise of all or a portion of our outstandi</font><font style="display: inline;">ng options and warrants</font><font style="display: inline;"> will dilute the ownership interests of our stockholders.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 1B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">UNRESOLVED STAFF COMMENTS</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 49.5pt;text-indent: -13.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">None.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">31</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;">ITEM 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">PROPERTIES</font>
		</p>
		<p style="margin:6pt 0.7pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following chart indicates the </font><font style="display: inline;">facilit</font><font style="display: inline;">ies</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">that we lease, the location and size of </font><font style="display: inline;">each</font><font style="display: inline;"> facility and its designated use. </font><font style="display: inline;">We believe that these facilities are suitable and adequate for our current needs.</font>
		</p>
		<p style="margin:6pt 0.7pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:17.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:32.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:25.00%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;text-decoration:underline;">Location</font></p>
				</td>
				<td valign="bottom" style="width:17.48%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;text-decoration:underline;">Approximate Square Feet</font></p>
				</td>
				<td valign="bottom" style="width:32.52%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;text-decoration:underline;">Primary Functions</font></p>
				</td>
				<td valign="bottom" style="width:25.00%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;text-decoration:underline;">Lease Expiration Date</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:25.00%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Austin, Texas</font></p>
				</td>
				<td valign="top" style="width:17.48%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">4,218</font><font style="display: inline;"> sq. ft.</font></p>
				</td>
				<td valign="top" style="width:32.52%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ASPiRA LABS facility, </font><font style="display: inline;">r</font><font style="display: inline;">esearch </font><font style="display: inline;">and development, clinical and regulatory, sales and administrative offices</font></p>
				</td>
				<td valign="top" style="width:25.00%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">January</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">9</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:25.00%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Trumbull, Connecticut</font></p>
				</td>
				<td valign="top" style="width:17.48%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">10,681 sq. ft.</font></p>
				</td>
				<td valign="top" style="width:32.52%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Administrative offices and </font><font style="display: inline;">ASPiRA IVD </font><font style="display: inline;">laboratory facility</font></p>
				</td>
				<td valign="top" style="width:25.00%;background-color: #auto;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">June </font><font style="display: inline;">7, </font><font style="display: inline;">2021</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">LEGAL PROCEEDINGS</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">F</font><font style="display: inline;font-size:10pt;">rom time to time, we are involved in legal proceedings and regulatory proceedings arising out of our operations. We establish reserves for specific liabilities in connection with legal actions that </font><font style="display: inline;font-size:10pt;">we</font><font style="display: inline;font-size:10pt;"> deem to be probable and estimable. </font><font style="display: inline;font-size:10pt;">W</font><font style="display: inline;font-size:10pt;">e are not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on our financial position or results of operations.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">MINE SAFETY DISCLOSURES</font><font style="display: inline;font-weight:bold;">&nbsp;</font><font style="display: inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Not applicable.</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">32</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font><font style="display: inline;font-weight:bold;">PART II</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">MARKET FOR REGISTRANT&#x2019;S COMMON EQUITY</font><font style="display: inline;font-weight:bold;">, RELATED STOCKHOLDER</font><font style="display: inline;font-weight:bold;"> MATTERS</font><font style="display: inline;font-weight:bold;"> AND ISSUER PURCHASES OF EQUITY SECURITIES</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Our common stock </font><font style="display: inline;font-size:10pt;">is</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">traded on </font><font style="display: inline;font-size:10pt;">T</font><font style="display: inline;font-size:10pt;">he </font><font style="display: inline;font-size:10pt;">N</font><font style="display: inline;font-size:10pt;">ASDAQ</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Capital</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Market under the symbol &#x201C;VRML.&#x201D;</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On </font><font style="display: inline;font-size:10pt;">February 28</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;">2018</font><font style="display: inline;font-size:10pt;">, there were </font><font style="display: inline;font-size:10pt;">95 </font><font style="display: inline;font-size:10pt;">registered holders of record of our common stock. The closing price of our common stock on </font><font style="display: inline;font-size:10pt;">March </font><font style="display: inline;font-size:10pt;">2</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">201</font><font style="display: inline;font-size:10pt;">8</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">was $</font><font style="display: inline;font-size:10pt;">1.54</font><font style="display: inline;font-size:10pt;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following sets forth the quarterly high and low trading prices as reported by </font><font style="display: inline;">The </font><font style="display: inline;">NASDAQ Capital Market</font><font style="display: inline;"> for the periods indicated. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:21.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:21.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:21.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="middle" style="width:38.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="middle" style="width:38.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:21.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:18.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">High </font></p>
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:17.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Low&nbsp; </font></p>
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:17.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">High </font></p>
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:17.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Low&nbsp; </font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:21.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">First Quarter</font></p>
				</td>
				<td valign="middle" style="width:03.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2.85&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.95&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.94&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:14.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.00&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:21.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Second Quarter</font></p>
				</td>
				<td valign="middle" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2.22&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.52&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.58&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.00&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:21.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Third Quarter</font></p>
				</td>
				<td valign="middle" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.92&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.03&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.50&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.92&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:21.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Fourth Quarter</font></p>
				</td>
				<td valign="middle" style="width:03.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2.10&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.27&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.33&nbsp;
				</td>
				<td valign="middle" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.76&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Dividends</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have never paid or declared any dividend on our common stock and we do not anticipate paying cash dividends on our common stock in the foreseeable future. If we pay a cash dividend on our common stock, we also may be required to pay the same dividend on an as-converted basis on any outstanding warrants or other securities. Moreover, any preferred stock or other senior debt or equity securities to be issued and any future credit facilities might contain restrictions on our ability to declare and pay dividends on our common stock. We intend to retain all available funds and any future earnings to fund the development and expansion of our business.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Equity Compensation Plan Information</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We currently maintain two equity-based compensation plans that were approved by our stockholders.&nbsp;&nbsp;The plans are the Vermillion, Inc. 2000 Stock Plan (the &#x201C;2000 Plan&#x201D;) and the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Amended and Restated 2010 Stock Incentive Plan, as amended (the &#x201C;2010 Plan&#x201D;)</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2000 Plan.</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">The authority of </font><font style="display: inline;">Vermillion&#x2019;s </font><font style="display: inline;">Board of Directors to grant new stock options and awards under the 2000 Plan terminated in 2010.&nbsp; </font><font style="display: inline;">The</font><font style="display: inline;"> Board of Directors continues to administer the 2000 Plan with respect to the stock options that remain outstanding </font><font style="display: inline;">under the 2000 Plan</font><font style="display: inline;">.</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">At December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">options to purchase</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">18</font><font style="display: inline;">,0</font><font style="display: inline;">0</font><font style="display: inline;">0</font><font style="display: inline;"> shares of </font><font style="display: inline;">Vermillion&#x2019;s </font><font style="display: inline;">common </font><font style="display: inline;">stock remain</font><font style="display: inline;">ed</font><font style="display: inline;"> ou</font><font style="display: inline;">tstanding under the 2000 Plan.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2010 Plan.</font><font style="display: inline;"> &nbsp;The 2010 Plan </font><font style="display: inline;">is</font><font style="display: inline;"> administered by the Compensation Committee of </font><font style="display: inline;">Vermillion&#x2019;s </font><font style="display: inline;">Board</font><font style="display: inline;"> of Directors</font><font style="display: inline;">.&nbsp; </font><font style="display: inline;">Our</font><font style="display: inline;"> employees, directors, and consultants are eligible to receive awards under the 2010 Plan. The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights.&nbsp; </font><font style="display: inline;">We are</font><font style="display: inline;"> authorized to issue up to </font><font style="display: inline;">8,1</font><font style="display: inline;">22,983</font><font style="display: inline;"> shares of </font><font style="display: inline;">Vermillion&#x2019;s </font><font style="display: inline;">common stock under the 2010 Plan, subject to adjustment as provided in the 2010 Plan.</font><font style="display: inline;"> At </font><font style="display: inline;">December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">options to purchase</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">4,201,568</font><font style="display: inline;"> shares of </font><font style="display: inline;">common </font><font style="display: inline;">stock </font><font style="display: inline;">remain</font><font style="display: inline;">ed</font><font style="display: inline;"> outstanding under the 201</font><font style="display: inline;">0 Plan.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The number of shares of </font><font style="display: inline;">Vermillion&#x2019;s </font><font style="display: inline;">common stock to be issued upon exercise of outstanding stock options, the weighted-average exercise price of outstanding stock options and the number of shares available for future stock option grants and stock awards under equity compensation plans as of December&nbsp;31</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, were as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:left;text-justify:inter-ideograph;font-family:Baskerville Old Face;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:51.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">33</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:51.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:165.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;text-decoration:underline;">Plan Category </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:165.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:165.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights </font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:165.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:165.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights </font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:165.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:165.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Shares Reflected in First Column) </font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:165.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Equity compensation plans approved by security holders </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,219,568&nbsp;
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">(1)</font></p>
				</td>
				<td valign="middle" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.86&nbsp;
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">(2)</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,054,633&nbsp;
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">(3)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Equity compensation plans not approved by security holders </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,219,568&nbsp;
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,054,633&nbsp;
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.86%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="9" valign="top" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:31.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(1) Includes outstanding stock options for 18,000 shares of our common stock under the 2000 Plan and 4,201,568 shares of our common stock under the 2010 Plan.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="9" valign="top" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:31.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(2) Includes the weighted average stock price for outstanding stock options of $2.04 under the 2000 Plan and $1.86 for the 2010 Plan. </font></p>
				</td>
			</tr>
			<tr>
				<td colspan="9" valign="top" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(3) Represents shares of our common stock for the 2010 Plan. No future awards shall occur under the 2000 Plan.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_872"></a><font style="display: inline;font-size:10pt;">Performance Graph</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_4_873"></a><font style="display: inline;">Pursuant to </font><a name="_cp_text_1_874"></a><font style="display: inline;">the accompanying instructions, the information called for by </font><a name="_cp_text_4_875"></a><font style="display: inline;">Item 201(e) </font><a name="_cp_text_4_876"></a><font style="display: inline;">of Regulation S-K </font><a name="_cp_text_4_877"></a><font style="display: inline;">is not required.</font><a name="_cp_text_4_878"></a>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">SELECTED FINANCIAL DATA</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Per Item 301(c) of Regulation S-K, </font><font style="display: inline;">the </font><font style="display: inline;">information </font><font style="display: inline;">called for by Item 6 of Form 10-K </font><font style="display: inline;">is not required.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 49.5pt;text-indent: -49.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 49.5pt;text-indent: -49.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">34</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;"></font><font style="display: inline;font-weight:bold;">ITEM 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CON</font><font style="display: inline;font-weight:bold;">DITION AND RESULTS OF OPERATION</font><font style="display: inline;font-weight:bold;">S</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">You should read the following discussion and analysis in conjunction with our Consolidated Financial Statements and related Notes thereto, included on pages F-1 through </font><font style="display: inline;font-style:italic;">F-</font><font style="display: inline;font-style:italic;">19</font><font style="display: inline;font-style:italic;">&nbsp;</font><font style="display: inline;font-style:italic;">of this Annual Report on Form 10-K, and &#x201C;Risk Factors&#x201D;, which are discussed in Item 1A.&nbsp;&nbsp;The statements below contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act.&nbsp;&nbsp;See "Forward-Looking Statements" on page </font><font style="display: inline;font-style:italic;">1 &nbsp;</font><font style="display: inline;font-style:italic;">of this Annual Report on Form 10-K.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">O</font><font style="display: inline;font-size:10pt;">verview</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our vision is </font><font style="display: inline;">to drive the advancement of women&#x2019;s health by providing innovative methods to detect, monitor and manage the treatment of </font><font style="display: inline;color:#000000;">both benign and malignant </font><font style="display: inline;">gynecologic disease, </font><font style="display: inline;color:#000000;">with our primary focus being diseases of the female pelvic cavity</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We have expanded our corporate strategy with the goal of transforming the Company from a technology license company to a </font><font style="display: inline;">global </font><font style="display: inline;">diagnostic and bio-analytic solutions provider. Our plan is to broaden our commercial focus from ovarian cancer to differential diagnosis of women with a range of gynecological disorders. Our strategy is being deployed in three phases.&nbsp;&nbsp;The three phases are a rebuild phase, which </font><font style="display: inline;color:#000000;">was completed in 2015, </font><font style="display: inline;">a transformation phase, which </font><font style="display: inline;">was</font><font style="display: inline;"> virtually complete</font><font style="display: inline;">d in 2017</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">with the exception of our </font><font style="display: inline;">continuing expansion of payer coverage</font><font style="display: inline;">, and a market expansion and growth phase, which we expect to </font><font style="display: inline;">continue </font><font style="display: inline;">in 201</font><font style="display: inline;">8</font><font style="display: inline;"> and 2019</font><font style="display: inline;">.&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We are dedicated to the discovery, development and commercialization of novel high-value </font><font style="display: inline;">diagnostic and bio-analytical solutions </font><font style="display: inline;">that help physicians diagnose, treat and improve outcomes for women. Our tests are intended to detect, characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy. A distinctive feature of our approach </font><font style="display: inline;">is the combination of multi-modal diagnostics and data. Our goal </font><font style="display: inline;">is to combine multiple biomarkers, other modalities and diagnostics, clinical risk factors and patient data into a single, reportable index score that has higher diagnostic accuracy than its constituents. We concentrate our development </font><font style="display: inline;">on</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">novel diagnostic tests for gynecologic disease, with an initial focus on ovarian cancer. We also intend to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others through collaborations with leading academic and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">research institutions. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Business:&nbsp; </font><font style="display: inline;">Our initial product, OVA1, is a blood test designed to, in addition to a physician&#x2019;s clinical assessment of a woman with a pelvic mass, identify women who are at high risk of having a malignant ovarian tumor prior to planned surgery. The FDA cleared OVA1 in September 2009, and we commercially launched OVA1 in March 2010. We have launched on a targeted basis</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">a second-generation biomarker panel known as Overa, which is intended to maintain our product&#x2019;s high sensitivity while improving specificity.&nbsp;&nbsp;We received FDA clearance for Overa on March 18, 2016. Overa uses the Roche cobasplatform.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In June 2014, </font><font style="display: inline;font-size:10pt;">we</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">launched ASPiRA LABS, a </font><font style="display: inline;font-size:10pt;">CLIA</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> certified national laboratory which specializes in applying biomarker-based technologies, to address critical needs in the management of gynecologic cancers </font><font style="display: inline;font-size:10pt;">and disease</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">. ASPiRA LABS provides expert diagnostic services using a state-of-the-art biomarker-based diagnostic algorithm to aid in clinical decision making and advance personalized treatment plans. The lab currently processes our OVA1 </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">and Overa </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">test</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">s</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">,</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> and w</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">e plan to expand the testing to other gynecologic conditions with high unmet need. &nbsp;We also plan to develop and perform LDTs at ASPiRA LABS.&nbsp;&nbsp;ASPiRA LABS holds a CLIA Certificate of Registration and a state laboratory license in California, </font><font style="display: inline;font-size:10pt;">Florida, Maryland, New York, Pennsylvania </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">and Rhode Island. </font><font style="display: inline;font-size:10pt;">This allows the lab to p</font><font style="display: inline;font-size:10pt;">rocess OVA1 </font><font style="display: inline;font-size:10pt;">and Overa </font><font style="display: inline;font-size:10pt;">on a national basis. </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">The </font><font style="display: inline;font-size:10pt;">CMS issued a provider number to</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> ASPiRA LABS in March 2015.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In 2016, we created a service within the ASPiRA channel strategy, &#x201C;an ASPiRA IVD Services Program&#x201D;. </font><font style="display: inline;font-size:10pt;">In April 2016, we formed ASPiRA IVD to offer IVD t</font><font style="display: inline;font-size:10pt;">rial services to third-party customers. ASPiRA IVD is a specialized laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize&nbsp;high-complexity&nbsp;assays.&nbsp;ASPiRA IVD was built around a core of laboratory&nbsp;expertise and an FDA-compliant quality system, and strives to deliver accurate and reliable&nbsp;results to its third-party customers suitable for&nbsp;FDA submission. ASPiRA IVD received a CLIA laboratory license in June 2016 and commenced operations in the second quarter of 2016.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In this</font><font style="display: inline;font-size:10pt;"> ASPiRA IVD</font><font style="display: inline;font-size:10pt;"> program, we </font><font style="display: inline;font-size:10pt;">are</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">leverag</font><font style="display: inline;font-size:10pt;">ing</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">our existing infrastructure and enhanc</font><font style="display: inline;font-size:10pt;">ing</font><font style="display: inline;font-size:10pt;"> our pipeline of future technologies by fostering relationships with IVD companies who are developing new diagnostics including companion diagnostics platforms. We believe this </font><font style="display: inline;font-size:10pt;">approach</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">will allow us to continue to be innovative in evaluating potential diagnostics. Our goal with the addition of this line of business is to invest in our short-term and long-term enterprise value while leveraging specimen bank, database, FDA experience, laboratory informatics and operating efficiency.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In the first half of 2017, ASPiRA IVD services landed two top pharmaceutical trial service agreements including one enrollment study.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Strategy:&nbsp; </font><font style="display: inline;">We are focused on the execution of five core strategic business drivers in ovarian cancer diagnostics and specialized laboratory servi</font><font style="display: inline;">c</font><font style="display: inline;">es to build long-term value for our investors: </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">35</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;punctuation-wrap:hanging;vertical-align:baseline;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Maximizing the existing OVA1 opportunity in the United States by lead</font><font style="display: inline;color:#000000;">ing</font><font style="display: inline;color:#000000;"> in payer coverage and commercialization of OVA1.&nbsp; </font><font style="display: inline;color:#000000;">This strategy included the launch of a </font><font style="display: inline;background-color: #FFFFFF;color:#000000;">CLIA</font><font style="display: inline;color:#000000;"> certified clinical laboratory, ASPiRA LABS, in June 2014</font><font style="display: inline;color:#000000;">, multiple publications, inclusion in the ACOG adnexal mass guidelines, payer traction and finally the addition of OVA1 to CMS National Fee schedule as of January 2018</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">E</font><font style="display: inline;color:#000000;">xpanding the distribution platform </font><font style="display: inline;color:#000000;">beyond the U.S. </font><font style="display: inline;color:#000000;">by launching Overa, a next generation biomarker panel, on a targeted basis while building the clinical utility and health economics foundation of</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">both OVA1 and Overa, which we believe may allow for better domestic market penetration and international expansion (FDA clearance for Overa was received </font><font style="display: inline;color:#000000;">i</font><font style="display: inline;color:#000000;">n March 2016)</font><font style="display: inline;color:#000000;">;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-bottom:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Leveraging our existing database and specimen bank while building the largest specimen and data repository of gynecologic pelvic mass patients worldwide;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;border-top:1pt none #D9D9D9;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 4)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">Expanding our product offerings</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;"> to additional pelvic disease conditions such as endometriosis and polycystic ovarian syndrome (PCOS)</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;"> by adding additional gynecologic bio-analytic solutions involving biomarkers, other modalities (e.g., imaging), clinical risk factors and patient data to aid diagnosis and risk stratification of women presenting with a pelvic mass disease</font><font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size:10pt;;"> 5)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">Expanding our </font><font style="display: inline;color:#000000;">revenue channels and </font><font style="display: inline;color:#000000;">customer offerings with the launch of our ASPiRA IVD laboratory services.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 54pt;punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;punctuation-wrap:hanging;vertical-align:baseline;font-family:Times New Roman;font-size: 10pt">
			<font style="color:#00C000;display: inline;color:#000000;text-decoration:none;">We</font><font style="display: inline;color:#000000;"> believe that these business drivers will contribute significantly to addressing unmet medical needs for women faced with gynecologic disease and other conditions and the continued development of our business.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">OVA1</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;">and Overa </font><font style="display: inline;color:#000000;">address a clear clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. Numerous studies have documented the benefit of referral of these women to gynecologic oncologists for their initial surgery. Prior to the clearance of OVA1, no blood test had been cleared by the FDA for physicians to use in the pre-surgical management of ovarian adnexal masses. OVA1 </font><font style="display: inline;color:#000000;">and Overa </font><font style="display: inline;color:#000000;">a</font><font style="display: inline;color:#000000;">re</font><font style="display: inline;color:#000000;"> qualitative serum test</font><font style="display: inline;color:#000000;">s</font><font style="display: inline;color:#000000;"> that utilize five well-established biomarkers and proprietary software cleared as part of the OVA1 510(k) to determine the likelihood of malignancy in women over age 18, with a pelvic mass for whom surgery is planned. OVA1 </font><font style="display: inline;color:#000000;">or Overa </font><font style="display: inline;color:#000000;">should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery.&nbsp;Incorrect use of OVA1 </font><font style="display: inline;color:#000000;">or Overa </font><font style="display: inline;color:#000000;">carries the risk of unnecessary testing, surgery and/or delayed diagnosis. OVA1 was developed through large pre-clinical studies in collaboration with numerous academic medical centers encompassing over 2,500 clinical samples. OVA1 was fully validated in a prospective multi-center clinical trial encompassing 27 sites reflective of the diverse nature of the clinical centers at which ovarian adnexal masses are evaluated.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">In March 2015, we entered into a new commercial agreement with Quest Diagnostics.&nbsp;&nbsp;Pursuant to this agreement, </font><font style="display: inline;color:#000000;">all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to </font><font style="display: inline;color:#000000;">Vermillion&#x2019;s wholly-owned subsidiary, ASPiRA LABS, </font><font style="display: inline;color:#000000;">as of August 10, 2015.&nbsp;&nbsp;Pursuant to this agreement, as amended as of March 1, 2018, Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens to ASPiRA LABS for testing </font><font style="display: inline;color:#000000;">through at least March 11, 2019 in exchange for a market value fee</font><font style="display: inline;color:#000000;">.&nbsp; </font><font style="display: inline;color:#000000;"> Per the terms of the </font><font style="display: inline;color:#000000;">new commercial </font><font style="display: inline;color:#000000;">agreement, we will not offer to existing or future Quest Diagnostics customers CA 125-II or other tests that Quest Diagnostics offers.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:normal;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">We have </font><font style="display: inline;font-size:10pt;color:#000000;">active </font><font style="display: inline;font-size:10pt;color:#000000;">international distribution agreements for Overa </font><font style="display: inline;font-size:10pt;color:#000000;">with </font><font style="display: inline;font-size:10pt;color:#000000;">Pro-Genetics LTD in Israel and MacroHealth, Inc. in the Philippines. The MacroHealth agreement </font><font style="display: inline;font-size:10pt;color:#000000;">wa</font><font style="display: inline;font-size:10pt;color:#000000;">s &nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">our first decentralized international agreement with Overa specimen testing to be performed in the Philippines.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Starting in</font><font style="display: inline;font-size:10pt;color:#000000;"> 2016, </font><font style="display: inline;font-size:10pt;color:#000000;">we were able</font><font style="display: inline;font-size:10pt;color:#000000;"> to </font><font style="display: inline;font-size:10pt;color:#000000;">make progress in </font><font style="display: inline;font-size:10pt;color:#000000;">achiev</font><font style="display: inline;font-size:10pt;color:#000000;">ing</font><font style="display: inline;font-size:10pt;color:#000000;"> positive medical policy and/or </font><font style="display: inline;font-size:10pt;color:#000000;">payer </font><font style="display: inline;font-size:10pt;color:#000000;">contract</font><font style="display: inline;font-size:10pt;color:#000000;">s.</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">We have continued to make progress with increased payer positive medical polices for a current estimated total of over 12</font><font style="display: inline;font-size:10pt;color:#000000;">5</font><font style="display: inline;font-size:10pt;color:#000000;"> million covered lives</font><font style="display: inline;font-size:10pt;color:#000000;"> as of March </font><font style="display: inline;font-size:10pt;color:#000000;">1</font><font style="display: inline;font-size:10pt;color:#000000;">, 2018</font><font style="display: inline;font-size:10pt;color:#000000;">. This represents an increase from an estimated 80 million covered lives </font><font style="display: inline;font-size:10pt;color:#000000;">as</font><font style="display: inline;font-size:10pt;color:#000000;"> of </font><font style="display: inline;font-size:10pt;color:#000000;">December 31, </font><font style="display: inline;font-size:10pt;color:#000000;">2016.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Novitas Solutions, the Medicare contractor, covers and reimburses for OVA1. This local coverage determination from Novitas Solutions essentially provides national coverage for patients enrolled in Medicare as well as Medicare Advantage health plans. However, ASPiRA LABS initially experienced difficulty in obtaining payment from Novitas Solutions for most claims submitted due to Novitas Solutions&#x2019; administrative requirements. In October 2016, Novitas Solutions updated its administrative requirements for OVA1 reimbursement which has improved our ability to obtain reimbursement for OVA1 from Novitas Solutions.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:normal;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">In October 2016, we launched our pelvic mass specimen and data repository and began the collection of patient consents </font><font style="display: inline;font-size:10pt;color:#000000;">under </font><font style="display: inline;font-size:10pt;color:#000000;">Institutional</font><font style="display: inline;font-size:10pt;color:#000000;"> Review Board (&#x201C;IRB&#x201D;) for collection and cataloguing of serum samples for future research purposes.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.92%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">36</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;line-height:107.92%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-size:10pt;">In November 2016, The American College of Obstetricians and Gynecologists ("ACOG&#x201D;) issued Practice Bulletin Number 174 which included OVA1 as a &#x201C;</font><font style="display: inline;font-size:10pt;">Multivariate </font><font style="display: inline;font-size:10pt;">Index Assay&#x201D;. This bulletin outlines ACOG's &#x201C;new&#x201D; clinical management guidelines for adnexal mass management.&nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.92%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">These new clinical management guidelines replace the July 2007 version, Practice Bulletin </font><font style="display: inline;font-size:10pt;">Number </font><font style="display: inline;font-size:10pt;">83. Practice Bulletins summarize current information on techniques and clinical management issues for the practice of obstetrics and gynecology. Practice Bulletins are evidence-based documents, and recommendations are based on the evidence.</font><font style="display: inline;font-size:10pt;">&nbsp;&nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Under Practice Bulletin Number 174, t</font><font style="display: inline;font-size:10pt;">he only Level A recommendation for the work up of the adnexal mass is </font><font style="display: inline;font-size:10pt;">a &nbsp;</font><font style="display: inline;font-size:10pt;">pelvic ultrasound. If </font><font style="display: inline;font-size:10pt;">a pelvic </font><font style="display: inline;font-size:10pt;">ultrasound is unable to definitively diagnose either a benign condition or a malignancy, clinicians have the ability to do </font><font style="display: inline;font-size:10pt;">a &nbsp;</font><font style="display: inline;font-size:10pt;">further work up with biomarker panels such as OVA1 (MIA), which has a Level B evidence designation</font><font style="display: inline;color:#000000;font-size:10pt;">. Based on this, OVA1 has now achieved parity with CA125 as a Level B recommendation for the management of adnexal masses, but OVA1 is the only recommended Level B tool </font><font style="display: inline;font-style:italic;color:#000000;font-size:10pt;">that has FDA clearance for use</font><font style="display: inline;color:#000000;font-size:10pt;"> assessing ovarian cancer risk in </font><font style="display: inline;font-size:10pt;">women of all stages, ages, and cancer types.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">On November 16, 2017, we announced the acceptance and publication of a novel paper</font><font style="display: inline;color:#000000;font-size:10pt;">, &#x201C;</font><font style="display: inline;color:#000000;font-size:10pt;text-decoration:underline;">Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers</font><font style="display: inline;color:#000000;font-size:10pt;">&#x201D; &nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">in the journal </font><font style="font-style:italic;display: inline;font-weight:bold;color:#000000;font-size:10pt;">American Health and Drug Benefits</font><font style="font-weight:bold;display: inline;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The paper details the base case of a budget impact model that dynamically tracks the effect of OVA1 adoption in lieu of CA125 in the appropriate patient population on overall cost, both at a plan and per member per month (</font><font style="display: inline;color:#000000;font-size:10pt;">&#x201C;</font><font style="display: inline;color:#000000;font-size:10pt;">PMPM</font><font style="display: inline;color:#000000;font-size:10pt;">&#x201D;</font><font style="display: inline;color:#000000;font-size:10pt;">) level. Claims data from a total of over 92,000 health plan members, comprising over 48,000 commercially insured members and 44,000 Medicare beneficiaries, were used in the development of the model. Sensitivity analysis revealed potential savings of up to $0.17 PMPM for commercially insured patients and up to $0.05 </font><font style="display: inline;color:#000000;font-size:10pt;">PMPM </font><font style="display: inline;color:#000000;font-size:10pt;">for Medicare beneficiaries. These results of the budget impact model base case support the use of OVA1 instead of CA125, by indicating that cost-savings can be achieved, while reaping the clinical benefits of improved diagnostic accuracy, early disease detection, and reductions in multiple, and possibly non-medically necessary, referrals to gynecologic oncologists.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Critical Accounting Policies and Estimates</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our significant accounting policies are described in Note 1, Basis for Presentation and Summary of Significant Accounting and Reporting Policies, of the Notes to the Consolidated Financial Statements included in this Annual Report on Form 10-K.&nbsp;&nbsp;The Consolidated Financial Statements are prepared in conformity with </font><font style="display: inline;">generally accepted accounting principles in the United States of America</font><font style="display: inline;"> (&#x201C;GAAP&#x201D;)</font><font style="display: inline;">. Preparation of the financial statements requires us to make </font><font style="display: inline;">critical </font><font style="display: inline;">judgments, estimates, and assumptions that affect the amounts of assets and liabilities in the financial statements and revenues and expenses during the reporting periods (and related disclosures). We believe the policies discussed below are the Company&#x2019;s critical accounting policies, as they include the more significant, subjective, and complex judgments and estimates made when preparing our consolidated financial statements</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Revenue Recognition</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;text-decoration:underline;">Product Revenue</font><font style="display: inline;font-style:italic;font-size:10pt;text-decoration:underline;">.</font><font style="display: inline;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">The Company derives product revenue from sales of </font><font style="display: inline;font-size:10pt;">OVA1 and </font><font style="display: inline;font-size:10pt;">Overa through ASPiRA LABS.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;background-color: #FFFFFF;">The Company has adopted ASC 954-605,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-style:italic;font-size:10pt;background-color: #FFFFFF;">Health Care Entities&#x2014;Revenue Recognition,&nbsp;</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">as </font><font style="display: inline;font-size:10pt;">revenue from laboratory services has become significant to the Company</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">The Company's product revenue is generated by performing diagnostic services using its OVA1 </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">and Overa </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">test</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">s</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">, and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1 </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">and Overa </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">test</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">s</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Estimates of amounts that the Company will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the patient&#x2019;s health plan. Some payers may not cover the OVA1</font><font style="display: inline;"> or Overa</font><font style="display: inline;"> test as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Service</font><font style="display: inline;font-style:italic;text-decoration:underline;"> Revenue</font><font style="display: inline;font-style:italic;text-decoration:underline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The Company&#x2019;s service revenue is generated by performing IVD trial services for third-party customers. In accordance with </font><font style="display: inline;">SEC</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Staff Accounting Bulletin </font><font style="display: inline;">Topic 13, service revenue is recognized when the following revenue recognition </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">37</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the fee is fixed or determinable; and (4)&nbsp;collectability is reasonably assured.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Revenue recognized when cash is received and on an accrual basis for </font><font style="display: inline;">three months and </font><font style="display: inline;">the year ended December 31, 201</font><font style="display: inline;">7</font><font style="display: inline;"> and 201</font><font style="display: inline;">6</font><font style="display: inline;"> was as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:37.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Year Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;text-decoration:underline;">(in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cash basis</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">507&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">487&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,022&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,720&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accrual basis</font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">151&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">193&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">831&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">600&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">IVD trial services (accrual basis)</font></p>
				</td>
				<td valign="top" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">140&nbsp;
				</td>
				<td valign="top" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">125&nbsp;
				</td>
				<td valign="top" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">268&nbsp;
				</td>
				<td valign="top" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">322&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total </font></p>
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">798&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">805&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,121&nbsp;
				</td>
				<td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,642&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Research and Development Costs</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Research and development costs are expensed as incurred.&nbsp;&nbsp;Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. </font><font style="display: inline;">In addition, acquisitions of assets to be consumed in research and development</font><font style="display: inline;">, with no alternative future use,</font><font style="display: inline;"> are expensed as incurred as research and development costs. </font><font style="display: inline;">Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Patent Costs</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within selling, general and administrative expenses on the consolidated statements of operations. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We </font><font style="display: inline;">record the fair value of non-cash stock-based compensation costs</font><font style="display: inline;"> for stock options and stock purchase rights related to </font><font style="display: inline;">the 2010 </font><font style="display: inline;">Plan. </font><font style="display: inline;">We estimate t</font><font style="display: inline;">he fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. </font><font style="display: inline;">We use the straight-line method to amortize </font><font style="display: inline;">t</font><font style="display: inline;">he fair value over the vesting period of the award. </font><font style="display: inline;">These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The expected life of options is based on historical data of our actual experience with the options we have granted and represents the period of time that the options granted are expected to be outstanding.&nbsp;&nbsp;This data includes employees&#x2019; expected exercise and post-vesting employment termination behaviors.&nbsp;&nbsp;The expected stock price volatility is estimated using </font><font style="display: inline;">our</font><font style="display: inline;"> historical volatility in deriving the expected volatility assumption.&nbsp;&nbsp;We made an assessment that </font><font style="display: inline;">our historic</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">volatility is mo</font><font style="display: inline;">st</font><font style="display: inline;"> representative of future stock price trends.&nbsp;&nbsp;The expected dividend yield is based on the estimated annual dividends that we expect to pay over the expected life of the options as a percentage of the market value of our common stock as of the grant date.&nbsp;&nbsp;The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Contingencies</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We account for contingencies in accordance with ASC 450 Contingencies ("ASC 450"). ASC 450 requires that an estimated loss from a loss contingency shall be accrued when information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires us to use our judgment. We believe that our accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from our estimates. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Income Taxes</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We account for income taxes using the liability method.&nbsp;&nbsp;Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates.&nbsp;&nbsp;A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">38</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">Accounting Standard Codification Topic 740-10-50 (&#x201C;ASC Topic 740-10-50&#x201D;), &#x201C;Accounting for Uncertainty in Income Taxes&#x201D; clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with ASC Topic 740, Income Taxes. ASC Topic 740-10-50 provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We recognize interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the </font><font style="display: inline;">C</font><font style="display: inline;">onsolidated </font><font style="display: inline;">S</font><font style="display: inline;">tatement </font><font style="display: inline;">of </font><font style="display: inline;">O</font><font style="display: inline;">perations</font><font style="display: inline;">. Accrued interest and penalties are included within the related liability lines in the </font><font style="display: inline;">C</font><font style="display: inline;">onsolidated </font><font style="display: inline;">B</font><font style="display: inline;">alance </font><font style="display: inline;">S</font><font style="display: inline;">heet</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">New tax legislation, commonly referred to as the Tax Cuts and Jobs Act</font><font style="display: inline;"> (H.R. 1)</font><font style="display: inline;">, was enacted on December 22, 2017. ASC740, </font><font style="display: inline;font-style:italic;">Accounting for Income Taxes</font><font style="display: inline;">, requires companies to recognize the effect of tax law changes in the period of enactment even though the effective date for most provisions is for tax years beginning after December 31, 2017. Since our federal deferred tax asset was fully offset by a valuation allowance</font><font style="display: inline;">,</font><font style="display: inline;"> the reduction in the U.S. corporate income tax rate to 21% did not materially affect our financial statements. Significant provisions that are not yet effective but may impact income taxes in future years include: the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">repeal of the corporate Alternative Minimum Tax, the limitation on the current deductibility of net interest expense in excess of 30% of adjusted taxable income for levered balance sheets, a limitation on utilization of net operating losses generated after tax</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">year 2017 to 80% of taxable income, the unlimited carryforward of net operating losses generated after tax year 2017, temporary 100% expensing of certain business assets, additional limitations on certain general and administrative expenses, and changes in determining the excessive compensation limitation. Currently, we do not anticipate paying cash federal income taxes in the near term due to any of the legislative changes, primarily due to the availability of our net operating loss carryforwards. Future interpretations relating to the recently enacted U.S. federal income tax legislation which vary from our current interpretation and possible changes to state tax laws in response to the recently enacted federal legislation may have a significant effect on this projection.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Liquidity</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On March 22, 2016, we entered into an agreement</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">( the &#x201C;Loan Agreement&#x201D;) </font><font style="display: inline;">pursuant to which we may</font><font style="display: inline;"> borrow up to $4,000,000 from the DECD. Proceeds from the loan </font><font style="display: inline;">were</font><font style="display: inline;"> utilized primarily to fund the build-out, information technology infrastructure and other costs related to our Trumbull, Connecticut facility and operations. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, </font><font style="display: inline;">which occurs on&nbsp;April 15, 2026</font><font style="display: inline;">. As security for the loan, we have granted the </font><font style="display: inline;">DECD</font><font style="display: inline;"> a blanket security interest in our personal and intellectual property. The </font><font style="display: inline;">DECD&#x2019;s security interest in our </font><font style="display: inline;">intellectual property may be subordinated to a qualified institutional lender. Under the terms of the agreement, </font><font style="display: inline;"> as amended, </font><font style="display: inline;">we may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan </font><font style="display: inline;">if we achieve</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">certain job creation and retention milestones measured by March 1, 20</font><font style="display: inline;">21</font><font style="display: inline;"> (the &#x201C;Measurement Date&#x201D;)</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">Conversely, i</font><font style="display: inline;">f we are </font><font style="display: inline;">either </font><font style="display: inline;">unable to meet these job creation </font><font style="display: inline;">and retention </font><font style="display: inline;">milestones</font><font style="display: inline;">, namely, hiring </font><font style="display: inline;">and retaining for a consecutive two-year period </font><font style="display: inline;">40 </font><font style="display: inline;">full-</font><font style="display: inline;">time employees with a specified average annual salary</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">by the Measurement Date</font><font style="display: inline;">,</font><font style="display: inline;"> or do not maintain our Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount</font><font style="display: inline;"> plus a penalty of 5%</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of the total funded l</font><font style="display: inline;">oan</font><font style="display: inline;">.</font><font style="display: inline;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">An initial disbursement of $2,000,000&nbsp;was made to the Company on April 15, 2016 under the Loan Agreement.</font><font style="display: inline;"> The remaining $2,000,000 will be advanced if and when the Company achieves certain</font><font style="display: inline;"> other</font><font style="display: inline;"> future milestones.</font><font style="display: inline;"> The loan may be prepaid at any time without premium or penalty.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On </font><font style="display: inline;">February 17, 2017</font><font style="display: inline;">, the Company completed a private placement pursuant to which certain investors purchased </font><font style="display: inline;color:#000000;">3,747,125 </font><font style="display: inline;">shares of </font><font style="display: inline;">Vermillion</font><font style="display: inline;"> common stock at a price of </font><font style="display: inline;">$1.40</font><font style="display: inline;"> per share. </font><font style="display: inline;">Vermillion</font><font style="display: inline;"> also issued warrants to purchase shares of common stock at a price of </font><font style="display: inline;">$0.125</font><font style="display: inline;"> per warrant share in the private placement. </font><font style="display: inline;">Net</font><font style="display: inline;"> proceeds of the private placement </font><font style="display: inline;">were </font><font style="display: inline;">approximately $</font><font style="display: inline;">5,100,000</font><font style="display: inline;"> after deducting offering expenses. The warrants </font><font style="display: inline;">are</font><font style="display: inline;"> exercisable for </font><font style="display: inline;color:#000000;">2,810,338</font><font style="display: inline;"> shares of </font><font style="display: inline;">Vermillion </font><font style="display: inline;">common stock at </font><font style="display: inline;">$1.80</font><font style="display: inline;"> per share</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;color:#000000;">The warrants may be exercised from time to time beginning August 17, 2017 and expire on the fifth anniversary of the date of issuance </font><font style="display: inline;">or, if earlier, five business days after </font><font style="display: inline;">Vermillion</font><font style="display: inline;"> delivers notice that the closing price per share of its </font><font style="display: inline;">common stock </font><font style="display: inline;">exceeded the </font><font style="display: inline;">exercise price </font><font style="display: inline;">for 20 consecutive trading days during the exercise period</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In December 2014, the Company issued warrants to purchase up to an aggregate of 4,166,659 shares of Vermillion&nbsp;common stock at an exercise price of $2.00 per share in conjunction with a December 2014 private placement of Vermillion common stock.&nbsp;&nbsp;The warrants would have expired by their original terms on December 23, 2017.</font><font style="display: inline;font-family:Calibri;font-size:10pt;"> &nbsp; &nbsp;</font><font style="display: inline;font-size:10pt;">On August 31, 2017, certain holders exercised warrants to purchase 3,796,818 shares of Vermillion common stock in consideration for the Company agreeing to reduce the exercise price to $1.00 per share of Vermillion common stock.</font><font style="display: inline;font-family:Calibri;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">The Company issued 3,796,818 shares of Vermillion common stock and received&nbsp;$3,796,818 in aggregate gross proceeds (approximately $3,57</font><font style="display: inline;font-size:10pt;">6</font><font style="display: inline;font-size:10pt;">,000 net of transaction costs).</font><font style="display: inline;font-family:Calibri;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_1_17"></a><font style="display: inline;font-size:10pt;">We have</font><font style="display: inline;font-size:10pt;"> incurred significant net losses and negative cash flows from operations since inception, and as a result ha</font><font style="display: inline;font-size:10pt;">ve</font><font style="display: inline;font-size:10pt;"> an accumulated deficit of approximately $</font><font style="display: inline;font-size:10pt;">3</font><font style="display: inline;font-size:10pt;">96</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;">053</font><font style="display: inline;font-size:10pt;">,000</font><font style="display: inline;font-size:10pt;"> at December 31, </font><font style="display: inline;font-size:10pt;">201</font><font style="display: inline;font-size:10pt;">7</font><font style="display: inline;font-size:10pt;">. The Company expects to incur a net loss in </font><font style="display: inline;font-size:10pt;">201</font><font style="display: inline;font-size:10pt;">8</font><font style="display: inline;font-size:10pt;"> as well</font><font style="display: inline;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-size:10pt;">In order to continue our operations as currently planned through 2018 and beyond, we will need to raise additional capital. Given the </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">39</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-size:10pt;">above conditions, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company expects to raise capital through a variety of sources, which may include the </font><font style="display: inline;">exercise of common stock</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">warrants, </font><font style="display: inline;">(</font><font style="display: inline;font-style:italic;">e.g.</font><font style="display: inline;">, the warrants to purchase </font><font style="display: inline;color:#000000;">2,810,338</font><font style="display: inline;"> shares of Vermillion common stock at $</font><font style="display: inline;">1.80</font><font style="display: inline;"> per share, which warrants were issued in </font><font style="display: inline;">February 2017</font><font style="display: inline;"> and expire </font><font style="display: inline;">i</font><font style="display: inline;">n &nbsp;</font><font style="display: inline;">February</font><font style="display: inline;"> 20</font><font style="display: inline;">22 or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period</font><font style="display: inline;">), </font><font style="display: inline;">public </font><font style="display: inline;">and private </font><font style="display: inline;">equity </font><font style="display: inline;">offerings</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">debt </font><font style="display: inline;">financing, collaborati</font><font style="display: inline;">ons</font><font style="display: inline;">, licensing arrangements, </font><font style="display: inline;">grants and government funding and strategic alliances</font><font style="display: inline;">. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the </font><font style="display: inline;">Company&#x2019;s </font><font style="display: inline;">business, results of operations and financial condition. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:10pt;">In connection with a private placement offering of common stock and warrants we completed in May 2013, we entered into a stockholders agreement which, among other things, gives two of the primary investors in that</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;">offering the right to participate in any future equity offerings by the Company on the same price and terms as other investors.&nbsp;In addition, the stockholders agreement prohibits us from taking certain material actions without the consent of at least one of the two primary investors in that offering.&nbsp;These material actions include: </font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Making any acquisition with </font><font style="display: inline;font-size:10pt;color:#000000;">a value greater than $2 million;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Offering, selling or issuing any securities senior to Vermillion&#x2019;s common stock or any securities that are convertible into or exchangeable or exercisable for securities rank</font><font style="display: inline;font-size:10pt;color:#000000;">ing senior to Vermillion&#x2019;s common stock;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Taking any action that would result in a change in control of the Company or an insolvency event; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Paying or declaring dividends on any securities of the Company or distributing any assets of the Company other than in the ordinary course of business or repurchasing any outstanding securities of the Company.</font></p></td></tr></table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">The foregoing rights terminate for each stockholder when that stockholder ceases to beneficially own less than 50% of the shares and warrants (taking into account shares issued upon exercise of the warrants), in the aggregate, that were purchased at the closing of the 2013 private placement.</font><font style="display: inline;font-family:Arial Unicode MS;font-size:10pt;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:9pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The information set forth in</font><font style="display: inline;color:#000000;"> Note 2 to our consolidated financial statements</font><font style="display: inline;color:#000000;"> contained in Part II, Item 8, </font><font style="display: inline;color:#000000;">&#x201C;Financial Statements and Supplementary Data,&#x201D; of this Annual Report on Form 10-K is hereby incorporated herein by reference</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Results of Operations &#x2013; Year Ended December 31, </font><font style="display: inline;font-size:10pt;color:#000000;">201</font><font style="display: inline;font-size:10pt;color:#000000;">7</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">as compared to Year Ended December 31, </font><font style="display: inline;font-size:10pt;color:#000000;">201</font><font style="display: inline;font-size:10pt;color:#000000;">6</font>
		</p>
		<p style="margin:6pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">The </font><font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">Company&#x2019;s </font><font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">selected summary financial and operating data for the years ended December 31, </font><font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">201</font><font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">7</font><font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">and </font><font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">201</font><font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">6</font><font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-weight:normal;font-size:10pt;color:#000000;">were as follows:</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-weight:normal;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-weight:normal;font-size:1pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-weight:normal;font-size:1pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Year Ended December 31,</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Increase (Decrease)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(dollars in thousands)</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Amount</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Revenue:</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Product </font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,853&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,320&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">533&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Service</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">268&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">322&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(54)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(17)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,121&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,642&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">479&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cost of revenue:</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Product </font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,756&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,974&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(218)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(11)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Service</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,158&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">724&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">434&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">60&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total cost of revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,914&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,698&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">216&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Gross profit / (loss)</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">207&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(56)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">263&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(470)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Operating expenses:</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">837&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,172&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,335)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(61)
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">40</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Sales and marketing </font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,268&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,798&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,530)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(37)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">General and administrative </font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,543&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,928&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(385)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(6)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total operating expenses </font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10,648&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14,898&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4,250)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(29)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(10,441)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14,954)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,513&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(30)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Interest (expense) / income, net </font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(42)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(28)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">50&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other (expense) / income, net </font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(28)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(200)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss </font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(10,497)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14,968)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,471&nbsp;
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(30)
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Product Revenue</font><font style="display: inline;font-weight:bold;color:#000000;">.</font><font style="display: inline;color:#000000;"> &nbsp;Product revenue was </font><font style="display: inline;color:#000000;">approximately </font><font style="display: inline;color:#000000;">$</font><font style="display: inline;color:#000000;">2,</font><font style="display: inline;color:#000000;">853</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;"> for the year ended December&nbsp;31,&nbsp;</font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">compared to $</font><font style="display: inline;color:#000000;">2,320</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;"> for the same period in </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">Revenue for ASPiRA LABS is being recognized when the OVA1 test is being performed</font><font style="display: inline;color:#000000;"> or </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">when amounts that will ultimately be realized can be estimated</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">All other ASPiRA LABS revenue is being recognized on </font><font style="display: inline;color:#000000;">a &nbsp;</font><font style="display: inline;color:#000000;">cash basis and thus recognition of revenue lags the performance of </font><font style="display: inline;color:#000000;">some</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">OVA1 test</font><font style="display: inline;color:#000000;">s</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">The 23% product revenue growth is due to improvement in the average unit price received per test compared to the prior year. The increase in average unit price was driven by an increase in client bill contracts, expansion of positive medical policy and contracting with payers, and&nbsp;improved billing and collection practices.</font><font style="display: inline;font-family:Calibri;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;color:#000000;">The number of OVA1 tests performed decreased 6% to 8,575&nbsp;OVA1 tests during the year ended December 31, 2017 compared to 9,125&nbsp;OVA1 tests for the </font><font style="display: inline;color:#000000;">prior year</font><font style="display: inline;color:#000000;">.&nbsp;The volume decrease was primarily due to the previously announced loss of a client bill customer in July 2017, &nbsp;which was concentrated in uncovered territories&nbsp;(territories not covered by an ASPiRA sales representative) and, to a lesser extent, the impact of hurricanes in two key areas (Texas and Florida). &nbsp;Partially </font><font style="display: inline;color:#000000;">off</font><font style="display: inline;color:#000000;">-</font><font style="display: inline;color:#000000;">setting </font><font style="display: inline;color:#000000;">the volume decrease was modest year-over-year growth in covered territories (territories covered by an ASPiRA sales representative).</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Service Revenue.&nbsp; </font><font style="display: inline;color:#000000;">Service revenue was $268,000 for the year ended December 31, 2017 compared to $</font><font style="display: inline;color:#000000;">322</font><font style="display: inline;color:#000000;">,000 for the same period in 2016, a decrease of $</font><font style="display: inline;color:#000000;">5</font><font style="display: inline;color:#000000;">4</font><font style="display: inline;color:#000000;">,000, or </font><font style="display: inline;color:#000000;">17</font><font style="display: inline;color:#000000;">%. &nbsp;Service revenue will vary from quarter to quarter based on the size of ongoing customer projects.&nbsp;Revenue for ASPiRA IVD is being recognized once certain revenue recognition criteria </font><font style="display: inline;color:#000000;">have </font><font style="display: inline;color:#000000;">been met (see Note 1 to the financial statements included in Part </font><font style="display: inline;color:#000000;">I</font><font style="display: inline;color:#000000;">I, Item V</font><font style="display: inline;color:#000000;">I</font><font style="display: inline;color:#000000;">II of this Form 10-K).</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Cost of Revenue</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;"> - Product</font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">Cost of product revenue was $1,756,000 for the year ended December 31, 2017 compared to $1,974,000 for the same period in 2016, representing a decrease of $218,000, or 11%, due to </font><font style="display: inline;color:#000000;">operating efficiencies</font><font style="display: inline;color:#000000;"> compared to the prior year.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Cost of Revenue - Service.</font><font style="display: inline;color:#000000;"> &nbsp;&nbsp;</font><font style="display: inline;color:#000000;">Cost of service revenue was $1,158,000 for the year ended December 31, 2017 compared to $724,000 for the same period in 2016, or an increase of 60%. &nbsp;ASPiRA IVD did not commence operations until June 2016 and thus included only seven months of expense compared to a full year of expense in 2017.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Research and Development Expenses</font><font style="display: inline;font-weight:bold;color:#000000;">.</font><font style="display: inline;color:#000000;"> &nbsp;Research and development expenses represent costs incurred to develop our technology and carry out clinical studies, and include personnel-related expenses, regulatory costs, reagents and supplies used in research and development laboratory</font><font style="display: inline;color:#000000;"> work, infrastructure expenses, </font><font style="display: inline;color:#000000;">contract services and other outside costs.&nbsp;&nbsp;Research and development expenses also include costs related to activities performed under contracts with our collaborators and strategic partners. Rese</font><font style="display: inline;color:#000000;">arch and development expenses </font><font style="display: inline;color:#000000;">decreased </font><font style="display: inline;color:#000000;">by $</font><font style="display: inline;color:#000000;">1,</font><font style="display: inline;color:#000000;">335</font><font style="display: inline;color:#000000;">,000, or </font><font style="display: inline;color:#000000;">61</font><font style="display: inline;color:#000000;">%, for </font><font style="display: inline;color:#000000;">the year ended December&nbsp;31,&nbsp;</font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">com</font><font style="display: inline;color:#000000;">pared to the same period in </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">This decrease was mainly due to decreases in collaborations</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">clinical trials, </font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">consultin</font><font style="display: inline;color:#000000;">g as </font><font style="display: inline;color:#000000;">Overa was cleared in March 2016 and the March 31, 2016 expiration of our collaboration agreement with </font><font style="display: inline;color:#000000;">JHU</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">In 2017, we internally performed o</font><font style="display: inline;color:#000000;">ngoing</font><font style="display: inline;color:#000000;"> product pipeline development</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">at </font><font style="display: inline;color:#000000;">a lower cost</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> including </font><font style="display: inline;color:#000000;">patient consents under IRB for </font><font style="display: inline;color:#000000;">our pelvic mass specimen and data repository and cataloguing of serum samples for future research purposes</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">We expect research and development expenses in 201</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">to be consistent with those of</font><font style="display: inline;color:#000000;"> 201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Sales and Marketing Expenses.&nbsp; </font><font style="display: inline;color:#000000;">Our sales and marketing expenses consist primarily of personnel-related expenses, education and promotional expenses, and infrastructure expenses.&nbsp;&nbsp;These expenses include the costs of educating physicians, laboratory personnel and other healthcare professionals regarding OVA1</font><font style="display: inline;color:#000000;"> and Overa</font><font style="display: inline;color:#000000;">.&nbsp;&nbsp;Sales and marketing expenses also include the costs of sponsoring continuing medical education, medical meeting participation and dissemination of scientific and health economic publications.&nbsp;&nbsp;Our personnel-related expenses include the cost of our field sales force, the subject matter experts responsible for market development. Sales and marketing expenses decreased by $</font><font style="display: inline;color:#000000;">2,530</font><font style="display: inline;color:#000000;">,000, or </font><font style="display: inline;color:#000000;">3</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">%, for the year ended December 31, 201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;"> compared to the </font><font style="display: inline;color:#000000;">prior year</font><font style="display: inline;color:#000000;">.&nbsp; </font><font style="display: inline;color:#000000;">This decrease was primarily due to a reduction in personnel and personnel expenses and decreases in consulting and marketing services compared to the prior year.</font><font style="display: inline;font-family:Calibri;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">We expect sales and marketing expenses to </font><font style="display: inline;color:#000000;">in</font><font style="display: inline;color:#000000;">crease in future periods </font><font style="display: inline;color:#000000;">as we expand our sales team in specific markets where we have broad payer coverage and key opinion leader support.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">General and Administrative Expenses</font><font style="display: inline;font-weight:bold;color:#000000;">.</font><font style="display: inline;color:#000000;"> &nbsp;General and administrative expenses consist primarily of personnel-related expenses, professional fees and other costs, including legal, finance and accounting expenses, and oth</font><font style="display: inline;color:#000000;">er infrastructure expenses</font><font style="display: inline;color:#000000;">. General and administrative</font><font style="display: inline;color:#000000;"> expenses </font><font style="display: inline;color:#000000;">de</font><font style="display: inline;color:#000000;">creased</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">by $</font><font style="display: inline;color:#000000;">3</font><font style="display: inline;color:#000000;">85</font><font style="display: inline;color:#000000;">,000, or </font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">%, for </font><font style="display: inline;color:#000000;">the year ended December&nbsp;31,&nbsp;</font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">com</font><font style="display: inline;color:#000000;">pared to the same period in </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">The decrease was primarily due to consulting services and ASPiRA IVD start-up expenses in 2016 not being repeated in 2017, partially offset by one-time charges for Senior Vice President, Finance &amp; Chief Accounting Officer severance and non-cash </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">41</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt"><font style="display: inline;">stock compensation totaling approximately $</font><font style="display: inline;">286</font><font style="display: inline;">,000.&nbsp;&nbsp;We expect general and administrative expenses </font><font style="display: inline;">in 2018 </font><font style="display: inline;">to be consistent </font><font style="display: inline;">with those of</font><font style="display: inline;"> 2017.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Times New Roman;text-justify:inter-ideograph;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Liquidity and Capital Resources</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We plan to continue to expend resources in the selling and marketing of OVA1 </font><font style="display: inline;">and Overa </font><font style="display: inline;">and developing additional diagnostic tests. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On March 22, 2016, we entered into </font><font style="display: inline;">the Loan A</font><font style="display: inline;">greement</font><font style="display: inline;"> pursuant to which we may</font><font style="display: inline;"> borrow up to $4,000,000 from the DECD.&nbsp;&nbsp;Proceeds from the loan </font><font style="display: inline;">were</font><font style="display: inline;"> utilized primarily to fund the build-out, information technology infrastructure and other costs related to our Trumbull, Connecticut facility and operations.&nbsp;&nbsp;The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, </font><font style="display: inline;">which occurs on&nbsp;April 15, 2026</font><font style="display: inline;">.&nbsp;&nbsp;As security for the loan, we have granted the </font><font style="display: inline;">DECD</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">a blanket security interest in our personal and intellectual property.&nbsp;&nbsp;The </font><font style="display: inline;">DECD&#x2019;s security interest in our </font><font style="display: inline;">intellectual property may be subordinated to a qualified institutional lender.&nbsp;&nbsp;Under the terms of the agreement, </font><font style="display: inline;">as amended, </font><font style="display: inline;">we may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan </font><font style="display: inline;">if we achieve</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">certain job creation and retention milestones measured by March 1, </font><font style="display: inline;">2021 (the &#x201C;Measurement Date&#x201D;)</font><font style="display: inline;">.&nbsp; </font><font style="display: inline;">Conversely, if we are </font><font style="display: inline;">either </font><font style="display: inline;">unable to meet these job creation </font><font style="display: inline;">and retention </font><font style="display: inline;">milestones, namely, hiring </font><font style="display: inline;">and retaining for a consecutive two-year period </font><font style="display: inline;">40 </font><font style="display: inline;">full-</font><font style="display: inline;">time employees with a specified average annual salary </font><font style="display: inline;">by the Measurement Date</font><font style="display: inline;"> or do not maintain our Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5%</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of the total funded l</font><font style="display: inline;">oan</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">An initial disbursement of $2,000,000&nbsp;was made to the Company on April</font><font style="display: inline;"> 15,</font><font style="display: inline;"> 2016 under the Loan Agreement.&nbsp;</font><font style="display: inline;">The remaining $2,000,000 will be </font><font style="display: inline;">advanced if and when the Company achieves certain</font><font style="display: inline;"> other future milestones. </font><font style="display: inline;">The loan may be prepaid at any time without premium or penalty.</font><font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On </font><font style="display: inline;">February 17, 2017</font><font style="display: inline;">, the Company completed a private placement pursuant to which certain investors purchased </font><font style="display: inline;color:#000000;">3,747,125</font><font style="display: inline;"> shares of </font><font style="display: inline;">Vermillion</font><font style="display: inline;"> common stock at a price of </font><font style="display: inline;">$1.40</font><font style="display: inline;"> per share. </font><font style="display: inline;">Vermillion</font><font style="display: inline;"> also issued warrants to purchase shares of common stock at a price of </font><font style="display: inline;">$0.125</font><font style="display: inline;"> per warrant share in the private placement. </font><font style="display: inline;">Net</font><font style="display: inline;"> proceeds of the private placement </font><font style="display: inline;">were </font><font style="display: inline;">approximately $</font><font style="display: inline;">5,100,000</font><font style="display: inline;"> after deducting offering expenses. The warrants </font><font style="display: inline;">are</font><font style="display: inline;"> exercisable for </font><font style="display: inline;color:#000000;">2,810,338</font><font style="display: inline;"> shares of </font><font style="display: inline;">Vermillion </font><font style="display: inline;">common stock at </font><font style="display: inline;">$1.80</font><font style="display: inline;"> per share</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;color:#000000;">The warrants expire on the fifth anniversary of the date of issuance </font><font style="display: inline;">or, if earlier, five business days after the Company delivers notice that the closing price per share of its </font><font style="display: inline;">common stock </font><font style="display: inline;">exceeded the </font><font style="display: inline;">exercise price </font><font style="display: inline;">for 20 consecutive trading days during the exercise period</font><font style="display: inline;color:#000000;">.</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In December 2014, the Company issued warrants to purchase up to an aggregate of 4,166,659 shares of Vermillion&nbsp;common stock at an exercise price of $2.00 per share in conjunction with a December 2014 private placement of Vermillion common stock.&nbsp;&nbsp;The warrants would have expired by their original terms on December 23, 2017.</font><font style="display: inline;font-family:Calibri;font-size:10pt;"> &nbsp; &nbsp;</font><font style="display: inline;font-size:10pt;">On August 31, 2017, certain holders exercised warrants to purchase 3,796,818 shares of Vermillion common stock in consideration for the Company agreeing to reduce the exercise price to $1.00 per share of Vermillion common stock.</font><font style="display: inline;font-family:Calibri;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">The Company issued 3,796,818 shares of Vermillion common stock and received&nbsp;$3,796,818 in aggregate gross proceeds (approximately $3,57</font><font style="display: inline;font-size:10pt;">6</font><font style="display: inline;font-size:10pt;">,000 net of transaction costs).</font><font style="display: inline;font-family:Calibri;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company has</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">incurred significant net losses and negative cash flows from operations since inception. &nbsp;At December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, we had an accumulated deficit of </font><font style="display: inline;">$396,053,000</font><font style="display: inline;"> and stockholders' equity of </font><font style="display: inline;">$</font><font style="display: inline;">3,</font><font style="display: inline;">407</font><font style="display: inline;">,000</font><font style="display: inline;">. &nbsp;On December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, we had </font><font style="display: inline;">$</font><font style="display: inline;">5,</font><font style="display: inline;">539</font><font style="display: inline;">,000</font><font style="display: inline;"> of cash and cash equivalents and </font><font style="display: inline;">$</font><font style="display: inline;">2,</font><font style="display: inline;">609</font><font style="display: inline;">,000</font><font style="display: inline;"> of current liabilities. </font><font style="display: inline;">The Company expects to incur a net loss in 2018 as well. </font><font style="display: inline;">In order to continue our operations as currently planned through 2018 and beyond, we will need to raise additional capital. Given the above conditions, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">There can be no assurance that </font><font style="display: inline;">we </font><font style="display: inline;">will achieve or sustain profitability or positive cash flow from operations.&nbsp;In addition, while we expect to grow revenue with the addition of ASPiRA LABS, there is no assurance of our ability to generate substantial revenues and cash flows from ASPiRA LABS</font><font style="display: inline;">&#x2019;</font><font style="display: inline;"> operations. </font><font style="display: inline;">We expect cash from our products</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and services</font><font style="display: inline;"> to be our only material, recurring source of cash in </font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">O</font><font style="display: inline;font-size:10pt;">ur management believes that the successful achievement of our business objectives will require additional financing.&nbsp;We expect to raise capital through a variety of sources, which may include </font><font style="display: inline;font-size:10pt;">the exercise of common stock warrants, public and private equity</font><font style="display: inline;font-size:10pt;"> offerings, debt</font><font style="display: inline;font-size:10pt;"> financing, </font><font style="display: inline;font-size:10pt;">collaborati</font><font style="display: inline;font-size:10pt;">ons</font><font style="display: inline;font-size:10pt;">, licensing arrangements, grants and government funding</font><font style="display: inline;font-size:10pt;"> and</font><font style="display: inline;font-size:10pt;"> strategic alliances.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Any additional equity financing may be dilutive to stockholders, and debt financing, if available, may involve restrictive</font><font style="display: inline;font-size:10pt;"> covenants and potential dilution to stockholders. If we obtain additional funds through arrangements with collaborators or strategic partners, we may be required to relinquish our rights to certain technologies or products that we might otherwise seek to retain. Additional funding may not be available when needed or on terms acceptable to us. If we are unable to obtain additional capital, we may not be able to continue our sales and marketing, research and development, or other operations on the scope or scale of current activity</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;"> and that could have a material adverse effect on the business</font><font style="display: inline;font-size:10pt;">, financial condition and results of operations</font><font style="display: inline;font-size:10pt;">.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our</font><font style="display: inline;"> future liquidity and capital requirements will depend upon many factors, including, among others:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;color:#000000;">resources devoted to establish sales, marketing and distribution capabilities; </font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">42</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;color:#000000;">the rate of </font><font style="display: inline;color:#000000;">OVA</font><font style="display: inline;color:#000000;">1</font><font style="display: inline;color:#000000;"> and Overa</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">adoption by physicians and patients;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;color:#000000;">the insurance payer community&#x2019;s acceptance of and reimbursement for OVA1 and Overa;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;color:#000000;">the successful targeted launch of Overa;</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;color:#000000;">resources devoted to our IVD trials laboratory and services;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;color:#000000;">the revenue generated by our IVD trial services business;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;color:#000000;">our </font><font style="display: inline;color:#000000;">plans</font><font style="display: inline;color:#000000;"> to acquire or invest in other products, technologies and businesses; </font><font style="display: inline;color:#000000;">and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
				<font style="margin:0pt 0pt 3pt;font-family:Symbol;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 3pt;">
			<font style="display: inline;color:#000000;">the market price of our common stock;</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Cash and cash equivalents as of December&nbsp;31,&nbsp;</font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and December&nbsp;31, </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">were</font><font style="display: inline;color:#000000;"> &nbsp;$</font><font style="display: inline;color:#000000;">5,</font><font style="display: inline;color:#000000;">539</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;"> and</font><font style="display: inline;color:#000000;"> &nbsp;$</font><font style="display: inline;color:#000000;">5,242</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;">, respectively.&nbsp;&nbsp;At December&nbsp;31,&nbsp;</font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">, working capital was $</font><font style="display: inline;color:#000000;">3,</font><font style="display: inline;color:#000000;">696</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">$</font><font style="display: inline;color:#000000;">3,547</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;">, respectively</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Net cash used in </font><font style="display: inline;color:#000000;">operating activities was $</font><font style="display: inline;color:#000000;">8,1</font><font style="display: inline;color:#000000;">29</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;"> for the year ended December 31, </font><font style="display: inline;color:#000000;">2017</font><font style="display: inline;color:#000000;">, resulting primarily from $</font><font style="display: inline;color:#000000;">10,497</font><font style="display: inline;color:#000000;">,000 net loss incurred partially offset by $1,</font><font style="display: inline;color:#000000;">439</font><font style="display: inline;color:#000000;">,000 of stock-based compensation expense</font><font style="display: inline;color:#000000;"> and $786,000 of depreciation and amortization expense.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Net cash used in </font><font style="display: inline;color:#000000;">operating activities was $</font><font style="display: inline;color:#000000;">13,963,000</font><font style="display: inline;color:#000000;"> for the year ended December 31, </font><font style="display: inline;color:#000000;">2016</font><font style="display: inline;color:#000000;">, resulting primarily from $</font><font style="display: inline;color:#000000;">14,</font><font style="display: inline;color:#000000;">968</font><font style="display: inline;color:#000000;">,000 net loss incurred</font><font style="display: inline;color:#000000;"> partially offset by</font><font style="display: inline;color:#000000;"> $1,</font><font style="display: inline;color:#000000;">179</font><font style="display: inline;color:#000000;">,000 of stock-based compensation expense</font><font style="display: inline;color:#000000;"> and $723,000 of depreciation and amortization expense</font><font style="display: inline;color:#000000;">. Net cash used in operating activities also included $</font><font style="display: inline;color:#000000;">903</font><font style="display: inline;color:#000000;">,000 of cash used from changes in operating assets and liabilities and primarily from </font><font style="display: inline;color:#000000;">de</font><font style="display: inline;color:#000000;">creases in</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">accrued liabilities</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Net cash used in investing activities was $</font><font style="display: inline;color:#000000;">60</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;"> for </font><font style="display: inline;color:#000000;">the year ended December 31, 2017</font><font style="display: inline;color:#000000;"> due to purchases </font><font style="display: inline;color:#000000;">of </font><font style="display: inline;color:#000000;">property and equipment.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Net cash used in investing activities was $</font><font style="display: inline;color:#000000;">1,261,000</font><font style="display: inline;color:#000000;"> for the year ended December 31, 2016, due to purchases of computer equipment and software and </font><font style="display: inline;color:#000000;">build-out of the ASPiRA IVD lab at our Trumbull, Connecticut facility</font><font style="display: inline;color:#000000;">. &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Net cash provided by financing activities was $</font><font style="display: inline;color:#000000;">8,</font><font style="display: inline;color:#000000;">486</font><font style="display: inline;color:#000000;">,000 for the year ended December 31, 201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">which consisted primarily of </font><font style="display: inline;color:#000000;">net </font><font style="display: inline;color:#000000;">proceeds from </font><font style="display: inline;color:#000000;">our February 2017 offering of common stock and warrants totaling $5,127,000 and </font><font style="display: inline;color:#000000;">the </font><font style="display: inline;color:#000000;">August 2017 </font><font style="display: inline;color:#000000;">exercis</font><font style="display: inline;color:#000000;">e</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">of </font><font style="display: inline;color:#000000;">repriced </font><font style="display: inline;color:#000000;">warrants totaling $3,57</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Net cash provided by </font><font style="display: inline;color:#000000;">financing activities was $1,824</font><font style="display: inline;color:#000000;">,000 for </font><font style="display: inline;color:#000000;">the year ended December 31, 2016,</font><font style="display: inline;color:#000000;"> which consisted primarily of </font><font style="display: inline;color:#000000;">net </font><font style="display: inline;color:#000000;">proceeds from</font><font style="display: inline;color:#000000;"> the DECD loan less loan repayments made.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;font-weight:bold;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Off-Balance Sheet Arrangements</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">As of December&nbsp;31, </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">we</font><font style="display: inline;color:#000000;"> had no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">ITEM 7A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;color:#000000;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Pursuant</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">Item 305(e) of Regulation S-K, </font><font style="display: inline;color:#000000;">the </font><font style="display: inline;color:#000000;">information </font><font style="display: inline;color:#000000;">called for by Item 7A </font><font style="display: inline;color:#000000;">is not required.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">ITEM 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;color:#000000;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Our consolidated financial statements, including consolidated balanc</font><font style="display: inline;color:#000000;">e sheets as of December 31, </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">, &nbsp;</font><font style="display: inline;color:#000000;">consolidated statements of operations</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">for t</font><font style="display: inline;color:#000000;">he years ended December 31, </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">, consolidated statements of </font><font style="display: inline;color:#000000;">changes in </font><font style="display: inline;color:#000000;">stockholders&#x2019; equity</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">for the years ended December 31,</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">, consolidated statements of cash flows for t</font><font style="display: inline;color:#000000;">he years ended December 31, </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">and notes to our consolidated financial statements, together with </font><font style="display: inline;color:#000000;">a &nbsp;</font><font style="display: inline;color:#000000;">report thereon of</font><font style="display: inline;color:#000000;"> our independent registered public accounting firm</font><font style="display: inline;color:#000000;"> are attached hereto as pages F-</font><font style="display: inline;color:#000000;">1</font><font style="display: inline;color:#000000;"> through </font><font style="display: inline;color:#000000;">F-</font><font style="display: inline;color:#000000;">19</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">ITEM 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;color:#000000;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">None</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">ITEM 9A.</font><font style="display: inline;font-weight:bold;color:#000000;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;color:#000000;">CONTROLS AND PROCEDURES</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Evaluation of </font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Disclosure Controls and Procedures</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">We </font><font style="display: inline;font-size:10pt;color:#000000;">maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">43</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-size:10pt;">the S</font><font style="display: inline;font-size:10pt;">EC</font><font style="display: inline;font-size:10pt;">&#x2019;s rules&nbsp;and </font><font style="display: inline;font-size:10pt;">regulations</font><font style="display: inline;font-size:10pt;">, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and </font><font style="display: inline;font-size:10pt;">Chief</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief </font><font style="display: inline;font-size:10pt;">Financial</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(</font><font style="display: inline;font-size:10pt;">e</font><font style="display: inline;font-size:10pt;">) and </font><font style="display: inline;font-size:10pt;">Rule </font><font style="display: inline;font-size:10pt;">15d-15(</font><font style="display: inline;font-size:10pt;">e</font><font style="display: inline;font-size:10pt;">) under the Exchange Act, as of Dec</font><font style="display: inline;font-size:10pt;">ember 31, </font><font style="display: inline;font-size:10pt;">201</font><font style="display: inline;font-size:10pt;">7</font><font style="display: inline;font-size:10pt;">.&nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Based on that evaluation, </font><font style="display: inline;font-size:10pt;">our</font><font style="display: inline;font-size:10pt;"> Chief Executive Officer and Chief </font><font style="display: inline;font-size:10pt;">Financial</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">Officer</font><font style="display: inline;font-size:10pt;"> have</font><font style="display: inline;font-size:10pt;"> concluded that as of </font><font style="display: inline;font-size:10pt;">December 3</font><font style="display: inline;font-size:10pt;">1, </font><font style="display: inline;font-size:10pt;">201</font><font style="display: inline;font-size:10pt;">7</font><font style="display: inline;font-size:10pt;">,</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">our</font><font style="display: inline;font-size:10pt;"> disclosure controls and procedures, as defined in Rule</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">13a-15(e)</font><font style="display: inline;font-size:10pt;"> and Rule 15(d)-15(e)</font><font style="display: inline;font-size:10pt;"> under the Exchange Act, were effective.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">Management Report</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">o</font><font style="display: inline;font-weight:bold;font-style:italic;font-size:10pt;">n Internal Control over Financial Reporting</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We are responsible for establishing and maintaining adequate internal control over our financial reporting. We have assessed the effectiveness of internal control over financial reporting as of December&nbsp;31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">. Our assessment was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission </font><font style="display: inline;">(&#x201C;</font><font style="display: inline;">COSO</font><font style="display: inline;">&#x201D;)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">entitled &#x201C;</font><font style="display: inline;">Internal Control</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">-</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Integrated Framework</font><font style="display: inline;"> &nbsp;(</font><font style="display: inline;">2013</font><font style="display: inline;">)</font><font style="display: inline;">.</font><font style="display: inline;">&#x201D;</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with </font><font style="display: inline;">GAAP</font><font style="display: inline;">. Our internal control over financial reporting includes those policies and procedures that: </font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;"><p style="width:27pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;"><p style="width:27pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and board of directors; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;"><p style="width:27pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;color:#000000;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.</font></p></td></tr></table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Based on using the COSO criteria, </font><font style="display: inline;color:#000000;">management concluded</font><font style="display: inline;color:#000000;"> our internal control over financial reporting as of December&nbsp;31, </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">was effective.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">This Annual Report on Form 10-K does not include an attestation report of </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> independent registered public accounting firm regarding internal control over financial reporting.&nbsp;&nbsp;&nbsp;Management&#x2019;s assessment of the effectiveness of </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> internal control over financial reporting as of December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;">31, </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">, was not subject to attestation by </font><font style="display: inline;color:#000000;">our</font><font style="display: inline;color:#000000;"> independent registered public accounting firm pursuant to rules of the SEC that permit </font><font style="display: inline;color:#000000;">a smaller reporting company </font><font style="display: inline;color:#000000;">to provide only management&#x2019;s report in </font><font style="display: inline;color:#000000;">the Company&#x2019;s</font><font style="display: inline;color:#000000;"> Annual Report on Form 10-K.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Changes in internal control over financial reporting.</font><font style="display: inline;font-weight:bold;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">There was no change in our internal control over financial reporting that occurred during the quarter ended December&nbsp;31, </font><font style="display: inline;color:#000000;">201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt;text-indent:31.5pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">ITEM 9B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;color:#000000;">OTHER INFORMATION</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-decoration:none;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;text-decoration:none;color:#000000;">On </font><font style="display: inline;text-decoration:none;color:#000000;">March </font><font style="display: inline;text-decoration:none;color:#000000;">7</font><font style="display: inline;text-decoration:none;color:#000000;">, 2018</font><font style="display: inline;text-decoration:none;color:#000000;">,</font><font style="display: inline;text-decoration:none;color:#000000;">&nbsp;</font><font style="display: inline;text-decoration:none;color:#000000;">Vermillion</font><font style="display: inline;text-decoration:none;color:#000000;"> entered into the First Amendment to Assistance Agreement by and between the State of Connecticut Acting by the DECD and </font><font style="display: inline;text-decoration:none;color:#000000;">Vermillion</font><font style="display: inline;text-decoration:none;color:#000000;"> (the &#x201C;Amendment&#x201D;) effective </font><font style="display: inline;text-decoration:none;color:#000000;">as of </font><font style="display: inline;text-decoration:none;color:#000000;">March </font><font style="display: inline;text-decoration:none;color:#000000;">7</font><font style="display: inline;text-decoration:none;color:#000000;">, 2018</font><font style="display: inline;text-decoration:none;color:#000000;">.&nbsp;&nbsp;The Amendment amends the Loan Agreement, pursuant to which the Company may borrow up to $4,000,000 from the DECD. An initial disbursement of $2,000,000&nbsp;was made to </font><font style="display: inline;text-decoration:none;color:#000000;">Vermillion</font><font style="display: inline;text-decoration:none;color:#000000;"> on April 15, 2016 under the Loan Agreement. The primary purpose of the Amendment is to extend by one year the original measurement date by which </font><font style="display: inline;text-decoration:none;color:#000000;">Vermillion</font><font style="display: inline;text-decoration:none;color:#000000;"> must hire and retain for a consecutive two-year period 40 full</font><font style="display: inline;text-decoration:none;color:#000000;">-</font><font style="display: inline;text-decoration:none;color:#000000;">time employees with a specified average annual salary.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Under the terms of the </font><font style="display: inline;color:#000000;">Loan A</font><font style="display: inline;color:#000000;">greement, as amended, </font><font style="display: inline;color:#000000;">Vermillion</font><font style="display: inline;color:#000000;"> may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan if it achieves certain job creation and retention milestones measured by March 1, 2021 (the &#x201C;Measurement Date&#x201D;). Conversely, if </font><font style="display: inline;color:#000000;">Vermillion</font><font style="display: inline;color:#000000;"> is </font><font style="display: inline;color:#000000;">either </font><font style="display: inline;color:#000000;">unable to meet these job creation </font><font style="display: inline;color:#000000;">and retention </font><font style="display: inline;color:#000000;">milestones, namely, hiring and retaining for a consecutive two-year period 40 </font><font style="display: inline;color:#000000;">full-</font><font style="display: inline;color:#000000;">time employees with a specified average annual salary by the Measurement Date</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> or does not maintain its Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5%</font><font style="display: inline;color:#000000;"> of the funded loan</font><font style="display: inline;color:#000000;">.&nbsp;&nbsp;The original Measurement Date was March 1, 2020.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">44</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Oracle Board Designee</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Pursuant to the Stockholders Agreement, dated as of May 13, 2013, by and among Vermillion, Oracle Partners, LP and Oracle Ten Fund Master, LP (together, &#x201C;Oracle&#x201D;), Jack W. Schuler and the other purchasers party thereto, Oracle has the right to designate one individual (such individual, an &#x201C;Oracle Designee&#x201D;) to serve on Vermillion&#x2019;s board of directors for so long as Oracle continues to beneficially own a specified number of shares of Company common stock.&nbsp;&nbsp;Since September 2013, Eric Varma has served as the Oracle Designee.&nbsp;&nbsp;On March 8, 2018, Mr. Varma notified Vermillion that he does not intend to stand for re-election at Vermillion&#x2019;s 2018 annual meeting of stockholders.&nbsp;&nbsp;Oracle has not yet notified Vermillion of the person who will succeed Mr. Varma as the Oracle Designee.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">45</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font><font style="display: inline;font-weight:bold;color:#000000;">PART III</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">DIRECTORS,</font><font style="display: inline;font-weight:bold;"> EXECUTIVE OFFICERS </font><font style="display: inline;font-weight:bold;">AND CORPORATE GOVERNANCE</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The information regarding our directors, committees of our Board of Directors, our director nomination process, and our executive officers </font><font style="display: inline;">appearing under the heading </font><font style="display: inline;">&#x201C;Proposal 1: Election of Directors,&#x201D; </font><font style="display: inline;">"</font><font style="display: inline;">Corporate Governance," "</font><font style="display: inline;">Management</font><font style="display: inline;">" and </font><font style="display: inline;">"Section 16(a) Beneficial Ownership Reporting Compliance,"</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">of our proxy statement relating to our </font><font style="display: inline;">a</font><font style="display: inline;">nnual </font><font style="display: inline;">m</font><font style="display: inline;">eeting </font><font style="display: inline;">of </font><font style="display: inline;">s</font><font style="display: inline;">tockholders </font><font style="display: inline;">to be held </font><font style="display: inline;">in</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(the &#x201C;</font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Proxy Statement&#x201D;) is incorporated by reference.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Our code of ethics is applicable to all employees, including both our Chief Executive Officer</font><font style="display: inline;"> and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Chief </font><font style="display: inline;">Financial Officer.&nbsp;&nbsp;This code of ethics is publicly available on our website at </font><font style="display: inline;text-decoration:underline;">www.</font><font style="display: inline;text-decoration:underline;">vermillion</font><font style="display: inline;text-decoration:underline;">.com</font><font style="display: inline;">.&nbsp; </font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">EXECUTIVE COMPENSATION</font>
		</p>
		<p style="margin:6pt 0.7pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;font-weight:bold;"></font><font style="display: inline;">The information appearing under the headings</font><font style="display: inline;"> "Board Compensation," </font><font style="display: inline;">"Compensation Discussion and Analysis,"</font><font style="display: inline;"> &nbsp;"</font><font style="display: inline;">Compensation Discussion and Analysis </font><font style="display: inline;">- &nbsp;</font><font style="display: inline;">Executive </font><font style="display: inline;">Officer </font><font style="display: inline;">Compensation,"</font><font style="display: inline;"> "Corporate Governance &#x2013; Compensation Committee Interlocks and Insider Participation" and "Compensation Committee</font><font style="display: inline;"> Report</font><font style="display: inline;">" &nbsp;</font><font style="display: inline;">of the </font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Proxy Statement is incorporated by reference.</font></font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font>
		</p>
		<p style="margin:6pt 0.7pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;">The information appearing under the heading &#x201C;Security Ownership of Certain Beneficial Owners and Management&#x201D; of the </font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Proxy Statement is incorporated by reference.</font></font>
		</p>
		<p style="margin:6pt 0.7pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The</font><font style="display: inline;"> equity compensation </font><font style="display: inline;">plan</font><font style="display: inline;"> information</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">contained in </font><font style="display: inline;">Part II </font><font style="display: inline;">Item 5 of this Form 10-K </font><font style="display: inline;">is incorporated by reference</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font>
		</p>
		<p style="margin:6pt 0.7pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;">The information appearing under the heading</font><font style="display: inline;">s</font><font style="display: inline;"> &#x201C;Certain Relationships and Related Transactions&#x201D; and "Corporate Governance" of the </font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Proxy Statement is incorporated by reference.</font></font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 14.</font><font style="display: inline;font-weight:bold;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">PRINCIPAL ACCOUNT</font><font style="display: inline;font-weight:bold;">ANT</font><font style="display: inline;font-weight:bold;"> FEES AND SERVICES</font>
		</p>
		<p style="margin:6pt 0.7pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The information appearing under the heading &#x201C;</font><font style="display: inline;">Ratification of the Selection of the </font><font style="display: inline;">Independent </font><font style="display: inline;">Registered </font><font style="display: inline;">Public Account</font><font style="display: inline;">ing Firm for Vermillion</font><font style="display: inline;">&#x201D; of the </font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Proxy Statement is incorporated by reference.</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">PART IV</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">ITEM 15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS</font><font style="display: inline;font-weight:bold;">,</font><font style="display: inline;font-weight:bold;"> FINANCIAL STATEMENT SCHEDULES</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:157pt;"><font style="display: inline;">(a)</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;">LIST OF DOCUMENTS FILED AS PART OF THIS REPORT:</font></font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0.9pt 0pt 0pt;">
				<font style="margin:0pt 0.9pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt;margin:0pt 0.9pt 0pt 0pt;">
			<font style="display: inline;font-style:italic;color:#000000;">Financial Statements</font></p></td></tr></table></div>
		<p style="margin:0pt 0.9pt 0pt 72pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The financial statements and notes thereto, and the report of the independent registered public accounting firm thereon, are set forth on pages F-1 </font><font style="display: inline;color:#000000;">through </font><font style="display: inline;color:#000000;">F-</font><font style="display: inline;color:#000000;">19</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 72pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:60pt;"><font style="display: inline;color:#000000;">(b)</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;color:#000000;">EXHIBITS</font></font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Exhibit</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:46.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 8pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:24.75pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:18pt;text-align:center"><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Incorporated by Reference</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"></font></font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Filed</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;text-decoration:underline;color:#000000;">Number</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 8pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:23.7pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:23.3pt;text-align:center"><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Exhibit Description</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"></font></font></p>
				</td>
				<td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;;font-size: 8pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Form</font><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"></font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;;font-size: 8pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">File No.</font><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"></font></p>
				</td>
				<td valign="bottom" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;;font-size: 8pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Exhibit</font><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"></font></p>
				</td>
				<td valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 8pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:5.5pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Filing Date</font><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"></font></font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;;font-size: 8pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Herewith</font><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 5pt">
						<font style="display: inline;font-size:5pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 5pt">
						<font style="display: inline;font-size:5pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 5pt">
						<font style="display: inline;font-size:5pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000095012310004797/f54711exv3w1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">3.1</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000095012310004797/f54711exv3w1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Fourth Amended and Restated Certificate of Incorporation of Vermillion, Inc. dated January&nbsp;22, 2010</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">000-31617</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">January&nbsp;25, 2010</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 5pt">
						<font style="display: inline;font-size:5pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">46</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td colspan="2" valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661714000044/c617-20140630ex32e1c2a07.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">3.2</font></a></p>
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661714000044/c617-20140630ex33cd4e6f1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">3.3</font></a></p>
				</td>
				<td valign="top" style="width:35.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661714000044/c617-20140630ex32e1c2a07.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation, effective June 19, 2014</font></a></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661714000044/c617-20140630ex33cd4e6f1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Fifth Amended and Restated Bylaws of Vermillion, Inc., effective June 19, 2014</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">10-Q</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">10-Q</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.23.3&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 14, 2014</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 14, 2014</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000091205700039015/ex-4_1.txt" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">4.1</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000091205700039015/ex-4_1.txt" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Form of Vermillion, Inc.&#x2019;s (formerly Ciphergen Biosystems, Inc.) Common Stock Certificate</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">S-1/A</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">333-32812</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August&nbsp;24, 2000</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:5.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000095012309073867/f54488exv10w1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">4.2</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:5.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000095012309073867/f54488exv10w1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Form of Securities Purchase Agreement by and among Vermillion, Inc. and the purchaser party thereto dated December 24, 2009</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:5.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:5.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">000-31617</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:5.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:5.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 29, 2009</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:5.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000119312513219609/d537389dex101.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">4.3</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000119312513219609/d537389dex101.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Securities Purchase Agreement dated May 8, 2013, by and among Vermillion, Inc. and the purchasers identified therein, </font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">May 14, 2013</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000119312513219609/d537389dex102.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">4.4</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000119312513219609/d537389dex102.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Stockholders Agreement dated May 13, 2013, by and among Vermillion, Inc., Oracle Partners, LP, Oracle Ten Fund Master, LP, Jack W. Schuler and other purchasers named therein.</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.2&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">May 14, 2013</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661716000090/c617-20160331xex10_2.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">4.5</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661716000090/c617-20160331xex10_2.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Promissory Note by Vermillion, Inc. in favor of the State of Connecticut, acting by and through the Department of Economic and Community Development, effective March 14, 2016</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">10-Q</font></p>
				</td>
				<td valign="top" style="width:11.82%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.2&nbsp;
				</td>
				<td valign="top" style="width:19.10%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">May 16, 2016</font></p>
				</td>
				<td valign="top" style="width:09.10%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000012/c617-20170217xex99_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">4.6</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000012/c617-20170217xex99_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Securities Purchase Agreement, dated February 13, 2017, among Vermillion, Inc. and the investors listed on Schedule I thereto</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">99.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 17, 2017</font></p>
				</td>
				<td valign="top" style="width:09.10%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000012/c617-20170217xex99_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">4.7</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000012/c617-20170217xex99_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Form of Warrant, issued February 13, 2017</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">99.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 17, 2017</font></p>
				</td>
				<td valign="top" style="width:09.10%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000051/c617-20170828xex4_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">4.8</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000051/c617-20170828xex4_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Form of Letter Agreement, by and</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">between Vermillion, Inc. and certain</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">warrant holders</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 28, 2017</font></p>
				</td>
				<td valign="top" style="width:09.10%;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000053/vrml-20171024xex4_6.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">4.9</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000053/vrml-20171024xex4_6.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Form of Indenture</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">S-3</font></p>
				</td>
				<td valign="top" style="width:11.82%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">333-221092</font></p>
				</td>
				<td valign="top" style="width:07.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4.6&nbsp;
				</td>
				<td valign="top" style="width:19.10%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">October 24, 2017</font></p>
				</td>
				<td valign="top" style="width:09.10%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000091205700039015/ex-10_4.txt" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.1</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000091205700039015/ex-10_4.txt" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Form of Stock Option Agreement</font></a><font style="display: inline;color:#000000;"> &nbsp;#</font></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">S-1/A</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">333-32812</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.4&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August&nbsp;24, 2000</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000091205700039015/ex-10_5.txt" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">2</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000091205700039015/ex-10_5.txt" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">2000 Stock Plan and related form of Stock Option Agreement #</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">S-1/A</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">333-32812</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.5&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August </font><font style="display: inline;color:#000000;">2</font><font style="display: inline;color:#000000;">4, 2000</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000095013407024013/f35603exv10w6.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">3</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000095013407024013/f35603exv10w6.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Amended and Restated 2000 Employee Stock Purchase Plan #</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">10-Q</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">000-31617</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.6&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">November&nbsp;14, 2007</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000095012310012014/f54915exv10w1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">4</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000095012310012014/f54915exv10w1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Vermillion, Inc. 2010 Stock Incentive Plan</font></a><font style="display: inline;color:#000000;"> &nbsp;#</font></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">000-31617</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February&nbsp;12, 2010</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000110465905012244/a05-4549_1ex10d7.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">5</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000110465905012244/a05-4549_1ex10d7.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Ciphergen Biosystems, Inc. 401(k) Plan #</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">10-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">000-31617</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.7&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">March&nbsp;22, 2005</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000091205700039015/ex-10_9.txt" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">6</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000091205700039015/ex-10_9.txt" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Form of Proprietary Information Agreement between Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) and certain of its employees</font></a><font style="display: inline;color:#000000;"> &nbsp;#</font></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">S-1/A</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">333-32812</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.9&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August&nbsp;24, 2000</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:34.65pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661713000038/c617-20131216ex1017f8575.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10</font><font style="display: inline;color:#000000;">.7</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:34.65pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661713000038/c617-20131216ex1017f8575.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Vermillion, Inc. Amended and Restated 2010 Stock Incentive Plan</font></a><font style="display: inline;color:#000000;"> &nbsp;#</font></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:34.65pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:34.65pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:34.65pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:34.65pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 17, 2013</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:34.65pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661715000043/c617-20150622ex10153a1b8.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.8</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661715000043/c617-20150622ex10153a1b8.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan #</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">June 22, 2015</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:40.95pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000119312512157371/d330697dex101.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.9</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:40.95pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000119312512157371/d330697dex101.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Employment Agreement between Eric J. Schoen and Vermillion, Inc. dated April 4, 2012 #</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:40.95pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:40.95pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:40.95pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:40.95pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">April 10, 2012</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:40.95pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661715000019/c617-20150406ex10139eeb3.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.1</font><font style="display: inline;color:#000000;">0</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661715000019/c617-20150406ex10139eeb3.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Employment Agreement between Vermillion, Inc. and Fred Ferrara dated April 1, 2015</font></a><font style="display: inline;color:#000000;"> &nbsp;#</font></p>
				</td>
				<td valign="top" style="width:08.18%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;height:41.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">April 6, 2015</font></p>
				</td>
				<td valign="top" style="width:09.10%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">47</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:07.72%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661714000067/c617-20141217ex991384e13.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.1</font><font style="display: inline;color:#000000;">1</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661714000067/c617-20141217ex991384e13.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Employment Agreement between Vermillion, Inc. and Valerie B. Palmieri effective&nbsp;&nbsp;January 1, 2015</font></a><font style="display: inline;color:#000000;"> &nbsp;#</font></p>
				</td>
				<td valign="top" style="width:08.18%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;background-color: #CCEEFF;height:41.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">99.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 17, 201</font><font style="display: inline;color:#000000;">4</font></p>
				</td>
				<td valign="top" style="width:09.10%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661715000033/c617-20150331ex10515388e.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.1</font><font style="display: inline;color:#000000;">2</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661715000033/c617-20150331ex10515388e.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Testing and Services Agreement between Vermillion, Inc., ASPiRA LABS, Inc. and Quest Diagnostics Incorporated, dated as of March 11, 2015</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">10-Q</font></p>
				</td>
				<td valign="top" style="width:11.82%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;height:41.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.5&nbsp;
				</td>
				<td valign="top" style="width:19.10%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">May 12, 2015</font></p>
				</td>
				<td valign="top" style="width:09.10%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661715000033/c617-20150331ex10695cec9.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.1</font><font style="display: inline;color:#000000;">3</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:5pt 0pt;line-height:normal;color:#000000;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661715000033/c617-20150331ex10695cec9.htm" style="-sec-extract:exhibit"><font style="display: inline;font-size:10pt;color:#000000;">Amendment No. 1 to the Testing Services Agreement dated March 11, 2015 among Vermillion, Inc., ASPiRA LABS, Inc. and Quest Diagnostics Incorporated dated April 10, 2015</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">10-Q</font></p>
				</td>
				<td valign="top" style="width:11.82%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;background-color: #CCEEFF;height:41.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.6&nbsp;
				</td>
				<td valign="top" style="width:19.10%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">May 12, 2015</font></p>
				</td>
				<td valign="top" style="width:09.10%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000017/c617-20170313xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">14</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:5pt 0pt;line-height:normal;color:#000000;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000017/c617-20170313xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;font-size:10pt;color:#000000;">Amendment No. 2 to Testing and Services Agreement, executed as of March 7, 2017 and effective as of March 11, 2017, by and among Vermillion, Inc., ASPiRA LABS, Inc. and Quest Diagnostics Incorporated</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;height:41.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">March 13, 2017</font></p>
				</td>
				<td valign="top" style="width:09.10%;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661718000003/vrml-20180306xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.15</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:5pt 0pt;line-height:normal;color:#000000;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661718000003/vrml-20180306xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;font-size:10pt;color:#000000;">Amendment No. 3 to Testing and Services Agreement, executed as of March 1, 2018 by and among Vermillion, Inc., ASPiRA LABS, Inc. and Quest Diagnostics Incorporated</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;background-color: #CCEEFF;height:41.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">March </font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">, 2018</font></p>
				</td>
				<td valign="top" style="width:09.10%;background-color: #CCEEFF;height:41.85pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661716000090/c617-20160331xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">16</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661716000090/c617-20160331xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Assistance Agreement by and between the State of Connecticut, acting by and through the Department of Economic and Community Development and Vermillion, Inc. effective March 22, 2016</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">10-Q</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">May 16, 2016</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661716000090/c617-20160331xex10_3.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">17</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661716000090/c617-20160331xex10_3.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Patent Security Agreement by Vermillion, Inc. in favor&nbsp;&nbsp;&nbsp;of the State of Connecticut, acting by and through the Department of Economic and Community Development, effective March 22, 2016</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">10-Q</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.3&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">May 16, 2016</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661716000090/c617-20160331xex10_4.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">18</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661716000090/c617-20160331xex10_4.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Security Agreement by Vermillion, Inc. in favor&nbsp;&nbsp;&nbsp;of the State of Connecticut, acting by and through the Department of Economic and Community Development, effective March 22, 2016</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">10-Q</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.4&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">May 16, 2016</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000071/vrml-20171220xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">19</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000071/vrml-20171220xex10_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Employment Agreement between Vermillion, Inc. and Robert Beechey dated December 18, 2017 </font></a><font style="display: inline;color:#000000;">#</font></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 20</font><font style="display: inline;color:#000000;">, 201</font><font style="display: inline;color:#000000;">7</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000071/vrml-20171220xex10_2.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.</font><font style="display: inline;color:#000000;">20</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000092661717000071/vrml-20171220xex10_2.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Consulting Agreement between Eric Schoen and Vermillion, Inc. dated December 18, 2017</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10.2&nbsp;
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 20</font><font style="display: inline;color:#000000;">, 201</font><font style="display: inline;color:#000000;">7</font></p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="vrml-20171231xex10_21.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">10.21</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:5pt 0pt;line-height:normal;color:#000000;font-family:Times New Roman;font-size: 10pt">
						<a href="vrml-20171231xex10_21.htm" style="-sec-extract:exhibit"><font style="display: inline;font-size:10pt;color:#000000;">First Amendment to the Assistance Agreement by and between the State of Connecticut, acting by and through the Department of Economic and Community Development and Vermillion, Inc. dated March 7, 2018</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:17.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Verdana;font-weight:bold;color:#000000;">&#x221A;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="http://www.sec.gov/Archives/edgar/data/926617/000119312510275703/dex141.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">14.1</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="http://www.sec.gov/Archives/edgar/data/926617/000119312510275703/dex141.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Code of Ethics</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">8-K</font></p>
				</td>
				<td valign="top" style="width:11.82%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">001-34810</font></p>
				</td>
				<td valign="top" style="width:07.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14.1&nbsp;
				</td>
				<td valign="top" style="width:19.10%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 7, 2010</font></p>
				</td>
				<td valign="top" style="width:09.10%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="vrml-20171231xex21_0.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">21.0</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="vrml-20171231xex21_0.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Subsidiaries of Registrant</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Verdana;font-weight:bold;color:#000000;">&#x221A;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:5pt;color:#000000;">&#xFEFF;</font><a href="vrml-20171231xex23_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">23.1</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="vrml-20171231xex23_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Consent of BDO USA, LLP, Independent Registered Public Accounting Firm</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Verdana;font-weight:bold;color:#000000;">&#x221A;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="vrml-20171231xex31_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">31.1</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="vrml-20171231xex31_1.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Verdana;font-weight:bold;color:#000000;">&#x221A;</font></p>
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">48</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="vrml-20171231xex31_2.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">31.2</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="vrml-20171231xex31_2.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Verdana;font-weight:bold;color:#000000;">&#x221A;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><a href="vrml-20171231xex32_0.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">32.0</font></a></p>
				</td>
				<td colspan="2" valign="top" style="width:36.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<a href="vrml-20171231xex32_0.htm" style="-sec-extract:exhibit"><font style="display: inline;color:#000000;">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Verdana;font-weight:bold;color:#000000;">&#x221A;&#x221A;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">101&nbsp;
				</td>
				<td valign="top" style="width:35.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Interactive Data Files</font></p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Verdana;font-weight:bold;color:#000000;">&#x221A;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:35.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:07.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Verdana;font-weight:bold;color:#000000;">&#x221A;</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display: inline;color:#000000;">F</font><font style="display: inline;color:#000000;">iled</font><font style="display: inline;color:#000000;"> herewith</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Verdana;font-weight:bold;color:#000000;">&#x221A;&#x221A; </font><font style="display: inline;color:#000000;">Furnished herewith</font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">#</font><font style="display: inline;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font><font style="display: inline;color:#000000;">Management contract or compensatory plan or arrangement.</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:65pt;"><font style="display: inline;color:#000000;">&#x2020;</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;color:#000000;"></font><font style="display: inline;color:#000000;">Confidential treatment has been granted with respect to certain provisions of this agreement. Omitted portions have been filed separately with the SEC.</font></font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 72pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0.7pt 6pt 63.35pt;text-indent: -63.35pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">ITEM 16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FORM 10-K SUMMARY</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">None.</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			&nbsp;
		</p></div><div style="margin-left:36pt;margin-right:36pt;">
		<p style="margin:0pt 0.9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">49</font><font style="display: inline;"></font>

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0.9pt 0pt 0pt;text-align:center;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;color:#000000;">VERMILLION</font><font style="display: inline;font-weight:bold;color:#000000;">, INC.</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:493pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;color:#000000;"></font></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:64.70%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:35.30%;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;text-decoration:underline;">Page No.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Report of Independent Registered Public Accounting Firm</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">F-1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Consolidated Balance Sheets at December 31, </font><font style="display: inline;color:#000000;">2017 </font><font style="display: inline;color:#000000;">and </font><font style="display: inline;color:#000000;">2016</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">F-2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Consolidated Statements of Operations for the years ended </font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 31, </font><font style="display: inline;color:#000000;">2017</font><font style="display: inline;color:#000000;"> and </font><font style="display: inline;color:#000000;">2016</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">F-3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Consolidated Statements of Changes in Stockholders&#x2019; Equity for the years ended</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 31, </font><font style="display: inline;color:#000000;">2017</font><font style="display: inline;color:#000000;"> and </font><font style="display: inline;color:#000000;">2016</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">F-4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Consolidated Statements of Cash Flows for the years ended</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 31, </font><font style="display: inline;color:#000000;">2017</font><font style="display: inline;color:#000000;"> and </font><font style="display: inline;color:#000000;">2016</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">F-5</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:64.70%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:35.30%;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:64.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Notes to Consolidated Financial Statements</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:35.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">F-6</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			&nbsp;
		</p></div><div style="margin-left:36pt;margin-right:36pt;">
		<p style="margin:12pt 0pt 0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;font-family:Arial;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:12pt 0pt 0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;font-family:Arial;;font-size: 10pt"><font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Report of Independent Registered Public Accounting Firm</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">Board of Directors and Stockholders</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">Vermillion, Inc.</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">Austin, Texas</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Opinion on the Consolidated Financial Statements </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">We have audited the accompanying consolidated balance sheets of Vermillion, Inc. (the &#x201C;Company&#x201D;) </font><font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">and subsidiaries </font><font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">as of December 31, 2017 and 2016, the related consolidated statements of operations, changes in stockholders&#x2019; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#x201C;consolidated financial statements&#x201D;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2017 and 2016, and the results of their operations and their cash flows for the years then ended</font><font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;">,</font><font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;"> in conformity with accounting principles generally accepted in the United States of America.</font>
		</p>
		<p style="margin:12pt 0pt 4.7pt 45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:-45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Going Concern Uncertainty</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has net cash flows deficiencies that raise substantial doubt about its ability to continue as a going concern. Management&#x2019;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Basis for Opinion</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#x201C;PCAOB&#x201D;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </font><font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of </font><font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. </font><font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">We believe that our audits provide a reasonable basis for our opinion.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">/s/ BDO USA, LLP</font>
		</p>
		<p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">We have served as the Company's auditor since 2012.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">Austin, Texas</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial;font-size: 10pt">
			<font style="font-family:Arial;color:#FF00FF;font-size:10pt;display: inline;font-family:Times New Roman;color:#000000;">March 13, 2018</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">1</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Vermillion, Inc. </font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Consolidated Balance Sheets</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"> (Amounts in Thousands, Except Share and Par Value Amounts)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="top" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">December 31, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="top" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Assets</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Current assets:</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cash and cash equivalents </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,539&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,242&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accounts receivable </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">205&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">275&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Prepaid expenses and other current assets </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">459&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">498&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Inventories</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">102&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">93&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total current assets </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,305&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,108&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Property and equipment, net </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,181&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,911&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other assets</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">11&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total assets </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7,497&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,019&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Liabilities and Stockholders&#x2019; Equity</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Current liabilities:</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accounts payable </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">745&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">881&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accrued liabilities </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,650&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,464&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Short-term debt</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">185&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">182&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other current liabilities</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">29&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">34&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total current liabilities </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,609&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,561&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Long-term debt</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,481&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,667&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other non-current liabilities</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">29&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total liabilities </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,090&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,257&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Commitments and contingencies (Note 6)</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Stockholders&#x2019; equity:</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at December&nbsp;31, 2017 and 2016</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Common stock, $0.001 par value, 150,000,000 shares authorized; 60,036,017 and 52,328,492 shares issued and outstanding at December&nbsp;31, 2017 and 2016, respectively </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">60&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">52&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Additional paid-in capital </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">399,400&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">389,266&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accumulated deficit </font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(396,053)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(385,556)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total stockholders&#x2019; equity</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,407&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,762&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total liabilities and stockholders&#x2019; equity</font></p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7,497&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,019&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;background-color:yellow;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">See accompanying Notes to Consolidated Financial Statements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">2</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Vermillion, Inc. </font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Consolidated </font><font style="display: inline;font-weight:bold;">Statements of Operations</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">(Amounts in Thousands, Except Share and Per Share Amounts)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;background-color:yellow;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#FF0000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Year Ended December 31, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:14.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Revenue:</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Product</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,853&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,320&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Service</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">268&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">322&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total revenue </font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,121&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,642&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cost of revenue:</font><font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">(1) </font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Product</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,756&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,974&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Service</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,158&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">724&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total cost of revenue</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,914&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,698&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Gross profit / (loss)</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">207&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(56)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Operating expenses:</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Research and development</font><font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">(2) </font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">837&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,172&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Sales and marketing</font><font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">(3)</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,268&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,798&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">General and administrative</font><font style="display: inline;color:#000000;font-size:5pt;vertical-align:super;line-height:100%">(4)</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,543&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,928&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total operating expenses </font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10,648&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14,898&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Loss from operations</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(10,441)
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14,954)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Interest (expense) income, net</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(42)
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(28)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other (expense) / income, net&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss </font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(10,497)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14,968)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Deemed dividend on warrant repricing</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(942)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(11,439)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14,968)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss per share attributable to common stockholders - basic and diluted </font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.20)
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.29)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Weighted average common shares used to compute basic and diluted net loss per common share </font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">56,943,596&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">52,197,969&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:14.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Non-cash stock-based compensation expense included in expenses:</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(1) Cost of revenue</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">136&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">115&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(2) Research and development</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">71&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(3) Sales and marketing</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">160&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">108&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(4) General and administrative</font></p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,134&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">885&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">See accompanying Notes to Consolidated Financial Statements</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">3</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;background-color:yellow;"></font><font style="display: inline;font-weight:bold;">Vermillion, Inc.</font><font style="display: inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Consolidated Statements of Changes in Stockholders&#x2019; Equity</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">(Amounts in Thousands, Except Share Amounts)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;background-color:yellow;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">Common Stock </font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">Shares </font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">Amount </font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">Additional Paid-In Capital </font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">Accumulated Deficit </font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:36.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">Total Stockholders&#x2019; Equity</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">Balance at December 31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">52,113,059&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">52&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">388,082&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(370,588)
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">17,546&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Net loss </font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(14,968)
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(14,968)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Common stock issued in conjunction with exercise of stock options</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,541&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Common stock issued for restricted stock awards</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">211,892&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">334&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">334&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Stock compensation charge </font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">845&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">845&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">Balance at December 31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 52,328,492&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">52&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">389,266&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(385,556)
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,762&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Net loss </font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(10,497)
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(10,497)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Common stock and warrants issued in conjunction with private placement sale, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,747,125&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">5,123&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">5,127&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Common stock issued in conjunction with exercise of warrants, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,796,818&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,572&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,576&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Common stock issued for restricted stock awards</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">163,582&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">335&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">335&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">Stock compensation charge </font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,104&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">-</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,104&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:47.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:9pt;">Balance at December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;"> 60,036,017&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">60&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">399,400&nbsp;
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(396,053)
				</td>
				<td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,407&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">See accompanying Notes to Consolidated Financial Statements</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.4pt;text-indent:14.4pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 0pt 14.4pt;text-indent:14.4pt;text-align:center;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;background-color:yellow;"></font><font style="display: inline;font-weight:bold;">Vermillion</font><font style="display: inline;font-weight:bold;">, Inc.</font><font style="display: inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.4pt;text-indent:14.4pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Consolidated Statements of Cash Flows</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.4pt;text-indent:14.4pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">(Amounts in Thousands)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;background-color:yellow;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Year Ended December 31, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Cash flows from operating activities:</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(10,497)
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14,968)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Adjustments to reconcile net loss to net cash used in operating activities:</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Depreciation and amortization </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">786&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">723&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Stock-based compensation expense </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,439&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,179&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Loss on sale and disposal of property and equipment </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Changes in operating assets and liabilities:</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accounts receivable </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">70&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(188)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Prepaid expenses and other assets </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">28&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">142&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Inventories </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(9)
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(6)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accounts payable, accrued liabilities and other liabilities</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">50&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(851)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net cash used in operating activities </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,129)
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(13,963)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Cash flows from investing activities:</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Purchase of property and equipment </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(60)
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,261)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net cash used in investing activities </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(60)
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,261)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Cash flows from financing activities:</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Proceeds from private placement offering of common stock and warrants, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,127&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Proceeds from exercise of common stock warrants, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,576&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Proceeds from issuance of DECD loan, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,967&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Principal repayment of DECD loan</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(183)
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(118)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Repayment of capital lease obligations</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(34)
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(30)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Proceeds from issuance of common stock from exercise of stock options</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net cash provided by financing activities </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,486&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,824&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net increase / (decrease) in cash and cash equivalents </font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">297&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(13,400)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cash and cash equivalents, beginning of year</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,242&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,642&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cash and cash equivalents, end of year</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,539&nbsp;
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,242&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Supplemental disclosure of cash flow information:</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cash paid during the period for interest</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">47&nbsp;
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">38&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Supplemental disclosure of non-cash investing and financing activities:</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Deemed dividend on warrant repricing</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">942&nbsp;
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:71.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">See accompanying Notes to Consolidated Financial Statements</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.4pt;text-indent:14.4pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">5</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 0pt 14.4pt;text-indent:14.4pt;text-align:center;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;background-color:yellow;"></font><font style="display: inline;font-weight:bold;">Vermillion, Inc.</font><font style="display: inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0.9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Notes to Consolidated Financial Statements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">NOTE 1:</font><font style="display: inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;">Basis of Presentation and Summary of Significant Accounting and Reporting Policies</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Organization</font>
		</p>
		<p style="margin:6pt 0pt 0pt 4.3pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Vermillion, Inc. (&#x201C;Vermillion&#x201D;; Vermillion and its wholly-owned subsidiaries are collectively referred to as the &#x201C;Company&#x201D;) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease.&nbsp; </font><font style="display: inline;font-size:10pt;">T</font><font style="display: inline;font-size:10pt;">he Company </font><font style="display: inline;font-size:10pt;">sells</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">the </font><font style="display: inline;font-size:10pt;">OVA1&#x2122; </font><font style="display: inline;font-size:10pt;">and Overa&#x2122; </font><font style="display: inline;font-size:10pt;">risk of malignancy test</font><font style="display: inline;font-size:10pt;">s</font><font style="display: inline;font-size:10pt;"> for </font><font style="display: inline;font-size:10pt;">ovarian cancer</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">(&#x201C;OVA1&#x201D;</font><font style="display: inline;font-size:10pt;"> and &#x201C;Overa&#x201D;</font><font style="display: inline;font-size:10pt;">). </font><font style="display: inline;font-size:10pt;">Until August 2015, t</font><font style="display: inline;font-size:10pt;">he Company </font><font style="display: inline;font-size:10pt;">distributed </font><font style="display: inline;font-size:10pt;">OVA1 through Quest Diagnostics Incorporated (&#x201C;Quest Diagnostics&#x201D;) (see Note 3)</font><font style="display: inline;font-size:10pt;">. Since August 2015, the Company has distributed </font><font style="display: inline;font-size:10pt;">all</font><font style="display: inline;font-size:10pt;"> tests </font><font style="display: inline;font-size:10pt;">through </font><font style="display: inline;font-size:10pt;">Vermillion&#x2019;s </font><font style="display: inline;font-size:10pt;">wholly-owned&nbsp;Clinical Laboratory Improvement Amendments of 1988 (&#x201C;CLIA&#x201D;) certified clinical laboratory, ASPiRA LABS, Inc</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;"> (&#x201C;ASPiRA</font><font style="display: inline;font-size:10pt;"> LABS</font><font style="display: inline;font-size:10pt;">&#x201D;). </font><font style="display: inline;font-size:10pt;">The Company also offers in-vitro diagnostic (&#x201C;IVD&#x201D;) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (&#x201C;ASPiRA IVD&#x201D;), which was formed in April 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize&nbsp;high-complexity&nbsp;assays.&nbsp;ASPiRA IVD was built around a core of laboratory&nbsp;expertise and a United States Food and Drug Administration (&#x201C;FDA&#x201D;)-compliant quality system, and strives to deliver&nbsp;accurate and reliable&nbsp;results to its third-party customers suitable for&nbsp;FDA submission.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Liquidity</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As discussed in Note 6, on March 22, 2016, the Company entered into a</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">loan</font><font style="display: inline;"> agreement</font><font style="display: inline;">, as amended</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(the &#x201C;Loan Agreement&#x201D;)</font><font style="display: inline;">,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">pursuant to which it may</font><font style="display: inline;"> borrow up to </font><font style="display: inline;">$4,000,000</font><font style="display: inline;"> from the State of Connecticut Department of Economic and Community Development (&#x201C;DECD&#x201D;). </font><font style="display: inline;">An initial disbursement of </font><font style="display: inline;">$2,000,000</font><font style="display: inline;">&nbsp;was made to the Company on April 15, 2016 under the Loan Agreement.</font><font style="display: inline;"> &nbsp;The remaining </font><font style="display: inline;">$2,000,000</font><font style="display: inline;"> will be </font><font style="display: inline;">advanced </font><font style="display: inline;">if and when the Company achieves</font><font style="display: inline;"> certain </font><font style="display: inline;">other </font><font style="display: inline;">future milestones.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The loan may be prepaid at any time without premium or penalty.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased </font><font style="display: inline;color:#000000;">3,747,125</font><font style="display: inline;"> shares of Vermillion common stock at a price of </font><font style="display: inline;">$1.40</font><font style="display: inline;"> per share. Vermillion also issued warrants to purchase shares of common stock at a price of </font><font style="display: inline;">$0.125</font><font style="display: inline;"> per warrant </font><font style="display: inline;">share in the private placement. </font><font style="display: inline;">Aggregate gross </font><font style="display: inline;">proceeds of the private placement were approximately</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">$5,597,000</font><font style="display: inline;"> &nbsp;(</font><font style="display: inline;">approximately </font><font style="display: inline;">$5,1</font><font style="display: inline;">27</font><font style="display: inline;">,000</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">net of</font><font style="display: inline;"> transaction costs)</font><font style="display: inline;">. The warrants are exercisable for </font><font style="display: inline;color:#000000;">2,810,338</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;">shares of Vermillion common stock at </font><font style="display: inline;">$1.80</font><font style="display: inline;"> per share. </font><font style="display: inline;color:#000000;">The warrants expire on the fifth anniversary of the date of issuance </font><font style="display: inline;">or, if earlier, five business days after </font><font style="display: inline;">Vermillion</font><font style="display: inline;"> delivers notice that the closing price per share of its </font><font style="display: inline;">c</font><font style="display: inline;">ommon </font><font style="display: inline;">stock </font><font style="display: inline;">exceeded the </font><font style="display: inline;">exercise price </font><font style="display: inline;">for 20 consecutive trading days during the exercise period</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In December 2014, the Company issued warrants to purchase up to an aggregate of </font><font style="display: inline;color:#000000;">4,166,659</font><font style="display: inline;color:#000000;"> shares of Vermillion&nbsp;common stock at an exercise price of </font><font style="display: inline;color:#000000;">$2.00</font><font style="display: inline;color:#000000;"> per share in conjunction with a December 2014 private placement of Vermillion common stock.&nbsp;&nbsp;The warrants </font><font style="display: inline;">would have </font><font style="display: inline;color:#000000;">expire</font><font style="display: inline;">d</font><font style="display: inline;color:#000000;"> by their original terms on December 23, 2017.</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;color:#000000;">On August 31, 2017, certain holders exercised warrants to purchase </font><font style="display: inline;color:#000000;">3,796,818</font><font style="display: inline;color:#000000;"> shares of Vermillion common stock in consideration for the Company agreeing to reduce the exercise price to </font><font style="display: inline;color:#000000;">$1.00</font><font style="display: inline;color:#000000;"> per share of Vermillion common stock.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;">The Company issued </font><font style="display: inline;color:#000000;">3,796,818</font><font style="display: inline;color:#000000;"> shares of Vermillion common stock and received </font><font style="display: inline;color:#000000;">$3,796,818</font><font style="display: inline;color:#000000;"> in aggregate gross proceeds (approximately </font><font style="display: inline;color:#000000;">$3,57</font><font style="display: inline;color:#000000;">6</font><font style="display: inline;color:#000000;">,000</font><font style="display: inline;color:#000000;"> net of transaction costs).</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of </font><font style="display: inline;">approximately </font><font style="display: inline;">$</font><font style="display: inline;">3</font><font style="display: inline;">96</font><font style="display: inline;">,</font><font style="display: inline;">053</font><font style="display: inline;">,000</font><font style="display: inline;"> at December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">. The Company expects to incur a net loss in </font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">as well</font><font style="display: inline;">. The Company&#x2019;s management believes that successful achievement of the business objectives will require additional financing.&nbsp; The Company expects to raise capital through a variety of sources, which may include the </font><font style="display: inline;">exercise of common stock warrants</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">public </font><font style="display: inline;">and private </font><font style="display: inline;">equity </font><font style="display: inline;">offerings</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">debt </font><font style="display: inline;">financing, collaborati</font><font style="display: inline;">on</font><font style="display: inline;">s, licensing arrangements, </font><font style="display: inline;">grants and government funding and strategic alliances</font><font style="display: inline;">. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the business, results of operations and financial condition. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations.&nbsp;&nbsp;Management expects cash from product </font><font style="display: inline;">and </font><font style="display: inline;">ASPiRA IVD</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">sales to be the Company&#x2019;s only material, recurring source of cash in </font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">.</font><font style="display: inline;"> Given the above conditions, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">6</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;">Basis of Consolidation</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.&nbsp;&nbsp;All intercompany transactions have been eliminated in consolidation.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Use of Estimates</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (&#x201C;GAAP&#x201D;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.&nbsp;&nbsp;The primary estimates underlying the Company&#x2019;s consolidated financial statements include assumptions regarding </font><font style="display: inline;">revenue recognition as well as </font><font style="display: inline;">variables used in calculating the fair value of the Company&#x2019;s equity awards, income taxes and contingent liabilities.&nbsp;&nbsp;Actual results could differ from those estimates.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes.&nbsp;&nbsp;Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper.&nbsp;&nbsp;The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Fair Value Measurement</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Accounting Standards Codification </font><font style="display: inline;">(&#x201C;ASC&#x201D;) </font><font style="display: inline;">Topic 820</font><font style="display: inline;">,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-style:italic;">Fair Value and Measurements</font><font style="display: inline;"> (&#x201C;ASC 820&#x201D;), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Level 1 - Quoted prices in active markets for identical assets or liabilities. </font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"> Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Concentration of Credit Risk</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable.&nbsp;&nbsp;The Company maintains cash and cash equivalents in recognized financial institutions in the United States.&nbsp; </font><font style="display: inline;">The funds are insured by the FDIC up to a maximum of $250,000, but are otherwise unprotected.&nbsp; </font><font style="display: inline;">The Company has not experienced any losses associated with deposits of cash and cash equivalents. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The Company does not invest in derivative instruments or engage in hedging activities.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Accounts receivable</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Virtually all </font><font style="display: inline;">accounts </font><font style="display: inline;">receivable are derived from sales made to customer</font><font style="display: inline;">s</font><font style="display: inline;"> located in North America.&nbsp;&nbsp;The Company performs ongoing credit evaluations of its customer&#x2019;s financial condition and generally does not require collateral.&nbsp;&nbsp;The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable.&nbsp; </font><font style="display: inline;">Accounts receivable at December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">was from </font><font style="display: inline;">20</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">customers.&nbsp; </font><font style="display: inline;">Accounts receivable at December 31, </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">was</font><font style="display: inline;"> from </font><font style="display: inline;">1</font><font style="display: inline;">6</font><font style="display: inline;"> customer</font><font style="display: inline;">s</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Property and Equipment</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally </font><font style="display: inline;">three</font><font style="display: inline;"> to </font><font style="display: inline;">five</font><font style="display: inline;"> years. </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">7</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable.&nbsp;&nbsp;If property and equipment are considered to be impaired, an impairment loss is recognized.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Revenue Recognition</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Product Revenue:&nbsp; </font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">The Company has adopted ASC 954-605,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-style:italic;font-size:10pt;background-color: #FFFFFF;">Health Care Entities&#x2014;Revenue Recognition,&nbsp;</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">as </font><font style="display: inline;font-size:10pt;">revenue from laboratory services has become significant to the Company</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> and Overa</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> test</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;">s</font><font style="display: inline;font-size:10pt;background-color: #FFFFFF;"> may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Estimates of amounts that the Company will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the patient&#x2019;s health plan. Some payers may not cover the OVA1 </font><font style="display: inline;font-size:10pt;">or Overa </font><font style="display: inline;font-size:10pt;">test as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">Service Revenue:&nbsp; </font><font style="display: inline;font-size:10pt;">The Company&#x2019;s service revenue is generated by performing IVD trial services for third-party customers. In accordance with </font><font style="display: inline;font-size:10pt;">SEC Staff Accounting Bulletin </font><font style="display: inline;font-size:10pt;">Topic 13, service revenue is recognized when the following revenue recognition criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the fee is fixed or determinable; and (4)&nbsp;collectability is reasonably assured.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Research and Development Costs</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Research and development costs are expensed as incurred.&nbsp;&nbsp;Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf</font><font style="display: inline;"> of the Company</font><font style="display: inline;">. In addition, acquisitions of assets to be consumed in research and development</font><font style="display: inline;">, with no alternative future use,</font><font style="display: inline;"> are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Patent Costs</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately </font><font style="display: inline;">$</font><font style="display: inline;">258</font><font style="display: inline;">,</font><font style="display: inline;">000</font><font style="display: inline;"> and </font><font style="display: inline;">$</font><font style="display: inline;">308</font><font style="display: inline;">,000</font><font style="display: inline;"> for the years ended December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">, respectively.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Stock-Based Compensation</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Amended and Restated 2010 Stock Incentive Plan</font><font style="display: inline;">, as amended</font><font style="display: inline;"> (the &#x201C;2010 Plan&#x201D;). The Company estimates the fair value of stock options using a Black-Scholes option valuation model</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">This model </font><font style="display: inline;">requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each </font><a name="_cp_text_1_372"></a><font style="display: inline;">award. The Company uses the straight line method to amortize the fair value over the vesting period of the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">8</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding.&nbsp;&nbsp;This data includes employees&#x2019; expected exercise and post-vesting employment termination behaviors.&nbsp; </font><font style="display: inline;">The e</font><font style="display: inline;">xpected stock price volatility is estimated using Company historical volatility</font><font style="display: inline;">&nbsp;</font><a name="_cp_text_1_375"></a><font style="display: inline;">in deriving the expected volatility assumption</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">T</font><font style="display: inline;">he Company made an assessment that Company historic volatility is mo</font><font style="display: inline;">st</font><font style="display: inline;"> representative of future stock price trends</font><font style="display: inline;">.&nbsp;&nbsp;The expected dividend yield is based on the estimated annual dividends that </font><font style="display: inline;">are</font><font style="display: inline;"> expected to be paid over the expected life of the options as a percentage of the market value of </font><font style="display: inline;">the Company&#x2019;s </font><font style="display: inline;">common stock as of the grant date.&nbsp;&nbsp;The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date.&nbsp;&nbsp;The Company uses the straight-line method to amortize the fair value over the vesting period of the award.</font><font style="display: inline;"> The Company records stock-based compensation net of estimated forfeitures</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options </font><font style="display: inline;">is </font><font style="display: inline;">recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Contingencies</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company accounts for contingencies in accordance with ASC 450 </font><font style="display: inline;font-style:italic;">Contingencies</font><font style="display: inline;"> ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management&#x2019;s judgment. Management believes that </font><font style="display: inline;">the Company&#x2019;s </font><font style="display: inline;">accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management&#x2019;s estimates. </font><font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Income Taxes</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company accounts for income taxes using the liability method.&nbsp;&nbsp;Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">ASC Topic 740, </font><a name="_cp_text_1_378"></a><font style="font-style:italic;border-bottom-style:solid;border-bottom-width:1pt;height:100%;text-indent:0pt;">Accounting for Uncertainty in</font><font style="display: inline;font-style:italic;">&nbsp;</font><font style="display: inline;font-style:italic;">Income Taxes </font><font style="display: inline;">clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">New tax legislation, commonly referred to as the Tax Cuts and Jobs Act (H.R. 1), was enacted on December 22, 2017. ASC740, </font><font style="display: inline;font-style:italic;">Accounting for Income Taxes</font><font style="display: inline;">, requires companies to recognize the effect of tax law changes in the period of enactment even though the effective date for most provisions is for tax years beginning after December 31, 2017. Since our federal deferred tax asset was fully offset by a valuation allowance, the reduction in the U.S. corporate income tax rate to </font><font style="display: inline;">21%</font><font style="display: inline;"> did not materially affect our financial statements. Significant provisions that are not yet effective but may impact income taxes in future years include: the</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">repeal of the corporate Alternative Minimum Tax, the limitation on the current deductibility of net interest expense in excess of </font><font style="display: inline;">30%</font><font style="display: inline;"> of adjusted taxable income for levered balance sheets, a limitation on utilization of net operating losses generated after tax year 2017 to </font><font style="display: inline;">80%</font><font style="display: inline;"> of taxable income, the unlimited carryforward of net operating losses generated after tax year 2017, temporary </font><font style="display: inline;">100%</font><font style="display: inline;"> expensing of certain business assets, additional limitations on certain general and administrative expenses, and changes in determining the excessive compensation limitation. Currently, we do not anticipate paying cash federal income taxes in the near term due to any of the legislative changes, primarily due to the availability of our net operating loss carryforwards. Future interpretations relating to the recently enacted U.S. federal income tax legislation which vary from our current interpretation and possible changes to state tax laws in response to the recently enacted federal legislation may have a significant effect on this projection.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">9</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;font-style:italic;">Net Loss Per Share</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period.&nbsp;&nbsp;Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Financial instrument</font><font style="display: inline;">s include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt are at cost, which approximates fair value due to the short maturity of those instruments.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Segment Reporting</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company operates </font><font style="display: inline;">one</font><font style="display: inline;"> reportable segment.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">NOTE </font><font style="display: inline;font-weight:bold;">2</font><font style="display: inline;font-weight:bold;">:</font><font style="display: inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;">Recent Accounting Pronouncements</font><font style="display: inline;font-weight:bold;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In June 2016, the </font><font style="display: inline;font-size:10pt;">Financial Accounting Standards Board (the &#x201C;FASB&#x201D;)</font><font style="display: inline;font-size:10pt;"> issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This </font><font style="display: inline;font-size:10pt;">update</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">change</font><font style="display: inline;font-size:10pt;">s the impairment model </font><font style="display: inline;font-size:10pt;">from the currently used incurred loss methodology </font><font style="display: inline;font-size:10pt;">to an expected loss methodology, which will result in the more timely rec</font><font style="display: inline;font-size:10pt;">ognition of losses. The</font><font style="display: inline;font-size:10pt;"> ASU </font><font style="display: inline;font-size:10pt;">is scheduled to be</font><font style="display: inline;font-size:10pt;"> effect</font><font style="display: inline;font-size:10pt;">ive</font><font style="display: inline;font-size:10pt;"> in 2020</font><font style="display: inline;font-size:10pt;">. The Company is currently assessing the impact of this ASU on </font><font style="display: inline;font-size:10pt;">its consolidated</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">financial statements.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In February 2016, the FASB </font><font style="display: inline;font-size:10pt;">issued </font><font style="display: inline;font-size:10pt;">ASU 2016-02, </font><font style="display: inline;font-style:italic;font-size:10pt;">Leases</font><font style="display: inline;font-size:10pt;">. The new standard establishes a right-of-use (</font><font style="display: inline;font-size:10pt;">&#x201C;</font><font style="display: inline;font-size:10pt;">ROU</font><font style="display: inline;font-size:10pt;">&#x201D;</font><font style="display: inline;font-size:10pt;">) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently </font><font style="display: inline;font-size:10pt;">in the early stages of </font><font style="display: inline;font-size:10pt;">evaluating the impact of the pending adoption of the new standard on </font><font style="display: inline;font-size:10pt;">its</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">consolidated financial statements.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.92%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#x201C;ASU 2014-09&#x201D;), </font><font style="display: inline;font-family:inherit;font-size:10pt;">to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. </font><font style="display: inline;font-size:10pt;">This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. </font><font style="display: inline;font-family:inherit;font-size:10pt;">The Company adopted the new revenue recognition standard as of January 1, 2018 using the modified retrospective method. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.92%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company </font><font style="display: inline;font-size:10pt;">has completed</font><font style="display: inline;font-size:10pt;"> its analysis of the effect ASU 2014-09 will have on its Service Revenue</font><font style="display: inline;font-size:10pt;"> and</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:inherit;font-size:10pt;">believes that the adoption of ASU </font><font style="display: inline;font-family:inherit;font-size:10pt;">2014-09 </font><font style="display: inline;font-family:inherit;font-size:10pt;">will not result in a material cumulative catch-up adjustment under the modified retrospective method, or have a material impact on the Company's financial position or results of operations.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.92%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company </font><font style="display: inline;font-size:10pt;">has</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">also </font><font style="display: inline;font-size:10pt;">substantially completed</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">its analysis of the effect ASU 2014-09 will have on&nbsp;its Product Revenue</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;However, the Company is continuing to analyze data</font><font style="display: inline;font-size:10pt;"> as there is</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">a &nbsp;</font><font style="display: inline;font-size:10pt;">long collection cycle on some accounts </font><font style="display: inline;font-size:10pt;">and thus the passage of time provides more accurate data for analysis.</font><font style="display: inline;font-size:10pt;"> Revenue that </font><font style="display: inline;font-size:10pt;">was </font><font style="display: inline;font-size:10pt;">recognized upon the ultimate receipt of cash under the Company&#x2019;s </font><font style="display: inline;font-size:10pt;">p</font><font style="display: inline;font-size:10pt;">r</font><font style="display: inline;font-size:10pt;">evious</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">revenue recognition policy </font><font style="display: inline;font-size:10pt;">has</font><font style="display: inline;font-size:10pt;"> be</font><font style="display: inline;font-size:10pt;">en</font><font style="display: inline;font-size:10pt;"> reassessed under the new standard</font><font style="display: inline;font-size:10pt;"> and will now be recognized upon performance of the OVA1 or Overa test</font><font style="display: inline;font-size:10pt;">. The Company </font><font style="display: inline;font-size:10pt;">also </font><font style="display: inline;font-size:10pt;">review</font><font style="display: inline;font-size:10pt;">ed</font><font style="display: inline;font-size:10pt;"> its patient account population to determine the appropriate distribution of patient accounts </font><font style="display: inline;font-size:10pt;">by payer</font><font style="display: inline;font-size:10pt;"> &nbsp;(</font><font style="display: inline;font-style:italic;font-size:10pt;">i.e.</font><font style="display: inline;font-size:10pt;">, Medicare, patient pay, other third-party payer, </font><font style="display: inline;font-style:italic;font-size:10pt;">etc</font><font style="display: inline;font-size:10pt;">.) into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">10</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;line-height:107.92%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;font-size:10pt;">were evaluated on a contract-by-contract basis. </font><font style="display: inline;font-family:inherit;font-size:10pt;">The Company has estimated that a cumulative effect adjustment of approximately </font><font style="display: inline;font-family:inherit;font-size:10pt;">$</font><font style="display: inline;font-family:inherit;font-size:10pt;">4</font><font style="display: inline;font-family:inherit;font-size:10pt;">00,000</font><font style="display: inline;font-family:inherit;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:inherit;font-size:10pt;">to </font><font style="display: inline;font-family:inherit;font-size:10pt;">$</font><font style="display: inline;font-family:inherit;font-size:10pt;">7</font><font style="display: inline;font-family:inherit;font-size:10pt;">00,000</font><font style="display: inline;font-family:inherit;font-size:10pt;"> will</font><font style="display: inline;font-family:inherit;font-size:10pt;"> be recognized as of January 1, 2018 to beginning accumulated deficit and accounts receivable to reflect the </font><font style="display: inline;font-family:inherit;font-size:10pt;">recognition of revenue from accounts previously recognized on the cash basis of accounting.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.92%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-family:Calibri;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">NOTE 3:</font><font style="display: inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;">Strategic Alliance And Secured Line Of Credit with Quest Diagnostics Incorporated</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:107.92%;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">I</font><font style="display: inline;font-size:10pt;">n March 2015, the Company reached a</font><font style="display: inline;font-size:10pt;">n</font><font style="display: inline;font-size:10pt;"> agreement with Quest Diagnostics that terminated the </font><font style="display: inline;font-size:10pt;">previous </font><font style="display: inline;font-size:10pt;">Strategic Alliance Agreement with Quest Diagnostics. The Company also entered into a commercial agreement with Quest Diagnostics. Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion&#x2019;s wholly-owned subsidiary, ASPiRA LABS, as of August 2015. </font><font style="display: inline;font-size:10pt;">Pursuant to this agreement, as amended </font><font style="display: inline;font-size:10pt;">as of March </font><font style="display: inline;font-size:10pt;">1</font><font style="display: inline;font-size:10pt;">, 201</font><font style="display: inline;font-size:10pt;">8</font><font style="display: inline;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-size:10pt;">Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least </font><font style="display: inline;font-size:10pt;">March 11, 201</font><font style="display: inline;font-size:10pt;">9</font><font style="display: inline;font-size:10pt;"> in exchange for a market value fee. Per the terms of the new commercial agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers.</font><font style="display: inline;font-family:Calibri;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Note 4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and Equipment</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">T</font><font style="display: inline;">he components of property and equipment as of December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">were as follo</font><font style="display: inline;">ws</font><font style="display: inline;font-weight:bold;">:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(in thousands)</font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Machinery and equipment </font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,400&nbsp;
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,381&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Demonstration equipment </font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">39&nbsp;
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">39&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Computer equipment and software </font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,055&nbsp;
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,029&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Furniture and fixtures </font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">120&nbsp;
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">127&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Leasehold improvements</font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">706&nbsp;
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">704&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Gross property and equipment </font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,320&nbsp;
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,280&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Accumulated depreciation and amortization </font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,139)
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,369)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:55.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Property and equipment, net </font></p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,181&nbsp;
				</td>
				<td valign="middle" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:18.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,911&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Depreciation expense for property and equipment was </font><font style="display: inline;">$</font><font style="display: inline;">7</font><font style="display: inline;">86</font><font style="display: inline;">,000</font><font style="display: inline;"> and </font><font style="display: inline;">$</font><font style="display: inline;">723</font><font style="display: inline;">,000</font><font style="display: inline;"> for the years ended December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">, respectively.</font><font style="display: inline;"> The accumulated amortization of assets under capital lease obligations was </font><font style="display: inline;">$</font><font style="display: inline;">193</font><font style="display: inline;">,000</font><font style="display: inline;"> and the net book value of assets under capital lease obligations was </font><font style="display: inline;">$</font><font style="display: inline;">39</font><font style="display: inline;">,000</font><font style="display: inline;"> as of December 31, 201</font><font style="display: inline;">7</font><font style="display: inline;">.</font><font style="display: inline;"> The </font><font style="display: inline;">accumulated amortization of assets under capital lease obligations was </font><font style="display: inline;">$</font><font style="display: inline;">116</font><font style="display: inline;">,000</font><font style="display: inline;"> and the </font><font style="display: inline;">net book value of assets under capital lease obligations was </font><font style="display: inline;">$1</font><font style="display: inline;">16</font><font style="display: inline;">,000</font><font style="display: inline;"> as of December 31, 201</font><font style="display: inline;">6</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">11</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-weight:bold;">NOTE </font><font style="display: inline;font-weight:bold;">5</font><font style="display: inline;font-weight:bold;">:</font><font style="display: inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;">Accrued Liabilities</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The components of accrued liabilities as of December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">20</font><font style="display: inline;">1</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">were as follows:</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:58.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(in thousands)</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="middle" style="width:02.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Payroll and benefits related expenses </font></p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:17.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">867&nbsp;
				</td>
				<td valign="middle" style="width:02.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:17.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">541&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Collaboration and research agreements expenses </font></p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">358&nbsp;
				</td>
				<td valign="middle" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">414&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Professional services</font></p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">216&nbsp;
				</td>
				<td valign="middle" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">217&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Tax-related liabilities </font></p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other accrued liabilities </font></p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">209&nbsp;
				</td>
				<td valign="middle" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:17.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">288&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total accrued liabilities </font></p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:17.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,650&nbsp;
				</td>
				<td valign="middle" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:17.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,464&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">NOTE 6:</font><font style="display: inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;">Commitments</font><font style="display: inline;font-weight:bold;">,</font><font style="display: inline;font-weight:bold;"> Contingencies</font><font style="display: inline;font-weight:bold;">&nbsp;</font><font style="display: inline;font-weight:bold;">and debt</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;">As of December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, the annual amounts of future minimum payments under certain of the Company&#x2019;s </font><font style="display: inline;">contractual obligations were</font><font style="display: inline;">:</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-weight:bold;font-style:italic;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="13" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Payments Due by Period</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(in thousands)</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Less Than 1 Year</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">1-3 Years</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">3-5 Years</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">More Than 5 Years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Operating Leases</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">574&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">258&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">261&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">55&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Capital Leases</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Debt Obligations</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,860&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">221&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">442&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">442&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">755&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total Contractual Obligations</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,454&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">499&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">703&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">497&nbsp;
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:13.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">755&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.14%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In addition, </font><font style="display: inline;">the Company has minimum royalty obligations (described below in non-cancelable collaboration obligations and other commitments) and minimum quantities of reagent purchases from the manufacturer of certain laboratory instruments.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Development </font><font style="display: inline;font-weight:bold;font-style:italic;">L</font><font style="display: inline;font-weight:bold;font-style:italic;">oan</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:10pt;">On March 22, 2016, the Company entered into </font><font style="display: inline;font-size:10pt;">the Loan Agreement</font><font style="display: inline;font-size:10pt;"> with the DECD, pursuant to which the Company may borrow up to </font><font style="display: inline;font-size:10pt;">$4,000,000</font><font style="display: inline;font-size:10pt;"> from the DECD.&nbsp;&nbsp;Proceeds from the loan </font><font style="display: inline;font-size:10pt;">were</font><font style="display: inline;font-size:10pt;"> utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company&#x2019;s Trumbull, Connecticut facility and operations.&nbsp;&nbsp;The loan bears interest at a fixed rate of </font><font style="display: inline;font-size:10pt;">2.0%</font><font style="display: inline;font-size:10pt;"> per annum and requires equal monthly payments of principal and interest until maturity, </font><font style="display: inline;font-size:10pt;">which occurs on&nbsp;April 15, 2026</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;As security for the loan, the Company has granted the DECD a blanket security interest in the Company&#x2019;s personal and intellectual property.&nbsp;&nbsp;The DECD&#x2019;s security interest in the Company&#x2019;s intellectual property may be subordinated to a qualified institutional lender.&nbsp;&nbsp;Under the terms of the </font><font style="display: inline;font-size:10pt;">Loan </font><font style="display: inline;font-size:10pt;">Agreement, </font><font style="display: inline;font-size:10pt;">as amended, </font><font style="display: inline;font-size:10pt;">the Company may be eligible for forgiveness of up to </font><font style="display: inline;font-size:10pt;">$2,000,000</font><font style="display: inline;font-size:10pt;"> of the principal amount of the </font><font style="display: inline;font-size:10pt;">loan if the Company achieves certain job creation and retention milestones by March 1, 20</font><font style="display: inline;font-size:10pt;">21</font><font style="display: inline;font-size:10pt;"> (the &#x201C;Measurement Date&#x201D;)</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;</font><font style="display: inline;font-size:10pt;">Conversely, i</font><font style="display: inline;font-size:10pt;">f the Company is </font><font style="display: inline;font-size:10pt;">either </font><font style="display: inline;font-size:10pt;">unable to meet these job creation </font><font style="display: inline;font-size:10pt;">and retention </font><font style="display: inline;font-size:10pt;">milestones</font><font style="display: inline;font-size:10pt;">, namely, hiring </font><font style="display: inline;font-size:10pt;">and retaining for a consecutive two-year period</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:10pt;">40</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">full-</font><font style="display: inline;font-size:10pt;">time</font><font style="display: inline;font-size:10pt;"> employees with a specified average annual salary</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">by the Measurement Date</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">and retaining those employees for a </font><font style="display: inline;font-size:10pt;">two</font><font style="display: inline;font-size:10pt;"> year period </font><font style="display: inline;font-size:10pt;">or does not maintain the Company&#x2019;s Connecticut operations for a period of </font><font style="display: inline;font-size:10pt;">10</font><font style="display: inline;font-size:10pt;"> years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">plus a penalty of </font><font style="display: inline;font-size:10pt;">5%</font><font style="display: inline;font-size:10pt;"> of the total funded l</font><font style="display: inline;color:#000000;font-size:10pt;">oan</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">An initial disbursement of </font><font style="display: inline;font-size:10pt;">$2,000,000</font><font style="display: inline;font-size:10pt;">&nbsp;was made to the Company on April 15, 2016 under the Loan Agreement</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;The Agreement provides that the remaining </font><font style="display: inline;font-size:10pt;">$2,000,000</font><font style="display: inline;font-size:10pt;"> will be advanced if and when the Company </font><font style="display: inline;font-size:10pt;">achieves</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">certain </font><font style="display: inline;font-size:10pt;">other </font><font style="display: inline;font-size:10pt;">future milestones</font><font style="display: inline;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">The loan may be prepaid at any time without premium or penalty</font><a name="T7"></a><a name="T8"></a><a name="T9"></a><font style="display: inline;font-size:10pt;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">12</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;font-size:10pt;">&nbsp; &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The balance </font><font style="display: inline;font-size:10pt;">of the</font><font style="display: inline;font-size:10pt;"> DECD loan was </font><font style="display: inline;font-size:10pt;">$1,66</font><font style="display: inline;font-size:10pt;">6</font><font style="display: inline;font-size:10pt;">,000</font><font style="display: inline;font-size:10pt;"> and </font><font style="display: inline;font-size:10pt;">$1,849,000</font><font style="display: inline;font-size:10pt;"> at December</font><font style="display: inline;font-size:10pt;"> 31, </font><font style="display: inline;font-size:10pt;">2017 and </font><font style="display: inline;font-size:10pt;">2016</font><font style="display: inline;font-size:10pt;">, respectively</font><font style="display: inline;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Operating Leases</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease, including its principal facility and CLIA laboratory located </font><font style="display: inline;">in </font><font style="display: inline;">Austin, Texas.&nbsp; </font><font style="display: inline;">As of December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the Company&#x2019;s</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Austin, Texas lease include</font><font style="display: inline;">d</font><font style="display: inline;"> an </font><font style="display: inline;">annual base rent of </font><font style="display: inline;">$</font><font style="display: inline;">86</font><font style="display: inline;">,000</font><font style="display: inline;"> and annual estimated common area charges, taxes and insurance of </font><font style="display: inline;">$</font><font style="display: inline;">46</font><font style="display: inline;">,000</font><font style="display: inline;">.&nbsp;&nbsp;The </font><font style="display: inline;">lease </font><font style="display: inline;">exp</font><font style="display: inline;">i</font><font style="display: inline;">res on </font><font style="display: inline;">January</font><font style="display: inline;"> 31, 201</font><font style="display: inline;">9</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s</font><font style="display: inline;"> Trumbull, Connecticut lease includes an aggregate annual base rent of </font><font style="display: inline;">$32,000</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and annual estimated common area charges, taxes and insurance of </font><font style="display: inline;">$</font><font style="display: inline;">9</font><font style="display: inline;">5</font><font style="display: inline;">,000</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The lease expires on </font><font style="display: inline;">June 8, 2021</font><font style="display: inline;">.</font><font style="display: inline;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Rental expense under operating leases for the years ended December&nbsp;31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">totaled </font><font style="display: inline;">$</font><font style="display: inline;">2</font><font style="display: inline;">5</font><font style="display: inline;">4</font><font style="display: inline;">,</font><font style="display: inline;">000</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">$</font><font style="display: inline;">234</font><font style="display: inline;">,000</font><font style="display: inline;">, respectively.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Capital</font><font style="display: inline;font-weight:bold;font-style:italic;"> Lease</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In April 2015, the Company leased a laboratory instrument for a total initial payment of </font><font style="display: inline;">$125,000</font><font style="display: inline;"> and ongoing payments of approximately </font><font style="display: inline;">$3,500</font><font style="display: inline;"> per month for </font><font style="display: inline;">36</font><font style="display: inline;"> months after delivery. The agreement also requires minimum annual purchases of reagents from the manufacturer of the equipment. The laboratory instrument was placed into service on July 1, 2015.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The accumulated amortization of assets under capital lease obligations was </font><font style="display: inline;">$</font><font style="display: inline;">193</font><font style="display: inline;">,000</font><font style="display: inline;"> and the net book value of assets under capital lease obligations was </font><font style="display: inline;">$</font><font style="display: inline;">39</font><font style="display: inline;">,000</font><font style="display: inline;"> as of December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">The accumulated amortization of assets under capital lease obligations was </font><font style="display: inline;">$</font><font style="display: inline;">116</font><font style="display: inline;">,000</font><font style="display: inline;"> and the net book value of assets under capital lease obligations was </font><font style="display: inline;">$</font><font style="display: inline;">116</font><font style="display: inline;">,000</font><font style="display: inline;"> as of December 31, 201</font><font style="display: inline;">6</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Non</font><font style="display: inline;font-weight:bold;font-style:italic;">-</font><font style="display: inline;font-weight:bold;font-style:italic;">cancelable Collaboration Obligations and Other </font><font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Commitments</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">ha</font><font style="display: inline;">d</font><font style="display: inline;"> a research collaboration agreement with The Johns Hopkins University School of Medicine (&#x201C;JHU&#x201D;)</font><font style="display: inline;color:#000000;"> directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human diseas</font><font style="display: inline;">e</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;"> This agreement expire</font><font style="display: inline;">d</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">on</font><font style="display: inline;"> March </font><font style="display: inline;">31, </font><font style="display: inline;">2016.&nbsp;&nbsp;Collaboration expenses under the JHU collaboration were </font><font style="display: inline;">$</font><font style="display: inline;">15</font><font style="display: inline;">,000</font><font style="display: inline;"> and </font><font style="display: inline;">$</font><font style="display: inline;">264</font><font style="display: inline;">,000</font><font style="display: inline;"> for the years ended December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">, respectively.&nbsp;&nbsp;Collaboration expenses under the JHU collaboration are included in research and development expenses.&nbsp;&nbsp;In addition, under the terms of the amended research collaboration agreement, </font><font style="display: inline;">Vermillion </font><font style="display: inline;">is</font><font style="display: inline;"> required to pay the greater of </font><font style="display: inline;">4%</font><font style="display: inline;"> royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of </font><font style="display: inline;">$57,500</font><font style="display: inline;">.</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">R</font><font style="display: inline;">oyalty </font><font style="display: inline;">expense</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">for the years ended December&nbsp;31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">totaled </font><font style="display: inline;">$</font><font style="display: inline;">116</font><font style="display: inline;">,000</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">$</font><font style="display: inline;">92</font><font style="display: inline;">,000</font><font style="display: inline;">, respectively.</font><font style="display: inline;color:#000000;"> &nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;color:#000000;">Contingent Liabilities </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">F</font><font style="display: inline;font-size:10pt;">rom time to time, </font><font style="display: inline;font-size:10pt;">the Company is</font><font style="display: inline;font-size:10pt;"> involved in legal proceedings and regulatory proceedings arising </font><font style="display: inline;font-size:10pt;">from</font><font style="display: inline;font-size:10pt;"> operations.&nbsp; </font><font style="display: inline;font-size:10pt;">The Company</font><font style="display: inline;font-size:10pt;"> establish</font><font style="display: inline;font-size:10pt;">es</font><font style="display: inline;font-size:10pt;"> reserves for specific liabilities in connection with legal actions that </font><font style="display: inline;font-size:10pt;">management</font><font style="display: inline;font-size:10pt;"> deem</font><font style="display: inline;font-size:10pt;">s</font><font style="display: inline;font-size:10pt;"> to be probable and estimable.&nbsp; </font><font style="display: inline;font-size:10pt;">T</font><font style="display: inline;font-size:10pt;">he Company is</font><font style="display: inline;font-size:10pt;"> not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on </font><font style="display: inline;font-size:10pt;">the Company&#x2019;s</font><font style="display: inline;font-size:10pt;"> financial position or results of operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">NOTE 7:</font><font style="display: inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;">Common Stock</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2017</font><font style="display: inline;font-weight:bold;font-style:italic;"> Private Placement</font><font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On </font><font style="display: inline;">February 17, 2017</font><font style="display: inline;">, the Company completed a private placement pursuant to which certain investors purchased </font><font style="display: inline;color:#000000;">3,747,125</font><font style="display: inline;"> shares of </font><font style="display: inline;">Vermillion</font><font style="display: inline;"> common stock at a price of </font><font style="display: inline;">$1.40</font><font style="display: inline;"> per share. </font><font style="display: inline;">Vermillion</font><font style="display: inline;"> also issued warrants to purchase shares of common stock at a price of </font><font style="display: inline;">$0.125</font><font style="display: inline;"> per warrant share in the private placement. </font><font style="display: inline;">Net</font><font style="display: inline;"> proceeds of the private placement </font><font style="display: inline;">were </font><font style="display: inline;">approximately </font><font style="display: inline;">$5,127</font><font style="display: inline;">,000</font><font style="display: inline;"> after deducting offering expenses. The warrants </font><font style="display: inline;">are</font><font style="display: inline;"> exercisable for </font><font style="display: inline;color:#000000;">2,810,338</font><font style="display: inline;"> shares of </font><font style="display: inline;">Vermillion </font><font style="display: inline;">common stock at </font><font style="display: inline;">$1.80</font><font style="display: inline;"> per share</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;color:#000000;">The warrants may be exercised from time to time beginning August 17, 2017 and expire on the fifth anniversary of the date of issuance </font><font style="display: inline;">or, if earlier, five business days after </font><font style="display: inline;">Vermillion</font><font style="display: inline;"> delivers notice that the closing price per share of its </font><font style="display: inline;">common stock </font><font style="display: inline;">exceeded the </font><font style="display: inline;">exercise price </font><font style="display: inline;">for 20 consecutive trading days during the exercise period</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">13</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">The </font><font style="display: inline;">sale</font><font style="display: inline;"> of common stock and </font><font style="display: inline;">issuance of </font><font style="display: inline;">warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is </font><font style="display: inline;">$</font><font style="display: inline;">804</font><font style="display: inline;">,000</font><font style="display: inline;"> and to the common stoc</font><font style="display: inline;">k is </font><font style="display: inline;">approximately </font><font style="display: inline;">$</font><font style="display: inline;">4,323</font><font style="display: inline;">,000</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Warrants</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Warrants outstanding as of December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">were as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:21.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:21.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:21.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Exercise Price</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of Shares Outstanding under Warrant</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Issuance Date</font></p>
				</td>
				<td valign="bottom" style="width:21.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Expiration Date</font></p>
				</td>
				<td valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">per Share</font></p>
				</td>
				<td valign="bottom" style="width:21.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:22.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">December 31, 2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 23, 2014</font></p>
				</td>
				<td valign="bottom" style="width:21.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 23, 2017</font></p>
				</td>
				<td valign="bottom" style="width:12.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.00</font></p>
				</td>
				<td valign="bottom" style="width:21.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:22.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,166,659&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 17, 2017</font></p>
				</td>
				<td valign="bottom" style="width:21.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 17, 2022</font></p>
				</td>
				<td valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.80</font></p>
				</td>
				<td valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,810,338&nbsp;
				</td>
				<td valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:21.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,810,338&nbsp;
				</td>
				<td valign="bottom" style="width:22.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,166,659&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:9.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:21.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:9.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:9.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.20%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:9.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.48%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:9.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">See Note 1 regarding the August 2017 repricing and partial exercise of the common stock warrants issued on December 23, 2014.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">NOTE 8</font><font style="display: inline;font-weight:bold;">:</font><font style="display: inline;font-weight:bold;"> &nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">Loss Per Share</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The reconciliation of the numerators and denominators of basic and diluted loss per share for the years ended December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">was as fol</font><font style="display: inline;">lows</font><font style="display: inline;">:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Loss</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Shares</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Per Share</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(In thousands, except per share data)</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">(Numerator) </font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">(Denominator) </font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Amount </font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Year ended December 31, 2016:</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss available to common shareholders - basic </font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14,968)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 52,197,969</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.29)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards </font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss available to common shareholders - diluted </font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14,968)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 52,197,969</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.29)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Year ended December 31, 2017:</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(10,497)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Deemed dividend on warrant repricing</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(942)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss available to common shareholders - basic </font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(11,439)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 56,943,596</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.20)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards </font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net loss available to common shareholders - diluted </font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(11,439)
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 56,943,596</font></p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.20)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:58.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Due to net losses for the years ended December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">,</font><font style="display: inline;"> diluted loss per share is calculated using the weighted average number of common shares outstanding and excludes the effects of potential </font><font style="display: inline;">shares of </font><font style="display: inline;">common stock that are antidilutive.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The potential shares of common stock that have been excluded from the diluted loss per share calculation above for the years ended December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">were as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:52.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:52.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:52.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="3" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Year Ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:52.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="middle" style="width:03.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:52.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Stock options </font></p>
				</td>
				<td valign="bottom" style="width:22.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,219,568&nbsp;
				</td>
				<td valign="middle" style="width:03.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,451,073&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:52.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Stock warrants </font></p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,810,338&nbsp;
				</td>
				<td valign="middle" style="width:03.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,166,659&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:52.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Unvested restricted stock awards</font></p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,704&nbsp;
				</td>
				<td valign="middle" style="width:03.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7,752&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:52.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Potential common shares </font></p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7,031,610&nbsp;
				</td>
				<td valign="middle" style="width:03.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:22.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7,625,484&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">14</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt;font-family:Times New Roman;;font-size: 1pt"><font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">NOTE 9:</font><font style="display: inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;">Employee Benefit Plans</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2000 Stock Plan</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Under the Amended and Restated 2000 Stock Plan (the &#x201C;2000 Plan&#x201D;), options could be granted at prices not lower than </font><font style="display: inline;">85%</font><font style="display: inline;"> and </font><font style="display: inline;">100%</font><font style="display: inline;"> of the fair market value of the common stock for non-statutory and statutory stock options, respectively.&nbsp;&nbsp;Options generally vest monthly over a period of </font><font style="display: inline;">four</font><font style="display: inline;"> years and unexercised options generally expire </font><font style="display: inline;">ten</font><font style="display: inline;"> years from the date of grant.&nbsp;&nbsp;The authority of Vermillion&#x2019;s Board of Directors to grant new stock options and awards under the 2000 Plan terminated in 2010.&nbsp; </font><font style="display: inline;">There were </font><font style="display: inline;">no</font><font style="display: inline;"> stock options under the 2000 Stock Plan exercised during the year ended December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;"> or </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">No</font><font style="display: inline;"> additional shares of common stock were reserved for future option grants under the 2000 Plan. </font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">2010 Stock Incentive Plan</font><font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Under the 2010 Plan, employees, directors and consultants of the Company are eligible to receive awards. The 2010 Plan is administered by the Compensation Committee of Vermillion</font><font style="display: inline;">&#x2019;s</font><font style="display: inline;"> Board of Directors. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. </font><font style="display: inline;">&nbsp;</font><font style="display: inline;">I</font><font style="display: inline;">n &nbsp;</font><font style="display: inline;">June</font><font style="display: inline;"> 2015</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">Vermillion</font><font style="display: inline;">&#x2019;s stockholders approved an increase of </font><font style="display: inline;">4,500,000</font><font style="display: inline;"> in the number of shares available for issuance under the 2010 Plan for a total of </font><font style="display: inline;">8,122,983</font><font style="display: inline;"> shares.</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">Unexercised options generally expire </font><font style="display: inline;">ten</font><font style="display: inline;"> years from the date of grant. </font><font style="display: inline;">There were no options exercised during the year ended December 31, 2017. </font><font style="display: inline;">Options to purchase </font><font style="display: inline;">3,541</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shares of common stock were exercised during the year ended December 31, </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During the year ended December 31, 201</font><font style="display: inline;">7</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">Vermillion</font><font style="display: inline;"> issued </font><font style="display: inline;">to Vermillion</font><font style="display: inline;">&#x2019;s</font><font style="display: inline;"> Board of Directors </font><font style="display: inline;">131,250</font><font style="display: inline;"> shares of restricted stock </font><font style="display: inline;">under</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the 2010 Plan having a fair value of </font><font style="display: inline;">$281,000</font><font style="display: inline;"> as payment for services rendered in 201</font><font style="display: inline;">7</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The Company also issued to certain consultants </font><font style="display: inline;">32,332</font><font style="display: inline;"> shares of restricted stock </font><font style="display: inline;">under </font><font style="display: inline;">the 2010 Plan having a fair value of </font><font style="display: inline;">$5</font><font style="display: inline;">4</font><font style="display: inline;">,000</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">During the year ended December 31, 201</font><font style="display: inline;">6</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">Vermillion</font><font style="display: inline;"> issued </font><font style="display: inline;">to Vermillion</font><font style="display: inline;">&#x2019;s</font><font style="display: inline;"> Board of Directors </font><font style="display: inline;">197,727</font><font style="display: inline;"> shares of restricted stock </font><font style="display: inline;">under</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">the 2010 Plan having a fair value of </font><font style="display: inline;">$3</font><font style="display: inline;">1</font><font style="display: inline;">0,000</font><font style="display: inline;"> as payment for services rendered in 201</font><font style="display: inline;">6</font><font style="display: inline;">.</font><font style="display: inline;"> The Company also issued to certain consultants </font><font style="display: inline;">14,165</font><font style="display: inline;"> shares of restricted stock </font><font style="display: inline;">under </font><font style="display: inline;">the 2010 Plan having a fair value of </font><font style="display: inline;">$</font><font style="display: inline;">18,000</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The activity related to shares available for grant under the 2000 Plan and the 2010 Plan for the years ended December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">was as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;background-color:yellow;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2000 Stock Plan </font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2010 Stock Option Plan</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Total </font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Shares available at December 31, 2015</font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,371,505&nbsp;
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,371,505&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Options canceled </font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">33,050&nbsp;
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,243,217&nbsp;
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,276,267&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Reduction in shares reserved </font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(33,050)
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(33,050)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Options granted </font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,413,070)
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,413,070)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Restricted stock units granted</font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(211,892)
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(211,892)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Shares available at December 31, 2016</font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,989,760&nbsp;
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,989,760&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Options canceled </font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,050&nbsp;
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">776,455&nbsp;
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">779,505&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Reduction in shares reserved </font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3,050)
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3,050)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Options granted </font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,548,000)
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,548,000)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Restricted stock units granted</font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(163,582)
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(163,582)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Shares available at December 31, 2017</font></p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,054,633&nbsp;
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,054,633&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:53.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The stock option activity under the 2000 Plan and 2010 Plan for the years ended December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">was as follows:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">15</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Number of Shares </font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average Exercise Price </font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Aggregate Intrinsic Value </font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average Remaining Contractual&nbsp;&nbsp;Term </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Options outstanding at December 31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,317,811&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2.29&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">91&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.24&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,413,070&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.33&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3,541)
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.30&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Canceled </font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,276,267)
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2.21&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Options outstanding at December 31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,451,073&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.70&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">41&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,548,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2.05&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Canceled </font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(779,505)
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.51&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Options outstanding at December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,219,568&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.86&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,033&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.02&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 5pt">
						<font style="display: inline;color:#000000;font-size:5pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Shares exercisable:</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,855,662&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.99&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">427&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7.06&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Shares expected to vest:</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,938,403&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.77&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">606&nbsp;
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.77&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The range of exercise prices for options outstanding and exercisable at December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">is as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;background-color:yellow;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Exercise Price </font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Options Outstanding </font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted&nbsp;&nbsp;Average Exercise Price </font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average&nbsp;&nbsp;Remaining Life in Years </font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Options Exercisable </font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:53.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Weighted Average Exercise Price </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 0.01</font></p>
				</td>
				<td valign="top" style="width:03.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">-</font></p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 1.30</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">435,625&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 0.99</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.74&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">188,489&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.00&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 1.31</font></p>
				</td>
				<td valign="top" style="width:03.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">-</font></p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 1.64</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,369,168&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 1.50</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.01&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">561,957&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.52&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 1.65</font></p>
				</td>
				<td valign="top" style="width:03.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">-</font></p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 2.08</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,038,500&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 1.96</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7.44&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">660,131&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.95&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 2.09</font></p>
				</td>
				<td valign="top" style="width:03.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">-</font></p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 11.55</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,376,275&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 2.43</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.23&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">445,085&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.05&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 0.01</font></p>
				</td>
				<td valign="top" style="width:03.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">-</font></p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="top" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 11.55</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,219,568&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 1.86</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.02&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,855,662&nbsp;
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="top" style="width:11.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.99&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:40.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total Intrinsic Value of Options Exercised</font></p>
				</td>
				<td valign="bottom" style="width:03.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:25.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total Fair Value of Vested Options</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Year ended December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:25.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:03.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:25.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,272&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Year ended December 31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:25.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1&nbsp;
				</td>
				<td valign="bottom" style="width:03.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:25.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,562&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Stock-based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">Employee Stock-based Compensation Expense </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company records stock-based compensation net of estimated forfeitures</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">The assumptions used to calculate the fair value of options granted under the 2010 Plan that were incorporated in the Black-Scholes pricing model for the years ended December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">were as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="7" valign="top" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;text-decoration:underline;">Year Ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="3" valign="top" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="top" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="top" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Dividend yield </font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Volatility </font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">69&nbsp;
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">77&nbsp;
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">16</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Risk-free interest rate </font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.77&nbsp;
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.96&nbsp;
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Expected lives (years) </font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4.0&nbsp;
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4.0&nbsp;
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Weighted average fair value</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.11&nbsp;
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:17.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.77&nbsp;
				</td>
				<td valign="bottom" style="width:06.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;">The allocation of </font><font style="display: inline;">employee </font><font style="display: inline;">stock-based compensation expense by functional area for the years ended December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">was as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;background-color:yellow;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Year Ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(in thousands)</font></p>
				</td>
				<td valign="top" style="width:02.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="top" style="width:02.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:22.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Cost of sales</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:22.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">82&nbsp;
				</td>
				<td valign="bottom" style="width:03.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:22.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">93&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
				<td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">71&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Sales and marketing </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">150&nbsp;
				</td>
				<td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">101&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">914&nbsp;
				</td>
				<td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">759&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total </font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:22.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,152&nbsp;
				</td>
				<td valign="bottom" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:22.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,024&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of </font><font style="display: inline;">December</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, total unrecognized</font><font style="display: inline;"> compensation cost related to </font><font style="display: inline;">un</font><font style="display: inline;">vested </font><font style="display: inline;">stock option awards was approximately </font><font style="display: inline;">$</font><font style="display: inline;">2,147</font><font style="display: inline;">,000</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and the related weighted average period over which it is expected to be recognized was </font><font style="display: inline;">2.</font><font style="display: inline;">56</font><font style="display: inline;"> years.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">401(k)</font><font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">Plan</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s 401(k) Plan allows eligible employees to defer up to an annual limit of the lesser of </font><font style="display: inline;">90.0%</font><font style="display: inline;"> of eligible compensation or a maximum contribution amount subject to the Internal Revenue Service annual contribution limit.&nbsp;&nbsp;The Company is not required to make contributions under the 401(k) Plan.&nbsp;&nbsp;During the years ended </font><font style="display: inline;">December&nbsp;31, 201</font><font style="display: inline;">7</font><font style="display: inline;"> and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">, the Company did not contribute to the 401(k) Plan.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">NOTE 10:</font><font style="display: inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">There was </font><font style="display: inline;">no</font><font style="display: inline;"> income tax expense or benefit for the years ended December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">or </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">because of net losses during those years. These</font><font style="display: inline;"> net loss</font><font style="display: inline;">es</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">were </font><font style="display: inline;">generated from domestic operations.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Based on the available objective evidence</font><font style="display: inline;"> and uncertainty about the timing and amount of any future profits</font><font style="display: inline;">, the Company has provided a full valuation allowance against </font><font style="display: inline;">our </font><font style="display: inline;">net deferred tax assets at December&nbsp;31,&nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The components of </font><font style="display: inline;">net </font><font style="display: inline;">deferred tax assets at December&nbsp;31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">were as follows:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Year Ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(in thousands)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net operating losses</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">17,768&nbsp;
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22,861&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Amortization - R&amp;D intangibles</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,091&nbsp;
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,327&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,461&nbsp;
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,903&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total deferred tax assets </font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23,320&nbsp;
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">31,091&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Valuation allowance </font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(23,320)
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(31,091)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Deferred tax assets </font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:3.75pt;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:3.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Deferred tax liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net deferred tax asset</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective tax rate for the years ended December&nbsp;31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">was as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr></table>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">17</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Year Ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2017</font></p>
				</td>
				<td valign="top" style="width:02.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Tax at federal statutory rate </font></p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">34&nbsp;
				</td>
				<td valign="top" style="width:02.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="top" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">34&nbsp;
				</td>
				<td valign="top" style="width:02.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">State tax, net of federal benefit </font></p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1&nbsp;
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1&nbsp;
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">74&nbsp;
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">291&nbsp;
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Change in warrant valuation</font></p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Net operating loss and credit reduction due to section 382 limitations</font></p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(327)
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Permanent items</font></p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2)
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2)
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Change in Federal Tax Rate (2017 Tax Reform)</font></p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(111)
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3&nbsp;
				</td>
				<td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Effective income tax rate </font></p>
				</td>
				<td valign="top" style="width:11.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="top" style="width:02.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
				<td valign="top" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:11.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="top" style="width:02.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, the Company had </font><font style="display: inline;">pre-tax</font><font style="display: inline;"> net operating loss </font><font style="display: inline;">carryforwards </font><font style="display: inline;">of approximately </font><font style="display: inline;">$</font><font style="display: inline;">71</font><font style="display: inline;">,000,000</font><font style="display: inline;"> for federal and </font><font style="display: inline;">$</font><font style="display: inline;">1</font><font style="display: inline;">73</font><font style="display: inline;">,000,000</font><font style="display: inline;"> for state tax purposes.&nbsp;&nbsp;If not utilized, these carryforwards begin to expire in </font><font style="display: inline;">202</font><font style="display: inline;">7</font><font style="display: inline;"> for federal purposes and </font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">for state purposes. In </font><font style="display: inline;">201</font><font style="display: inline;">8</font><font style="display: inline;">, approximately </font><font style="display: inline;">$</font><font style="display: inline;">12</font><font style="display: inline;">,000,000</font><font style="display: inline;"> of </font><font style="display: inline;">the Company&#x2019;s </font><font style="display: inline;">state net operating loss will expire.</font><font style="display: inline;"> As of December 31, 20</font><font style="display: inline;">1</font><font style="display: inline;">6</font><font style="display: inline;">, we had a net operating</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">loss of approximately </font><font style="display: inline;">$</font><font style="display: inline;">59</font><font style="display: inline;">,000</font><font style="display: inline;">,000</font><font style="display: inline;"> for federal</font><font style="display: inline;"> and </font><font style="display: inline;">$16</font><font style="display: inline;">7</font><font style="display: inline;">,000,000</font><font style="display: inline;"> for state tax purposes.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s ability to use net operating loss and tax credit carryforwards may be restricted due to ownership change limitations, as required by Section 382 of the Internal Revenue Code of 1986, as amended (&#x201C;Section 382&#x201D;)</font><font style="display: inline;">,</font><font style="display: inline;"> as well as similar state provisions. These</font><font style="display: inline;"> ownership changes may also limit</font><font style="display: inline;"> the amount of net operating loss</font><font style="display: inline;"> and tax</font><font style="display: inline;"> credit carryforwards that can be utilized annually to offset future taxable income and tax</font><font style="display: inline;">, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We believe that Section 382 ownership changes occurred as a result of our follow-on public offerings in 2011, 2013 and 2015.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Any limitation </font><font style="display: inline;">may result in the expiration of a portion of the net operating loss and credit carryforwards before utilization</font><font style="display: inline;"> as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of our valuation allowance</font><font style="display: inline;">.</font><font style="display: inline;"> Due to the existence of a valuation allowance, it is not expected that</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">such </font><font style="display: inline;">limitations, if any, will </font><font style="display: inline;">have an </font><font style="display: inline;">impact </font><font style="display: inline;">on </font><font style="display: inline;">our </font><font style="display: inline;">results of operations or financial position.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Tax Cuts and Jobs Act (the </font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;color:#000000;">Act&#x201D;) was enacted on December 22, 2017. The Act reduces the U.S. federal corporate tax rate from </font><font style="display: inline;color:#000000;">35</font><font style="display: inline;color:#000000;"> percent to </font><font style="display: inline;color:#000000;">21</font><font style="display: inline;color:#000000;"> percent. In the year ended December 31, 2017, the Company revised its estimated annual effective rate to reflect a change in its U.S. federal statutory rate from 34 percent to 21 percent. The rate change is effective on January 1, 2018; therefore, the Company&#x2019;s U.S. statutory tax rate for the fiscal year ended December 31, 2018, will be 21 percent.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">At December 31, 2017, the Company has not completed its accounting for the tax effects of enactment of the Act; however, in certain cases, as described below, the Company has made a reasonable estimate of the effects on existing deferred tax balances. In other cases, the Company has not been able to make a reasonable estimate and continues to account for those items based on existing accounting under ASC 740, Income Taxes, and the provisions of the tax laws that were in effect immediately prior to enactment. The Securities and Exchange Commission has issued guidance that allows for a measurement period of up to one year after the enactment date of the Act to finalize the recording of the related tax impacts. The final transitional impacts of the Act may differ from the initial estimates.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color:yellow;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Provisional amounts</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Deferred tax assets and liabilities: Certain domestic-related deferred tax assets and liabilities were remeasured based on the rates at which they are expected to reverse in the future, which is generally 21 percent. As a valuation allowance is recorded for the full amount of these deferred tax assets and liabilities, the remeasurement of the deferred tax assets and liabilities was offset by a corresponding remeasurement of the valuation allowance.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We believe that it is more likely than not that the benefit from certain deferred tax assets will not be realized due to the h</font><font style="display: inline;">istory of our operating losses. In recognition of this risk, we have provided a valuation allowance on the deferred tax assets relating to these assets.&nbsp; </font><font style="display: inline;">The valuation allowance was </font><font style="display: inline;">$</font><font style="display: inline;">23</font><font style="display: inline;">,000,000</font><font style="display: inline;"> and </font><font style="display: inline;">$</font><font style="display: inline;">31</font><font style="display: inline;">,000,000</font><font style="display: inline;"> at December 31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">, respectively. The </font><font style="display: inline;">de</font><font style="display: inline;">crease </font><font style="display: inline;">of </font><font style="display: inline;">$</font><font style="display: inline;">8</font><font style="display: inline;">,000,000</font><font style="display: inline;"> between </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">is primarily due to </font><font style="display: inline;">adjustments to the </font><font style="display: inline;">domestic </font><font style="display: inline;">deferred tax assets related to the net operating losses</font><font style="display: inline;"> and the change in the federal </font><font style="display: inline;">income tax rate from </font><font style="display: inline;">34%</font><font style="display: inline;"> to </font><font style="display: inline;">21%</font><font style="display: inline;">&nbsp;</font><font style="display: inline;color:#000000;">under</font><font style="display: inline;color:#000000;"> the Act</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company </font><font style="display: inline;">file</font><font style="display: inline;">s</font><font style="display: inline;"> income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. </font><font style="display: inline;">The Company has n</font><font style="display: inline;">ot been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December&nbsp;31, </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">18</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Courier New;font-size: 12pt">

			&nbsp;

		</p>

</div>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">the Company&#x2019;s f</font><font style="display: inline;">ederal returns for the years ended </font><font style="display: inline;">201</font><font style="display: inline;">4</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">through </font><font style="display: inline;">the current period </font><font style="display: inline;">and most state returns for the years ended </font><font style="display: inline;">201</font><font style="display: inline;">3</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">through </font><font style="display: inline;">the current period </font><font style="display: inline;">are still open to examination. In addition, all </font><font style="display: inline;">of the </font><font style="display: inline;">net operating loss</font><font style="display: inline;"> carryforwards</font><font style="display: inline;"> and research and development credit</font><font style="display: inline;">s generated in years earlier than 201</font><font style="display: inline;">4</font><font style="display: inline;"> and 201</font><font style="display: inline;">3</font><font style="display: inline;">, respectively, are still</font><font style="display: inline;"> subject to Internal Revenue Service audit. </font><font style="display: inline;">The federal and California tax returns for the year ended December 31, 201</font><font style="display: inline;">6</font><font style="display: inline;"> reflect research and development carryforwards of </font><font style="display: inline;">$5,</font><font style="display: inline;">430</font><font style="display: inline;">,000</font><font style="display: inline;"> and </font><font style="display: inline;">$5,</font><font style="display: inline;">31</font><font style="display: inline;">7</font><font style="display: inline;">,000</font><font style="display: inline;">, respectively. </font><font style="display: inline;">The Company has recognized additional deferred tax assets for federal and California research and development credits of </font><font style="display: inline;">$</font><font style="display: inline;">46</font><font style="display: inline;">,000</font><font style="display: inline;"> and </font><font style="display: inline;">$</font><font style="display: inline;">35</font><font style="display: inline;">,000</font><font style="display: inline;"> for the year ended December 31, 201</font><font style="display: inline;">7</font><font style="display: inline;">, respectively.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of December&nbsp;31, </font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, our gross unrecognized tax benefits are approximately </font><font style="display: inline;">$10,</font><font style="display: inline;">82</font><font style="display: inline;">8</font><font style="display: inline;">,000</font><font style="display: inline;"> which are attributable to research and development credit</font><font style="display: inline;"> carryforwards</font><font style="display: inline;">.&nbsp;&nbsp;A reconciliation of the change in the Company&#x2019;s unrecognized tax benefits is as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:33.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:33.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;font-size: 1pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:5.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:5.25pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(in thousands)</font></p>
				</td>
				<td valign="middle" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Federal Tax</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">State Tax</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Balance at December 31, 2015</font></p>
				</td>
				<td valign="middle" style="width:24.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 5,335</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 5,246</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 10,581</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Increase in tax position during 2016</font></p>
				</td>
				<td valign="middle" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 95</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 71</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 166</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Decrease due to expirations</font></p>
				</td>
				<td valign="middle" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Balance at December 31, 2016</font></p>
				</td>
				<td valign="middle" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 5,430</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 5,317</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 10,747</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Increase in tax position during 2017</font></p>
				</td>
				<td valign="middle" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 46</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 35</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 81</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Decrease due to expirations</font></p>
				</td>
				<td valign="middle" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Balance at December 31, 2017</font></p>
				</td>
				<td valign="middle" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 5,476</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 5,352</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;"> 10,828</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The increase for the year ended December 31, 201</font><font style="display: inline;">7</font><font style="display: inline;"> relates to a position taken in the current year.&nbsp;&nbsp;The increase for the year ended December 31, 201</font><font style="display: inline;">6</font><font style="display: inline;"> is related to tax positions taken during 201</font><font style="display: inline;">6</font><font style="display: inline;"> and prior years.&nbsp;&nbsp;If the </font><font style="display: inline;">$11</font><font style="display: inline;">,000,000</font><font style="display: inline;"> of unrecognized income tax benefit is recognized, approximately $11</font><font style="display: inline;">,000,000</font><font style="display: inline;"> would impact the effective tax rate in the period in which each of the benefits is recognized.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We do not expect our unrecognized tax benefits to change significantly over the next 12&nbsp;months. We recognize interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the consolidated statement of operations and comprehensive loss. We have </font><font style="display: inline;">not</font><font style="display: inline;"> recorded any interest or penalties as a result of uncertain tax positions as of December&nbsp;31, 201</font><font style="display: inline;">7</font><font style="display: inline;"> and 201</font><font style="display: inline;">6</font><font style="display: inline;">. Accrued interest and penalties would be included within the related liability in the consolidated balance sheet.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;background-color:yellow;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">NOTE 11:</font><font style="display: inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;">Related Party Transactions</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;color:#000000;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On December 18, 2017, the Company entered into a consulting agreement</font><font style="display: inline;font-size:10pt;"> for a term of up to </font><font style="display: inline;font-size:10pt;">five</font><font style="display: inline;font-size:10pt;"> months</font><font style="display: inline;font-size:10pt;"> with the Company&#x2019;s former Senior Vice President, Finance and Chief Accounting Officer.&nbsp;&nbsp;Pursuant to the terms of the consulting agreement, the </font><font style="display: inline;font-size:10pt;">consultant is providing</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">accounting and finance services </font><font style="display: inline;font-size:10pt;">related to the </font><font style="display: inline;font-size:10pt;">transition of financial leadership</font><a name="_cp_text_1_91"></a><font style="display: inline;font-size:10pt;">. The Company will pay </font><a name="_cp_text_4_92"></a><font style="display: inline;font-size:10pt;">$150</font><font style="display: inline;font-size:10pt;"> per hour</font><a name="_cp_text_1_93"></a><font style="display: inline;font-size:10pt;"> for such</font><font style="display: inline;font-size:10pt;"> consulting services.&nbsp;&nbsp;The consultant</font><font style="display: inline;font-size:10pt;"> will also </font><a name="_cp_text_1_95"></a><font style="display: inline;font-size:10pt;">remain eligible for payout under the </font><a name="_cp_text_1_96"></a><font style="display: inline;font-size:10pt;">Company&#x2019;s 2017 Corporate Incentive Plan </font><font style="display: inline;font-size:10pt;">if he satisfactorily meets certain performance obligations as outlined in the consulting agreement.</font><font style="display: inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On </font><font style="display: inline;">January 18, </font><font style="display: inline;">201</font><font style="display: inline;">6</font><font style="display: inline;">, the Company entered into a consulting agreement with a member of Vermillion&#x2019;s Board of Directors.&nbsp;&nbsp;Pursuant to the terms of the consulting agreement, </font><font style="display: inline;">the consultant</font><font style="display: inline;"> provide</font><font style="display: inline;">d</font><font style="display: inline;"> consulting services regarding </font><font style="display: inline;">business strategies and operational plans and </font><font style="display: inline;">was</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">paid </font><font style="display: inline;">$375</font><font style="display: inline;"> per hour</font><font style="display: inline;"> or a minimum of </font><font style="display: inline;">$51,750</font><font style="display: inline;"> for the period </font><font style="display: inline;">up </font><font style="display: inline;">to the </font><font style="display: inline;">expiration of the </font><font style="display: inline;">agreement on March 31, 2016</font><font style="display: inline;">.</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">During the year ended December 31, 2016, </font><font style="display: inline;">the consultant</font><font style="display: inline;"> was paid </font><font style="display: inline;">$52,000</font><font style="display: inline;">&nbsp;for services provided pursuant to the consulting agreement.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			&nbsp;
		</p></div><div style="margin-left:36pt;margin-right:36pt;">
		<p style="margin:0pt 0pt 6pt;text-align:center;font-weight:bold;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">F-</font><font style="display: inline;"></font><font style="display: inline;">19</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt 28.8pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-weight:bold;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">SIGNATURES</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Vermillion, Inc.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Date:&nbsp; </font><font style="display: inline;">March </font><font style="display: inline;">13</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:239pt;"><font style="display: inline;">/s/ </font><font style="display: inline;">Valerie </font><font style="display: inline;">B. </font><font style="display: inline;">Palmieri</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"></font></font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Valerie </font><font style="display: inline;">B. </font><font style="display: inline;">Palmieri</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">President and</font><font style="display: inline;"> Chief Executive Officer</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(Principal Executive Officer)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Date:&nbsp; </font><font style="display: inline;">March </font><font style="display: inline;">13</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font></p>
				</td>
				<td valign="top" style="width:261.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:239pt;"><font style="display: inline;">/s/ </font><font style="display: inline;">Robert Beechey</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"></font></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:261.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Robert Beechey</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Chief </font><font style="display: inline;">Financial </font><font style="display: inline;">Officer</font><font style="display: inline;"> (Principal Financial Officer</font><font style="display: inline;"> and Principal Accounting Officer</font><font style="display: inline;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:32.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:49.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.22%;padding:0pt 5.4pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:51.8pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:51.8pt;text-align:center"><font style="display: inline;font-weight:bold;">Name</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;font-weight:bold;"></font></font></p>
				</td>
				<td valign="bottom" style="width:49.26%;padding:0pt 5.4pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:98.2pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:98.2pt;text-align:center"><font style="display: inline;font-weight:bold;">Title</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;font-weight:bold;"></font></font></p>
				</td>
				<td valign="bottom" style="width:18.52%;padding:0pt 5.4pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:40pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;font-weight:bold;">Date</font><font style="display: inline;font-weight:bold;"></font></font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.22%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:134.6pt;"><font style="display: inline;">/s/ </font><font style="display: inline;">Valerie B. Palmieri</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"></font></font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Valerie B. Palmieri</font></p>
				</td>
				<td valign="bottom" style="width:49.26%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">President and</font><font style="display: inline;"> Chief Executive Officer</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">(Principal Executive Officer)</font><font style="display: inline;"> and Director</font></p>
				</td>
				<td valign="bottom" style="width:18.52%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">13</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.22%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:134.6pt;"><font style="display: inline;">/s/ </font><font style="display: inline;">Robert Beechey</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"></font></font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Robert Beechey</font></p>
				</td>
				<td valign="bottom" style="width:49.26%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Chief </font><font style="display: inline;">Financial </font><font style="display: inline;">Officer (Principal Financial Officer</font><font style="display: inline;"> and Principal Accounting Officer</font><font style="display: inline;">)</font></p>
				</td>
				<td valign="bottom" style="width:18.52%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">13</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.22%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:111.6pt;"><font style="display: inline;">/s/ James </font><font style="display: inline;">T</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">LaFrance</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"></font></font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">James T. LaFrance</font></p>
				</td>
				<td valign="bottom" style="width:49.26%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Chairman of the Board of Directors</font></p>
				</td>
				<td valign="bottom" style="width:18.52%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">13</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.22%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:134.6pt;"><font style="display: inline;">/s/ </font><font style="display: inline;">James S. Burns</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"></font></font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">James S. Burns</font></p>
				</td>
				<td valign="bottom" style="width:49.26%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Director</font></p>
				</td>
				<td valign="bottom" style="width:18.52%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">13</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.22%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:29.6pt;"><font style="display: inline;">/s/ Veronica G. H. </font><font style="display: inline;">Jorda</font><font style="display: inline;">n</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"></font><font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Veronica G. H. Jordan</font></p>
				</td>
				<td valign="bottom" style="width:49.26%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Director</font></p>
				</td>
				<td valign="bottom" style="width:18.52%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">13</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.22%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:31.6pt;"><font style="display: inline;">/</font><font style="display: inline;">s/ David Schreiber</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">David Schreiber</font></p>
				</td>
				<td valign="bottom" style="width:49.26%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Director</font></p>
				</td>
				<td valign="bottom" style="width:18.52%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">13</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.22%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:67.6pt;"><font style="display: inline;">/s/ Carl Severinghaus</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"></font></font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Carl Severinghaus</font></p>
				</td>
				<td valign="bottom" style="width:49.26%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Director</font></p>
				</td>
				<td valign="bottom" style="width:18.52%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">13</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.22%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;font-family:Times New Roman;font-size: 10pt">
						<font style="text-indent:0pt;margin-left:0pt; padding-right:134.6pt;"><font style="display: inline;">/s/ </font><font style="display: inline;">Eric Varma</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:right"><font style="display: inline;"></font></font></p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Eric Varma</font></p>
				</td>
				<td valign="bottom" style="width:49.26%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Director</font></p>
				</td>
				<td valign="bottom" style="width:18.52%;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">March </font><font style="display: inline;">13</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">8</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;">1</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
